Page last updated: 2024-11-04

glycerol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID753
CHEMBL ID692
CHEBI ID178017
CHEBI ID17754
CHEBI ID131416
CHEBI ID189439
MeSH IDM0009417

Synonyms (713)

Synonym
25618-55-7
8043-29-6
dg 31:3
dag 31:3
diacylglycerol 31:3
CHEBI:178017
dg(31:3)
diacylglycerol(31:3)
dag(31:3)
CHEBI:17754 ,
glycerolum
oelsuess
propane-1,2,3-triol
glyzerin
C0066
d-glycerol
l-glycerol
dg(35:0)
glycerol; propane-1,2,3-triol
glycerol (inn)
D00028
glycerin (jp17/usp)
brn 0635685
nsc 9230
collyrium fresh-eye drops
einecs 200-289-5
propanetriol (van)
glycerolum [inn-latin]
glycerin [jan]
clyzerin, wasserfrei [german]
glycerin, natural
glicerol [inn-spanish]
glysanin
nsc-9230
glycerine
90 technical glycerine
1,3-trihydroxypropane
wln: q1yq1q
glyrol
glyceritol
ophthalgan
nsc9230 ,
osmoglyn
dagralax
glycerin, synthetic
glycyl alcohol
glycerin, anhydrous
trihydroxypropane
1,3-propanetriol
synthetic glycerin
propanetriol
vitrosupos
synthetic glycerine
GOL ,
inchi=1/c3h8o3/c4-1-3(6)2-5/h3-6h,1-2h
caswell no. 469
glycerinum
ai3-00091
hsdb 492
incorporation factor
ifp ,
optim
fema no. 2525
glycerine mist
cristal
moon
citifluor af 2
star
glycerin mist
bulbold
glicerina [dcit]
ccris 2295
grocolene
glycerin (mist)
epa pesticide chemical code 063507
glyceol
NCGC00090950-02
NCGC00090950-01
1,2,3-propanetriol
1,2,3-trihydroxypropane
56-81-5
glycerin
C00116
glycerol ,
1,2,3-trihydroxypropanol
glycerolglycerin; propane-1,2,3-triol
glycerol, >99%, fcc, fg
glycerol, >=99.5%
glycerol, for molecular biology, >=99%
glycerin, meets usp testing specifications
glycerol, bioxtra, >=99% (gc)
glycerol, bioreagent, suitable for cell culture, suitable for insect cell culture, suitable for electrophoresis, >=99% (gc)
NCGC00090950-03
MOLMAP_000024
glycerol, bioultra, for molecular biology, anhydrous, >=99.5% (gc)
glycerol-gelatine, for mounting (histochemical slides)
glycerol, spectrophotometric grade, >=99.5%
8DFDFCD7-1ED2-4373-845E-054F5AD00089
G0316
ins no.422
m 314429
e422
ins-422
glycerol 85%
pzn 7474853
glycerin,anhydrous
e-422
monoctanoin component d
tryhydroxypropane
CHEMBL692
BMSE000184
FT-0669018
dag 35:0
diacylglycerol(35:0)
dg 35:0
diacylglycerol 35:0
CHEBI:131416
CHEBI:189439
dag(35:0)
AKOS000120102
A831186
NCGC00090950-04
NCGC00090950-05
clyzerin, wasserfrei
4-01-00-02751 (beilstein handbook reference)
glycerin [usp:jan]
pdc6a3c0ox ,
glycerol [inn]
glicerina
unii-pdc6a3c0ox
neutracett
artifical tears
glicerol
ec 200-289-5
QSPL 181
BMSE000856
BMSE000807
tox21_202077
NCGC00259626-01
tox21_300144
NCGC00253975-01
glycerin base
107283-02-3
heterochromatin-specific nonhistone chromosomal protein hp-1
nsc-759633
pharmakon1600-01300020
nsc759633
dtxsid9020663 ,
dtxcid40662
cas-56-81-5
tox21_111043
FT-0626742
11003-00-2
glycerin [orange book]
glycerin [usp-rs]
glycerin [hsdb]
glycerin [ii]
glycerol [ep monograph]
glycerol [mart.]
glycerol [ep impurity]
glycerol [mi]
glycerol [fhfi]
glycerin [vandf]
glycerin [inci]
glycerol [who-dd]
glycerinum [hpus]
glycerol 85% [who-dd]
glycerolum [who-ip latin]
glycerin,anhydrous [vandf]
glycerol [who-ip]
2-propanol, 1,3-dihydroxy-
glycerin [usp monograph]
S2766
BRD-K73866522-001-02-6
gtpl5195
2W97
90 technical glycerin
emery 912
pricerine 9091
emery 916
2-hydroxylpropane-1,3-diol
8013-25-0
wurcs=2.0/1,1,0/[h2h]/1/
BP-31039
df-2
mfcd00004722
FT-0697060
glyceol opthalgan
rg-s
glycerol, molecular biology grade
glycerol, ultrapure
glycerol, ultrapure, spectrophotometric grade
glycerol, ultrapure, hplc grade
F0001-1470
glycerol, analytical standard
glycerol, puriss. p.a., acs reagent, anhydrous, dist., >=99.5% (gc)
glycerol, jis special grade, >=99.0%
glycerol, saj first grade, >=98.0%
glycerin, united states pharmacopeia (usp) reference standard
glycerol, acs reagent, >=99.5%
glycerol, puriss., meets analytical specification of ph. eur., bp, usp, fcc, e422, anhydrous, 99.0-101.0% (alkalimetric)
glycerol, reagentplus(r), >=99%
glycerol, tested according to ph.eur., anhydrous
glycerol, >=99% (gc)
glycerol, reagentplus(r), >=99.0% (gc)
glycerol, usp, 99.0-101.0%
glycerol, biochemical grade
D92249
mackstat h 66
e 422
glycerol, technical grade, 95%
glycerol, ar, >=99.5%
glycerol, p.a., acs reagent, reag. iso, reag. ph. eur., 98.0-101.0%
glycerin, pharmaceutical secondary standard; certified reference material
glycerol, acs reagent, 99.5%
glycerol, vetec(tm) reagent grade, 99%
glycerol, lr, >=98%
glycerol, vetec(tm) reagent grade
HY-B1659
101662-08-2
144086-03-3
glycerin usp grade
CS-6964
DB09462
glycerin; propane-1,2,3-triol
153050-05-6
pentrioxido sulfurico glycerincol
Q132501
glycerol min 98%, anhydrous
dynastin 7
STL199174
1h-thieno[3,4-d]imidazole-4-pentanamide, hexahydro-2-oxo-n-[6-oxo-6-(2-propenylamino)hexyl]-, (3as,4
STR02073
SB83762
EN300-19328
glycerol-(od)3
26403-55-4
gmdansu ampoule
glycerol-saline diluent
nymphsyn face mask
wellage concentrated illumination expert
zenibell snail intensive
wellage post procedure
bliss gvschildren
all in one dual mask
lemon glycerineswabsticks
mizon enjoy vital up time anti wrinkle mask
dr deep atodeepsoap
bliss gvs
walgreens children glycerin
doctors choice glycerin lubricant eye drops
noblesse homme refresh
origin horse sheet mask
hydra lifting firming moisturizing cream
vitamin b5 velvet mask
perfect v lifting premium plus mask
oasis tears pfpreservative-free lubricant eye
baby essence
glycerin liquid laxative enema(kaisalilu)
huitomi pack
repiel timeless aqua shot bio mask
huitomi
siseundeusi scalp essence
keragel
walgreens adult glycerinlaxative
queen perfume hair
truezyme healing scalp tonic
oceantears
rubelli wine foot packs
skinbutak go young magiccream
isleaf botanic shield deep pore cleasing foam
cizar first calming toner
age defense pro prebiotic technology econature
apple bubble
renewal serum
repiel perfect fit mask moisturizing
glycerolum (inn-latin)
hydra rose mask
im sorry for my skin mask-brightening
la roche posay laboratoire dermatologique cicaplast defense b5
my lovely butts
beerx cold sore treatment
walgreens children glycerinlaxative
lanbelle anti-wrinkle eye
wellage 4d gold essence
tamhada ii synergy whitening mask
ato all
tmc-a anti hairloss
ultra soothing mask 1pc
modlina peptide soothing essential hydrogel mask pack
tonymoly intense care snail
anti wrinkle effect ample
pure hydrogel mask pack
fedora concentrating hydro toner
resurface mask
wettrust gold
c-more glycerin lubricant eye drops
vela contour neck and chin toning firming serum
co2 polymer mask pack
sella natural hair
by pharmicell lab the prestige
naturalth goat milk moisture toner
medi hydro dp toner
wellage black aqua roll mask pack
medi hydro dp stem c ampoule
mewrinkle
leaders mediu brightening milk pack
diona cell illuminating booster
elikin whitening maskpack
jena cell super cell serum plus
an adc egf wrinkle eye
znsp repair
longevity recovery serum
hyalucollagen moisturizernormal and dry skin
oasis tearspreservative-free lubricant eye
inclear
dr deep all in one cleansing
oerbeua clearing mask
isleaf botanic shield pollutant defending mask
effective hair strengthen
tomatox magic massage pack
inibebe organic soapberry wash
diona cell regeneration booster
anti aging hydrogel mask pack
leaders mediu nutrition grain pack
3 en 1 cleanser. deep cleansing
cvs pharmacy glycerinlaxative
mefactory piggy peeling pad
sella classic natural cleansing bar
makeup remover
dr deep enrich nourishingcream
premium natural bl hydrogel mask pack
yozum secret
wellage intensive repair serum
oerbeua energizing mask
antizom
glicerolo
im sorry for my skin mask-revitalizing
rayderm re-generating serum
illite whitening
bio dna serum
eyeganics organic tears
mermaid tears
rubelli wine hand packs
lanbelle vitamin cell
jena cell vl volume lift gravity essence
glowing marigold mask
leader glycerin
oerbeua mattifying mask
repiel timeless redness shot bio mask
correway personal lubricant
amuldy kids
ginsenoside rg1 rejuvenating moisturizing
glycerin (usp-rs)
vitalizing energizing nourishing cream
lemon glycerin swabsticks
cicatrix skin protectant
siseundeusi bless bathandshampoo
banacos cica-aid centella peptide toner
instamix g emollient concentrate
deer velvet ampoule
siseundeusi bless lip
desmaquillante ojos weye
coca-glycerine control
ac clear sheet mask
hyalucollagen moisture skin
qyo qyo tangerine bright moist foam cleanser
glicerol (inn-spanish)
clapiel vita c serum
cvs pharmacy glycerin suppositorieslaxative
pororo friends smart pore guide mask pack
leaders mediu clearing strawberry pack
medpride lemon glycerin
g3s ampoule
glycerol-saline control
fedora firming intensive eye
fedora cinderella
intense care galactomyces first essence
dr.nuell mugwort shaking pack
topwin speedy enema
hwang geum-san gold hair
oasis tears pluspreservative-free lubricant eye
dr. gloderm tabrx moisture
ten ten cell
pearl rewhite transfusion dna kit
wellage double lift mask pack moisturizing hydrogel mask
oasis tears pf pluspreservative-free lubricant eye
yejimiin feminine wash jeju herb
optimel manuka forte eye gel
jnh a-clear propolis spot serum
moisture essence mist
egf-fgf ampoule
hydra lifting firming plus serum 24h
glycerin suppository
medpridelemon
ac all
wellage vital nio enrich
leader glycerinlaxative
fedora oriental spa ampoule
fedora concentrating hydro serum
tonymoly naturalth goat milk premium eye
tracys dog personal lubricant300ml
a06ag04
queen79 noble gold eyecream
the21 days hair nutrient serum
truezyme active enzyme scalp and hair
oerbeua moisture mask
elikin aqua maskpack
hahnemann sneezing
dr. gloderm time to moisture mask
tourmaline relief transfusion dna kit
remember serum
isleaf botanic shield facial barrier gelcream
tamhada synergy moisturizing mask
glycylalcohol
the cica serum plus
quick cleansing dry tissue
oasis tearslubricant eye
tamhada ii synergy anti-wrinkle face mask
ac control daily mask
natural savon 4in1 plus
placeutica wire lift face fit 365 mask
moisture hydrogel mask pack
oerbeua purifying cleanser foam
oasis tears plus
queen79 noble goldcream
oasis tears pf plus
spearmint aromatherapy mask27g
dr. a anti pollution pollustop ato
pro radiance renascent an infinite energizer
dr. gloderm tabrx moisture mask
repiel timeless line shot bio mask
h2 365 clean
hyalucollagen moisture
dr deep naturalshampoo
oerbeua heating pore cray pack
aloevera soothing gel 98%
dynarex hydrogel
aewajin derma hydrocell 24k gold serum
eye cleansing
rayderm hydrating toner
ultra moisturizing essence
atono2 oxygen baby bath and
siseundeusi luminant pack cleanser
wellage vita red injec-tion mask
moisture cream
the prestige
evereden multi-purpose healing balm
massage cream
lanbelle egf fgf ampule
amazing ampoule
pororo friends moistful mask pack
queen79 noble gold aquacream
li om fermentation form elastic care secret serum
an12 secret therapy feminine cleanser
prevention oncology mouth rinse
huitomi serum
repiel perfect fit mask lightening
oerbeua firming mask
nymphsyn intensive serum
infant glycerin laxative
keragelt
snail bee high content120ml
tamhada ii synergy moisturing mask
dr.nuell brightening mask pack
regener-eyeslite
ing ampoule
anti wrinkle effect eye
mecell rose coenzyme q10 serum mask pack
dr.serse serum
diapia 24k gold snailgel eye patch
a06ax01
ultra rejuve 7s ampoule
vision clarity eye drop
3ce liqu id eye liner black
biotrue hydration boost
regener-eyes
jena cell vl volume lift
noblesse homme refresh toner
shine control sebum regulating gel
lanbelle egf duo moisturizer
repovesolutionb
glycerol (ep monograph)
blister balmprotective lip treatment
isleaf clinic lime cleansing foam
glycerol (mart.)
pink sweet potato facial cleansing
soriso bright aqua moisture
3ce liqu id eye liner brown
perfect v lifting premium mask
derma first duo
oasis tears pf
dna couple mask
suria premium jojoba foam cleanser
querencia creamfor nail
monagra
pororo friends tong tong firming mask pack
lemon glycerin
pick me pad make-up remover
nymphsyn eye
diapia 24k gold snail firminggel mask
biotoc regen
glycerin 25%
oerbeua radiant mask
lavietox b project re set firming essence
ato pollen
sella natural baby
glycerin toner
leaders mediu glossy honey pack
stratuscare adult glycerin
pepticol 5s ampoule
2x first essence
b bind rejuvenating neoendorphin mask pack
tamnamo essential hair
atono2 oxygen bubble foam
pure hydrogel apple zone
medi hydro dp mist
dr deep bodylotion
reborncell m-clinic
formula h
anti wrinkle effect
miracle ato
adult glycerin laxative
atono2 oxygen pure bath and
wellage vital nio nutritional rich
natural cocktail pack
renovating regenerating nourishing cream
glycerin cream
perfect v lifting premium eye mask
skinbutak gold magic cleanser
amethyst reelastic transfusion dna kit
chica y chico killing star cleanser
siseundeusi ultra spot
lanbelle lanbio
sella premium natural cleansing bar
wellage wrinkle reduced vials
obeo 7way moisture
dr. b anti pollution bubble mask
pediatric glycerin laxative
saphire rehydro transfusion dna kit
scar serum
stratuscare glycerin laxative pediatric
by pharmicell lab beaucell dual hydrogel mask
miru oriental whitening ampoule
renovating regenerating serum
glyzigen single dose intimate gel
mianju mask pack
correct combo
dr.nuell true deep mosturizing
premiu serum mask
derma glide
dead skin perfect cleanser
renovating regenerating moisturizing cream
dr deep deep fresh
silkriller 3d gold pure rich gel
derm-apply
merdevie firecream
inner beauty cleansing tissue
cp medi theraphy
melatonin sheet mask
wrinkle power filling
placeutica wire lift face neck
cp medi
hair treatment premium
oerbeua shining mask
zenibell snail intensivecream
burzangmury gold treatment
perfect v lifting premium black mask
lanbelle masque de genie
glycerin mist (acgih,osha)
doobony mosrepel
truezyme baby shampooandbody wash
dr vita clinic gently vita exfoliator
o sha mpoo premium
burzangmury gold
optimel manuka dry eye drops
j9 ultra advanced intensive recovery serum
firming camellia mask
atono2 oxygen baby cream
truezyme healing multi tonic
balmers hanryeoncho scalp scooling mud pack
limpiador de ojos weye
olsubeta
cellpium shinyline
placeutica wire lift face fit amoule
la face all in one
the all medicare v pla synergy moisturizing mask
remember hydrosol double effect
non-sheet serumst
repiel timeless mela shot bio mask
hum cc
cvs pharmacy childrens glycerin suppositorieslaxative
repiel perfect fit mask soothing
sun killing grapefruit
biellee pollen whitening wrinkle time repair ampoule
glycerin (usp monograph)
derma honey mask
dr.nuell propolis real 90 ampoule
necbody all in one
black paint rubar
oerbeua smoothing mask
wellage vital nio waterlock toner
queens rose elysee concen trate dual ampoule
glycerin essence
bk cell 5days of secret aqua moisturizing
dr deep propolis synergy serum
galentic hydrogel
peptide easter
anti wrinkle eye serum
whimela shining implant
walgreens adult glycerin
colds runny nose
hydra lifting firming nourishing cream
dr deep bodylotion mini
oasis tears
lanbelle clear toner
hyalucollagen moisturizercombination skin
the banham peony 365 plus
lightening brightening moisturizing serum
oriental fermented
korean cypress hair
find bichon cleansing mask
avedana glycerinlaxative
glizigen gel intimate
hydra lifting firming fresh serum 24h
bk cell 5days of secret mystic cleansing
moran
cp bebe
danchun jade oriental herb cosmetics
la roche posay laboratoire dermatologique cicaplast defense b5 skin protectant
repiel smart hand mask milky moisture
man power pack
repovesolutiona
glycerin based gentle and effective laxative adult constipation relief
cp bebe wash
tonymoly latte art cappuccino cre am in scrub
glycerin (usp:jan)
regener-eyespro
hyalucollagen essence
oerbeua hydrating mask
naturalth goat milk moisture
clear eyes advanced dry and itchy
glizigen skin protectant
bueno anti-wrinkle peptide
mycellcare
dr joe lab vitamin c serum
or serum
elikin anti wrinkle maskpack
tangerine hand
aewajin derma hydrocell
zenibell snail intensive toner
tonymoly my sunny watery sun gel
skinbutak go young magiclotion
vitalising tonic
soriso bright aqua pack
pro radiance renascent an infinite energizer moisturizer
lemon glycerine
medi hydro dp
clenziderm therapeutic moisturizer
nymphsyn maximizer
znsp ampoule
avedana glycerin
rayderm re-generating cream
all-in-one cleanser
repiel smart foot mask ultra rich
atono2 oxygen baby soothing gel
hair regenerator
fedora concentrating hydro moisturizer
im v-tox
flex power cream
dr. althea foaming cleanser and bubble o2 mask
oerbeua soothing mask
queen79 noble gold serum
wrinkle repair sheet mask
sella classic natural gold serum
yeo danbi
glycerin, concentrated
lift eyecream
sayak
vitamin c serum
isleaf botanic shield shieldig mist
lebody face renewal
diapia adl turmeric pearl foaming cleanser
bk cell 5days of secret purity wrinkle lifting
fall in rub (love) hand
leaders mediu moisturizing jasmine pack
glycerinadult
pesticide code: 063507.
miracle of the mose hair bar
glycerin laxative
oerbeua calming mask
cizar first calming
an adc sp intensive wrinkle eye
glyzigen gel intimate
oseque cyber shine oxygen mask cleanser
guerison all in one tocx
boumatic syst x premium
absolute ppc
anti wrinkle hand essence
repiel perfect fit mask firming
refining pore clear pack
glycerol (ep impurity)
hyalucollagen moisture toner
lanbelle lans tamanu
oerbeua nourishing mask
lanbelle whitening gelmaskpack grapefruit therapy
ala-c cell clinic solution
instamix emollient concentrate ec
ruby reborn transfusion dna kit
pick me pad azulene moisture
medi hydro dp bb
glycerin (ii)
glycerol for injection

Research Excerpts

Overview

Glycerol preservation is a reliable alternative with good therapeutic outcomes in the short and interim postoperative period. Polyglycerol is a highly hydrophilic polymer with good biocompatibility and therefore represents an alternative polymer to PEG.

ExcerptReferenceRelevance
"Glycerol preservation is a reliable alternative with good therapeutic outcomes in the short and interim postoperative period. "( Intermediate outcomes of therapeutic penetrating keratoplasty for severe microbial keratitis using glycerol-preserved donor corneas during the COVID-19 pandemic.
Chaurasia, S; Das, S; Fernandes, M; Kamra, D; Mohamed, A; Murthy, SI; Roy, A; Sharma, S, 2021
)
2.28
"Polyglycerol is a highly hydrophilic polymer with good biocompatibility and therefore represents an alternative polymer to PEG."( Linear Polyglycerol for N-terminal-selective Modification of Interleukin-4.
Haag, R; Hauptstein, N; Licha, K; Lühmann, T; Meinel, L; Tully, M, 2022
)
1.59
"Glycerol is a biodiesel byproduct. "( Glycerol-assisted degradation of dibenzothiophene by Paraburkholderia sp. C3 is associated with polyhydroxyalkanoate granulation.
Ching, T; Li, QX; Ortega Ramírez, CA; Yoza, B, 2022
)
3.61
"Glycerol is an important quality indicator for foodstuffs. "( Quantitative determination of glycerol concentration in aqueous glycerol solutions by metamaterial-based terahertz spectroscopy.
Liang, W; Zhang, C; Zhou, Q; Zuo, J, 2022
)
2.45
"Glycerol is a potential sustainable feedstock, and biorefining processes to convert glycerol into value-added chemicals have been developed over the past decade. "( Identification of a Novel Alditol Oxidase from Thermopolyspora flexuosa with Potential Application in D-Glyceric Acid Production.
Chen, Z; Fei, K; Gao, XD; Hu, Y; Li, Z; Xu, X, 2022
)
2.16
"Glycerol ester (GE) is a kind of important lipid in milk, which varies greatly depending on many factors. "( SWATH-MS2&1: Development and Validation of a Pseudotargeted Lipidomics Method for the Analysis of Glycerol Esters in Milk.
Chen, X; Li, R; Liu, Y; Shi, J; Sun, X; Xu, YJ; Zhang, S, 2022
)
2.38
"Glycerol is a well-recognized substrate for new glucose production via gluconeogenesis in the liver. "( Glycerol's contribution to lactate production outside of a glucose intermediate in fasting humans.
Shah, A; Su, X; Wang, Y; Wondisford, FE, 2022
)
3.61
"Glycerol is a byproduct from the biodiesel industry that can be biotransformed by Escherichia coli to high added-value products such as succinate under aerobic conditions. "( Metabolomics for the design of new metabolic engineering strategies for improving aerobic succinic acid production in Escherichia coli.
Bolivar, J; Cabrera, G; Cantero, D; Goodacre, R; Hollywood, KA; Lloyd, JR; Muhamadali, H; Soto, Z; Valle, A; Xu, Y, 2022
)
2.16
"Glycerol is a compatible solute and a stabiliser of proteins."( The role of the glycerol transporter channel Fps1p in cellular proteostasis during enhanced proteotoxic stress.
Das, E; Roy, I; Sethi, R; Singh, K, 2022
)
1.79
"Glycerol is an ideal carbon source for large-scale fermentation due to its low cost and favorable maintenance of the fermentation process."( Development of a Glycerol-Inducible Expression System for High-Yield Heterologous Protein Production in Bacillus subtilis.
Chen, Q; Cui, W; Han, L; Luo, J; Zhou, Z, 2022
)
1.78
"Glycerol is an ideal co-substrate for xylitol production with Kluyveromyces marxianus. "( Improving glycerol utilization during high-temperature xylitol production with Kluyveromyces marxianus using a transient clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 system.
Chang, K; Huang, Y; Li, F; Li, P; Liu, Y; Ren, L; Wang, Y; Xia, Y; Xu, D; Zhang, B, 2022
)
2.57
"Glycerol is a viscous liquid that has been reported to increase the speed of sound of phantoms."( Characterizing Viscoelastic Polyvinyl Alcohol Phantoms for Ultrasound Elastography.
Bisht, SR; Kakkar, M; Marapureddy, SG; Mercado-Shekhar, KP; Paul, A; Sharma, A; Thareja, P, 2023
)
1.63
"Glycerol is an abundant liquid waste from bioenergy plants with a projected volume of 6 million tons by 2025, accounting for about 10% of biodiesel and 2.5% of bioethanol yields."( Biocatalytic gateway to convert glycerol into 3-hydroxypropionic acid in waste-based biorefineries: Fundamentals, limitations, and potential research strategies.
Akor, J; Akter, S; Qi, X; Ragauskas, AJ; Rupani, PF; Zabed, HM; Zhang, C; Zhang, Y; Zhao, M,
)
1.14
"Glycerol is a symmetrical, small biomolecule with high flexibility in molecular conformations. "(
Aono, R; Ding, W; Dohi, H; Nishida, Y; Uzawa, H, 2023
)
2.35
"Glycerol is a key metabolite for lipid accumulation in insulin-sensitive tissues. "( Increased Aquaporin-7 Expression Is Associated with Changes in Rat Brown Adipose Tissue Whitening in Obesity: Impact of Cold Exposure and Bariatric Surgery.
Becerril, S; Catalán, V; Cienfuegos, JA; da Silva, IV; Frühbeck, G; Gómez-Ambrosi, J; Hernández-Pardos, AW; Méndez-Giménez, L; Moncada, R; Ramírez, B; Rodríguez, A; Soveral, G; Valentí, V, 2023
)
2.35
"Glycerol is a substrate for gluconeogenesis and fatty acid esterification in the liver, processes which are upregulated in obesity and may contribute to excess fat accumulation. "( Glycerol as a precursor for hepatic de novo glutathione synthesis in human liver.
Cree, MG; Derderian, SC; Finn, E; Fuller, KNZ; Inge, TH; Jin, ES; Lovell, MA; Malloy, CR; Reyes, YG; Schoen, JA; Sharma, G, 2023
)
3.8
"CDP-glycerol is a nucleotide-diphosphate-activated version of glycerol. "( A Cell-Free Multi-enzyme Cascade Reaction for the Synthesis of CDP-Glycerol.
Alberto Alcalá-Orozco, E; Fiebig, T; Grote, V; Klamt, S; Reichl, U; Rexer, T, 2023
)
1.7
"Glycerol is a cryoprotectant used widely for the cryopreservation of animal sperm, but it is linked to a decrease in fertility. "( Is glycerol a good cryoprotectant for sperm cells? New exploration of its toxicity using avian model.
Blesbois, E; Brillard, JP; Carvalho, AV; Chen, LR; Gérard, N; Grasseau, I; Lin, HH; Mermillod, P; Reynaud, K, 2023
)
2.97
"Glycerol is a cryoprotectant widely used in the freezing of mammalian semen, but no study has demonstrated its optimum concentration and the appropriate exposure time for equine species."( Freezing of equine semen is influenced by exposure time and concentration of the cryoprotectant glycerol.
Acosta, IB; Corcini, CD; Filho, JS; Fracaro, PL; Hartwig, FP; Rosa Curcio, BD; Souza Gatti, NL; Varela Junior, AS,
)
1.79
"Glycerol (Gly) is a natural, low-cost, trifunctional monomer, with a production expected to grow significantly, and thus an excellent candidate for the synthesis of hyperbranched polyesters for pharmaceutical and biomedical applications."( Polyglycerol Hyperbranched Polyesters: Synthesis, Properties and Pharmaceutical and Biomedical Applications.
Bikiaris, DN; Boccaccini, AR; Christodoulou, E; Kontonasaki, E; Liverani, L; Nakiou, EA; Zamboulis, A, 2019
)
1.79
"Glycerol is a by-product produced from biodiesel, fatty acid, soap and bioethanol industries. "( A review of recent developments on kinetics parameters for glycerol electrochemical conversion - A by-product of biodiesel.
Abnisa, F; Aroua, MK; Cognet, P; Daud, WAW; Lee, CS; Pérès, Y; Rahim, SANM, 2020
)
2.24
"Glycerol is a byproduct of biodiesel production and is generated in large amounts, which has resulted in an increased interest in its valorization. "( Preparative-Scale Enzymatic Synthesis of rac-Glycerol-1-phosphate from Crude Glycerol Using Acid Phosphatases and Phosphate.
Ditrich, K; Faber, K; Hall, M; Staśko, M; Tasnádi, G, 2020
)
2.26
"Glycerol kinase (GK) is a key enzyme of glycerol metabolism. "( Affinity shift of ATP upon glycerol binding to a glycerol kinase from the hyperthermophilic archaeon Thermococcus kodakarensis KOD1.
Angkawidjaja, C; Hokao, R; Kanaya, S; Katsumi, R; Koga, Y; Matsumura, H; Takano, K, 2020
)
2.3
"Glycerol is a by-product of biodiesel, and it has a great application prospect to be transformed to synthesize high value-added compounds. "( Engineering of glycerol utilization in Pseudomonas chlororaphis GP72 for enhancing phenazine-1-carboxylic acid production.
Feng, TT; Hu, HB; Liu, WH; Song, C; Wang, W; Yue, SJ; Zhang, CH; Zhang, XH; Zheng, YF, 2020
)
2.35
"Glycerol is a co-solvent for water extraction that has been shown to be highly effective for obtaining polyphenol extracts under atmospheric conditions. "( Glycerol as Alternative Co-Solvent for Water Extraction of Polyphenols from
Huamán-Castilla, NL; Mariotti-Celis, MS; Martínez-Cifuentes, M; Pérez-Correa, JR, 2020
)
3.44
"Glycerol is an organic waste material that can be used for the production of microbial biomass, consequently providing valuable biocatalysts promoting the generation of electrical current in microbial fuel cells (MFCs). "( Application of organic waste glycerol to produce crude extracts of bacterial cells and microbial hydrogenase-the anode enzymes of bio-electrochemical systems.
Blbulyan, S; Dziameshka, V; Poladyan, A; Semashko, T; Trchоunian, A; Zhukouskaya, L, 2020
)
2.29
"Glycerol is a natural substance, inexpensive and non-toxic, and it is a principal by-product of biodiesel industry resulting from the transesterification process."( Glycerol and Glycerol-Based Deep Eutectic Mixtures as Emerging Green Solvents for Polyphenol Extraction: The Evidence So Far.
Lalas, S; Makris, DP, 2020
)
2.72
"Glycerol is a common by-product of industrial biodiesel syntheses. "( An overview on the conversion of glycerol to value-added industrial products via chemical and biochemical routes.
da Silva, RM; Gomes E Silva, NC; Lima, PJM; Neto, CACG; Nunes, YL; Sousa Dos Santos, JC; Souza, JEDS, 2022
)
2.45
"Glycerol is a clinical biomarker of lipolysis that is mainly produced by adipose tissues. "( DietSee: An on-hand, portable, strip-type biosensor for lipolysis monitoring via real-time amperometric determination of glycerol in blood.
Degrelle, SA; Delile, S; Denechaud, PD; Moog, S; Moro, C; Mouisel, E; O'Gorman, D; Torre, C, 2021
)
2.27
"Glycerol is an attractive raw material for the production of useful chemicals using microbial cells. "(
Hirasawa, T; Kawai, K; Kondo, A; Orishimo, R; Shirai, T; Yuzawa, T, 2021
)
2.06
"Glycerol is an abundant byproduct of biodiesel production that has significant industrial value and can be converted into dihydroxyacetone (DHA). "( The first in-depth exploration of the genome of the engineered bacterium, Gluconobacter thailandicus.
Ali, A; Liu, C; Liu, X; Liu, Y; Zhang, P, 2022
)
2.16
"Glycerol is a humectant, which reduces water activity when added to the diet. "( Palatability, digestibility, and metabolizable energy of dietary glycerol in adult cats.
Kessler, AM; Machado, GS; Marx, FR; Pezzali, JG; Trevizan, L, 2017
)
2.14
"Glycerol is a common fuel considered for bioenergy applications. "( Hybrid molecular/enzymatic catalytic cascade for complete electro-oxidation of glycerol using a promiscuous NAD-dependent formate dehydrogenase from Candida boidinii.
Abdellaoui, S; Atanassov, P; Matanovic, I; Minteer, SD; Seow Chavez, M; Stephens, AR, 2017
)
2.13
"Glycerol is a by-product of many industrial processes and huge amounts of it are generated in the form of waste, thereby necessitating a search for the method of its disposal. "( Valorization of waste glycerol for the production of poly (3-hydroxybutyrate) and poly (3-hydroxybutyrate-co-3-hydroxyvalerate) copolymer by Cupriavidus necator and extraction in a sustainable manner.
Gahlawat, G; Soni, SK, 2017
)
2.21
"Glycerol is a byproduct during biodiesel production. "( [Improving β-carotene production in Escherichia coli by metabolic engineering of glycerol utilization pathway].
Dong, Y; Hu, K; Li, Q; Li, X; Zhang, X, 2017
)
2.12
"Glycerol is a promising carbon source for bio-production and is particularly attractive because it is produced in excess as a biodiesel byproduct. "( Optimal
Ohashi, S; Shimizu, H; Toya, Y, 2018
)
1.92
"Glycerol is a main co-product of biodiesel production. "( Bacterial glycerol oxidation coupled to sulfate reduction at neutral and acidic pH.
Almeida, PF; Dimitrov, MR; Liebensteiner, MG; Quintella, CM; Sánchez-Andrea, I; Santos, SC; Stams, AJM; van Gelder, AH, 2018
)
2.33
"Polyglycerol (PG) is a well-known cosmetic ingredient and important precursor for the synthesis of a variety of cosmetic ingredients, such as surfactants, emulsifiers, and conditioning agents for hair and skin. "( Designing new functional cosmetic ingredients from polyglycerol, a versatile bio-based platform for improved sustainability.
Fevola, MJ; Sun, FC; York, SE,
)
0.94
"Glycerol, which is an inevitable by-product of biodiesel production, is an ideal carbon source for the production of carotenoids due to its low price, good availability and chemically reduced status, which results in a low requirement for additional reducing equivalents. "( Construction of an alternative glycerol-utilization pathway for improved β-carotene production in Escherichia coli.
Bi, CH; Guo, JY; Hu, KL; Li, QY; Zhang, XL, 2018
)
2.21
"Glycerol kinase (GK) is a multifunctional enzyme located at the interface of carbohydrate and fat metabolism. "( The ATP-stimulated translocation promoter (ASTP) activity of glycerol kinase plays central role in adipogenesis.
Dipple, KM; Nazarian, R; Parr, LS; Rahib, L; Sriram, G, 2018
)
2.16
"Glycerol is an alternative substrate providing a variety of economic and metabolic advantages."( Fed-batch production of l-tryptophan from glycerol using recombinant Escherichia coli.
Sprenger, GA; Trachtmann, N; Tröndle, J; Weuster-Botz, D, 2018
)
1.47
"Glycerol is a major byproduct of biodiesel production, and enzymes that oxidize this compound have been long sought after. "( Structure-Based Engineering of Phanerochaete chrysosporium Alcohol Oxidase for Enhanced Oxidative Power toward Glycerol.
Binda, C; de Vasconcellos, SP; Dijkman, WP; Fraaije, MW; Mattevi, A; Nguyen, QT; Romero, E, 2018
)
2.14
"Glycerol is an inexpensive and renewable resource for fuels and chemicals production and is available as a byproduct of biodiesel production."( Homoethanol Production from Glycerol and Gluconate Using Recombinant
Fan, Z; Huang, H; Kasuga, T; Li, S; Lin, H; Tao, W; Walters, E; Wang, Y, 2019
)
1.53
"Glycerol is an attractive substrate for microbial fermentations due to its higher degree of reduction compared to glucose. "( Involvement of the external mitochondrial NADH dehydrogenase Nde1 in glycerol metabolism by wild-type and engineered Saccharomyces cerevisiae strains.
Aßkamp, MR; Klein, M; Nevoigt, E, 2019
)
2.19
"Glycerol is an interesting alternative carbon source in industrial bioprocesses due to its higher degree of reduction per carbon atom compared to sugars. "( Glycerol as a substrate for Saccharomyces cerevisiae based bioprocesses - Knowledge gaps regarding the central carbon catabolism of this 'non-fermentable' carbon source.
Klein, M; Nevoigt, E; Xiberras, J, 2019
)
3.4
"Glycerol is a major by-product in bioethanol fermentation by the yeast Saccharomyces cerevisiae, and decreasing glycerol formation for increased ethanol yield has been a major research effort in the bioethanol field. "( 3' Truncation of the GPD1 promoter in Saccharomyces cerevisiae for improved ethanol yield and productivity.
Ding, WT; Liu, JJ; Zhang, GC, 2013
)
1.83
"Glycerol is an important compound participating in the lipid metabolism and energy conversion of body. "( An improved GC-MS method in determining glycerol in different types of biological samples.
Shen, Y; Xu, Z, 2013
)
2.1
"Glycerol is an attractive feedstock for biofuels production since it is generated as a major byproduct in biodiesel industry; therefore, we investigated the conversion of glycerol to bioethanol using E."( Development of glycerol-utilizing Escherichia coli strain for the production of bioethanol.
Choi, HS; Kim, SW; Lee, SJ; Park, C; Thapa, LP; Yoo, HY, 2013
)
1.46
"Hyperglycerolemia is a very rare genetic disorder caused by glycerol kinase deficiency. "( Pseudo-hypertriglyceridaemia or hyperglycerolemia?
Arrobas-Velilla, T; Cañizares Díaz, I; Cruz Mengibar, MC; Fabiani-Romero, F; Gómez-Gerique, JA; Mondéjar-García, R; Orive de Diego, A,
)
0.92
"Glycerol is a major by-product of industrial ethanol production and its formation consumes up to 4 % of the sugar substrate. "( Engineering of the glycerol decomposition pathway and cofactor regulation in an industrial yeast improves ethanol production.
Guo, Z; Shi, G; Tang, Y; Zhang, L, 2013
)
2.16
"Glycerol kinase is a highly conserved enzyme that functions at the interface of lipid synthesis and carbohydrate metabolism."( Reduced glycerol incorporation into phospholipids contributes to impaired intra-erythrocytic growth of glycerol kinase knockout Plasmodium falciparum parasites.
Coetzer, TL; Naidoo, K, 2013
)
1.55
"Glycerol is an important renewable feedstock as it is the major by-product of the biodiesel production process; here we present an alternative way to convert this low-cost substrate into value-added products, such as erythritol."( Enhanced production of erythritol by Yarrowia lipolytica on glycerol in repeated batch cultures.
Furgała, J; Mirończuk, AM; Rakicka, M; Rymowicz, W, 2014
)
1.37
"Glycerol is an endogenous substance that is on the World Anti-Doping Agency's list of prohibited threshold substances due to its potential use as a plasma volume expansion agent. "( A population study of urine glycerol concentrations in elite athletes competing in North America.
Eichner, D; Kelly, BN; Madsen, M; Nair, V; Sharpe, K,
)
1.87
"Glycerol is an effective carbon source for the production of scl- and mcl-polyhydroxyalkanoates (PHAs) by Pseudomonas spp. "( Production of filmable medium-chain-length polyhydroxyalkanoates produced from glycerol by Pseudomonas mediterranea.
Catara, AF; Damigella, A; Fragalà, M; Mineo, PG; Palmeri, R; Pappalardo, F; Rescifina, A, 2014
)
2.07
"Glycerol is a small molecule that serves as an important intermediate between carbohydrate and lipid metabolism."( Metabolic impact of the glycerol channels AQP7 and AQP9 in adipose tissue and liver.
Lebeck, J, 2014
)
1.43
"Glycerol is an attractive carbon source for biofuel production since it is cheap and abundant due to the increasing demand for renewable and clean energy sources, which includes production of biodiesel. "( Metabolic engineering of Escherichia coli to enhance hydrogen production from glycerol.
Maeda, T; Tran, KT; Wood, TK, 2014
)
2.07
"Glycerol is a promising carbon source used to anaerobically produce rhamnolipid."( Optimization of culture medium for anaerobic production of rhamnolipid by recombinant Pseudomonas stutzeri Rhl for microbial enhanced oil recovery.
Han, S; Hao, J; Liang, X; Mandlaa, M; Shi, R; Zhang, Y; Zhao, F, 2014
)
1.12
"Glycerol is a dietary supplement capable mimicking CR by shifting metabolism away from glycolysis and towards oxidative phosphorylation."( Glycerol extends lifespan of Brachionus manjavacas (Rotifera) and protects against stressors.
Johnston, RK; Snell, TW, 2014
)
2.57
"Glycerol is a naturally occurring substance; therefore, the threshold is set as 1.0 mg/mL in the WADA technical document (WADA TD2013DL)."( Possibility of analytical finding of glycerol caused by self-catheterization in doping control.
Kageyama, S; Nishitani, Y; Okano, M,
)
1.13
"Glycerol is an important commodity chemical."( Photosynthetic production of glycerol by a recombinant cyanobacterium.
Branco dos Santos, F; Du, W; Hellingwerf, KJ; Lu, X; Savakis, P; Tan, X, 2015
)
1.43
"Glycerol is an inexpensive and abundant source for biofuel production on a large scale. "( Beneficial knockouts in Escherichia coli for producing hydrogen from glycerol.
Maeda, T; Sanchez-Torres, V; Tran, KT; Wood, TK, 2015
)
2.09
"Glycerol mixture is a viscous, long-lasting solution preferentially used by Japanese ESD experts."( High-pressure injection of glycerol with HybridKnife for ESD is feasible and increases the ease and speed of the procedure: an in vivo study in pigs and first use in human.
Carrier, P; Couquet, CY; Debette-Gratien, M; Jacques, J; Le-Sidaner, A; Legros, R; Loustaud-Ratti, V; Sautereau, D; Tabouret, T; Valgueblasse, V, 2015
)
1.44
"Glycerol is a cheap and widely used carbon source that can be applied in PHB production process."( Improved productivity of poly (3-hydroxybutyrate) (PHB) in thermophilic Chelatococcus daeguensis TAD1 using glycerol as the growth substrate in a fed-batch culture.
Cui, B; Huang, S; Xu, F; Zhang, R; Zhang, Y, 2015
)
1.35
"Glycerol is an interesting feedstock for biomaterials such as biofuels and bioplastics because of its abundance as a by-product during biodiesel production. "( Production of polyhydroxybutyrate and alginate from glycerol by Azotobacter vinelandii under nitrogen-free conditions.
Hashimoto, W; Murata, K; Yamamoto, M; Yoneyama, F, 2015
)
2.11
"Glycerol is a naturally occurring polyol in the human body, essential for several metabolic processes. "( Systematic analysis of glycerol: colourimetric screening and gas chromatography-mass spectrometric confirmation.
Aquino Neto, FR; Cavalcante, KM; de Oliveira, ML; Pereira, HM; Sardela, VF; Scalco, FB; Silva, DR; Simoni, RE, 2015
)
2.17
"Glycerol is a by-product in the biodiesel production process and considered as one of the prospective carbon sources for microbial fermentation including lactic acid fermentation, which has received considerable interest due to its potential application. "( L-Lactic acid production from glycerol coupled with acetic acid metabolism by Enterococcus faecalis without carbon loss.
Abdel-Rahman, MA; Bonkohara, K; Iwamoto, M; Murakami, N; Noguchi, T; Oba, M; Sakai, K; Shimoda, M; Sonomoto, K; Tashiro, Y; Zendo, T, 2016
)
2.17
"Glycerol is a key yeast metabolite in winemaking because it contributes to improve the organoleptic properties of wine. "( RNA binding protein Pub1p regulates glycerol production and stress tolerance by controlling Gpd1p activity during winemaking.
Aranda, A; Matallana, E; Orozco, H; Picazo, C; Sepúlveda, A, 2016
)
2.15
"Glycerol is a major by-product of the biodiesel industry. "( Metabolic networks to generate pyruvate, PEP and ATP from glycerol in Pseudomonas fluorescens.
Alhasawi, A; Appanna, VD; Thomas, SC, 2016
)
2.12
"Glycerol is an important cardiac energy production substrate, especially during exercise, in conjunction with fatty acids and glucose."( The Effect of a High-Protein Diet and Exercise on Cardiac AQP7 and GLUT4 Gene Expression.
Karaca, A; Palabiyik, O; Sipahi, T; Taştekin, E; Tokuç, B; Vardar, SA; Yamasan, BE, 2016
)
1.16
"Glycerol is an attractive feedstock for bioenergy and bioconversion processes but its use in microbial fuel cells (MFCs) for electrical energy recovery has not been investigated extensively. "( Glycerol-fed microbial fuel cell with a co-culture of Shewanella oneidensis MR-1 and Klebsiella pneumonae J2B.
Jeon, BH; Kim, C; Kim, JR; Lee, CR; Song, YE, 2016
)
3.32
"Glycerol is a key compound for the understanding of the microbiology of hypersaline environments. "( Glycerol metabolism in hypersaline environments.
Oren, A, 2017
)
3.34
"Glycerol is an ideal candidate due to its availability and low cost."( Engineering an Obligate Photoautotrophic Cyanobacterium to Utilize Glycerol for Growth and Chemical Production.
Atsumi, S; Kanno, M, 2017
)
1.41
"Glycerol is a common cryoprotective agent used in cryopreservation protocols but this agent is toxic at high concentrations."( The effect of additive compounds on glycerol-induced damage to human chondrocytes.
Elliott, JAW; Hahn, J; Jomha, NM; Korbutt, GS; Laouar, L, 2017
)
1.45
"Glycerol is an important resource for production of value-added bioproducts due to its large availability from the biodiesel industry as a by-product. "( Efficient anaerobic production of succinate from glycerol in engineered Escherichia coli by using dual carbon sources and limiting oxygen supply in preceding aerobic culture.
Huang, B; Li, Q; Li, Z; Wu, H; Ye, Q, 2017
)
2.15
"Glycerol is a trihydroxy alcohol that has been included for many years in topical dermatological preparations. "( Glycerol and the skin: holistic approach to its origin and functions.
Darlenski, R; Fluhr, JW; Surber, C, 2008
)
3.23
"Glycerol is an important byproduct of bioethanol and biodiesel production processes. "( Glycerol fermentation by (open) mixed cultures: a chemostat study.
Kleerebezem, R; Poldermans, R; Temudo, MF; van Loosdrecht, MC, 2008
)
3.23
"Glycerol proved to be a better cryoprotectant than DMA in terms of maintaining motility, plasma membrane integrity and high mitochondrial membrane potential; however, there was no difference between cryoprotectants with regards to their ability to prevent chromatin relaxation."( Individual variability in post-thaw sperm survival in a captive koala population.
Holt, WV; Johnston, SD; Nicolson, V; Pyne, M; Zee, YP, 2009
)
1.07
"Glycerol is an important osmolyte when Dunaliella survive in various salt environments, and G3pdh is a key enzyme in glycerol metabolism."( Effects of salinity changes on the growth of Dunaliella salina and its isozyme activities of glycerol-3-phosphate dehydrogenase.
Chen, H; Jiang, JG; Wu, GH, 2009
)
1.29
"Glycerol is an attractive feedstock for biofuels since it accumulates as a byproduct during biodiesel operations; hence, here we consider converting glycerol to hydrogen using the formate hydrogen lyase system of Escherichia coli which converts pyruvate to hydrogen. "( An evolved Escherichia coli strain for producing hydrogen and ethanol from glycerol.
Hu, H; Wood, TK, 2010
)
2.03
"Glycerol is a by-product of biodiesel produced by transesterification and is contained in the glycerol phase together with many other materials such as soaps, remaining catalyst, water, and esters formed during the process. "( Treatment of glycerol phase formed by biodiesel production.
Hájek, M; Skopal, F, 2010
)
2.17
"Glycerol is a byproduct produced in great quantity by biodiesel industries in transesterification reactions. "( Theoretical investigation of the interaction of glycerol with aluminum and magnesium phthalocyanines.
Camargo, AJ; Camargo, LT; Napolitano, HB; Pérez, CN; Silva, VH, 2010
)
2.06
"Glycerol is an integral component of cell membranes."( [Use of intracerebral microdialysis in severe traumatic brain injury].
Abe, Y; Kawai, N; Kawakita, K; Kuroda, Y; Tamiya, T; Yano, T, 2010
)
1.08
"Glycerol is an agro-industrial residue generated in high amounts during the biodiesel production. "( Kinetic analysis of a Saccharomyces cerevisiae strain adapted for improved growth on glycerol: Implications for the development of yeast bioprocesses on glycerol.
Gorret, N; Guillouet, SE; Lesage, J; Ochoa-Estopier, A, 2011
)
2.04
"Glycerol is a residue generated during biodiesel production and represents around 10% of the total product output. "( Generation of an evolved Saccharomyces cerevisiae strain with a high freeze tolerance and an improved ability to grow on glycerol.
Compagno, C; Galafassi, S; Merico, A; Popolo, L; Ragni, E, 2011
)
2.02
"Glycerol is a major by-product from biodiesel production, and developing new uses for glycerol is imperative to overall economics and sustainability of the biodiesel industry. "( Production of arabitol from glycerol: strain screening and study of factors affecting production yield.
Ju, LK; Koganti, S; Kuo, TM; Kurtzman, CP; Smith, N, 2011
)
2.11
"Glycerol is a major by-product of ethanol fermentation by Saccharomyces cerevisiae and typically 2-3% of the sugar fermented is converted to glycerol. "( Elimination of glycerol and replacement with alternative products in ethanol fermentation by Saccharomyces cerevisiae.
Bauer, FF; Divol, B; Jain, VK; Prior, BA, 2011
)
2.16
"Glycerol is a by-product of biodiesel production. "( Tartronate semialdehyde reductase defines a novel rate-limiting step in assimilation and bioconversion of glycerol in Ustilago maydis.
Ji, L; Koh, CM; Liu, Y; Sun, L, 2011
)
2.03
"Raw glycerol is a byproduct of biodiesel production that currently has low to negative value for biodiesel producers. "( Purification and structural characterization of fengycin homologues produced by Bacillus subtilis LSFM-05 grown on raw glycerol.
Alves, OL; de Faria, AF; Durrant, LR; Eberlin, MN; Garcia, JS; Grossman, MJ; Silva, ÍS; Stéfani, D; Vaz, BG, 2011
)
1.14
"Glycerol is a primary energy source for heterotrophic haloarchaea and a major component of "salty" biodiesel waste. "( Activity and transcriptional regulation of bacterial protein-like glycerol-3-phosphate dehydrogenase of the haloarchaea in Haloferax volcanii.
Martin, JH; Maupin-Furlow, JA; Rawls, KS, 2011
)
2.05
"Glycerol is an effective reference material for NMR fecal fat analysis."( Glycerol as a reference material for fecal fat quantitation using low-resolution time domain ¹H NMR spectroscopy.
Corsetti, JP; Lefevre, BH; Ryan, D; Sakpal, M; Sterry, J, 2011
)
3.25
"Glycerol metabolism is a typical biological oxidoreductive reaction. "( Influence of blocking of 2,3-butanediol pathway on glycerol metabolism for 1,3-propanediol production by Klebsiella oxytoca.
Guo, Q; Li, J; Li, Y; Wang, X; Yang, G; Zhang, G, 2012
)
2.07
"Glycerol is a by-product generated in large amounts during the production of biofuels. "( Production of erythritol and mannitol by Yarrowia lipolytica yeast in media containing glycerol.
Gładkowski, W; Rywińska, A; Tomaszewska, L, 2012
)
2.04
"Glycerol is an important osmolyte for Dunaliella salina to resist osmotic stress."( Comparative analysis on the key enzymes of the glycerol cycle metabolic pathway in Dunaliella salina under osmotic stresses.
Chen, H; Jiang, JG; Lu, Y, 2012
)
1.36
"Glycerol is an ideal building block for the synthesis of complex molecules, because it is inexpensive and highly functionalized. "( The efficient desymmetrization of glycerol using scaffolding catalysis.
Giustra, ZX; Tan, KL, 2013
)
2.11
"Glycerol is an attractive substrate for biohydrogen production because, in theory, it can produce 3 mol of hydrogen per mol of glycerol. "( Biohydrogen production by dark fermentation of glycerol using Enterobacter and Citrobacter Sp.
Constanti, M; Maru, BT; Medina, F; Stchigel, AM; Sueiras, JE,
)
1.83
"Glycerol is a preferable carbon source compared to glucose for Y. lipolytica."( Transcriptional repression by glycerol of genes involved in the assimilation of n-alkanes and fatty acids in yeast Yarrowia lipolytica.
Fukuda, R; Horiuchi, H; Iwama, R; Kobayashi, S; Mori, K; Ohta, A, 2013
)
1.4
"Glycerol is a marker of cellular membrane breakdown."( Delayed increase in extracellular glycerol with post-traumatic electrographic epileptic activity: support for the theory that seizures induce secondary injury.
Becker, DP; Bergsneider, M; Glenn, T; Hovda, DA; Kelly, D; Martin, NA; Nenov, V; Vespa, P, 2002
)
1.32
"Glycerol dehydrase is an enzyme that catalyzes dehydration of glycerol into beta-propionaldehyde. "( Determination of vitamin B12 using the enzyme glycerol dehydrase.
Fukuda, M; Hioki, R; Iwama, M; Kii, K; Nirasawa, M; Nishikawa, N; Ryugo, H; Yamada, K; Yamada, S, 2004
)
2.02
"Glycerol is a key compound in the regulation of several metabolic pathways in Saccharomyces cerevisiae. "( Yeast orthologues associated with glycerol transport and metabolism.
Lucas, C; Neves, L; Oliveira, R, 2004
)
2.05
"Glycerol preservation is an effective method for long-term preservation of skin allografts and has a potential use in preserving arterial allografts. "( Morphological and functional alterations in glycerol preserved rat aortic allografts.
Borstlap, J; Fahner, PJ; Idu, MM; Legemate, DA; Pfaffendorf, M; van Gulik, TM; van Marle, J; Vanbavel, E, 2004
)
2.03
"Glycerol is considered to be a marker of cell membrane degradation and thus cellular lysis. "( Association between elevated brain tissue glycerol levels and poor outcome following severe traumatic brain injury.
Alves, OL; Bullock, R; Clausen, T; Doppenberg, E; Reinert, M; Zauner, A, 2005
)
2.04
"Glycerol is an attractive chemical agent for achieving dramatic reductions in tissue turbidity, but its net effects on healthy tissue are not fully understood."( Influence of glycerol on the mechanical reversibility and thermal damage susceptibility of collagenous tissues.
Humphrey, JD; Wells, PB; Yeh, AT, 2006
)
1.42
"Glycerol is an important by-product from the increasing European bio-diesel production."( On-line near infrared monitoring of glycerol-boosted anaerobic digestion processes: evaluation of process analytical technologies.
Esbensen, KH; Holm-Nielsen, JB; Lomborg, CJ; Oleskowicz-Popiel, P, 2008
)
1.34
"Glycerol is a by-product obtained during the production of biodiesel."( Pyrolysis of glycerol for the production of hydrogen or syn gas.
Bakhshi, NN; Dalai, AK; Valliyappan, T, 2008
)
1.44
"Glycerol is an attractive renewable building block for the synthesis of di- and triglycerols, which have numerous applications in the cosmetic and pharmaceutical industries. "( Glycerol etherification over highly active CaO-based materials: new mechanistic aspects and related colloidal particle formation.
Erné, BH; Kuipers, BW; Meeldijk, JD; Ruppert, AM; Weckhuysen, BM, 2008
)
3.23
"Glycerol is a renewable resource for it is formed as a byproduct during biodiesel production. "( Development of a new bioprocess for production of 1,3-propanediol I.: Modeling of glycerol bioconversion to 1,3-propanediol with Klebsiella pneumoniae enzymes.
Németh, A; Sevella, B, 2008
)
2.01
"Glycerol is a nonprotein calorie source that can be autoclaved with amino acids and stored."( Use of glycerol in peripheral parenteral nutrition.
Fairfull-Smith, RJ; Freeman, JB; Stoski, D, 1982
)
1.44
"Glycerol is a potent osmotic dehydrating agent with additional effects on brain metabolism. "( Glycerol: a review of its pharmacology, pharmacokinetics, adverse reactions, and clinical use.
Frank, MS; Hilty, MD; Nahata, MC,
)
3.02
"Glycerol solutions are a safe, effective means to achieve a long-term state of hyperhydration. "( Glycerol-induced hyperhydration: its effects on fluid compartments in the rat.
Lyons, TP; Riedesel, ML, 1993
)
3.17
"Glycerol is an irritant of colonic mucosa."( Intracolonic injection of glycerol: a model for abdominal pain in irritable bowel syndrome?
Bueno, L; Camman, F; Delvaux, M; Fioramonti, J; Frexinos, J; Louvel, D; Staumont, G, 1996
)
1.32
"The glycerol preservation is a method with low costs and has practical advantages such as antibacterial and virucidal effects."( Morphology of glycerol-preserved human cadaver skin.
du Pont, JS; Hoekstra, MJ; Kamperdijk, EW; Richters, CD; van Baare, J, 1996
)
1.14
"Glycerol functions as an intracellular osmolyte in S."( Expression of bacterial mtlD in Saccharomyces cerevisiae results in mannitol synthesis and protects a glycerol-defective mutant from high-salt and oxidative stress.
Bartiss, A; Chaturvedi, V; Wong, B, 1997
)
1.23
"Glycerol (Gly) is a hydrophilic, absorbable, and energy-rich solute that could make water absorption more efficient. "( Enhancement of intestinal water absorption and sodium transport by glycerol in rats.
Fisher, SE; Sia, MC; Wapnir, RA, 1996
)
1.97
"Glycerol is a naturally occurring 3-carbon alcohol in the human body. "( Glycerol. Biochemistry, pharmacokinetics and clinical and practical applications.
Griffin, SE; Robergs, RA, 1998
)
3.19
"Glycerol is a known agent in the therapy of chronic tic douloureux. "( Glycerol gangliotomy of the second dorsal cervical root in rats: an experimental study to evaluate a minimal invasive approach for the treatment of the chronic cervicogenic headache.
Jansen, J; Kolle, M; Ludwig, HC, 1998
)
3.19
"Glycerol is a low molecular weight solute (MW 92 D) that can be used as an osmotic agent in continuous ambulatory peritoneal dialysis (CAPD). "( Peritoneal transport characteristics with glycerol-based dialysate in peritoneal dialysis.
de Waart, DR; Krediet, RT; Smit, W; Struijk, DG,
)
1.84
"Glycerol is a small and simple molecule produced in the breakdown of glucose, proteins, pyruvate, triacylglycerols and other glycerolipid, as well as release from dietary fats. "( Glycerol: a neglected variable in metabolic processes?
Brisson, D; Gaudet, D; Hudson, TJ; St-Pierre, J; Vohl, MC, 2001
)
3.2
"Glycerol acts as a plasticizer and thermal stabilizer of the proteins and increases the range of temperatures (80-175 degrees C) at which the material can be processed."( Processability of cottonseed proteins into biodegradable materials.
Crespy, A; Ferry, L; Grevellec, J; Marquié, C; Vialettes, V, 2001
)
1.03
"Glycerol is a major fermentation product of Saccharomyces cerevisiae that contributes to the sensory character of wine. "( Decreasing acetic acid accumulation by a glycerol overproducing strain of Saccharomyces cerevisiae by deleting the ALD6 aldehyde dehydrogenase gene.
de Barros Lopes, M; Eglinton, JM; Heinrich, AJ; Henschke, PA; Langridge, P; Pollnitz, AP, 2002
)
2.02
"Raw glycerol is an industrial feedstock appearing in increasing quantities as the main by-product of bio-diesel production facilities. "( Yarrowia lipolytica as a potential producer of citric acid from raw glycerol.
Aggelis, G; Chevalot, I; Marc, I; Muniglia, L; Papanikolaou, S, 2002
)
1.11
"Glycerol is a hyperosmolar agent that is claimed to reduce brain oedema."( Glycerol for acute stroke: a Cochrane systematic review.
Boysen, G; Cantisani, TA; Celani, MG; Ricci, S; Righetti, E; Sterzi, R, 2002
)
2.48
"Glycerol, found to be a very good substrate for diol dehydratase as well as a potent inactivator, atypically, did not induce cob(II)alamin formation to any detectable extent."( Mechanism of action of adenosylcobalamin: glycerol and other substrate analogues as substrates and inactivators for propanediol dehydratase--kinetics, stereospecificity, and mechanism.
Bachovchin, WW; Eagar, RG; Moore, KW; Richards, JH, 1977
)
1.24
"Glycerol was found to be a precursor of glucose and this conversion seemed to proceed more rapidly in the pregnant rat than in the virgin rat."( Glycerol metabolism in the pregnant and virgin rats.
Gilbert, M; Ricquier, D, 1977
)
2.42
"Glycerol seems to be a viable fuel source in the traumatized patient, being associated with nitrogen retention and minimal thermal effect. "( Hypercaloric glycerol in injured patients.
Askanazi, J; Blaustein, J; Bursztein, S; Kirvelä, O; Mansour, B; Singer, P; Yoshimura, N, 1992
)
2.1
"Glycerol is a dietary component which is metabolized primarily by the liver and kidney where it is used mainly for glucose synthesis. "( Effect of glycerol and dihydroxyacetone on hepatic lipogenesis.
Carmona, A; Freedland, RA, 1989
)
2.12
"Glycerol 3-phosphate is an initial metabolite in the biosynthesis of phosphoglycerides and triacylglycerols. "( Glycerol kinase deficiency inhibits glycerol utilization in phosphoglyceride and triacylglycerol biosynthesis.
Bartley, JA; Ward, R, 1985
)
3.15

Effects

Glycerol has a dual effect on NR fluorescence: it eliminates kinetic anomalies resulting from limited solubility and self-interactions, but it also quenchesNR fluorescence. It has an action to enhance pulmonary tumorigenesis in mice treated with 4-nitroquinoline 1-oxide (4NQO)

Glycerol is a waste product of the biodiesel industry that serves as a highly reduced carbon source for some microorganisms. Glycerol has been applied as a nontoxic CPA for multiple tissues but not adipose tissue.

ExcerptReferenceRelevance
"Glycerol has a dual effect on NR fluorescence: it eliminates kinetic anomalies resulting from limited solubility and self-interactions, but it also quenches NR fluorescence."( Kinetic anomalies in the interactions of Nile red with microalgae.
Pick, U; Rachutin-Zalogin, T, 2012
)
1.1
"Glycerol has a neurolytic effect on the dog's trigeminal ganglion."( Experimental trigeminal glycerol injection in dogs: histopathological evaluation by light and electron microscopy.
Benli, K; Erbengi, A; Erbengi, T; Işik, N; Pamir, MN; Ruacan, S, 2002
)
1.34
"As glycerol has a chemical structure similar to that of potential ligands of CmeR, the structure obtained mimics the induced form of CmeR."( Crystal structure of the transcriptional regulator CmeR from Campylobacter jejuni.
Gu, R; Li, M; McDermott, G; Shi, F; Su, CC; Yu, EW; Zhang, Q, 2007
)
0.85
"Glycerol has an action to enhance pulmonary tumorigenesis in mice treated with 4-nitroquinoline 1-oxide (4NQO). "( Active oxygen generation by alveolar macrophage in mice treated with carcinogen and promoter.
Ichikawa, T; Yano, T, 1993
)
1.73
"Glycerol has a rate and volume of distribution similar to urea. "( Hemodialysis with glycerol dialysate.
Cook, J; Meyer, R; Murrin, C; Van Stone, JC, 1979
)
2.04
"Glycerol has a non-specific neurotoxic effect which is equal for tactile and nociceptive fibres."( Sensory disturbance following percutaneous retrogasserian glycerol rhizotomy.
Bergenheim, AT; Brophy, BP; Laitinen, LV, 1989
)
1.24
"Glycerol dispersion has been proposed to further tune the acoustic properties and to incorporate hydrophilic additives into SEBS gel."( Glycerol-in-SEBS gel as a material to manufacture stable wall-less vascular phantom for ultrasound and photoacoustic imaging.
Bachmann, L; Cabrelli, LC; Carneiro, AAO; da Cruz Junior, LB; Pavan, TZ; Uliana, JH, 2021
)
2.79
"Glycerol has been applied as a nontoxic CPA for multiple tissues but not adipose tissue."( The effect of glycerol as a cryoprotective agent in the cryopreservation of adipose tissue.
Gao, YM; Li, QF; Tan, PC; Xie, Y; Zhang, PQ; Zhang, XJ; Zheng, DN; Zhou, SB, 2022
)
1.8
"Glycerol has several advantages over commonly employed mobile phase modifiers, such as the high safety, the low UV cut-off point, low flammability, low volatility, the green features, and the biodegradability."( Glycerol as a new mobile phase modifier for green liquid chromatographic determination of ascorbic acid and glutathione in pharmaceutical tablets.
Fekry, M; Habib, A; Mabrouk, MM; Mansour, FR, 2022
)
2.89
"Glycerol has become a waste product of the biodiesel industry that serves as a highly reduced carbon source for some microorganisms."( Identification of Enzymatic Bottlenecks for the Aerobic Production of Malate from Glycerol by the Systematic Gene Overexpression of Anaplerotic Enzymes in
Bolivar, J; Cabrera, G; Cantero, D; Romero, A; Soto-Varela, ZE; Valle, A, 2021
)
1.57
"Glycerol has been recently used to induce muscle adiposity in mice. "( Glycerol induces early fibrosis in regenerating rat skeletal muscle.
Hosaka, YZ; Mahdy, MAA; Warita, K, 2018
)
3.37
"Glycerol has been associated with membrane degradation and may support glycerol as a biomarker for vascular endothelial breakdown."( Prostacyclin Affects the Relation Between Brain Interstitial Glycerol and Cerebrovascular Pressure Reactivity in Severe Traumatic Brain Injury.
Eklund, A; Hägglund, L; Koskinen, LD; Olivecrona, M; Sundström, N, 2019
)
1.48
"Glycerol has been employed as the plasticizer and glutaraldehyde (GD) as a cross-linker."( Tuning the mechanical and physicochemical properties of cross-linked protein films.
Chaudhury, S; Dasgupta, S; Parveen, S, 2019
)
1.24
"Glycerol has attracted the attention of scientific and industrial communities due to its generation in bulk quantities as a byproduct of biofuel industries. "( Fermentation of glycerol and production of valuable chemical and biofuel molecules.
Clomburg, JM; Gonzalez, R; Mattam, AJ; Yazdani, SS, 2013
)
2.18
"Glycerol metabolism has been well studied biochemically. "( Glycerol affects root development through regulation of multiple pathways in Arabidopsis.
Hu, J; Wang, J; Zhang, Y; Zhou, Y, 2014
)
3.29
"Glycerol has high viscosity, low vapor pressure, and sufficient electrical conductivity."( Sample preparation to observe the straight and flat posture of silkworm embryo under scanning electron microscopy via glycerol substitution method.
Dai, F; Hou, Y; Lei, Z; Li, C; Liu, W; Lu, C; Zhang, Q, 2014
)
1.33
"Glycerol has become a desirable feedstock for the production of fuels and chemicals due to its availability and low price, but many barriers to commercialization remain. "( Microaerobic conversion of glycerol to ethanol in Escherichia coli.
Black, RW; Campbell, P; Le, TQ; Li, M; Monticello, DJ; Puthli, S; Wong, MS, 2014
)
2.14
"Glycerol has the latent capacity to act as a plasma volume expander and disguise blood doping practices. "( Quantitative analysis of glycerol levels in human urine by liquid chromatography-tandem mass spectrometry.
Dong, Y; Feng, F; He, G; Lu, J; Ma, Y; Shen, L; Wang, X; Wu, Y; Xu, Y; Yan, K; Yang, Z, 2014
)
2.15
"Glycerol has become an important carbon source for biotechnology and reports on production of L-Phe from glycerol are available."( Improvement of L-phenylalanine production from glycerol by recombinant Escherichia coli strains: the role of extra copies of glpK, glpX, and tktA genes.
Albermann, C; Gottlieb, K; Sprenger, GA, 2014
)
1.38
"Glycerol has emerged as a cheap waste material due to blooming biodiesel manufacturing units worldwide. "( Bioconversion of crude glycerol to polyhydroxyalkanoate by Bacillus thuringiensis under non-limiting nitrogen conditions.
Kalia, VC; Kumar, P; Lee, JK; Patel, SK; Ray, S, 2015
)
2.17
"Glycerol has been reported as a component of cutin, contributing up to 14% by weight of total released monomers."( Quantitative analysis of glycerol in dicarboxylic acid-rich cutins provides insights into Arabidopsis cutin structure.
Li-Beisson, Y; Ohlrogge, J; Pollard, M; Yang, W, 2016
)
1.46
"Glycerol has long served the topical prescriptive and personal care industry as a versatile and functional active and inactive ingredient. "( Evaluation of additive effects of hydrolyzed jojoba (Simmondsia chinensis) esters and glycerol: a preliminary study.
Gacula, M; Marshall, B; Meyer, J; Rheins, L, 2008
)
2.01
"Glycerol has the potential of being a low-cost and extremely versatile building block. "( Oxidation of glycerol by 2,2,6,6-tetramethylpiperidine-N-oxyl (TEMPO) in the presence of laccase.
Guebitz, G; Liebminger, S; Siebenhofer, M, 2009
)
2.16
"Glycerol has become an ideal feedstock for the microbial production of bio-based chemicals due to its abundance, low cost, and high degree of reduction. "( Metabolic engineering of Escherichia coli for the production of succinate from glycerol.
Blankschien, MD; Clomburg, JM; Gonzalez, R, 2010
)
2.03
"Glycerol has recently been shown to shorten, whereas oxaloacetate has been found to extend, life span in C."( Proteotoxicity and the contrasting effects of oxaloacetate and glycerol on Caenorhabditis elegans life span: a role for methylglyoxal?
Hipkiss, AR, 2010
)
1.32
"Glycerol has become an attractive carbon source in the biotechnology industry owing to its low price and reduced state. "( Production of 1,2-propanediol from glycerol in Saccharomyces cerevisiae.
Jung, JY; Lee, J; Oh, MK; Yun, HS, 2011
)
2.09
"Glycerol has a dual effect on NR fluorescence: it eliminates kinetic anomalies resulting from limited solubility and self-interactions, but it also quenches NR fluorescence."( Kinetic anomalies in the interactions of Nile red with microalgae.
Pick, U; Rachutin-Zalogin, T, 2012
)
1.1
"Glycerol has been used as a means to legitimately hyperhydrate the body in an attempt to offset the deleterious effects of dehydration. "( Identifying plasma glycerol concentration associated with urinary glycerol excretion in trained humans.
Harmon, ME; Nelson, JL; Robergs, RA, 2011
)
2.14
"Glycerol has become an ideal feedstock for producing fuels and chemicals. "( Analysis of the production process of optically pure D-lactic acid from raw glycerol using engineered Escherichia coli strains.
Cardona, CA; Gonzalez, R; Posada, JA, 2012
)
2.05
"Glycerol has the potential to improve the profitability of biodiesel in a biorefinery scenario."( Valorization of biodiesel derived glycerol as a carbon source to obtain added-value metabolites: Focus on polyunsaturated fatty acids.
Abad, S; Turon, X,
)
1.13
"Glycerol has enhanced its biotechnological importance since it is a byproduct of biodiesel synthesis. "( New insights into Escherichia coli metabolism: carbon scavenging, acetate metabolism and carbon recycling responses during growth on glycerol.
Bolivar, F; Castañeda, HM; Encarnación, S; Flores, N; Gosset, G; Hernández-Chávez, G; Martínez-Batallar, G; Martínez-Gómez, K; Ramírez, OT, 2012
)
2.03
"Glycerol has a neurolytic effect on the dog's trigeminal ganglion."( Experimental trigeminal glycerol injection in dogs: histopathological evaluation by light and electron microscopy.
Benli, K; Erbengi, A; Erbengi, T; Işik, N; Pamir, MN; Ruacan, S, 2002
)
1.34
"Glycerol has been shown to cross the plasma membrane of Saccharomyces cerevisiae through (1) a H(+)/symport detected in cells grown on non-fermentable carbon sources, (2) the constitutively expressed Fps1p channel and (3) by passive diffusion. "( Fps1p channel is the mediator of the major part of glycerol passive diffusion in Saccharomyces cerevisiae: artefacts and re-definitions.
Lages, F; Lucas, C; Oliveira, R; Silva-Graça, M, 2003
)
2.01
"Free glycerol has been identified as a major solute in plasma of pupae of the silk moth, Hyalophora cecropia. "( The chemistry of insect hemolymph. III. Glycerol.
MEYER, WL; WYATT, GR, 1959
)
1.02
"Glycerol has been the most widely used cryopreservation agent for spermatozoa and a wide range of factors affect its action on sperm viability and fertilizing capacity. "( Field and in vitro assay of three methods for freezing ram semen.
Alvarez, M; Anel, E; Anel, L; Boixo, JC; Chamorro, CA; de Paz, P; González, M; Kaabi, M; Manso, A, 2003
)
1.76
"Glycerolysis has been widely applied in industry for the chemical production of food MAGs under high temperature."( Enzymatic production of monoacylglycerols containing polyunsaturated fatty acids through an efficient glycerolysis system.
Engelrud, U; Rebsdorf, M; Xu, X; Yang, T, 2005
)
1.33
"As glycerol has a chemical structure similar to that of potential ligands of CmeR, the structure obtained mimics the induced form of CmeR."( Crystal structure of the transcriptional regulator CmeR from Campylobacter jejuni.
Gu, R; Li, M; McDermott, G; Shi, F; Su, CC; Yu, EW; Zhang, Q, 2007
)
0.85
"Glycerol metabolism has been implicated in insulin signaling and perturbations in glycerol uptake and catabolism are linked to obesity in humans."( Structure of glycerol-3-phosphate dehydrogenase, an essential monotopic membrane enzyme involved in respiration and metabolism.
Chinte, U; Du, S; Yeh, JI, 2008
)
1.44
"1. Glycerol has been used for the treatment of intracranial hypertension, cerebral oedema and glaucoma. "( Intraperitoneal glycerol induces oxidative stress in rat kidney.
Feksa, LR; Rech, VC; Rieger, E; Wannmacher, CM, 2008
)
1.31
"Glycerol kinase has been purified by preparing a post-nuclear, particulate fraction and solubilizing the enzyme with 0.5% (w/v) Triton X-100."( Studies on glycerol kinase and its role in ATP synthesis in Trypanosoma brucei.
Bowman, IB; Hammond, DJ, 1980
)
1.37
"The glycerol test has been introduced into the oto neurological diagnosis of Bell's palsy. "( Glycerol test for Bell's palsy.
Amabile, G; Celestino, D; Cianfrone, G; Ralli, G, 1983
)
2.27
"Glycerol therefore has no effect on the low-temperature (condensed) monolayers but causes expansion of the high-temperature (expanded) monolayers."( Interactions of phospholipid monolayers with carbohydrates.
Chapman, D; Crowe, JH; Crowe, LM; Whittam, MA, 1984
)
0.99
"Glycerol treatment has no effect on ouabain-sensitive channels although it inhibits markedly the K-flux through the physostigmine-sensitive pathway."( The subcellular location of potassium flux pathways in frog skeletal muscle.
Kovács, T; Pfliegler, G; Szabó, B, 1981
)
0.98
"Glycerol has been used in cerebral edema for hyperosmolar dehydration of brain tissue, but only empirical relationships govern this use. "( Effect of glycerol and hyperosmolality on intracranial pressure.
Painter, MJ; Pirikitakuhlr, P; Pitlick, WH; Wessel, HB, 1982
)
2.11
"Glycerol has been utilized extensively clinically to reverse the adverse effects of cerebral edema."( Glycerol and methylprednisolone in lung contusion.
Gonzalez, A; Just-Viera, JO; Santiago-Delpin, E, 1980
)
2.43
"Glycerol has long been used for the preservation of skin allografts. "( Effect of glycerol on intracellular virus survival: implications for the clinical use of glycerol-preserved cadaver skin.
Boyce, SG; Freedlander, E; Ghosh, MM; Kudesia, G; MacNeil, S; Marshall, L, 1995
)
2.14
"Glycerol has been proposed as a substitute osmotic agent for glucose in peritoneal dialysis fluids. "( Glycerol toxicity for human peritoneal mesothelial cells in culture: comparison with glucose.
Knapowski, J; Witowski, J, 1994
)
3.17
"Glycerol release has been generally accepted as an index of lipolysis in the intact heart. "( The hydrolysis of glycerol-3-phosphate into glycerol in cardiac tissue: possible consequences for the validity of glycerol release as a measure of lipolysis.
Coumans, WA; de Groot, MJ; de Jong, YF; van der Vusse, GJ, 1994
)
2.07
"Glycerol has been used for a long time as a viral preservation medium in tissue samples at a 50 per cent concentration, however after a limited time span viruses could no longer be detected. "( Virucidal effect of glycerol as used in donor skin preservation.
Buitenwerf, J; du Pont, JS; Hoekstra, MJ; van Baare, J, 1994
)
2.05
"Glycerol has an action to enhance pulmonary tumorigenesis in mice treated with 4-nitroquinoline 1-oxide (4NQO). "( Active oxygen generation by alveolar macrophage in mice treated with carcinogen and promoter.
Ichikawa, T; Yano, T, 1993
)
1.73
"Glycerol ingestion has been shown to mediate hyperhydration; however, the mechanism(s) responsible for this improved fluid retention is not well understood. "( Glycerol hyperhydration: hormonal, renal, and vascular fluid responses.
DeLuca, JP; Freund, BJ; Montain, SJ; Pandolf, KB; Sawka, MN; Valeri, CR; Young, AJ, 1995
)
3.18
"Glycerol has been demonstrated to serve as the major osmolyte of Saccharomyces cerevisiae. "( The control of intracellular glycerol in Saccharomyces cerevisiae influences osmotic stress response and resistance to increased temperature.
Kelders, M; Mager, WH; Reijenga, KA; Siderius, M; Van Wuytswinkel, O, 2000
)
2.04
"The glycerol method has no contraindications for pulmonary and hepatic echinococcosis."( [An improvement in a new method for the surgical treatment of echinococcosis].
Biriukov, IuV; Chebyshev, NV; Eshankulov, US; Il'khamov, FA; Kovalenko, FP; Rasulov, SM; Sadykov, RV; Sadykov, VM; Streliaeva, AV,
)
0.61
"Glycerol has been shown to lower the heat denaturation temperature (T(m)) of dehydrated lysozyme while elevating the T(m) of hydrated lysozyme (. "( Molecular dynamics of solid-state lysozyme as affected by glycerol and water: a neutron scattering study.
Bell, LN; Neumann, DA; Tsai, AM, 2000
)
1.99
"Glycerol has long been known to play fundamental roles in several vital physiological processes, in prokaryotes and eukaryotes, and is an important intermediate of energy metabolism."( Glycerol: a neglected variable in metabolic processes?
Brisson, D; Gaudet, D; Hudson, TJ; St-Pierre, J; Vohl, MC, 2001
)
2.47
"Glycerol has been long known to suppress the growth of various cell types."( Glycerol suppresses proliferation of rat hepatocytes and human HepG2 cells.
Aoki, T; Demetriou, AA; Hui, T; Inderbitzin, D; Mizuguchi, T; Rozga, J; Sugiyama, N, 2002
)
2.48
"Glycerol has a rate and volume of distribution similar to urea. "( Hemodialysis with glycerol dialysate.
Cook, J; Meyer, R; Murrin, C; Van Stone, JC, 1979
)
2.04
"The glycerol test also has been reported as being effective for the same purpose but only in Meniere patients with fluctuating hearing loss (Klockhoff & Lindblom, 1966)."( A comparison of the furosemide and glycerol tests for Meniere's disease. With special reference to the bilateral lesion.
Futaki, T; Kitahara, M; Morimoto, M,
)
0.89
"The glycerol-DHA kinase has been purified 210-fold from extracts, and its molecular weight was determined to be 50,000 by gel filtration."( Phosphorylation of glycerol and dihydroxyacetone in Acetobacter xylinum and its possible regulatory role.
Benziman, M; Weinhouse, H, 1976
)
1.06
"Glycerol has been found active in experimental various models of cerebral oedema."( [Toxicological and pharmacological studies of glycerol].
Cadel, S; Dalla Vedova, R; Wassermann, A,
)
1.11
"Glycerol has been injected intravenously in guinea pig and its effects on the pressure in the cochlear fluids have been studied. "( Glycerol effects on the perilymphatic and cerebro-spinal fluid pressure.
Agerup, B; Angelborg, C,
)
3.02
"Glycerol alone has no such effect."( The effect of organic cryosolvents on actin structure: studies by small angle X-ray scattering.
Axelos, MA; Pajot-Augy, E, 1992
)
1
"Glycerol has commonly been employed as a cryoprotectant in cryopreservation of human spermatozoa. "( Glycerol permeability of human spermatozoa and its activation energy.
Critser, JK; Gao, DY; Kleinhans, FW; Mazur, P; Noiles, EE; Watson, PF, 1992
)
3.17
"Glycerol has a non-specific neurotoxic effect which is equal for tactile and nociceptive fibres."( Sensory disturbance following percutaneous retrogasserian glycerol rhizotomy.
Bergenheim, AT; Brophy, BP; Laitinen, LV, 1989
)
1.24
"Glycerol has only a marginal effect on the appearance of the EPR spectra, and does not alleviate the "g-strain.""( EPR of azurins from Pseudomonas aeruginosa and Alcaligenes denitrificans demonstrates pH-dependence of the copper-site geometry in Pseudomonas aeruginosa protein.
Aasa, R; Canters, GW; Groeneveld, CM; Reinhammar, B, 1987
)
0.99
"Glycerol and polymyxin have been shown by X-ray diffraction to induce interdigitated bilayers in phosphatidylcholine (PC) and phosphatidylglycerol (PG), respectively (McDaniel, R.V., et al. "( Phase transitions and fatty acid spin label behavior in interdigitated lipid phases induced by glycerol and polymyxin.
Boggs, JM; Rangaraj, G, 1985
)
1.93
"1. A glycerol teichoic acid has been extracted from cell walls of Bacillus stearothermophilus B65 and its structure examined. "( The glycerol teichoic acid from the cell wall of Bacillus stearothermophilus B65.
Wicken, AJ, 1966
)
1.32
"Free glycerol has been found to be present in the lens."( The metabolism of glucose by the rabbit lens in the presence and absence of oxygen.
Van Heyningen, R, 1965
)
0.7

Actions

Glycerol plays an important role in the adaptation of fungi to various microenvironments and stressors, including heat shock, anoxic conditions and osmotic stress. Glycerol could inhibit all the major steps of insulin aggregation.

ExcerptReferenceRelevance
"Glycerol inclusion may increase starter intake, ADG, ruminal fermentation, and in"( Effect of heat-treated canola meal and glycerol inclusion on performance and gastrointestinal development of Holstein calves.
Burakowska, K; Górka, P; Kent-Dennis, C; Kowalski, ZM; Laarveld, B; Penner, GB, 2020
)
1.55
"Glycerol plays an important role in the adaptation of fungi to various microenvironments and stressors, including heat shock, anoxic conditions and osmotic stress. "( Predicted Glycerol 3-Phosphate Dehydrogenase Homologs and the Glycerol Kinase GlcA Coordinately Adapt to Various Carbon Sources and Osmotic Stress in
Gu, H; Lu, L; Ma, Z; Meng, X; Zhang, C, 2018
)
2.33
"Glycerol could inhibit all the major steps of insulin aggregation."( Glycerol inhibits the primary pathways and transforms the secondary pathway of insulin aggregation.
Deep, S; Saha, S, 2016
)
2.6
"Glycerol plays an important role in the osmoadaptation responses of Saccharomyces cerevisiae. "( Glycerol accumulation in the dimorphic yeast Saccharomycopsis fibuligera: cloning of two glycerol 3-phosphate dehydrogenase genes, one of which is markedly induced by osmotic stress.
Jia, LH; Jiang, N; Lin, YP; Yan, H, 2008
)
3.23
"Glycerol and sucrose cause a significant increase in the rate of hydride transfer, but lead to a reduction in the magnitude of the kinetic isotope effect as well as an extension of the temperature range over which "passive" protein dynamics (rather than "active" gating motions) dominate the reaction."( Solvent effects on environmentally coupled hydrogen tunnelling during catalysis by dihydrofolate reductase from Thermotoga maritima.
Allemann, RK; Evans, RM; Loveridge, EJ, 2008
)
1.07
"Glycerol plays multi-functional roles in cellular physiology. "( Bovine oocytes and early embryos express mRNA encoding glycerol kinase but addition of glycerol to the culture media interferes with oocyte maturation.
Hamano, S; Okawara, S; Tetsuka, M, 2009
)
2.04
"Glycerol and urea can activate beta-cells via their rapid uptake across the beta-cell plasma membrane, possibly via AQP7. "( Contrasting effects of glycerol and urea transport on rat pancreatic beta-cell function.
Beauwens, R; Best, L; Brown, PD; Delporte, C; Malaisse, WJ; Perret, J; Sener, A; Virreira, M; Yates, AP, 2009
)
2.11
"Glycerol continued to increase during initial reperfusion."( Continuous assessment of intrahepatic metabolism by microdialysis during and after portal triad clamping.
Björnstedt, M; D'souza, MA; Isaksson, B; Jersenius, U; Lundell, L; Nowak, G; Permert, J; Ungerstedt, J, 2011
)
1.09
"glycerol levels were lower and i.p."( Intraperitoneal glycerol levels and lactate/pyruvate ratio: early markers of postoperative complications.
Hörer, TM; Jansson, K; Norgren, L, 2011
)
1.44
"The glycerol plays the dual role of hierarchically assembling the metal-organic composites and stabilizing the structures during the subsequent conversions."( Multitemplates for the hierarchical synthesis of diverse inorganic materials.
Bian, Z; Li, H; Nuckolls, C; Wang, J; Xiao, S; Zhu, J, 2012
)
0.86
"Glycerol kinase plays a critical role in metabolism by converting glycerol to glycerol 3-phosphate in an ATP dependent reaction. "( Glycerol hypersensitivity in a Drosophila model for glycerol kinase deficiency is affected by mutations in eye pigmentation genes.
Dipple, KM; Jackson, GR; Wightman, PJ, 2012
)
3.26
"80% glycerol leads to 23% increase of light transmittance and 24% decrease of diffuse reflectance."( Synergistic effect of hyperosmotic agents of dimethyl sulfoxide and glycerol on optical clearing of gastric tissue studied with near infrared spectroscopy.
Wang, RK; Xu, X, 2004
)
1.04
"Alkylglycerols evoked an increase in free intracellular calcium concentration [Ca2+]i, in a dose-dependent manner."( Regulation of calcium signalling by 1-O-alkylglycerols in human Jurkat T lymphocytes.
Khan, NA; Legrand, AB; Pédrono, F, 2004
)
1.04
"Thus glycerol appears to cause predominant posterior orientation of cilia by stimulating cAMP-dependent phosphorylation on those proteins."( Augmented ciliary reorientation response and cAMP-dependent protein phosphorylation induced by glycerol in triton-extracted Paramecium.
Inoue, H; Kamachi, H; Kitani, T; Noguchi, M; Ogawa, T, 2005
)
1
"AD. Glycerol is known to increase stratum corneum (SC) hydration, improve epidermal barrier function and decrease clinical signs of inflammation."( Placebo-controlled, double-blind, randomized, prospective study of a glycerol-based emollient on eczematous skin in atopic dermatitis: biophysical and clinical evaluation.
Breternitz, M; Elsner, P; Fluhr, JW; Kowatzki, D; Langenauer, M, 2008
)
1.06
"Glycerol caused an increase in the normal length of M."( Growth of Mycobacterium lepraemurium in cultures of mouse peritoneal macrophages.
Andersen, RN; Change, YT; Vaituzis, Z, 1967
)
0.97
"The glycerol-induced increase in MR and HQR was not attenuated by any of the treatments used."( Regional haemodynamic effects of dopamine and its prodrugs L-dopa and gludopa in the rat and in the glycerol-treated rat as a model for acute renal failure.
Drieman, JC; Smits, JF; Struijker Boudier, HA; Thijssen, HH; van Essen, H; van Kan, FJ, 1994
)
0.99
"The glycerol-induced increase was completely inhibited when a high vitamin E diet was provided for 4 weeks after 4NQO injection."( Is vitamin E a useful agent to protect against oxy radical-promoted lung tumorigenesis in ddY mice?
Ichikawa, T; Ishikawa, G; Yano, T, 1993
)
0.77
"glycerolgenesis can produce high level of glycerol whereas ethanol and other byproducts was nearly zero."( [The effect of oxygen supply on production of glycerol with Candida glycerolgenesis].
Fang, HY; Jin, HR; Zhuge, J, 2000
)
1.29
"Glycerol was found to suppress the pH changes because of its "salt buffer" effect."( Measurement of the pH of frozen buffer solutions by using pH indicators.
Morita, M; Orii, Y, 1977
)
0.98
"Glycerol-induced increase in atrial rate was a calcium-dependent mechanism sensitive to nifedipine."( Chronotropic response to hyperosmotic solutions of isolated rat atria.
Camilión De Hurtado, MC; Gende, OA, 1987
)
0.99
"Glycerol did not increase the efficiency of transformation by either chromosomal DNA or linearized plasmid DNA."( Effect of glycerol on plasmid transfer in genetically competent Haemophilus influenzae.
Stuy, JH; Walter, RB, 1986
)
1.39
"Glycerol increase was less in heat-acclimated rats than in other groups."( Metyrapone-induced thermogenesis in cold- and heat-acclimated rats.
Kuroshima, A; Ohno, T, 1986
)
0.99
"Glycerol appeared to increase the peritoneal permeability as indicated by an increased KBD value for total protein."( Kinetics of peritoneal dialysis with glycerol and glucose as osmotic agents.
Bergström, J; Lindholm, B; Werynski, A,
)
1.13
"Glycerol failed to increase recovery."( Effect of rehydration on recovery, repair, and growth of injured freeze-dried Salmonella anatum.
Busta, FF; Jezeski, JJ; Ray, B, 1971
)
0.97

Treatment

Glycerol in treated plasma is then quantitatively converted to glycerol-3-phosphate (G3P), which is isolated by column chromatography and counted for 14C radio-activity. Glycerol treatment has no effect on ouabain-sensitive channels although it inhibits markedly the K-flux through the physostigmine-sensitive pathway.

ExcerptReferenceRelevance
"Glycerol organosolv pretreatment (GOP) is considered an efficient method to deconstruct lignocellulose for producing fermentable sugars. "( Utilization of lignocellulosic biomass by glycerol organosolv pretreatment for biobutanol production integrated with bioconversion of residual glycerol into value-added products.
Cao, J; Gao, L; Gui, Z; Luo, H; Shi, Y; Wang, S; Xie, F; Yang, R; Zhou, T, 2023
)
2.62
"Glycerol treatment resulted in significant hematological and biochemical alterations as well as significant renal and hepatic oxidative stress."( Olive leaf extract modulates glycerol-induced kidney and liver damage in rats.
Abugomaa, A; Elbadawy, M, 2020
)
1.57
"Glycerol treatment evoked significant increases in rhabdomyolysis-related markers (creatine kinase and LDH). "( Using Green Biosynthesized Lycopene-Coated Selenium Nanoparticles to Rescue Renal Damage in Glycerol-Induced Acute Kidney Injury in Rats.
Abdel Moneim, AE; Al-Amer, O; Al-Brakati, A; Alsharif, KF; Alzahrani, KJ; Bauomy, AA; Habotta, OA; Kabrah, S; Kassab, RB; Lokman, MS; Oyouni, AA, 2021
)
2.28
"Glycerol treatment induced significant elevation of serum creatinine kinase and aspartate aminotransferase levels followed by the marked elevation of serum blood urea nitrogen and creatinine levels, which caused serious damage to renal tubules."( Dynamic changes in Bach1 expression in the kidney of rhabdomyolysis-associated acute kidney injury.
Morimatsu, H; Omori, E; Shimizu, H; Takahashi, T; Yamaoka, M, 2017
)
1.18
"Glycerol treatment caused significant renal histological abnormalities and functional impairment (increased urea and creatinine)."( Diacerein protects against glycerol-induced acute kidney injury: Modulating oxidative stress, inflammation, apoptosis and necroptosis.
Abd-Ellatif, RN; Atef, MM; Hafez, YM; Hegab, II; Sadek, MT, 2019
)
1.53
"Upon glycerol treatment, G3P level and root development did not change in glycerol kinase mutant gli1, but G3P level increased in gpdhc1 and fad-gpdh mutants, which resulted in more severely impaired root development."( Glycerol affects root development through regulation of multiple pathways in Arabidopsis.
Hu, J; Wang, J; Zhang, Y; Zhou, Y, 2014
)
2.3
"Glycerol treatment improved rotifer swimming performance in older age classes and maintained more mitochondrial activity."( Glycerol extends lifespan of Brachionus manjavacas (Rotifera) and protects against stressors.
Johnston, RK; Snell, TW, 2014
)
2.57
"Glycerol treatment prevented HUFA degradation in whole blood reference material for 30 d (45 ± 0.4 to 46.8 ± 0.1, means ± SDs) compared to untreated saline controls (45.9 ± 1.0 to 6.8 ± 0.2)."( Cryopreservation prevents iron-initiated highly unsaturated fatty acid loss during storage of human blood on chromatography paper at -20°C.
Metherel, AH; Stark, KD, 2015
)
1.14
"Glycerol treatment significantly increased serum creatinine (SCr) and blood urea nitrogen (BUN) levels."( Renoprotective effect of low-molecular-weight sulfated polysaccharide from the seaweed Laminaria japonica on glycerol-induced acute kidney injury in rats.
Li, X; Wang, J; Zhang, H; Zhang, Q, 2017
)
1.39
"Glycerol treatment produced significant renal structural abnormalities and functional impairment (increased urea and creatinine). "( Protective effect of quinacrine against glycerol-induced acute kidney injury in rats.
Al Asmari, AK; Al Sadoon, KT; Obaid, AA; Tariq, M; Yesunayagam, D, 2017
)
2.17
"Glycerol treatment reduced the volume of preneoplastic lesions by decreasing the proliferative status of liver foci, increasing the expression of p53 and p21 proteins and reducing the expression of cyclin D1 and cyclin-dependent kinase 1. "( Attenuation of liver cancer development by oral glycerol supplementation in the rat.
Alvarez, ML; Capiglioni, AM; Carrillo, MC; Ceballos, MP; Lorenzetti, F; Parody, JP; Pisani, GB; Quiroga, AD; Ronco, MT, 2018
)
2.18
"Glycerol treatment also inhibited the in vitro degradation of CTA1 by the core 20S proteasome."( Stabilization of the tertiary structure of the cholera toxin A1 subunit inhibits toxin dislocation and cellular intoxication.
Banerjee, T; Massey, S; Pande, AH; Tatulian, SA; Taylor, M; Teter, K, 2009
)
1.07
"The glycerol treated PEDOT-PSS silk thread showed a tensile strength of 1000 cN in both wet and dry states."( Conductive polymer combined silk fiber bundle for bioelectrical signal recording.
Nakashima, H; Torimitsu, K; Tsukada, S, 2012
)
0.86
"glycerol; significant treatment effect)."( Feeding behaviors of transition dairy cows fed glycerol as a replacement for corn.
Carvalho, ER; Donkin, SS; Eicher, SD; Schmelz-Roberts, NS; White, HM; Wilcox, CS, 2012
)
1.36
"Glycerol treatment caused severe ARF which invariably led to death of the rats. "( Ameliorative effect of hepatocyte growth factor on glycerol-induced acute renal failure with acute tubular necrosis.
Kawamura, T; Mori-Kudo, I; Nagano, T; Noguchi, H; Taiji, M; Tsuchida, A, 2002
)
2.01
"Glycerol treatment resulted in marked renal oxidative stress and deranged renal functions which significantly improved by trimetazidine and deferoxamine treatments."( Attenuation of glycerol-induced acute renal failure in rats by trimetazidine and deferoxamine.
Chander, V; Chopra, K; Singh, D, 2003
)
1.39
"Glycerol treated rats exhibited collecting duct and medullary ascending limb dilation and casts, with focal tubular damage, confined mainly to the superficial cortex."( Nephroprotective effects of pentoxifylline in experimental myoglobinuric acute renal failure.
Avramovic, V; Djordjevic, V; Mitic-Zlatkovic, M; Savic, V; Stefanovic, V; Vlahovic, P, 2002
)
1.04
"Glycerol treatment by itself induced hemolysis during processing, which was more pronounced in HGM cells. "( Stability after thawing of RBCs frozen with the high- and low-glycerol method.
Bakker, JC; Brand, A; Koning, JG; Lagerberg, JW; Lelkens, CC; Noorman, F; Stekkinger, PS; Truijens-de Lange, R; Verhoeven, AJ, 2003
)
2
"Glycerol treatment resulted in marked renal oxidative stress and significantly deranged renal functions. "( Carvedilol, an antihypertensive drug with antioxidant properties, protects against glycerol-induced acute renal failure.
Chander, V; Chopra, K; Singh, D,
)
1.8
"When glycerol-treated cultures were submitted to a strictly regulated cooling rate (-3 degrees C min(-1)), they attained the control culture density within 13 d after thawing."( Cryopreservation of the unicellular marine alga, Nannochloropsis oculata.
Poncet, JM; Véron, B, 2003
)
0.77
"Glycerol-treated group replicates had delayed cell replication and were negative for FeLV p27 antigen and provirus at passages 1 to 4 and 2 to 4, respectively."( Antiretroviral efficacy of a 98% solution of glycerol or ethylene oxide for inactivation of feline leukemia virus in bone.
Coronado, GS; Swenson, CL, 2004
)
1.3
"glycerol treatment was initiated within the first days after stroke onset."( Glycerol for acute stroke.
Boysen, G; Cantisani, T; Celani, MG; Ricci, S; Righetti, E; Sterzi, R, 2004
)
2.49
"Glycerol treatment resulted in a marked renal oxidative stress and significantly deranged the renal functions."( Protective effect of naringin, a bioflavonoid on glycerol-induced acute renal failure in rat kidney.
Chander, V; Chopra, K; Singh, D, 2004
)
1.3
"Glycerol treatment resulted in a marked decrease in tissue and urine nitric oxide levels, renal oxidative stress and significantly deranged the renal functions along with deterioration of renal morphology."( Molsidomine, a nitric oxide donor and L-arginine protects against rhabdomyolysis-induced myoglobinuric acute renal failure.
Chander, V; Chopra, K, 2005
)
1.05
"4. Glycerol treatment caused severe ARF: a marked renal oxidative stress, significantly increased CK activity, urea and creatinine levels and decreased plasma NO levels."( Protective effects of L-carnitine on myoglobinuric acute renal failure in rats.
Atmaca, G; Aydogdu, N; Kaymak, K; Taskiran, R; Tastekin, E; Yalcin, O,
)
0.65
"Glycerol treatment at 310 K introduces an IMP redistribution, outlined by the appearance of several smooth areas on the fracture faces of the cytoplasmic membrane, which is prevented by glutaraldehyde prefixation at the same temperature."( Effects of glutaraldehyde and glycerol on freeze-fractured Escherichia coli.
Arancia, G; Crateri, PT; Valente, FR, 1980
)
1.27
"Glycerol treatment has no effect on ouabain-sensitive channels although it inhibits markedly the K-flux through the physostigmine-sensitive pathway."( The subcellular location of potassium flux pathways in frog skeletal muscle.
Kovács, T; Pfliegler, G; Szabó, B, 1981
)
0.98
"Glycerol in treated plasma is then quantitatively converted to glycerol-3-phosphate (G3P), which is isolated by column chromatography and counted for 14C radio-activity."( The determination of the specific activity of plasma glycerol.
Gauthier, C; Layberry, R, 1982
)
1.24
"1. Glycerol treatment enhanced NADH- and NADPH-driven active oxygen formation and thiobarbituric acid reactive substances (TBARS) in the lungs of ddY mice treated with 4-nitroquinoline 1-oxide (4NQO). "( Oxidative stress as a modulating factor of pulmonary tumorigenesis in mice; comparative study on two different strains.
Ichikawa, T; Ishikawa, G; Yano, T, 1993
)
0.91
"In glycerol-treated rats, the total ET receptor density in kidney cortex and medulla was increased to 294 and 1172 fmol/mg of protein, with ETA/ETB ratios of 52:48 and 31:69, respectively."( Endothelin receptor subtypes A and B are up-regulated in an experimental model of acute renal failure.
Braquet, P; Chabrier, PE; Cornet, S; Gillard-Roubert, V; Guilmard, C; Pirotzky, E; Plas, P; Pourmarin, L; Roubert, P, 1994
)
0.8
"Glycerol treatment also stabilized immature (core-glycosylated) delta F508 and CFTR molecules that are normally degraded rapidly."( Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation.
Kopito, RR; Krouse, ME; Sato, S; Ward, CL; Wine, JJ, 1996
)
2.46
"Glycerol treatment only reduced, but did not eliminate twitches developed by muscles 7 days after injection."( External calcium dependence of extensor digitorum longus muscle contractility during bupivacaine-induced regeneration.
Fichter-Gagnepain, V; Louboutin, JP; Noireaud, J, 1996
)
1.02
"Glycerol treatment does not affect the structural integrity of the skin; cells are well preserved but dead."( Immunogenicity of glycerol-preserved human cadaver skin in vitro.
du Pont, JS; Hoekstra, MJ; Kamperdijk, EW; Richters, CD; van Baare, J,
)
1.19
"Glycerol treatment significantly increased performance by 5% compared with the placebo group, as assessed by total work in the variable-workload phase (P < 0.04)."( Glycerol hyperhydration improves cycle time trial performance in hot humid conditions.
Burke, L; Dobson, GP; Fallon, K; Hahn, A; Hitchins, S; Martin, DT; Yates, K, 1999
)
2.47
"glycerol treatment in acute stroke, either ischaemic or haemorrhagic, influences death rates and functional outcome in the short or long term and whether the treatment is safe."( Glycerol for acute stroke.
Boysen, G; Cantisani, T; Celani, MG; Ricci, S; Righetti, E; Sterzi, R, 2000
)
2.47
"The glycerol-frozen RBCs treated with 2500 cGy before deglycerolization had a mean freeze-thaw-wash recovery of 87 percent and a mean 24-hour posttransfusion survival of 86 percent after storage for 3 days at 4 degrees C in a 0.9-percent NaCl and 0.2-percent glucose solution. "( In vitro and in vivo measurements of gamma-radiated, frozen, glycerolized RBCs.
Cassidy, GP; Pivacek, LE; Ragno, G; Valeri, CR, 2001
)
1.11
"V. glycerol treatment in acute stroke, either ischaemic or haemorrhagic, influences death rates and functional outcome in the short or long term and whether the treatment is safe."( Glycerol for acute stroke: a Cochrane systematic review.
Boysen, G; Cantisani, TA; Celani, MG; Ricci, S; Righetti, E; Sterzi, R, 2002
)
2.27
"Glycerol-treated muscle fiber bundles were fixed at their rest length in 50 mM KC1, 2 mM MgC1(2), and 10 micron CaC1(2) at pH 7.8 and 0 degrees C in the presence of sufficient amounts of ATP, creatine kinase, and creatine phosphate. "( Acceleration of the ATPase activity of glycerol-treated muscle fibers by repeated stretch-release cycles.
Arata, T; Mukohata, Y; Tonomura, Y, 1978
)
1.97
"The glycerol-treated spermatozoa appeared normal after glycerol addition but were bent or coiled after both glycerol removal procedures."( The effects of glycerol removal on cation concentration and morphology of chicken spermatozoa.
Howarth, B; Westfall, FD, 1977
)
1.09
"Glycerol treatment (50, 15 and 8% sequentially) of myotubes was used to remove plasma membrane blisters and a plasma membrane-enriched fraction was isolated from these blisters using a modified Dextran T500-polyethylene-glycol 6000 aqueous two-phase polymer system."( Separation of plasma membrane markers by glycerol-induced blistering of muscle cells.
Vandenburgh, HH, 1977
)
1.24
"8. Glycerol treatment had little if any effect on the kinetics of delayed rectifier currents."( Effects of glycerol treatment and maintained depolarization on charge movement in skeletal muscle.
Chandler, WK; Rakowski, RF; Schneider, MF, 1976
)
1.16
"In glycerol treated muscle peripheral vacuolation frequently occurred; black reaction product penetrated only as far as the vacuoles and into dilated Z-line tubules, but was virtually absent from the rest of the TS."( The ultrastructure of normal and glycerol treated muscle in the ghost crab, Ocypode cursor.
Castel, M; Papir, D, 1975
)
1.05
"With glycerol treatment, growth is uniformly present."( Spontaneous host endothelial growth on bioprostheses. Influence of fixation.
Frater, RW; Gong, G; Hoffman, D; Liao, K; Macaluso, F; Nikolic, SD, 1992
)
0.74
"Glycerol treated animals showed significance in terms of reduction of brain water content and accumulation of lactate."( Effect of a prostacyclin derivative (OP-41483) and a hyperosmotic agent (glycerol) on brain edema and metabolism in cerebral ischemia.
Kashiwagi, F; Katayama, Y; Memezawa, H; Terashi, A, 1992
)
1.24
"In glycerol-treated cells proliferation was suppressed, the microfilament network was extensively reorganized and the microtubule network was more clearly defined, while the cell thickness, as observed by scanning electron microscopy (SEM), was decreased."( Glycerol alters cytoskeleton and cell adhesion while inhibiting cell proliferation.
Dinsdale, CJ; Mirza, FM; Wiebe, JP, 1992
)
2.24
"Glycerol-injected rats treated with BSO showed significantly worse renal failure than did rats given glycerol alone, while administration of GSH resulted in significant amelioration of glycerol-induced acute renal failure [glycerol treatment alone, blood urea nitrogen (BUN) = 96 +/- 10 and creatinine = 2.5 +/- 0.4 mg/dl; BSO + glycerol treatment, BUN = 123 +/- 7 and creatinine = 3.5 +/- 0.1 mg/dl (n = 9, P less than 0.05); GSH + glycerol treatment, BUN = 78 +/- 10 and creatinine = 1.25 +/- 0.2 mg/dl (n = 8, P less than 0.05)]."( Role of glutathione in an animal model of myoglobinuric acute renal failure.
Abul-Ezz, SR; Shah, SV; Walker, PD, 1991
)
1
"Glycerol treatment caused a dose-dependent ablation of spermatogenesis in a distinct area around the site of injection."( Evidence for a major role of inhibin in the feedback control of FSH in the male rat.
Bartlett, JM; de Kretser, DM; Fingscheidt, U; Nieschlag, E; Tsonis, CG; Weinbauer, GF, 1989
)
1
"Such glycerol-treated but not detubulated fibers were used as controls."( Anatomical distribution of voltage-dependent membrane capacitance in frog skeletal muscle fibers.
Huang, CL; Peachey, LD, 1989
)
0.73
"In glycerol treated rats, a peak in serum creatinine was seen on day 2 which returned to normal level by day 4."( Contrast media-induced lipid peroxidation in the rat kidney.
Moncada, R; Parvez, Z; Rahman, MA, 1989
)
0.79
"Glycerol treatment (0.4 or 1.2 M) altered but did not abolish twitch, tetanus, potassium, or caffeine contractures in the rat soleus at 37 degrees C. "( The effect of lithium and nitrate on potassium contractures in a glycerol-treated slow-twitch muscle of the rat.
Bruton, JD, 1988
)
1.96
"Glycerol treatments reduced but did not abolish twitch, tetanus, and potassium contracture tension and these changes were far less at 22 than at 37 degrees C."( Contraction of rat skeletal muscle after glycerol treatments.
Bruton, JD, 1988
)
1.26
"Glycerol-treated rats exhibited significantly increased urinary thromboxane B2(TXB)2, prostaglandin E2 (PGE2) and 6-ketoprostaglandin F1 alpha (6kPGF1 alpha) excretion and urine volume (UV). "( Is thromboxane a potent antinatriuretic factor and is it involved in the development of acute renal failure?
Bariety, J; Dontas, A; Gkikas, EL; Gkikas, G; Hatziantoniou, C; Papanicolaou, N; Paris, M, 1987
)
1.72
"Glycerol treated cryopreserved spermatozoa yielded a significantly higher (P less than 0.01) percentage of motile sperm and percentage of sperm with functionally intact membrane immediately after thawing than the spermatozoa not treated with glycerol but cryopreserved."( Nonbeneficial effects of glycerol on the oocyte penetrating capacity of cryopreserved and incubated human spermatozoa.
Jeyendran, RS; Perez-Pelaez, M; Van der Ven, HH; Zaneveld, LJ, 1985
)
1.29
"In glycerol-treated preparations, freeze-etching revealed that the cell walls consist of four layers, with the main plane of fracture between layers cw 2 and cw 3."( Location of the fracture faces within the cell envelope of Acinetobacter species strain MJT-F5-5.
Glauert, AM; Sleytr, UB; Thornley, MJ, 1974
)
0.77
"In glycerol-treated fibres the mean specific membrane capacitance was 1.0 muF/cm(2) in summer and 2.0 muF/cm(2) in winter."( Electrical properties of toad sartorius muscle fibres in summer and winter.
Dulhunty, AF; Gage, PW, 1973
)
0.77
"Glycerol-treated fibers have 90% of their tubular system insulated from the extracellular solution and 10% connected to the extracellular solution through a high resistance."( Impedance of frog skeletal muscle fibers in various solutions.
Clausen, C; Eisenberg, RS; Valdiosera, R, 1974
)
0.97
"The glycerol treatment results in a depression of the resting potential of up to 30 mV."( A lesion of the transverse tubules of skeletal muscle.
Howell, JN, 1969
)
0.73
"Treatment with glycerol, a reducer of brain edema, lowered the concentration of PUT only in CB, MB and MO."( Putrescine as a marker of the effects of 2-chloropropionic acid in the rat brain.
Camón, L; de Vera, N; Martínez, E, 2004
)
0.66
"Treatment with glycerol hyaluronate/carboxymethylcellulose resulted in 19 of 58 patients (33 percent) with no adhesions compared with 6 of 60 adhesion-free patients (10 percent) in the no treatment control group (P = 0.002)."( Prevention of postoperative abdominal adhesions by a novel, glycerol/sodium hyaluronate/carboxymethylcellulose-based bioresorbable membrane: a prospective, randomized, evaluator-blinded multicenter study.
Bauer, JJ; Beck, DE; Cohen, Z; Dayton, MT; Fleshner, PR; Holmdahl, L; Koruda, MJ; Larach, SW; Ludwig, KA; Senagore, AJ; Thirlby, RC; Weiss, EG; Wolff, BG, 2005
)
0.91
"The treatment with glycerol itself, but not Triton X-100 also induced a reversible contraction of the granular cell."( Contractility of isolated stratum granulosum cells.
Juhlin, L; Shelley, WB, 1982
)
0.58
"Rats treated with glycerol and HgCl2 showed rather severe acute renal failure, but the beta-ATP level at 55 min glycerol infusion was 87.3% and 92.4%, respectively, showing difference from that in normal rats."( [Glycerol-loading test in experimental acute renal failure using 31P magnetic resonance spectroscopy of the kidney].
Fukuda, Y; Ishii, H; Ishikawa, I; Shikura, N, 1993
)
1.52
"Treatment with glycerol alone did not induce apoptosis in the transfectants."( Restoration by glycerol of p53-dependent apoptosis in cells bearing the mutant p53 gene.
Matsumoto, H; Ohnishi, K; Ohnishi, T; Takahashi, A; Tamamoto, T; Wang, X, 1999
)
1
"untreated and glycerol occluded vs."( Glycerol accelerates recovery of barrier function in vivo.
Berardesca, E; Distante, F; Fluhr, JW; Gloor, M; Lazzerini, S; Lehmann, L, 1999
)
2.09
"Treatment of glycerol-injected rats with 0.03 mg kg-1 of CPX resulted in no significant improvements in a range of indices of renal function."( Further characterization of the protective effect of 8-cyclopentyl-1,3-dipropylxanthine on glycerol-induced acute renal failure in the rat.
Bowmer, CJ; Collis, MG; Munsey, TS; Panjehshahin, MR; Yates, MS, 1992
)
0.86
"Treatment with glycerol following pretreatment with colchicine, however, induced marked inner ear dysfunction with impaired sense of balance and audition."( The endolymphatic sac and inner ear homeostasis. II: Effect of glycerol on the sensory end organs with or without colchicine pretreatment.
Bagger-Sjöbäck, D; Rask-Andersen, H; Takumida, M, 1989
)
0.86
"Rats treated with glycerol and a hydroxyl radical scavenger, dimethylthiourea (DMTU), had significantly lower blood urea nitrogen (BUN) and creatinine."( Evidence suggesting a role for hydroxyl radical in glycerol-induced acute renal failure.
Shah, SV; Walker, PD, 1988
)
0.85

Toxicity

Glycerol phenylbutyrate (GPB) is safe and effective in reducing ammonia levels. Also, glycerol at high osmolality was not toxic and did not induce aberrations.

ExcerptReferenceRelevance
" The results are tabulated as LD50 ml/kg with 95% confidence limits."( Acute toxicity of various solvents in the mouse and rat. LD50 of ethanol, diethylacetamide, dimethylformamide, dimethylsulfoxide, glycerine, N-methylpyrrolidone, polyethylene glycol 400, 1,2-propanediol and Tween 20.
Bartsch, W; Dietmann, K; Fuchs, G; Sponer, G, 1976
)
0.26
" Both regimens were well tolerated; there were no adverse clinical reactions and no occurrences of phlebitis in either group."( Safety and efficacy of glycerol and amino acids in combination with lipid emulsion for peripheral parenteral nutrition support.
Bradford, RR; Day, AT; Gazzaniga, AB; Stellin, GP; Tominaga, GT; Waxman, K,
)
0.44
" These drugs, however, can sometimes cause adverse ocular or systemic effects."( Adverse effects of antiglaucoma medications.
Bartlett, JD, 1991
)
0.28
"In this study two zinc-oxide-based root canal sealers were compared for their tissue toxic response."( Cytotoxicity of eugenol in sealer containing zinc-oxide.
Aggarwal, PK; Chandra, S; Gulati, N; Jaiswal, JN; Singh, M, 1991
)
0.28
" The antioxidants glutathione, vitamin E and vitamin C reversed toxicity and antimitochondrial activity to a large extent implying that toxic free radical metabolites of the drug are of significance in cellular activity of MGBG."( Effect of antioxidants on the mitochondrial activity and toxicity of the cancer drug methylglyoxal bis (guanylhydrazone) in yeast and mammalian cells.
Cheng, LL; Collier, DC; Wilkie, D, 1990
)
0.28
"5 mg/kg showed any toxic reactions and different patterns of the body weight growth from these in the control group."( Immunological safety assessments of anti-IgE antibody which is detached from therapeutic immunoadsorbents for removing IgE.
Kidaka, T; Sato, H, 1989
)
0.28
" Also, glycerol at high osmolality was not toxic and did not induce aberrations, probably because rapid equilibration across the cell membrane precluded severe osmotic stress to the cells."( Effects of high osmotic strength on chromosome aberrations, sister-chromatid exchanges and DNA strand breaks, and the relation to toxicity.
Armstrong, MJ; Bean, CL; Bradley, MO; Deasy, DA; Galloway, SM; Kraynak, AR, 1987
)
0.73
" Results indicate that the glycerol containing solution is safe and contributes to an improvement in nitrogen homeostasis on a daily and cumulative basis."( Safety and efficacy of a new peripheral intravenously administered amino acid solution containing glycerol and electrolytes.
Bernstein, DM; Fairfull-Smith, R; Freeman, JB; Gazzaniga, AB; Gersovitz, M; Rodman, GH, 1983
)
0.78
" Highly purified, semi-synthetic human insulin offers a safe and effective means to explore the possible advantages of homologous human insulin in the management of diabetes mellitus."( Human insulin: study of safety and efficacy in man.
Alberti, KG; Burrin, JM; Hayes, TM; Heding, LG; Home, PD; Jones, MK; Newcombe, RG; Owens, DR, 1981
)
0.26
"The HOCM, diatrizoate, was more toxic to rat kidneys than the LOCM iohexol; PLA2, LPO and calcium load played a role in producing renal function impairment induced by diatrizoate meglumine; amlodipine protected the renal tissue from nephrotoxicity induced by diatrizoate."( Nephrotoxicity of high- and low-osmolar contrast media. The protective role of amlodipine in a rat model.
Duan, SB; Liu, FY; Liu, RH; Luo, JA; Peng, YM; Wu, HW; Yang, XL, 2000
)
0.31
" Pathologic analysis indicated that the cause of death was hemorrhagic necrosis of the kidneys, most likely caused by a toxic effect on the glomeruli and tubules."( An unexpected outcome during testing of commercially available demineralized bone graft materials: how safe are the nonallograft components?
Bostrom, MP; Dicarlo, E; Kennan, M; Lane, JM; Sandhu, H; Yang, X, 2001
)
0.31
"To evaluate the possible dose-dependent adverse effects of a commercially available demineralized bone matrix containing glycerol."( Dose-dependent toxicity of a commercially available demineralized bone matrix material.
Dawson, EG; Kanim, LE; Nagakawa, IS; Vinters, HV; Wang, JC; Yamane, BH, 2001
)
0.52
" The toxic effects of glycerol leading to acute renal failure have been documented."( Dose-dependent toxicity of a commercially available demineralized bone matrix material.
Dawson, EG; Kanim, LE; Nagakawa, IS; Vinters, HV; Wang, JC; Yamane, BH, 2001
)
0.63
" The rats were observed for adverse effects and early death."( Dose-dependent toxicity of a commercially available demineralized bone matrix material.
Dawson, EG; Kanim, LE; Nagakawa, IS; Vinters, HV; Wang, JC; Yamane, BH, 2001
)
0.31
" Safety was assessed by symptoms and signs (including colposcopy) of genital irritation, review of adverse events, and by changes in vaginal health as assessed by microscopy."( Expanded Phase I safety and acceptability study of 6% cellulose sulfate vaginal gel.
Ali, MM; Callahan, M; Chitlange, S; Hazari, K; Malonza, IM; Mirembe, F; Nakabiito, C; Odusoga, LO; Osinupebi, OA; Van Damme, L, 2005
)
0.33
"A vaginal application of 6% cellulose sulfate twice daily for seven consecutive days is as safe and well tolerated as a similar regimen of K-Y Jelly."( Expanded Phase I safety and acceptability study of 6% cellulose sulfate vaginal gel.
Ali, MM; Callahan, M; Chitlange, S; Hazari, K; Malonza, IM; Mirembe, F; Nakabiito, C; Odusoga, LO; Osinupebi, OA; Van Damme, L, 2005
)
0.33
" The histopathological analysis indicates the absence of inflammation on administration, suggesting that these formulations are safe during the studied period."( Biodegradable in situ gelling system for subcutaneous administration of ellagic acid and ellagic acid loaded nanoparticles: evaluation of their antioxidant potential against cyclosporine induced nephrotoxicity in rats.
Italia, JL; Ravi Kumar, MN; Sharma, G; Sonaje, K; Tikoo, K, 2007
)
0.34
"The LD50 (95% CI) of R, S and (R,S)-3-MCPD were 290."( [Study on acute toxicity of R, S and (R,S)-3-monchloropropane-1,2-diol].
Qian, G; Yin, L; Zhang, G; Zhang, H, 2007
)
0.34
" Strains isolated from acute cases of CBPP induced high cytotoxicity in the presence of glycerol, concomitant with the release of large amounts of toxic H2O2 that were found to be translocated into the cytoplasms of the host cells by close contact of the Mycoplasma strains with the host cells."( Cytotoxicity of Mycoplasma mycoides subsp. mycoides small colony type to bovine epithelial cells.
Bertoni, G; Bischof, DF; Frey, J; Janis, C; Vilei, EM, 2008
)
0.57
" Safety and acceptability appeared similar among the 3 study groups and no serious adverse events related to the study products were reported."( Phase I safety trial of two vaginal microbicide gels (Acidform or BufferGel) used with a diaphragm compared to KY jelly used with a diaphragm.
Ballagh, SA; Barnhart, K; Bell, AJ; Creinin, MD; Jamieson, DJ; Newman, DR; Weiner, DH; Williams, DL, 2007
)
0.34
"Acidform and BufferGel compared to KY Jelly, when used with diaphragm daily for 14 days, appeared to be safe and acceptable in a small study of low-risk abstinent women."( Phase I safety trial of two vaginal microbicide gels (Acidform or BufferGel) used with a diaphragm compared to KY jelly used with a diaphragm.
Ballagh, SA; Barnhart, K; Bell, AJ; Creinin, MD; Jamieson, DJ; Newman, DR; Weiner, DH; Williams, DL, 2007
)
0.34
" HAM were treated in vitro with these test dusts for 24 h; assays of cell viability and apoptosis showed that JSC-1 and TiO2 were comparable, and more toxic than saline control but less toxic than quartz."( Toxicity of lunar and martian dust simulants to alveolar macrophages isolated from human volunteers.
Hamilton, RF; Holian, A; James, JT; Lam, CW; Latch, JN, 2008
)
0.35
" This study aimed to determine the least toxic cryoprotective agent for Haliotis midae embryos."( Preliminary investigation to determine the cytotoxicity of various cryoprotectants on southern African abalone (Haliotis midae) embryos.
Roodt-Wilding, R; Roux, A; Sandenbergh, L, 2008
)
0.35
" First convincingly introduced by Baxter and Lathe in 1971, the concept that certain amides can block toxic effects of dimethyl sulfoxide (Me(2)SO) was contradicted by direct experiments in 1990."( Cryoprotectant toxicity neutralization.
Fahy, GM, 2010
)
0.36
" Adverse events were comparable for the two drugs; 2 subjects experienced hyperammonemic events on NaPBA while none occurred on GPB."( Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control.
Beliveau, M; Berry, SA; Diaz, GA; Dickinson, K; Gargosky, S; Lee, B; Marier, JF; Martinez, A; Mauney, J; Mian, A; Mokhtarani, M; Rhead, W; Scharschmidt, BF; Shchelochkov, O, 2010
)
0.36
" Moreover, patient's assessment of efficacy at Day 10 and the frequency and type of adverse events were noted."( Acute bacterial otitis externa: efficacy and safety of topical treatment with an antibiotic ear drop formulation in comparison to glycerol treatment.
Baues, CM; Mösges, R; Sahin, K; Schröder, T, 2011
)
0.57
" These substances are sorted according to their toxic effect and new excipients not yet used in the respiratory tract like HPMC can be classified in this scheme."( The MTT assay as tool to evaluate and compare excipient toxicity in vitro on respiratory epithelial cells.
Scherliess, R, 2011
)
0.37
" Our aim was to establish how safe and efficacious repeat glycerol rhizotomies were on a study of 179 PGRs performed in our institution."( Percutaneous glycerol rhizotomy for trigeminal neuralgia: safety and efficacy of repeat procedures.
Harries, AM; Mitchell, RD, 2011
)
0.98
" Paclitaxel elastic liposomal formulation seems to be a better alternative for safe and effective delivery of paclitaxel."( Evaluation of biosafety and intracellular uptake of Cremophor EL free paclitaxel elastic liposomal formulation.
Jain, S; Tiwary, AK; Utreja, P, 2012
)
0.38
"Multiple-CPA solutions were significantly less toxic than single-CPA solutions (P<0."( Cryoprotective agent toxicity interactions in human articular chondrocytes.
Almansoori, KA; Elliott, JA; Forbes, JF; Jomha, NM; Law, GK; McGann, LE; Prasad, V, 2012
)
0.38
" PG was the most toxic CPA when used in combinations."( Cryoprotective agent toxicity interactions in human articular chondrocytes.
Almansoori, KA; Elliott, JA; Forbes, JF; Jomha, NM; Law, GK; McGann, LE; Prasad, V, 2012
)
0.38
" In addition, major adverse effects were rare."( Efficacy and safety of endovenous foam sclerotherapy: meta-analysis for treatment of venous disorders.
Norris, A; Rathbun, S; Stoner, J, 2012
)
0.38
"EFS is a safe and effective therapy for the treatment of venous disorders."( Efficacy and safety of endovenous foam sclerotherapy: meta-analysis for treatment of venous disorders.
Norris, A; Rathbun, S; Stoner, J, 2012
)
0.38
" This compound had no toxic effects on human cells in vitro at concentrations up to 34 µM."( Stepwise synthesis of 2,3-O-dipalmitoyl-D-glyceric acid and an in vitro evaluation of its cytotoxicity.
Fukuoka, T; Habe, H; Kitamoto, D; Sakaki, K; Sato, S, 2012
)
0.38
" LD50 (median lethal dose) value of 3-MCPD 1-monopalmitate was determined 2676."( Acute oral toxicity of 3-MCPD mono- and di-palmitic esters in Swiss mice and their cytotoxicity in NRK-52E rat kidney cells.
Gao, BY; Jiang, YR; Liu, M; Luo, W; Ma, AN; Qin, F; Shi, HM; Wu, PP; Xu, XB; Yu, LL, 2012
)
0.38
" Thus BGL003 should be safe and suitable strategy to endow hydrophobic molecules with much hydrophilicity."( Cytotoxicity evaluation of symmetrically branched glycerol trimer in human hepatocellular carcinoma HepG2 cells.
Hattori, H; Ishizawa, K; Kono, M; Matsushita, T; Miyamoto, L; Nemoto, H; Tsuchiya, K; Watanabe, M, 2012
)
0.63
" Evaluation of the panel of products showed Gynol II (a spermicidal gel containing 2% nonoxynol-9), KY Jelly, and Replens were toxic to Lactobacillus."( Is wetter better? An evaluation of over-the-counter personal lubricants for safety and anti-HIV-1 activity.
Brown, ER; Cost, M; Dezzutti, CS; Kunjara Na Ayudhya, RP; Leblanc, MA; Moncla, B; Pickett, J; Pryke, K; Rohan, LC; Russo, J; Uranker, K; Wang, L, 2012
)
0.38
" BGL003 will be safe and suitable approach to improve hydrophilicity of hydrophobic compounds."( Acute oral toxicity evaluation of symmetrically branched glycerol trimer in ddY mice.
Fujii, S; Hattori, H; Ishizawa, K; Kono, M; Matsushita, T; Miyamoto, L; Nemoto, H; Tomida, Y; Tsuchiya, K; Watanabe, M, 2012
)
0.62
" Studies indicate that Cremophors, especially EL, have toxic side effects, but few data are available on endothelial and epithelial cells, which form biological barriers and are directly exposed to these molecules."( Kinetic analysis of the toxicity of pharmaceutical excipients Cremophor EL and RH40 on endothelial and epithelial cells.
Bocsik, A; Deli, MA; Kiss, L; Ozsvári, B; Puskás, LG; Szabó-Révész, P; Veszelka, S; Walter, FR, 2013
)
0.39
" In the meantime, habitats for that exploration, whether mobile or fixed, must be designed to limit human exposure to lunar dust to safe levels."( Estimate of safe human exposure levels for lunar dust based on comparative benchmark dose modeling.
James, JT; Lam, CW; Santana, PA; Scully, RR, 2013
)
0.39
"This study aims to investigate whether overexpressing the trehalose biosynthetic gene, otsBA operon, in β-carotene-producing recombinant Escherichia coli protects cells from toxic impurities in crude glycerol."( Improved tolerance of recombinant Escherichia coli to the toxicity of crude glycerol by overexpressing trehalose biosynthetic genes (otsBA) for the production of β-carotene.
Kim, CJ; Kim, SB; Kim, YG; Nguyen, Ado Q, 2013
)
0.81
" The LD50 value of 3-MCPD dipalmitate was determined to be 1780 mg/kg body weight (bw) for Wistar rats."( The toxicity of 3-chloropropane-1,2-dipalmitate in Wistar rats and a metabonomics analysis of rat urine by ultra-performance liquid chromatography-mass spectrometry.
Du, X; Li, J; Shi, W; Sun, C; Wang, M; Wang, S, 2013
)
0.39
" PAA plasma levels ≥ 500 μg/dL have been reported to be associated with reversible neurological adverse events (AEs) in cancer patients receiving PAA intravenously."( Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Bartley, J; Berquist, W; Berry, SA; Brown, RS; Coakley, D; Diaz, GA; Dickinson, K; Feigenbaum, A; Gallagher, R; Ghabril, M; Harding, C; Lee, B; Lemons, C; Lichter-Konecki, U; Longo, N; Mantry, P; McCandless, SE; Milikien, DA; Mokhtarani, M; Moors, T; Nagamani, SC; Norris, C; Rhead, W; Rockey, DC; Scharschmidt, BF; Schulze, A; Smith, W; Vierling, JM, 2013
)
0.39
"The toxic effects of paclitaxel (PTX) and its solubilizing agent cremophor EL (CREL) have been well established in vitro; however, the in vivo mechanisms underlying this toxicity remain unclear."( Systemic toxicity induced by paclitaxel in vivo is associated with the solvent cremophor EL through oxidative stress-driven mechanisms.
Campos, FC; Cecchini, AL; Cecchini, R; Martins-Pinge, MC; Panis, C; Victorino, VJ, 2014
)
0.4
" After 24h exposure, Acticoat™ and Flamazine™ cream were toxic to all tested cell lines."( Cytotoxicity testing of silver-containing burn treatments using primary and immortal skin cells.
Boonkaew, B; Cuttle, L; Kempf, M; Kimble, R, 2014
)
0.4
" Although it is difficult to prove that the search is complete, and it is possible that side-effects remain unreported, the combination of glycerol, hydroxyethyl cellulose and purified water is considered to be safe for intrauterine application and tubal patency testing, indicating an optimal risk-benefit ratio in clinical use."( Safety aspects and side-effects of ExEm-gel and foam for uterine cavity distension and tubal patency testing.
Emanuel, MH; Exalto, N; Stassen, M, 2014
)
0.6
" In this work, cholinium-based DESs comprised of choline chloride (ChCl) and choline acetate (ChAc) as the salt and urea (U), acetamide (A), glycerol (G) and ethylene glycol (EG) as the HBD were evaluated for their toxic effects on different living organisms such as Escherichia coli (a bacterium), Allium sativum (garlic, a plant) and hydra (an invertebrate), and their biodegradabilities were assessed by means of closed bottle tests."( Assessing the toxicity and biodegradability of deep eutectic solvents.
Chen, JX; Tang, YL; Wang, J; Wen, Q; Yang, Z, 2015
)
0.62
" The most efficient cationic vectors such as polyethylene imine (PEI) or polyamidoamine (PAMAM) can be highly toxic and may induce strong side effects due to their high cationic charge densities."( Systematic adjustment of charge densities and size of polyglycerol amines reduces cytotoxic effects and enhances cellular uptake.
Achazi, K; Haag, R; Hellmund, M; Ma, N; Neumann, F; Thota, BN, 2015
)
0.66
"The development of safe and effective delivery vectors is a great challenge for the medicinal application of RNA interference (RNAi)."( Amino Acid-Functionalized Dendritic Polyglycerol for Safe and Effective siRNA Delivery.
Cromwell, O; Guan, Z; Haag, R; Hellmund, M; Schlesener, C; Zeng, H, 2015
)
0.68
" Recently, we described a mathematical strategy for identifying minimally toxic CPA equilibration procedures based on the minimization of a toxicity cost function."( Toxicity Minimized Cryoprotectant Addition and Removal Procedures for Adherent Endothelial Cells.
Benson, JD; Davidson, AF; Glasscock, C; Higgins, AZ; McClanahan, DR, 2015
)
0.42
" Compared to inorganic arsenic, ROX was less toxic to wheat root elongation."( Phytotoxicity and uptake of roxarsone by wheat (Triticum aestivum L.) seedlings.
Blaney, L; Fu, QL; Zhou, DM, 2016
)
0.43
" Safe and acceptable topical HIV prevention methods that target the rectum are needed."( MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel.
Bekker, LG; Carballo-Diéguez, A; Chariyalertsak, S; Chitwarakorn, A; Cranston, RD; Galaska, B; Gonzales, P; Grossman, C; Hendrix, CW; Ho, KS; Holtz, TH; Jacobson, CE; Johnson, S; Kunjara Na Ayudhya, RP; Lama, JR; Leu, CS; Liu, AY; Liu, K; Lucas, J; Marzinke, MA; Mayer, KH; McGowan, I; Parikh, UM; Patterson, KB; Pickett, J; Piper, JM; Richardson, BA; Rooney, J; Schwartz, JL; Zorrilla, C, 2017
)
0.46
"Rectal application of RG TFV gel was safe in MSM and TGW."( MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel.
Bekker, LG; Carballo-Diéguez, A; Chariyalertsak, S; Chitwarakorn, A; Cranston, RD; Galaska, B; Gonzales, P; Grossman, C; Hendrix, CW; Ho, KS; Holtz, TH; Jacobson, CE; Johnson, S; Kunjara Na Ayudhya, RP; Lama, JR; Leu, CS; Liu, AY; Liu, K; Lucas, J; Marzinke, MA; Mayer, KH; McGowan, I; Parikh, UM; Patterson, KB; Pickett, J; Piper, JM; Richardson, BA; Rooney, J; Schwartz, JL; Zorrilla, C, 2017
)
0.46
" Toxic properties of 3-MCPD in kidney and testis have extensively been characterized."( Comparative proteomic analysis of 2-MCPD- and 3-MCPD-induced heart toxicity in the rat.
Braeuning, A; Buhrke, T; Frenzel, F; Lampen, A; Oberemm, A; Schultrich, K, 2017
)
0.46
" The activation of opioid receptors in peripheral inflamed tissue can reduce pain without central adverse effects such as sedation, apnoea, or addiction."( Polyglycerol-opioid conjugate produces analgesia devoid of side effects.
González-Rodríguez, S; Gupta, S; Haag, R; Joseph, J; Labuz, D; Machelska, H; Parr, MK; Quadir, MA; Rodriguez-Gaztelumendi, A; Schmelz, M; Spahn, V; Stein, C; Walker, KA; Zhang, X, 2017
)
1.01
"890 mg VG/L) were observed, and no adverse effects for PG/VG/nicotine were observed up to 438/544/6."( Toxicity of the main electronic cigarette components, propylene glycol, glycerin, and nicotine, in Sprague-Dawley rats in a 90-day OECD inhalation study complemented by molecular endpoints.
Elamin, A; Esposito, M; Guedj, E; Ho, J; Hoeng, J; Ivanov, NV; Kogel, U; Krishnan, S; Lebrun, S; Leroy, P; Martin, F; Nury, C; Peitsch, MC; Phillips, B; Schlage, WK; Sciuscio, D; Sharma, D; Titz, B; Vanscheeuwijck, P; Veljkovic, E; Vuillaume, G; Xiang, Y, 2017
)
0.46
" Safety endpoints included adverse events, hyperammonemic crises (HACs), and growth and development."( Safety and efficacy of glycerol phenylbutyrate for management of urea cycle disorders in patients aged 2months to 2years.
Berry, SA; Diaz, GA; Ficicioglu, C; Harding, CO; Lichter-Konecki, U; Longo, N; McCandless, SE; Robinson, B; Smith, WE; Vockley, J; Zori, R, 2017
)
0.77
" Adverse events occurring in at least 10% of patients while on GPB were neutropenia, vomiting, diarrhea, pyrexia, hypophagia, cough, nasal congestion, rhinorrhea, rash/papule."( Safety and efficacy of glycerol phenylbutyrate for management of urea cycle disorders in patients aged 2months to 2years.
Berry, SA; Diaz, GA; Ficicioglu, C; Harding, CO; Lichter-Konecki, U; Longo, N; McCandless, SE; Robinson, B; Smith, WE; Vockley, J; Zori, R, 2017
)
0.77
"GPB was safe and effective in UCD patients aged 2months to 2years."( Safety and efficacy of glycerol phenylbutyrate for management of urea cycle disorders in patients aged 2months to 2years.
Berry, SA; Diaz, GA; Ficicioglu, C; Harding, CO; Lichter-Konecki, U; Longo, N; McCandless, SE; Robinson, B; Smith, WE; Vockley, J; Zori, R, 2017
)
0.77
" Our data demonstrated that the PG/VG vehicle adversely affected cell viability and that a large number of e-liquids were more toxic than PG/VG."( Evaluation of e-liquid toxicity using an open-source high-throughput screening assay.
Davis, ES; Glish, GL; Keating, JE; Kochar, TK; Sassano, MF; Tarran, R; Wolfgang, MC; Zorn, BT, 2018
)
0.48
" Therefore, complementary work is needed to find the best dose and formulation of NaDES that are safe for the environment and animals and ultimately for humans."( Toxicity of Natural Deep Eutectic Solvent Betaine:Glycerol in Rats.
Benlebna, M; Bonafos, B; Casas, F; Coudray, C; Cruz Figueroa-Espinoza, M; Durand, E; Feillet-Coudray, C; Fouret, G; Ruesgas-Ramón, M, 2018
)
0.73
" Obtained data indicate toxic consequences of 2-MCPD exposure in the kidney and provide evidence that 2-MCPD exerts its cellular effects in rat kidney by mechanisms different from 3-MCPD."( Proteomic analysis of 2-monochloropropanediol (2-MCPD) and 2-MCPD dipalmitate toxicity in rat kidney and liver in a 28-days study.
Braeuning, A; Frenzel, F; Lampen, A; Oberemm, A, 2018
)
0.48
" Based on this, the present research evaluated the toxic effects of both compounds in different biological models through the investigation of survival and mortality percentages as a measure of acute toxicity on Daphnia similis and Oreochromis niloticus, larvicidal assay against Aedes aegypti, and cytotoxic activity on mammary cells."( Assessment of acute toxicity and cytotoxicity of fluorescent markers produced by cardanol and glycerol, which are industrial waste, to different biological models.
Antoniolli-Silva, ACMB; Beatriz, A; Braga, FC; Crispim, BDA; de Barros, LGML; de Lima, DP; de Souza, AP; Dos Santos Jaques, JA; Grisolia, AB; Oliveira, EJT; Oliveira, RJ; Pelizaro, BI; Pessatto, LR; Vani, JM, 2019
)
0.73
" The stability study indicated that the system was stable for storage and dilution with distilled water, while the safety testing showed that the micelle was safe for intravenous administration with low hemolysis rates and low allergic reaction rates."( A Novel Dantrolene Sodium-Loaded Mixed Micelle Containing a Small Amount of Cremophor EL: Characterization, Stability, Safety and Pharmacokinetics.
Jiang, D; Jin, W; Li, H; Meng, Y; Song, H; Tan, X; Wen, J; Zhang, Y; Zheng, W, 2019
)
0.51
" The primary endpoint was the rate of adverse events (AEs)."( Long-term safety and efficacy of glycerol phenylbutyrate for the management of urea cycle disorder patients.
Bartholomew, D; Berquist, W; Berry, SA; Canavan, C; Diaz, GA; Feigenbaum, A; Gallagher, RC; Harding, CO; Holt, RJ; Lichter-Konecki, U; Longo, N; McCandless, SE; Merritt, JL; Rhead, W; Schulze, A; Smith, WE; Vescio, T; Vockley, J; Wong, D; Zori, R, 2019
)
0.8
" The treatment emergent adverse events (TEAE) reported in ≥10% of adult or pediatric patients were consistent with the TEAEs reported in the previous safety extension studies with no increase in the overall incidence of TEAEs and no new TEAEs that indicated a new safety signal."( Long-term safety and efficacy of glycerol phenylbutyrate for the management of urea cycle disorder patients.
Bartholomew, D; Berquist, W; Berry, SA; Canavan, C; Diaz, GA; Feigenbaum, A; Gallagher, RC; Harding, CO; Holt, RJ; Lichter-Konecki, U; Longo, N; McCandless, SE; Merritt, JL; Rhead, W; Schulze, A; Smith, WE; Vescio, T; Vockley, J; Wong, D; Zori, R, 2019
)
0.8
"86) years in the present study with continued maintenance of ammonia control, similar rates of adverse events, and no new adverse events identified."( Long-term safety and efficacy of glycerol phenylbutyrate for the management of urea cycle disorder patients.
Bartholomew, D; Berquist, W; Berry, SA; Canavan, C; Diaz, GA; Feigenbaum, A; Gallagher, RC; Harding, CO; Holt, RJ; Lichter-Konecki, U; Longo, N; McCandless, SE; Merritt, JL; Rhead, W; Schulze, A; Smith, WE; Vescio, T; Vockley, J; Wong, D; Zori, R, 2019
)
0.8
" The Panel concluded that glycerin is safe as a cosmetic ingredient in the practices of use and concentration described in this safety assessment."( Safety Assessment of Glycerin as Used in Cosmetics.
Becker, LC; Belsito, DV; Bergfeld, WF; Gill, LJ; Heldreth, B; Hill, RA; Klaassen, CD; Liebler, DC; Marks, JG; Shank, RC; Slaga, TJ; Snyder, PW,
)
0.13
" A safety evaluation was so performed by calculating the systemic exposure damage, and the results were finally considered to be safe for consumers."( Development of a HS-SPME-GC-MS method for the analysis of phthalates in glycerin and liquid paraffin: application to safety evaluation of cosmetic packagings.
Coslédan, S; Ferret, PJ; Murat, P; Simon, V, 2020
)
0.56
" Glycerol phenylbutyrate (GPB) is safe and effective in reducing ammonia levels in patients with UCD above 2 months of age."( Glycerol phenylbutyrate efficacy and safety from an open label study in pediatric patients under 2 months of age with urea cycle disorders.
Ah Mew, N; Bannick, AA; Berry, SA; Canavan, C; Conway, RL; Diaz, GA; Hainline, B; Inbar-Feigenberg, M; Kok, T; Lichter-Konecki, U; Longo, N; McCandless, SE; Porter, MH; Schulze, A; Vescio, T; Zori, R, 2021
)
2.97
" All patients reported at least 1 treatment emergent adverse event with gastroesophageal reflux disease, vomiting, hyperammonemia, diaper dermatitis (37."( Glycerol phenylbutyrate efficacy and safety from an open label study in pediatric patients under 2 months of age with urea cycle disorders.
Ah Mew, N; Bannick, AA; Berry, SA; Canavan, C; Conway, RL; Diaz, GA; Hainline, B; Inbar-Feigenberg, M; Kok, T; Lichter-Konecki, U; Longo, N; McCandless, SE; Porter, MH; Schulze, A; Vescio, T; Zori, R, 2021
)
2.06
" Moreover, we describe the associated toxicity components in e-cigarettes, as well as the potential mechanism by which e-cigarettes exert toxic effects."( Toxicity of electronic cigarettes: A general review of the origins, health hazards, and toxicity mechanisms.
Cao, Y; Li, F; Li, M; Ma, X; Ma, Y; Wang, S; Wu, D; Zhang, T, 2021
)
0.62
" We conducted three experiments to: 1) evaluate the short-term in vitro toxicity of common CPAs in two closely related snake species, 2) determine the effectiveness of cryoprotectants for freezing and thawing semen in the Louisiana pinesnake, and 3) test the possible reduction in toxic effects of individual CPAs on semen of the Louisiana pinesnake by combining two of them."( Toxicity of cryoprotective agents to semen from two closely related snake species: The endangered Louisiana pinesnake (Pituophis ruthveni) and bullsnake (Pituophis cantenifer).
Reichling, S; Roberts, BM; Sandfoss, MR; Whittington, OM, 2021
)
0.62
"Most flavors used in e-liquids are generally recognized as safe for oral consumption, but their potential effects when inhaled are not well characterized."( Assessment of inhalation toxicity of cigarette smoke and aerosols from flavor mixtures: 5-week study in A/J mice.
Ashutosh, K; Cammack, L; Chia, C; Chua, CS; Corciulo, M; Diana, P; Glabasnia, A; Hoeng, J; Ivanov, N; Lee, KM; Leroy, P; Luettich, K; Merg, C; Moine, F; Peitsch, M; Piault, R; Sciuscio, D; Smith, C; Tung, CK; Vanscheeuwijck, P; Wong, ET, 2022
)
0.72
"05% lotion delivered in a proprietary blend of hydrating ingredients offers a safe and efficacious option that has minimal downtime for patients seeking non-procedural photo-rejuvenation of the chest."( A Prospective, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Efficacy, Safety, and Patient Satisfaction of Tretinoin 0.05% Lotion for Chest Rejuvenation.
Almukhtar, R; Angra, K; Fabi, S; Gonzalez, A; Lipp, M; Wood, E, 2022
)
0.72
" However, its therapeutic index is narrow, and it is prone to adverse side effects, along with an increased risk of toxicity, namely, cardio-, nephro-, hepato-, and neurotoxicity."( The effect of tacrolimus-induced toxicity on metabolic profiling in target tissues of mice.
Dang, R; Guo, J; Han, W; Li, Y; Meng, J; Si, Q; Wang, S; Wei, N; Wu, L; Xie, D, 2022
)
0.72
" OBJECTİVE: To investigate the toxic effects of different cryoprotectants and osmotic stress on Awassi ram sperm and to determine the relationship between oxidative and antioxidative status of the sperm."( Relationship between toxicity of cryoprotectants, osmotic and oxidative stresses in awassi ram sperm.
Aydilek, N; Bozkaya, F; Taskin, A; Varisli, O,
)
0.13
"Cryoprotectants without other additives have limited protection and glycerol can be toxic to spermatozoa."( Relationship between toxicity of cryoprotectants, osmotic and oxidative stresses in awassi ram sperm.
Aydilek, N; Bozkaya, F; Taskin, A; Varisli, O,
)
0.37

Pharmacokinetics

Healthy, mildly overweight (BMI = 25) subjects were administered the respective treatment. Body surface temperature, resting metabolic rate, blood pressure, heart rate, glucose, glycerol, nonesterified fatty acids, triglycerides were obtained for 8 hours post dose.

ExcerptReferenceRelevance
" The mean residence time and half-life were 20."( The pharmacokinetics of gamma-glutamyl-L-dopa in normal and anephric rats and rats with glycerol-induced acute renal failure.
Barber, HE; Boateng, YA; Lee, MR; MacDonald, TM; Petrie, JC; Whiting, PH, 1990
)
0.5
" The pharmacokinetic changes seen at a dose of 1 mg/kg, after jugular vein administration, were significant decreases in uraemic rats in the rate of entry of ICG into the liver (k12) and in the rate of movement of dye from liver to plasma (k21)."( The plasma clearance of indocyanine green in rats with acute renal failure: effect of dose and route of administration.
Bowmer, CJ; Emmerson, J; Yates, MS, 1983
)
0.27
" As only limited pharmacokinetic data after oral administration are available, studies were performed in 10 healthy subjects (2 female, 8 male, body weight 58-90 kg, age 23-47 years)."( Pharmacokinetics of glycerol administered orally in healthy volunteers.
Nau, R; Prange, HW; Sommer, S; Wieland, E, 1993
)
0.61
"Studies in humans and mice have demonstrated a nonlinear pharmacokinetic behavior of paclitaxel."( Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
Beijnen, JH; Nooijen, WJ; Sparreboom, A; van Tellingen, O, 1996
)
0.29
" Pharmacokinetic sampling was performed during the first and the second course, and the samples were analyzed using a validated high-performance liquid chromatographic assay."( Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol) and carboplatin in non-small cell lung cancer patients.
Beijnen, JH; Boschma, MU; Giaccone, G; Huizing, MT; Meerum Terwogt, J; Nannan Panday, VR; Schellens, JH; ten Bokkel Huinink, WW; van Tellingen, O; Veenhof, CH, 2000
)
0.31
" Based on these findings, we prospectively re-evaluated the linearity of paclitaxel disposition in patients using whole blood and plasma analysis, and sought to define a new pharmacokinetic model to describe the data."( Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles.
Brouwer, E; de Bruijn, P; Karlsson, MO; Nooter, K; Sparreboom, A; Stoter, G; van Zuylen, L; Verweij, J, 2001
)
0.31
" Pharmacokinetic parameters of unbound and total cisplatin and of topotecan lactone and total drug were not significantly different from historic control values (P>or=0."( Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies.
Brouwer, E; de Jonge, MJ; Gelderblom, H; Loos, WJ; Nooter, K; Sparreboom, A; Stoter, G; van der Burg, ME; Verweij, J, 2002
)
0.31
"1 of paclitaxel suggests that the drugs might also interact at the pharmacodynamic level."( Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients.
Baldini, E; Bocci, G; Conte, PF; Danesi, R; Del Tacca, M; Di Paolo, A; Fogli, S; Gennari, A; Innocenti, F; Salvadori, B, 2002
)
0.31
"The purpose of this study was to develop a population pharmacokinetic model for Cremophor EL used as a formulation vehicle for paclitaxel."( A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
Beijnen, JH; Mathôt, RA; Schellens, JH; van den Bongard, HJ; van Tellingen, O, 2002
)
0.31
" The nonlinear mixed-effect modelling (NONMEM) program was used for the population pharmacokinetic analysis."( A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
Beijnen, JH; Mathôt, RA; Schellens, JH; van den Bongard, HJ; van Tellingen, O, 2002
)
0.31
" The following pharmacokinetic parameters were estimated: volume of the central compartment (V1=2."( A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
Beijnen, JH; Mathôt, RA; Schellens, JH; van den Bongard, HJ; van Tellingen, O, 2002
)
0.31
"The population model was able to adequately describe the pharmacokinetic parameters and influence of covariates on the pharmacokinetics of Cremophor EL."( A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
Beijnen, JH; Mathôt, RA; Schellens, JH; van den Bongard, HJ; van Tellingen, O, 2002
)
0.31
" The hypersensitivity evaluation and pharmacokinetic behavior in rats were conducted to assess the new microemulsion."( An alternative paclitaxel microemulsion formulation: hypersensitivity evaluation and pharmacokinetic profile.
He, L; Wang, GL; Zhang, Q, 2003
)
0.32
" The objective of the present study was to compare the pharmacodynamic responses of ephedrine and sibutramine using surrogate markers of weight loss potential and potential adverse events."( Comparison of the acute pharmacodynamic responses after single doses of ephedrine or sibutramine in healthy, overweight volunteers.
Balderson, DE; Brouwer, KL; Lancaster, ME; Ng, C; Paulik, MA; Persky, AM; Song, MH, 2004
)
0.32
" Healthy, mildly overweight (BMI = 25) subjects were administered the respective treatment and pharmacokinetic and pharmacodynamic measurements (body surface temperature, resting metabolic rate, blood pressure, heart rate, glucose, glycerol, nonesterified fatty acids, triglycerides) were obtained for 8 hours post dose and for an additional 4 measurements during the sibutramine treatment period."( Comparison of the acute pharmacodynamic responses after single doses of ephedrine or sibutramine in healthy, overweight volunteers.
Balderson, DE; Brouwer, KL; Lancaster, ME; Ng, C; Paulik, MA; Persky, AM; Song, MH, 2004
)
0.51
" The goal of this study was to develop a semimechanistic population pharmacokinetic model to study the influence of CrEL on the oral absorption of paclitaxel."( Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.
Beijnen, JH; de Jonge, ME; Huitema, AD; Rodenhuis, S; Schellens, JH, 2005
)
0.33
" A population pharmacokinetic model was developed using the nonlinear mixed effect modelling program NONMEM."( Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.
Beijnen, JH; de Jonge, ME; Huitema, AD; Rodenhuis, S; Schellens, JH, 2005
)
0.33
" Covariate analysis did not reveal significant relationships with any of the pharmacokinetic parameters."( Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.
Beijnen, JH; de Jonge, ME; Huitema, AD; Rodenhuis, S; Schellens, JH, 2005
)
0.33
"A pharmacokinetic model was developed that described the pharmacokinetics of orally administered paclitaxel."( Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.
Beijnen, JH; de Jonge, ME; Huitema, AD; Rodenhuis, S; Schellens, JH, 2005
)
0.33
"The pharmacokinetics of panipenem in experimental renal failure animal models was investigated in order to identify the appropriate covariates affecting the pharmacokinetic behavior."( Quantitative evaluation of effect of renal failure on the pharmacokinetics of panipenem in rats.
Ishizuka, H; Naganuma, H; Soma, M; Tajima, N, 2005
)
0.33
"The aim of this study was to increase the understanding on the pharmacokinetic and tissue distribution of paclitaxel as influenced by formulation approach."( In vivo pharmacokinetic and tissue distribution studies in mice of alternative formulations for local and systemic delivery of Paclitaxel: gel, film, prodrug, liposomes and micelles.
Dhanikula, AB; Panchagnula, R; Singh, DR, 2005
)
0.33
" The purpose was to compare the two pharmacokinetic model structures when only total paclitaxel concentrations are available."( Comparison of two types of population pharmacokinetic model structures of paclitaxel.
Fransson, M; Gréen, H, 2008
)
0.35
" The pharmacokinetic behavior may depend on the interval between the intravenous administration of the two drugs."( Paclitaxel and pegylated liposomal doxorubicin in recurrent head and neck cancer: clinical and unexpected pharmacokinetic interactions.
Airoldi, M; Cattel, L; Dosio, F; Garzaro, M; Milla, P; Pedani, F,
)
0.13
" Co-administration of PLD markedly reduced Cmax and the area under the curve (AUC), and increased PTX clearance."( Paclitaxel and pegylated liposomal doxorubicin in recurrent head and neck cancer: clinical and unexpected pharmacokinetic interactions.
Airoldi, M; Cattel, L; Dosio, F; Garzaro, M; Milla, P; Pedani, F,
)
0.13
" The PTX pharmacokinetic profile was unexpectedly affected by different administration time intervals; in the 0 h arm the AUC was reduced to one fourth, therefore a schedule with PTX on day one, PLD on day two may be preferred."( Paclitaxel and pegylated liposomal doxorubicin in recurrent head and neck cancer: clinical and unexpected pharmacokinetic interactions.
Airoldi, M; Cattel, L; Dosio, F; Garzaro, M; Milla, P; Pedani, F,
)
0.13
" Body weight change and neutropenia were assessed as pharmacodynamic markers of toxicity."( Differential pharmacodynamic effects of paclitaxel formulations in an intracranial rat brain tumor model.
Harrold, JM; Mager, DE; Mazurchuk, RV; Straubinger, RM; Tamburlin, JH; Zhou, R, 2010
)
0.36
" Plasma pharmacokinetic parameters of valspodar in its polymeric micellar formulation were compared to its clinical formulation, which uses Cremophor EL and ethanol as solubilizing agents."( Development of a polymeric micellar formulation for valspodar and assessment of its pharmacokinetics in rat.
Binkhathlan, Z; Brocks, DR; Hamdy, DA; Lavasanifar, A, 2010
)
0.36
" For the 340 mg/m(2) treatment arm, AUC(INF) was similar between both formulations; Cmax was 17% lower for the suspension versus the injection formulation."( Tanespimycin pharmacokinetics: a randomized dose-escalation crossover phase 1 study of two formulations.
Berman, D; Burris, HA; Jones, S; Murthy, B, 2011
)
0.37
" In this study we used the population pharmacokinetic approach to explore the influence of predicted Cremophor EL concentrations on paclitaxel (Taxol) metabolites."( Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model.
Fransson, MN; Friberg, LE; Gréen, H; Litton, JE, 2011
)
0.37
" The results of pharmacokinetic and distribution properties of PTX in the microemulsion were similar to those of the PTX injection."( A novel paclitaxel microemulsion containing a reduced amount of Cremophor EL: pharmacokinetics, biodistribution, and in vivo antitumor efficacy and safety.
Chen, S; Nie, SF; Pan, WS; Wang, X; Wang, Y; Wu, KC; Zhang, Q; Zhang, X; Zhao, BX; Zhao, X, 2011
)
0.37
" Both acute hepatic and renal failure resulted in significantly increased area under the curve (AUC), prolonged elimination half-life (t(1/2β)), and reduced total body clearance (Cl(tot)) compared with respective controls (P<0."( Effects of acute hepatic and renal failure on pharmacokinetics of flunixin meglumine in rats.
Hwang, YH; Yun, HI, 2011
)
0.37
"The two formulations presented different pharmacokinetic behaviour."( Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion.
Chen, X; Liu, X; Scott, H; Sun, J; Wang, S; Zhang, Q; Zhang, X, 2012
)
0.38
" This study was designed to clarify changes in HGF pharmacokinetics in renal failure and to establish a pharmacokinetic model applicable to single and repeated doses."( Pharmacokinetic modeling of hepatocyte growth factor in experimental animals and humans.
Abe, T; Adachi, K; Fukuta, K; Kato, Y; Matsumoto, K; Nakamichi, N; Nakamura, T; Sano, K; Sugiura, T; Takahashi, S, 2013
)
0.39
"Management of a lipophilic-hydrophilic balance is a key element in drug design to achieve desirable pharmacokinetic characters."( A novel prodrug strategy for extremely hydrophobic agents: conjugation to symmetrically branched glycerol trimer improves pharmacological and pharmacokinetic properties of fenofibrate.
Abe, S; Hattori, H; Ishizawa, K; Kamiya, M; Kono, M; Matsushita, T; Miyamoto, L; Nemoto, H; Taoka, C; Tomida, Y; Tsuchiya, K; Watanabe, M, 2013
)
0.61
" In the present study, intracellular uptake, repeated dose 28 days sub-acute toxicity, anti-cancer activity, biodistribution and pharmacokinetic studies were conducted to determine in vivo performance of CF-PTX formulation in comparison to marketed paclitaxel formulation."( Anti-cancer, pharmacokinetic and biodistribution studies of cremophor el free alternative paclitaxel formulation.
Jain, SK; Kumar, N; Mahajan, M; Roy, P; Tiwary, AK; Utreja, P, 2014
)
0.4
" In vivo anti-cancer activity of CF-PTX was evaluated using Ehrlich ascites carcinoma (EAC) model in mice followed by biodistribution and pharmacokinetic studies."( Anti-cancer, pharmacokinetic and biodistribution studies of cremophor el free alternative paclitaxel formulation.
Jain, SK; Kumar, N; Mahajan, M; Roy, P; Tiwary, AK; Utreja, P, 2014
)
0.4
" Pharmacokinetic and biodistribution studies showed sustained plasma concentration of paclitaxel depicted by higher mean residence time (MRT; 18."( Anti-cancer, pharmacokinetic and biodistribution studies of cremophor el free alternative paclitaxel formulation.
Jain, SK; Kumar, N; Mahajan, M; Roy, P; Tiwary, AK; Utreja, P, 2014
)
0.4
" In this study, HGF was administered after the onset of renal injury, and pharmacokinetic analysis was performed simultaneously with an efficacious dose."( Pharmacokinetics and pharmacodynamics following intravenous administration of recombinant human hepatocyte growth factor in rats with renal injury.
Abe, T; Adachi, E; Adachi, K; Fukuta, K; Hirose-Sugiura, T; Ikebuchi, F; Kato, Y; Matsumoto, K; Yamashita, A, 2014
)
0.4
" In the pharmacokinetic study, rats subjected to glycerol injection or renal ischemia-reperfusion were used as models of AKI, and rats subjected to 5/6 nephrectomy were used as models of chronic kidney disease (CKD)."( Pharmacokinetics and pharmacodynamics following intravenous administration of recombinant human hepatocyte growth factor in rats with renal injury.
Abe, T; Adachi, E; Adachi, K; Fukuta, K; Hirose-Sugiura, T; Ikebuchi, F; Kato, Y; Matsumoto, K; Yamashita, A, 2014
)
0.66
"0 mg/kg, the elevation of blood urea nitrogen was suppressed, indicating that HGF had a pharmacodynamic effect."( Pharmacokinetics and pharmacodynamics following intravenous administration of recombinant human hepatocyte growth factor in rats with renal injury.
Abe, T; Adachi, E; Adachi, K; Fukuta, K; Hirose-Sugiura, T; Ikebuchi, F; Kato, Y; Matsumoto, K; Yamashita, A, 2014
)
0.4
" One participant had Tmax of 30 minutes."( Nicotine delivery, retention and pharmacokinetics from various electronic cigarettes.
Benowitz, NL; Dempsey, DA; Havel, C; Jacob, P; St Helen, G, 2016
)
0.43
" Although the average maximum plasma nicotine concentration in experienced e-cigarette users appears to be generally lower than what has been reported from tobacco cigarette use, the shape of the pharmacokinetic curve is similar, suggesting addictive potential."( Nicotine delivery, retention and pharmacokinetics from various electronic cigarettes.
Benowitz, NL; Dempsey, DA; Havel, C; Jacob, P; St Helen, G, 2016
)
0.43
"The aim of the present study was to determine whether Cremophor EL is a suitable surfactant that can be routinely applied to pharmacokinetic (PK) studies in early drug discovery without influencing the intrinsic PK characteristics of the new chemical entities (NCEs)."( Use of solubilizers in preclinical formulations: Effect of Cremophor EL on the pharmacokinetic properties on early discovery compounds.
Gordon, WP; Groessl, T; Liu, B; Richmond, W; Tuntland, T, 2016
)
0.43
"In this study of 14 days each of vaginal and rectal application of TFV reduced-glycerin 1% gel, we found only a small degree of cross-compartment distribution of TFV in RF and vaginal fluids and no pharmacodynamic activity in ex vivo testing."( Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing.
Balar, B; Dai, JY; Dezzutti, CS; Galaska, B; Hendrix, CW; Justman, JE; Kunjara Na Ayudhya, RP; Levy, L; Marzinke, MA; McGowan, I; Mushamiri, I; Nair, GL; Pan, Z; Piper, JM; Schwartz, JL, 2018
)
0.48
" Pharmacokinetic evaluations confirmed the longer retention of PTX in systemic circulation."( Formulation, optimization, hemocompatibility and pharmacokinetic evaluation of PLGA nanoparticles containing paclitaxel.
Ajmal, G; Bonde, GV; Kapoor, R; Mishra, B; Mittal, A; Mittal, P; Vardhan, H, 2019
)
0.51
" Pharmacokinetic (PK) studies were conducted in mice and the SBE-β-CD based formulation was compared with the Cremophor EL formulation."( Pharmacokinetic modeling of the blood-stable camptothecin analog AR-67 in two different formulations.
Adane, E; Leggas, M; Liu, X; Tang, F, 2019
)
0.51

Compound-Compound Interactions

Glycerol combined with IPL to enhance the transfer efficacy of IPL energy. Possible synergistic effect of royal jelly in combination with glycerol and dimethyl sulfoxide (DMSO) in sperm cryopreservation extender of Romanov ram.

ExcerptReferenceRelevance
"The [K+]/[Na+] ratio of rabbit renal cortical slices was used to examine, at 25 degrees C, the effects on viability of three cryoprotectant agents (CPA) (dimethyl sulfoxide (Me2SO), ethylene glycol, and glycerol) in combination with three vehicle solutions (Krebs-Henseleit (K-H), solution A, and RPS-2)."( Factors influencing renal cryopreservation. II. Toxic effects of three cryoprotectants in combination with three vehicle solutions in nonfrozen rabbit cortical slices.
Clark, P; Fahy, GM; Karow, AM, 1984
)
0.46
"Sixteen patients with intracerebral tumors received intraarterial cisplatin, teniposide, and BCNU combined with intravenous cisplatin, teniposide, and cytosine arabinoside."( Feasibility study of intraarterial vs intravenous cisplatin, BCNU, and teniposide combined with systemic cisplatin, teniposide, cytosine arabinoside, glycerol and mannitol in the treatment of primary and metastatic brain tumors.
Belanger, G; Benoit, B; DaSilva, V; Grahovac, Z; Hugenholtz, H; Richard, MT; Russell, N; Stewart, DJ, 1993
)
0.49
" Keratinocyte grafted areas without cadaver skin overgraft showed less mechanical stability than when the keratinocyte-fibrin glue suspension was combined with allogeneic STSG."( Cologne Burn Centre experience with glycerol-preserved allogeneic skin: Part II: Combination with autologous cultured keratinocytes.
Kaiser, HW; Stark, GB, 1994
)
0.56
"We describe the results of early hyperbaric oxygenation combined with nifedipine treatment for central retinal artery occlusion, and explain the results pathophysiologically."( Hyperbaric oxygenation combined with nifedipine treatment for recent-onset retinal artery occlusion.
Beiran, I; Miller, B; Nahum, Z; Reissman, P; Scharf, J,
)
0.13
"The present investigation was specifically designed to evaluate the ability of the glycerol test combined with pure tone audiometry, distortion-product otoacoustic emissions (DPOAEs), and vestibular evoked myogenic potentials (VEMPs) to diagnose endolymphatic hydrops early and to identify cases that may evolve toward Meniere's disease."( Vestibular evoked myogenic potentials and distortion-product otoacoustic emissions combined with glycerol testing in endolymphatic hydrops: their value in early diagnosis.
Cianfrone, G; Cuiuli, G; D'Amico, R; Gagliardi, M; Magliulo, G, 2004
)
0.77
"The aim of this study was to investigate in vitro the antimicrobial activity of calcium hydroxide [Ca(OH)2] in combination with different vehicles against endodontic pathogens."( In vitro evaluation of the susceptibility of endodontic pathogens to calcium hydroxide combined with different vehicles.
de Souza Filho, FJ; Ferraz, CC; Gomes, BP; Sena, NT; Vianna, ME; Zaia, AA, 2005
)
0.33
"We investigated the effect of compatible and non-compatible osmolytes in combination with macromolecular crowding on the kinetics of yeast hexokinase."( Effects of osmolytes on hexokinase kinetics combined with macromolecular crowding: test of the osmolyte compatibility hypothesis towards crowded systems.
Olsen, SN; Ramløv, H; Westh, P, 2007
)
0.34
" Reduced IC combined with intracranial volume insults leads to metabolic disturbances in a rat model."( Metabolic effects of a late hypotensive insult combined with reduced intracranial compliance following traumatic brain injury in the rat.
Contant, CF; Enblad, P; Goiny, M; Nilsson, P; Piper, I; Salci, K, 2010
)
0.36
" Glycerol was combined with IPL to enhance the transfer efficacy of IPL energy."( Observation of vasculature alternation by intense pulsed light combined with physicochemical methods.
Jung, B; Kang, H; Son, T, 2016
)
1.34
"The aim of this study was an experimental evaluation of the effectiveness of demineralized bone matrix (DBM) and collagenated heterologous bone graft (CHBG) used alone or in combination with platelet-rich fibrin on bone healing in sinus floor augmentation procedures."( Experimental Evaluation of the Effectiveness of Demineralized Bone Matrix and Collagenated Heterologous Bone Grafts Used Alone or in Combination with Platelet-Rich Fibrin on Bone Healing in Sinus Floor Augmentation.
Karaca, IR; Peker, E; Yildirim, B,
)
0.13
" The rabbit maxillary sinuses were divided into four groups according to the augmentation biomaterials obtained: demineralized bone matrix (Grafton DBM Putty, Osteotech; DBM group), DBM combined with platelet-rich fibrin (PRF; DBM + PRF group), collagenated heterologous bone graft (CHBG; Apatos Mix, OsteoBiol, Tecnoss; CHBG group), CHBG combined with PRF (CHBG + PRF group)."( Experimental Evaluation of the Effectiveness of Demineralized Bone Matrix and Collagenated Heterologous Bone Grafts Used Alone or in Combination with Platelet-Rich Fibrin on Bone Healing in Sinus Floor Augmentation.
Karaca, IR; Peker, E; Yildirim, B,
)
0.13
"There is no beneficial effect of the application of PRF in combination with demineralized bone matrix or collagenated heterologous bone graft on bone formation in sinus floor augmentation."( Experimental Evaluation of the Effectiveness of Demineralized Bone Matrix and Collagenated Heterologous Bone Grafts Used Alone or in Combination with Platelet-Rich Fibrin on Bone Healing in Sinus Floor Augmentation.
Karaca, IR; Peker, E; Yildirim, B,
)
0.13
"The purpose of this study was to examine the metabolic, lipolytic, and cardiovascular responses to supplementation with p-synephrine alone and in combination with caffeine during resistance exercise (RE)."( The Effects of Supplementation with p-Synephrine Alone and in Combination with Caffeine on Metabolic, Lipolytic, and Cardiovascular Responses during Resistance Exercise.
Bush, JA; Campbell, SC; Diamond, KB; Faigenbaum, AD; Kang, J; Kraemer, WJ; Leise, MD; Miller, HB; Nocera, VG; Ratamess, NA; Stohs, SJ,
)
0.13
"To determine the optimal method for detecting saccular endolymphatic hydrops (EH) in patients with Ménière's disease (MD) using a glycerol cervical vestibular evoked myogenic potential (cVEMP) test in combination with a tuning property test."( Detection of Saccular Endolymphatic Hydrops in Ménière's Disease Using a Modified Glycerol cVEMP Test in Combination With the Tuning Property Test.
Komiyama, S; Murofushi, T; Suizu, R, 2016
)
0.86
" The use of modified criteria for the glycerol cVEMP test in combination with the tuning property test resulted in the PR increasing to 75, 57, and 25%, respectively."( Detection of Saccular Endolymphatic Hydrops in Ménière's Disease Using a Modified Glycerol cVEMP Test in Combination With the Tuning Property Test.
Komiyama, S; Murofushi, T; Suizu, R, 2016
)
0.93
"This study was to investigate the feasibility of PGS combined with ChABC for repairing the transection of spinal cords (TSC) in rats."( Poly(glycerol sebacate) combined with chondroitinase ABC promotes spinal cord repair in rats.
Guo, Y; Kong, F; Pan, Q, 2018
)
0.99
"High-purity trilinolein and triolein were prepared by Novozym 435-catalyzed esterification reaction combined with column chromatography purification in this study."( Preparation of High-Purity Trilinolein and Triolein by Enzymatic Esterification Reaction Combined with Column Chromatography.
Chen, Z; Lan, T; Li, H; Pan, L; Wu, D; Zhao, B, 2019
)
0.51
" The aim of this study was to investigate the possible synergistic effect of royal jelly in combination with glycerol and dimethyl sulfoxide (DMSO) in sperm cryopreservation extender of Romanov ram."( Synergistic effect of royal jelly in combination with glycerol and dimethyl sulfoxide on cryoprotection of Romanov ram sperm.
Namvar, Z; Noghani, AE; Pashapour, S; Saberivand, A, 2022
)
1.18
" We have established the protocol 2-D difference gel electrophoresis (DIGE), combined with the fluorescence staining with Pro-Q Diamond, that successfully detects subtle changes of spot mobility caused by protein phosphorylation between Chlamydomonas samples."( 2-D DIGE Combined with Pro-Q Diamond Staining for the Identification of Protein Phosphorylation for Chlamydomonas reinhardtii : A Successful Approach.
Li, L, 2021
)
0.62
" Here, we evaluate methane and isobutane chemical ionization-single quadrupole mass spectrometry combined with high-temperature gas chromatography separations for mapping monoacylglycerols, diacylglycerols, and triacylglycerols in biodiesel."( Mapping Glyceride Species in Biodiesel by High-Temperature Gas Chromatography Combined with Chemical Ionization Mass Spectrometry.
Melville, A; Oxford, TL; Wojcik, R; Wright, BW; Wright, CW, 2021
)
0.81

Bioavailability

Mono- and diacylglycerols rich in omega-3 have a great interest due to their good bioavailability. The goal of the experiment was to verify bioavailability of immunosuppressive drug cyclosporine.

ExcerptReferenceRelevance
"The low ocular bioavailability of topically applied pilocarpine is attributed to extensive precorneal drug loss in conjection with the resistance to corneal penetration."( Mechanistic and quantitative evaluation of precorneal pilocarpine disposition in albino rabbits.
Lee, VH; Robinson, JR, 1979
)
0.26
"Methods are described for the determination of bioavailability of lipo- and hydro- soluble compounds in the rat."( Methodology for the determination of bioavailability of labeled residues.
Gallo-Torres, HE, 1977
)
0.26
"0 M, glycerin and propylene glycol increase significantly the intestinal absorption rate of theophylline from the small intestine of anesthetized rats."( Effect of various alcohols on intestinal net water flux and theophylline absorption in rats.
Houston, JB; Levy, G, 1975
)
0.25
" It can be concluded that aspirin granule prepared by GMS and GTL has a property of pancreatic lipase-sensitive dissolution, and its bioavailability is unaffected by food intake."( Preparation and evaluation of oral dosage form using acylglycerols. II. Effect of food ingestion on dissolution and absorption of aspirin from the granules prepared by acylglycerols in human subjects.
Matsumoto, M; Matsumoto, Y; Suda, M; Takayama, K; Watanabe, Y; Zhao, W, 1991
)
0.53
" These changes indicate a decreased absorption rate of endolymph in the endolymphatic sac."( Modulation of the endolymphatic sac function.
Bagger-Sjöbäck, D; Harada, Y; Rask-Andersen, H; Takumida, M, 1991
)
0.28
" Glycerol generally elicited a greater overall zinc absorption rate as well as an enhanced net water uptake than when sodium chloride was the osmotic agent when either Trp, His, or Pro was present."( Intestinal absorption of zinc: sodium-metal-ligand interactions.
Lee, SY; Stiel, L; Wapnir, RA, 1989
)
1.19
" The implications of this observation pertain to toxicity effects when EDTA is incorporated into ocular drug products for stability purposes, or novel stratagems for improving ocular bioavailability of topically applied drugs are employed."( Mechanisms of corneal drug penetration. I: In vivo and in vitro kinetics.
Grass, GM; Robinson, JR, 1988
)
0.27
" Although this represents a vast improvement, the low water solubility of these compounds reduces their bioavailability to the point where they are not practical substitutes for SHAM."( p-Alkyloxybenzhydroxamic acids, effective inhibitors of the trypanosome glycerol-3-phosphate oxidase.
Bienen, EJ; Clarkson, AB; Grady, RW, 1986
)
0.5
" The implications of this observation pertain to both toxicity effects, when EDTA is incorporated into ocular drug products for stability purposes, and novel strategems for improving ocular bioavailability of topically applied drugs."( Effects of calcium chelating agents on corneal permeability.
Grass, GM; Robinson, JR; Wood, RW, 1985
)
0.27
" Diazepam, which produces good tranquilization, is well absorbed when given orally though absorption is influenced by other drugs given at the same time."( New drugs--boon or bane? Premedication and intravenous induction agents.
Clarke, RS, 1983
)
0.27
" Butyric acid, by markedly reducing the absorption rate of aspirin, may be partially responsible for the unpredictable absorption of rectally administered aspirin."( Colonic absorption of acetylsalicylic acid in the rat.
Harmon, D; Hollander, D; Meshkinpour, H, 1984
)
0.27
" The solubility, metabolism, bioavailability and effectiveness of O6-benzylguanine as an adjuvant therapy with BCNU were compared using two vehicles, cremophor-EL and PEG 400."( Biodistribution of O6-benzylguanine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL.
Dolan, ME; Flora, KP; Friedman, HS; Grever, MR; Moschel, RC; Pegg, AE; Vishnuvajjala, BR, 1994
)
0.29
") instillation of saline suspended CyA to adult rats, the CyA plasma levels peaked at 30 min with a bioavailability of 78."( Pulmonary delivery of intratracheally instilled and aerosolized cyclosporine A to young and adult rats.
Dahlback, M; Eirefelt, S; Karlsson, BW; Lundin, PD; Pierzynowski, SG; Podlesny, J; Siwinska-Golebiowska, H; Taljanski, W; Westrom, BR, 1997
)
0.3
" When bioavailability parameters were compared following oral administration of the soft capsule and Diamicron to 16 healthy Korean male subjects, the parameters representing the amount of adsorption (i."( Accelerated oral absorption of gliclazide in human subjects from a soft gelatin capsule containing a PEG 400 suspension of gliclazide.
Chung, SJ; Hong, SS; Lee, MH; Lee, SH; Lee, YJ; Shim, CK, 1998
)
0.3
" However, the bioavailability of ET is rather poor following oral administration."( Effect of cod-liver oil extract on the buccal permeation of ergotamine tartrate.
Loftsson, T; Nagai, T; Obata, Y; Takayama, K; Tsutsumi, K, 1998
)
0.3
", enhancement, irritation, drug binding) which have to be expected and could have altered the integrity of the stratum corneum and therewith topical bioavailability of the drug."( Effect of concentration and degree of saturation of topical fluocinonide formulations on in vitro membrane transport and in vivo availability on human skin.
Haigh, JM; Imanidis, G; Schwarb, FP; Smith, EW; Surber, C, 1999
)
0.3
" The bioavailability of IFN-alpha after implantation of the matrix formulation prepared using all types of PGEFs, except for tetraglycerol triesters, was almost equivalent to that after injection of IFN-alpha solution; consequently, IFN-alpha in these matrices appears to remain stable during the release period."( Novel sustained-release dosage forms of proteins using polyglycerol esters of fatty acids.
Iga, K; Ogawa, Y; Yamagata, Y, 2000
)
0.75
"Benzyl and phenoxymethylene substituted oxadiazoles are potent and orally bioavailable beta3 adrenergic receptor (AR) agonists."( Synthesis and SAR of benzyl and phenoxymethylene oxadiazole benzenesulfonamides as selective beta3 adrenergic receptor agonist antiobesity agents.
Biftu, T; Candelore, MR; Cascieri, MA; Colandrea, VJ; Colwell, LF; Feng, DD; Fisher, MH; Forrest, MJ; Hom, GJ; Kuo, H; Liang, GB; MacIntyre, DE; Naylor, EM; Qian, X; Stearns, RA; Strader, CD; Weber, AE; Wyvratt, MJ, 2000
)
0.31
" These results suggest that surfactants such as Cremophor EL and Polysorbate 80 should not only support solubilization but can also modulate the P-glycoprotein system to improve the bioavailability of poorly absorbed drugs."( Effect of polyoxyl 35 castor oil and Polysorbate 80 on the intestinal absorption of digoxin in vitro.
Cloarec, A; Cornaire, G; Decourt, S; Houin, G; Legendre, JY; Saivin, S; Woodley, JF, 2000
)
0.31
"As part of our investigation into the development of orally bioavailable beta(3) adrenergic receptor agonists, we have identified a series of pyridylethanolamine analogues possessing a substituted thiazole benzenesulfonamide pharmacophore that are potent human beta(3) agonists with excellent selectivity against other human beta receptor subtypes."( Discovery of a potent, orally bioavailable beta(3) adrenergic receptor agonist, (R)-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4 -[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide.
Candelore, MR; Cascieri, MA; Chitty, D; Colwell, LF; Deng, L; Feeney, WP; Fisher, MH; Forrest, MJ; Hom, GJ; MacIntyre, DE; Mathvink, RJ; Miller, RR; Stearns, RA; Tolman, JS; Tota, L; Weber, AE; Wyvratt, MJ, 2000
)
0.31
"Recent studies in mice and patients have shown that the low oral bioavailability of paclitaxel can be increased by coadministration of P-glycoprotein blockers."( Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut.
Bardelmeijer, HA; Beijnen, JH; Malingré, MM; Ouwehand, M; Schellens, J; van Tellingen, O, 2002
)
0.31
" The bioavailability of paclitaxel was 31."( Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.
Buijs, D; Gelderblom, H; Nooter, K; Ouwens, L; Sparreboom, A; Stoter, G; van Zomeren, DM; Verweij, J, 2002
)
0.31
" It was the aim of this study to test whether the extremely low bioavailability of saquinavir can be increased dose-dependently in vivo by cremophor EL, an 'inactive' pharmaceutic aid known to inhibit PGP in vitro."( Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL.
Burhenne, J; Ding, R; Fricker, R; Haefeli, WE; Martin-Facklam, M; Mikus, G; Walter-Sack, I, 2002
)
0.31
" However, oral bioavailability of this highly lipophilic compound is extremely poor (<1%)."( Enhanced transport of a novel anti-HIV agent--cosalane and its congeners across human intestinal epithelial (Caco-2) cell monolayers.
Cushman, M; Hejchman, E; Mitra, AK; Pal, D; Patel, J; Udata, C, 2003
)
0.32
" In the subsequent study, we tested whether ascorbic acid enhanced the iron bioavailability or not."( The microencapsulated ascorbic acid release in vitro and its effect on iron bioavailability.
Ahn, J; Kwak, HS; Lee, J; Lee, JB, 2003
)
0.32
" The apparent first-order absorption rate constant from the peritoneal cavity (k(a)) of TXL was about one-twentieth of that of TXT."( Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles.
Furui, N; Furukawa, H; Fushida, S; Ishizaki, J; Jin, M; Miwa, K; Miyamoto, K; Nomura, M; Yamazaki, M; Yokogawa, K; Yoshihara, H, 2004
)
0.32
" The formulation was tested to determine its bioavailability enhancement in a non-flush/non-ligated rat ileal model."( Enhanced ileal absorption of a hydrophilic macromolecule, pentosan polysulfate sodium (PPS).
Dong, L; Nguyen, J; Wong, P; Yum, A, 2004
)
0.32
"The present study revealed that the self-nanoemulsified drug delivery system of all-trans-retinol acetate increased its dissolution rate and has the potential to enhance its bioavailability without interaction or incompatibility between the ingredients."( Preparation and in vitro characterization of self-nanoemulsified drug delivery system (SNEDDS) of all-trans-retinol acetate.
Al-Saidan, S; Khan, MA; Samy, AM; Taha, EI, 2004
)
0.32
" The bioavailability of paclitaxel was independent of the dose and of CrEL."( Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.
Beijnen, JH; de Jonge, ME; Huitema, AD; Rodenhuis, S; Schellens, JH, 2005
)
0.33
" Mean residence time of morphine was considerably prolonged without changing relative bioavailability in the case of the mixed base suppositories containing 15-17% HB750, compared with the Witepsol H15 suppository, clearly indicating that the mixed bases containing HB750 are expected to be useful for the design of controlled-release morphine suppositories."( Design of controlled-release morphine suppositories containing polyglycerol ester of fatty acid.
Higaki, K; Kimura, T; Takatori, T; Yamaguchi, T; Yamamoto, K, 2005
)
0.56
"Demineralized bone matrix grafts are osteoinductive due to the increase in bioavailability of bone morphogenetic proteins that occurs from demineralization."( The hydration characteristics of demineralized and nondemineralized allograft bone: Scientific perspectives on graft function.
Pietrzak, WS, 2006
)
0.33
" peak concentration (c(max)); peak time (t(max)); area under the curve (AUC); elimination rate constant (k); absorption rate constant (k(a)); Drug clearance (cl(t)), and the volume of distribution (v(d)) of sodium salicylate administered in fractionated coconut oil (FCO) have been compared with that from an aqueous and glycerin vehicles using a three-way crossover study in 12 rabbits."( Biopharmaceutic and pharmacokinetic studies following the oral administration of sodium salicylate in oily and aqueous vehicles to rabbit.
Alhamami, OM; Aljanabi, NH; Shalan, NM, 2006
)
0.33
" Oral bioavailability was studied on prepared SMEDDS hard capsules and compared with that of the conventional tablet in Beagle dogs in vivo."( [Preparation and evaluation of self-microemulsifying drug delivery systems containing atorvastatin].
Li, ZD; Shen, HR; Zhong, MK, 2005
)
0.33
" Oral bioavailability of atorvastatin SMEDDS was greater than that of the conventional tablet."( [Preparation and evaluation of self-microemulsifying drug delivery systems containing atorvastatin].
Li, ZD; Shen, HR; Zhong, MK, 2005
)
0.33
" Together, these results indicate that the bioavailability of ellagic acid can be improved by subcutaneous formulations administered as simple EA or EA nps."( Biodegradable in situ gelling system for subcutaneous administration of ellagic acid and ellagic acid loaded nanoparticles: evaluation of their antioxidant potential against cyclosporine induced nephrotoxicity in rats.
Italia, JL; Ravi Kumar, MN; Sharma, G; Sonaje, K; Tikoo, K, 2007
)
0.34
" These results suggested that the decreased CL/F of metoprolol in rats with glycerol-induced ARF is mainly a result of the increased initial absorption rate in the intestine followed by partial saturation of hepatic first-pass metabolism."( Pharmacokinetics and hepatic extraction of metoprolol in rats with glycerol-induced acute renal failure.
Hashimoto, Y; Taguchi, M; Taira, S; Tanabe, H, 2007
)
0.81
"To investigate the impact of a change in the proportions of lipid, surfactant and co-solvent on the solubilisation capacity of self-emulsifying formulations of danazol during in vitro dispersion and digestion studies and correlation with in vivo bioavailability in beagle dogs."( Increasing the proportional content of surfactant (Cremophor EL) relative to lipid in self-emulsifying lipid-based formulations of danazol reduces oral bioavailability in beagle dogs.
Charman, WN; Cuiné, JF; Edwards, GA; Porter, CJ; Pouton, CW, 2007
)
0.34
" The relative bioavailability of danazol after administration of a series of these formulations was also determined."( Increasing the proportional content of surfactant (Cremophor EL) relative to lipid in self-emulsifying lipid-based formulations of danazol reduces oral bioavailability in beagle dogs.
Charman, WN; Cuiné, JF; Edwards, GA; Porter, CJ; Pouton, CW, 2007
)
0.34
" Consistent with these data, the bioavailability of danazol decreased significantly when the lipid content in the formulations was reduced."( Increasing the proportional content of surfactant (Cremophor EL) relative to lipid in self-emulsifying lipid-based formulations of danazol reduces oral bioavailability in beagle dogs.
Charman, WN; Cuiné, JF; Edwards, GA; Porter, CJ; Pouton, CW, 2007
)
0.34
"The goal of the experiment was to verify bioavailability of immunosuppressive drug cyclosporine after oral administration, to determine, in particular, effect of triglycerides and polyglycerol esters on bioavailability of this lipophilic, poorly soluble drug."( Excipients and their role in absorption: Influencing bioavailability of cyclosporine by triglycerides and polyglycerol esters.
Andrysek, T, 2006
)
0.74
"Self-microemulsifying drug delivery systems (SMEDDS) are useful to improve the bioavailability of poorly water-soluble drugs by increasing their apparent solubility through solubilization."( Application of mixture experimental design to simvastatin apparent solubility predictions in the microemulsifion formed by self-microemulsifying.
Meng, J; Zheng, L, 2007
)
0.34
" The oral bioavailability of paclitaxel in TPGS 400/ethanol (7."( Enhanced oral bioavailability of paclitaxel by D-alpha-tocopheryl polyethylene glycol 400 succinate in mice.
Chang, YW; Chao, YS; Chen, CT; Chiang, TH; Ho, PY; Lin, HL; Lo, YK; Wu, HY; Wu, SH; Yao, HT; Yeh, TK, 2008
)
0.35
"Self-microemulsifying drug delivery systems (SMEDDS) were developed to overcome the problems of delivery and administration of piroxicam, a drug with low bioavailability and gastrointestinal irritation, The in vitro properties of it were assessed."( [Design and in vitro evaluation of self-microemulsifying drug delivery systems for piroxicam].
Nie, SF; Pan, WS; Sun, JY; Wang, J; Wang, Y; Zhou, XT, 2008
)
0.35
"This study aims to formulate and evaluate bioavailability of a self-nanoemulsified drug delivery system (SNEDDS) of a poorly water-soluble herbal active component oleanolic acid (OA) for oral delivery."( Formulation development and bioavailability evaluation of a self-nanoemulsified drug delivery system of oleanolic acid.
Chan, CK; Chang, Q; Meng, ZY; Sun, JB; Tong, HH; Wang, GN; Wang, YT; Xi, J; Zheng, Y, 2009
)
0.35
"P-glycoprotein (P-gp) located in the apicalmembranes of intestinal absorptive cells is an energy-dependent efflux pump which can reduce the bioavailability of a wide range of substrate drugs."( [Advances in the study of excipient inhibitors of intestinal P-glycoprotein].
Huang, JG; Li, G; Si, LQ; Yan, F, 2008
)
0.35
" The first-order peritoneal cavity-systemic circulation absorption rate constant of paclitaxel was 1/8 that of docetaxel."( Surfactants influence the distribution of taxanes in peritoneal dissemination tumor-bearing rats.
Ito, C; Kamijo, Y; Miyamoto, K; Nomura, M; Sai, Y, 2010
)
0.36
"A microemulsion system of docetaxel was prepared and evaluated for its solubilization capacity and oral bioavailability improvement."( Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation.
Choi, MK; Chung, SJ; Cui, FD; Kim, DD; Kim, JS; Mu, CF; Shim, CK; Yin, YM, 2009
)
0.35
" The mean bioavailability of valspodar was 42."( Pharmacokinetics of PSC 833 (valspodar) in its Cremophor EL formulation in rat.
Binkhathlan, Z; Brocks, DR; Hamdy, DA; Lavasanifar, A, 2010
)
0.36
"38 mg/kg had the larger AUC(0-t), the longer half-life and the prolonged circulation time with the mean bioavailability of 80."( Preparation of lorazepam-loaded microemulsions for intranasal delivery and its pharmacokinetics.
Hou, L; Sun, L; Yao, J; Zhang, ZQ; Zhou, JP, 2009
)
0.35
"To enhance oral bioavailability of matrine, a dedicated and newly emerging drug system called self-nanoemulsifying drug delivery system (SNEDDSs) was developed."( Preparation and evaluation of self-nanoemulsified drug delivery systems (SNEDDSs) of matrine based on drug-phospholipid complex technique.
Gong, T; Hao, X; Liu, J; Ruan, J; Yang, F; Zhang, Z; Zhu, D, 2010
)
0.36
" proteins) forming protein-phenol complexes that may reduce protein solubility, bioavailability to rumen microbes and deactivate plant enzymes."( Immunogold labelling to localize polyphenol oxidase (PPO) during wilting of red clover leaf tissue and the effect of removing cellular matrices on PPO protection of glycerol-based lipid in the rumen.
Cookson, A; Lee, MR; Sullivan, ML; Tweed, JK, 2010
)
0.56
"An attempt has been made in the present study to formulate soluble ocular inserts of aceclofenac to facilitate the bioavailability of the drug into the eye, as no eye drop solution could be formulated."( Glycerogelatin-based ocular inserts of aceclofenac: physicochemical, drug release studies and efficacy against prostaglandin E₂-induced ocular inflammation.
Gilhotra, RM; Mathurm, M, 2011
)
0.37
"The main objective of the study was to investigate the efficacy of microemulsion (ME) to facilitate bioavailability of puerarin (PUE) after oral and nasal administration."( Formulation optimization and bioavailability after oral and nasal administration in rabbits of puerarin-loaded microemulsion.
Cao, F; Cui, J; Gao, Y; Wang, H; Wang, J; Yu, A; Zhai, G, 2011
)
0.37
"Following epidural administration, cerebrospinal fluid bioavailability of local anesthetics is low, one major limiting factor being diffusion across the arachnoid mater barrier."( Ex vivo and in vivo diffusion of ropivacaine through spinal meninges: influence of absorption enhancers.
Brandhonneur, N; Chevanne, F; Deniau, AL; Dollo, G; Estèbe, JP; Le Corre, P; Legrand, A; Ratajczak-Enselme, M, 2011
)
0.37
"To improve dissolution and bioavailability of baicalin in solid prescription and screen the prescription of self-emulsifying drug delivery systems of baicalin."( [Prescription design and dissolution evaluation of self-emulsifying drug delivery systems of baicalin].
Luo, XQ; Yang, JQ, 2010
)
0.36
"The objective of the present study was to formulate a microemulsion system for oral administration to improve the solubility and bioavailability of fenofibrate."( Design of fenofibrate microemulsion for improved bioavailability.
Hu, L; Jia, Y; Niu, F; Wu, H; Yan, C; Yang, X, 2011
)
0.37
"Carvedilol, a widely prescribed cardiovascular drug for hypertension and congestive heart failure, exhibits low and variable bioavailability owing to poor absorption and extensive hepatic first-pass metabolism."( Development of optimized self-nano-emulsifying drug delivery systems (SNEDDS) of carvedilol with enhanced bioavailability potential.
Bandyopadhyay, S; Kapil, R; Katare, OO; Khurana, L; Singh, B, 2011
)
0.37
" A 384 % enhancement in oral bioavailability compared to Dox solution was observed following Dox-LIPOMER administration at 10 mg/kg body weight."( Lipomer of doxorubicin hydrochloride for enhanced oral bioavailability.
Benival, DM; Devarajan, PV, 2012
)
0.38
"Aqueous ammonia (NH3) solution can be used as an alternative absorption for the control of CO2 emitted from flue gases due to its high absorption capacity, fast absorption rate and low corrosion problem."( Vaporization reduction characteristics of aqueous ammonia solutions by the addition of ethylene glycol, glycerol and glycine to the CO2 absorption process.
Jeon, SB; Jung, JH; Kim, JY; Lee, GW; Oh, KJ; Seo, JB, 2012
)
0.59
" By virtue of extensive presystemic clearance, RLX bioavailability is only 2%."( Nanoemulsion liquid preconcentrates for raloxifene hydrochloride: optimization and in vivo appraisal.
Abdallah, OY; Elnaggar, YS; Elsheikh, MA; Gohar, EY, 2012
)
0.38
"6-fold compared with that of the commercially available ligustrazine injection (LI), suggesting enhanced bioavailability from the lipid-based emulsion."( Development of ligustrazine-loaded lipid emulsion: formulation optimization, characterization and biodistribution.
Kim, JO; Li, G; Marasini, N; Quan, Q; Wei, L; Yong, CS, 2012
)
0.38
"In order to quantify the relative oral bioavailability of 3-chloropropane-1,2-diol (3-MCPD) from 3-MCPD fatty acid diesters in vivo, 1,2-dipalmitoyl-3-chloropropane-1,2-diol (3-MCPD diester) and 3-MCPD were orally applied to rats in equimolar doses."( Relative oral bioavailability of 3-MCPD from 3-MCPD fatty acid esters in rats.
Abraham, K; Apel, E; Appel, KE; Berger-Preiss, E; Creutzenberg, O; Gerling, S; Lampen, A; Mielke, H, 2013
)
0.39
"Curcuminoid, a dietary polyphenolic compound, has poor water solubility and low bioavailability following oral administration."( Preparation and oral bioavailability study of curcuminoid-loaded microemulsion.
Chen, X; Meng, F; Ping, Q; Xiao, Y; Yang, L; Zhu, X; Zou, L, 2013
)
0.39
" A self-microemulsifying drug delivery system (SMEDDS) has been developed to enhance the solubility and oral bioavailability of oleanolic acid."( Self-microemulsifying drug delivery system for improved oral bioavailability of oleanolic acid: design and evaluation.
Dou, J; Huang, X; Su, L; Yang, R; Zhai, G, 2013
)
0.39
" This study aimed to investigate the influence of ARI on ARG and methylarginines metabolism, and to establish the relationship between disturbances in the latter and reduced NO bioavailability in ARI."( The influence of acute renal injury on arginine and methylarginines metabolism.
Gilinsky, MA; Sukhovershin, RA, 2013
)
0.39
"BCS class III hydrophilic compounds are often associated with low oral bioavailability due to their poor epithelial permeability in the gastrointestinal tract."( Enhanced bioavailability of poorly absorbed hydrophilic compounds through drug complex/in situ gelling formulation.
Dai, WG; Dong, LC; Song, Y, 2013
)
0.39
" However, the high toxicity and low bioavailability of current antimalarials and emerging drug resistance necessitates drug-delivery research."( Parasite impairment by targeting Plasmodium-infected RBCs using glyceryl-dilaurate nanostructured lipid carriers.
Basu, H; Jain, SA; Joshi, MD; Mathur, D; Pathak, S; Patravale, VB; Prabhu, PS; Sharma, S; Soni, U, 2014
)
0.4
"2-fold improved oral bioavailability of leuprolide oleate SMEDDS compared to a leuprolide acetate control solution."( In vivo evaluation of an oral self-microemulsifying drug delivery system (SMEDDS) for leuprorelin.
Bernkop-Schnürch, A; Hauptstein, S; Hintzen, F; Laffleur, F; Müller, C; Perera, G, 2014
)
0.4
" γ-T3 incorporated in SEDDS or Tocovid was orally administered to rats at different doses and absolute oral bioavailability from both formulations were determined."( Enhanced solubility and oral bioavailability of γ-tocotrienol using a self-emulsifying drug delivery system (SEDDS).
Alayoubi, A; Alqahtani, S; Kaddoumi, A; Nazzal, S; Sylvester, PW, 2014
)
0.4
" On oral administration it undergoes extensive first pass metabolism, which outweighs its absorbance through gastrointestinal tract (GIT) and bioavailability of the drug in systemic circulation."( A novel vesicular transdermal delivery of nifedipine - preparation, characterization and in vitro/in-vivo evaluation.
Jain, K; Jakki, SL; Kuppusamy, G; Natarajan, J; Sood, S; Venkatachalam, S; Yasam, VR, 2016
)
0.43
"Microemulsions show significant promise for enhancing the oral bioavailability of biopharmaceutics classification system (BCS) class II drugs, but how about class III drugs remains unclear."( Improving oral bioavailability of metformin hydrochloride using water-in-oil microemulsions and analysis of phase behavior after dilution.
Cai, J; Hu, H; Huang, M; Li, Y; Song, J; Tian, N; Wang, Y; Wu, C; Xing, Q, 2014
)
0.4
" The fractional rate of absorption of glycerol was not affected by variations in glycerol concentration in the buffer solution in the in vivo study."( The fate of glycerol entering the rumen of dairy cows and sheep.
Holtenius, K; Kronqvist, C; Martens, H; Werner Omazic, A; Zhongyan, L, 2015
)
1.07
"5% poloxamer 188 group, with absolute bioavailability 29."( Non-ionic surfactants as novel intranasal absorption enhancers: in vitro and in vivo characterization.
Ding, J; Li, J; Li, Y; Mao, S; Zhang, X, 2016
)
0.43
" Among the OG- and PG-peptide constructs, PG-peptide constructs exhibited an extended bioavailability compared to OG-peptide constructs and unconjugated peptide."( Tolerogenic modulation of the immune response by oligoglycerol- and polyglycerol-peptide conjugates.
Gupta, S; Haag, R; Hamann, A; Hoffmann, U; Kumar, S; Lauer, U; Pfeil, J; Poulsen, C, 2015
)
0.67
"The aim of this study was to examine the efficacy of self-nano phospholipid dispersions (SNPDs) based on Phosal(®) to improve the oral bioavailability of curcumin (CUR)."( Preparation, characterization and in vivo evaluation of curcumin self-nano phospholipid dispersion as an approach to enhance oral bioavailability.
Abdallah, OY; Allam, AN; Fouda, MA; Komeil, IA, 2015
)
0.42
"Itraconazole (ITR), an antifungal agent has poor bioavailability due to low aqueous solubility."( Formulation and evaluation of Itraconazole nanoemulsion for enhanced oral bioavailability.
Dhande, RD; Khunt, A; Patel, AA; Thakkar, HP, 2015
)
0.42
"The purpose of this work was to develop a new formulation to enhance the bioavailability and reduce the food effect of lurasidone using self-nanoemulsifying drug delivery systems (SNEDDSs)."( Enhanced oral bioavailability of lurasidone by self-nanoemulsifying drug delivery system in fasted state.
Chen, G; Lili, R; Miao, Y; Ouyang, P; Sun, J, 2016
)
0.43
"It was concluded that enhanced bioavailability and no food effect of lurasidone had been achieved by using SNEDDS."( Enhanced oral bioavailability of lurasidone by self-nanoemulsifying drug delivery system in fasted state.
Chen, G; Lili, R; Miao, Y; Ouyang, P; Sun, J, 2016
)
0.43
"Oral emodin, a natural anthraquinone and active component of many herbal medicines, is poorly bioavailable because of extensive first-pass glucuronidation."( Cremophor EL-based nanoemulsion enhances transcellular permeation of emodin through glucuronidation reduction in UGT1A1-overexpressing MDCKII cells.
Dong, D; Lu, D; Wang, S; Wu, B; Zhang, T, 2016
)
0.43
" It is unclear how emulsifiers affect the bioavailability of ingested PAEs contaminants and their toxicities."( Food Emulsifier Glycerin Monostearate Increases Internal Exposure Levels of Six Priority Controlled Phthalate Esters and Exacerbates Their Male Reproductive Toxicities in Rats.
Cao, WX; Gao, HT; Lu, L; Shen, Y; Xu, Q; Xu, R; Yan, YH; Zhou, X, 2016
)
0.43
"Efflux transporters are extensively distributed and expressed in the intestinal epithelium and contribute to the low oral bioavailability of flavonoids and flavonoid glucuronides by pumping these compounds back into intestinal lumen."( A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP.
Chen, M; Lam, CW; Xiao, L; Yi, T; Zhou, H, 2016
)
0.43
" The low oral bioavailability is a great challenge for oral formulation development."( Novel oral administrated paclitaxel micelles with enhanced bioavailability and antitumor efficacy for resistant breast cancer.
Ding, R; Fu, Y; Gong, T; Li, H; Luo, J; Zhang, T; Zhang, Z, 2017
)
0.46
"The goal of the present investigation was to improve ATV bioavailability and overcome complications attendant with peroral administration by developing a new nanovesicular system encapsulating ATV for its delivery via the transdermal route."( Transdermal delivery of atorvastatin calcium from novel nanovesicular systems using polyethylene glycol fatty acid esters: Ameliorated effect without liver toxicity in poloxamer 407-induced hyperlipidemic rats.
Aboud, HM; Ali, AA; Hassan, AH; Johnston, TP; Mahmoud, MO, 2017
)
0.46
" In situ single-pass perfusion studies demonstrated higher effective permeability coefficient and absorption rate constant for Cur nanoemulsions than for free Cur."( Therapeutic effects of curcumin nanoemulsions on prostate cancer.
Guan, YB; Jia, YY; Sun, YJ; Tian, YD; Wang, JL; Zhang, YQ; Zhou, SY, 2017
)
0.46
"Mono- and diacylglycerols rich in omega-3 have a great interest due to their good bioavailability and oxidation stability compared with other kind of omega-3 concentrates."( Substrates emulsification process to improve lipase-catalyzed sardine oil glycerolysis in different systems. Evaluation of lipid oxidation of the reaction products.
Beltrán, S; Melgosa, R; Sanz, MT; Solaesa, ÁG, 2017
)
1.03
" Vardenafil (VDF) is a relatively new phosphodiesterase-5 inhibitor that exhibits a limited oral bioavailability (≈15%) due to extensive first-pass metabolism."( Preparation and characterization of intravaginal vardenafil suppositories targeting a complementary treatment to boost in vitro fertilization process.
Abu Lila, AS; Ghazy, FS; Gomaa, E; Hasan, AA, 2018
)
0.48
" Their poor water-solubility and low bioavailability is a challenge to their incorporation into foods."( Encapsulation of carotenoids extracted from halophilic Archaea in oil-in-water (O/W) micro- and nano-emulsions.
Ammar, E; Chaari, M; Papadimitriou, V; Theochari, I; Xenakis, A, 2018
)
0.48
" We hypothesized that the ameliorating effect of HBO2 is caused by an increased bioavailability of NO, which can be attenuated by injection of the selective neuronal NO synthase inhibitor, 7-nitroindazole, preceding the HBO2 procedure."( Neuronal nitric oxide inhibition attenuates the protective effect of HBO2 during cyanide poisoning.
Hedetoft, M; Hyldegaard, O; Olsen, NV; Polzik, P,
)
0.13
" However, the use of paclitaxel is seriously limited (its bioavailability is <10%) due to several long-standing challenges: its poor water solubility (0."( Basic principles of drug delivery systems - the case of paclitaxel.
Aserin, A; Ezrahi, S; Garti, N, 2019
)
0.51
" The solubility of curcumin in simulated gastrointestinal fluids revealed that the significant increase of bioavailability takes place in the small intestinal fluid."( Natural Deep Eutectic Solvents as Agents for Improving Solubility, Stability and Delivery of Curcumin.
Cysewski, P; Jeliński, T; Przybyłek, M, 2019
)
0.51
" The size of the droplets formed in the aerosol can vary and contributes to drug deposition and ultimate bioavailability in the lung."( The Effect of Electronic Cigarette User Modifications and E-liquid Adulteration on the Particle Size Profile of an Aerosolized Product.
Halquist, MS; Kosmider, L; Mulder, HA; Patterson, JL; Peace, MR; Poklis, A; Poklis, JL; Turner, JBM, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" The renewability, bioavailability and typical structure of glycerol, therefore, discover conceivable application in serving the role of carbon and energy source for microbial biosynthesis of high value products."( Biochemical conversion of biodiesel by-product into malic acid: A way towards sustainability.
Bharathiraja, B; Gnansounou, E; Jayamuthunagai, J; Kumar, RP; Pandey, A; Selvakumari, IAE; Varjani, S, 2020
)
0.8
" Since ITZ is only weakly soluble in water, its bioavailability is limited."( Cholesterol Reduces Partitioning of Antifungal Drug Itraconazole into Lipid Bilayers.
Bunker, A; Dzieciuch-Rojek, M; Kepczynski, M; Poojari, C; Róg, T; Zak, A, 2020
)
0.56
" The drug has low and fluctuating oral bioavailability owing to its extensive hepatic first-pass metabolism and reduced water solubility."( Investigating the potential of utilizing glycerosomes as a novel vesicular platform for enhancing intranasal delivery of lacidipine.
Abdel Halim, SA; Badr-Eldin, SM; Naguib, MJ; Salah, S, 2020
)
0.56
" We show that the nanoparticle form of small molecules offers better antiamyloidogenic performance via enhanced bioavailability and multivalent binding with protein."( Small-Molecule-Functionalized Hyperbranched Polyglycerol Dendrimers for Inhibiting Protein Aggregation.
Debnath, K; Jana, NR; Mandal, S; Panja, P, 2020
)
0.81
" The results indicated that the presence of clay particles in the starch matrix reduced the water absorption rate of films in comparison to starch films containing glycerol but not clay particles."( Characterization and properties of non-granular thermoplastic starch-Clay biocomposite films.
Mansour, G; Marinopoulou, A; Prevezanos, M; Raphaelides, SN; Tzetzis, D; Zoumaki, M, 2020
)
0.75
" Nevertheless, chemical instability and low solubility of OXY in aqueous solutions reduce its bioavailability and hinder it from exerting neuroprotective activities."( Alkoxy glycerol enhanced activity of Oxyresveratrol in Alzheimer's disease by rescuing Tau protein.
Elumalai, P; Lakshmi, S; Sivan, S; Varija Raghu, S, 2021
)
1.08
"The purpose of this study was to use hydroxypropyl-β-cyclodextrin (HP-β-CD) as a novel carrier in solid SNEDDS and solid dispersions to enhance the solubility and oral bioavailability of poorly water-soluble dexibuprofen."( New potential application of hydroxypropyl-β-cyclodextrin in solid self-nanoemulsifying drug delivery system and solid dispersion.
Cheon, S; Choi, HG; Choi, YJ; Im, D; Ji, SH; Jin, SG; Kim, JO; Kim, JS; Lim, SJ; Oh, KT; Ud Din, F; Woo, MR; Youn, YS, 2021
)
0.62
"Candesartan cilexetil (CC), a prodrug of candesartan (CDT), is a class II BCS drug that suffers from poor oral bioavailability because of low aqueous solubility, P-gp efflux and first-pass metabolism."( New Peceol™/Span™ 60 Niosomes Coated with Chitosan for Candesartan Cilexetil: Perspective Increase in Absolute Bioavailability in Rats.
AbuElfadl, A; Boughdady, M; Meshali, M, 2021
)
0.62
" The synergistic combination of Peceol™ and Span™ 60 probably surmounted the P-gp efflux with an increase in oral absolute bioavailability of niosomes to five times that of CC suspension."( New Peceol™/Span™ 60 Niosomes Coated with Chitosan for Candesartan Cilexetil: Perspective Increase in Absolute Bioavailability in Rats.
AbuElfadl, A; Boughdady, M; Meshali, M, 2021
)
0.62
"The new niosomal formulations of CC containing Peceol™ with Span™ 60 and cholesterol either uncoated or coated with chitosan were a successful paradigm in achieving high oral absolute bioavailability and increased Caco-2 cells biocompatibility."( New Peceol™/Span™ 60 Niosomes Coated with Chitosan for Candesartan Cilexetil: Perspective Increase in Absolute Bioavailability in Rats.
AbuElfadl, A; Boughdady, M; Meshali, M, 2021
)
0.62
" Indeed, the solubility of 20 mg/L greatly limits the bioavailability of UDCA."( Glyceric Prodrug of Ursodeoxycholic Acid (UDCA): Novozym 435-Catalyzed Synthesis of UDCA-Monoglyceride.
Costa, S; Cristofori, V; Semeraro, B; Summa, D; Tamburini, E; Trapella, C; Zappaterra, F, 2021
)
0.62
" Vesicular systems are one such system that can ameliorate the bioavailability of the encapsulated drug by delivering the drug at the targeted site and can minimize the side effect."( A Discursive Review of Recent Development and Patents on Glycerosomes.
Awasthi, H; Singh, R; Srivastava, D; Zeeshan, F, 2023
)
0.91
" The results showed that the addition of plasticizer significantly improved the performance of starch straws, which greatly improved the mechanical properties, water absorption rate (WAR) and thermal stability."( Effects of polyols with different hydroxyl numbers on the structure and properties of starch straws.
Cui, B; Gao, S; Guo, L; Liu, P; Lu, L; Ma, C; Tan, C; Tao, H; Wu, Z; Yuan, F; Zou, F, 2023
)
0.91
" We previously described the synthesis of 1-O-octadecyl-2-O-benzyl-glycero-3-phospho-RVn (V2043), an orally bioavailable lipid prodrug of remdesivir nucleoside (RVn, GS-441524) with broad spectrum antiviral activity against viruses with pandemic potential."( Enhanced broad spectrum in vitro antiviral efficacy of 3-F-4-MeO-Bn, 3-CN, and 4-CN derivatives of lipid remdesivir nucleoside monophosphate prodrugs.
Beadle, JR; Carlin, AF; Clark, AE; Freshman, JE; Garretson, AF; Hostetler, KY; Lo, MK; McMillan, RE; Montgomery, JM; Murphy, J; Schooley, RT; Spiropoulou, CF; Valiaeva, N; Zhang, XQ, 2023
)
0.91

Dosage Studied

Glycerol dosing resulted in no change in apparent dewaterability. Single administration of potassium dichromate or glycerol is followed by a marked decrease of renal PAH excretion. The dose-response curve for L-750355-induced glycerolemia lies to the left of that for tachycardia.

ExcerptRelevanceReference
" 2-ME evoked a proliferative response in cultures of congenitally athymic (nu/nu) spleen cells that exhibited a similar but lower dose-response profile compared with that of heterozygous (nu/+) littermates."( Nonspecific activation of murine lymphocytes. I. Proliferation and polyclonal activation induced by 2-mercaptoethanol and alpha-thioglycerol.
Goodman, MG; Weigle, WO, 1977
)
0.46
"In human adipose tissue in vitro, dose-response curves of lipolytic agents in releasing free fatty acids and glycerol into an albumine-containing medium were followed."( Adrenergic lipolysis in human adipose tissue in vitro.
Kuhn, E; Wenke, M; Wenkeová, J, 1975
)
0.47
" Dosage influenced the degree of suppression from 8 to 100 micrograms, whereas suppression of background plaques required only 1 microgram of lipid-free teichoic acid."( Modulation of the immune response to sheep erythrocytes by lipid-free glycerol teichoic acid.
Chorpenning, FW; Cooper, HR; Lynch, JJ; Oldfather, JW, 1979
)
0.49
" Single administration of potassium dichromate or glycerol is followed by a marked decrease of renal PAH excretion in dependence on the time after the administration as well as on the dosage used."( Stimulation of kidney function in rats of different ages injured by nephrotoxic agents.
Bräunlich, H; Fleck, C; Stopp, M; Weise, C, 1979
)
0.51
" Salbutamol was given as an infusion in the same dosage as is used to inhibit uterine contractions in cases of premature labor and in obstetric emergencies."( The immediate effect of a beta-adrenergic agonist (salbutamol) on carbohydrate and lipid metabolism during the third trimester of pregnancy.
Joelsson, I; Larsson, A; Lunell, NO; Persson, B, 1977
)
0.26
" The rise in free fatty acids and glycerol in response to norepinephrine had the same time-course and dose-response characteristics in the sham-operated and lesioned animals, indicating comparable degrees of peripheral responsiveness to this hormone."( Ventromedial hypothalamic lesions and the mobilization of fatty acids.
Bray, GA; Nishizawa, Y, 1978
)
0.54
" Differences in diatrizoate concentration which existed between cortical and medullary zones in healthy kidneys at low dises were progressively eliminated as dosage increased, consistent with the osmatic fiutryiv rggrvy of diatrizoate."( Effect of dose on renal diatrizoate concentrations in experimental acute renal failure.
Gaunt, A; McLachlan, MS; Robinson, PJ, 1976
)
0.26
"The object of this investigation was the development of an implantable sustained-release dosage form, for the treatment of bone infections."( An implantable dosage form for the treatment of bone infections.
Dash, AK; Suryanarayanan, R, 1992
)
0.28
" Because of the drug's poor water solubility, ethoxylated plant fats and ethanol are added to the commercially available dosage forms."( Dosage forms of cyclosporine.
Yee, GC, 1991
)
0.28
" The decrease in hydrops was influenced by the dosage suggesting a stria metabolic response."( The effect of glycerol on short-term experimental endolymphatic hydrops.
Della Rocca, C; Magliulo, G; Muscatello, M; Ungari, C, 1991
)
0.64
" Compared with the C test, maintenance of glucagon level had only small and inconsistent effects on glucose Rd, but induced a shift to the right of the dose-response curve to insulin of EGP (apparent ED50: C test, 10."( Interactions of glucagon and free fatty acids with insulin in control of glucose metabolism.
Beylot, M; Chambrier, C; Cohen, R; Picard, S; Riou, JP; Vidal, H, 1990
)
0.28
" (b) In every group, it appeared that the slower the infusion rate of the same dosage became, the longer the reduction of ICP lasted."( Clinical study of mannitol and glycerol on raised intracranial pressure and on their rebound phenomenon.
Nakazawa, S; Node, Y, 1990
)
0.57
" Dose-response curves were constructed for insulin-stimulated glucose disposal."( Insulin resistance in type 1 (insulin-dependent) diabetes: dissimilarities for glucose and intermediary metabolites.
Krans, HM; Nijs, HG; Poorthuis, BJ; Radder, JK, 1990
)
0.28
" Whilst taking standard dosage regimes of glycerol, the stroke patients we studied manifested a degree of intravascular haemolysis but its consequences were not clinically significant; lysis probably ensued after venous blood acquiring high glycerol concentrations mixed with blood containing little or no glycerol."( Investigation of intravascular haemolysis during treatment of acute stroke with intravenous glycerol.
Chan, GT; Chan, TK; Kou, M; Kumana, CR; Lauder, IJ; Yu, YL, 1990
)
0.76
" Venous blood samples were obtained before dosing and at minutes 5, 10, 15, 30, 45, 60, 90, 120, 150, and 180."( Effect of paraxanthine on FFA mobilization after intravenous caffeine administration in humans.
Brown, DD; Hetzler, RK; Knowlton, RG; Perkins, RM; Somani, SM, 1990
)
0.28
" The low efficiency of Intraiodol could be fully compensated by an increase in dosage without any significant effect on sinusoidal blood flow."( Experimental investigation of a new iodinated lipid emulsion for computed tomography of the liver.
Ivancev, K; Lunderquist, A; McCuskey, P; McCuskey, R; Wretlind, A,
)
0.13
" Dose-response curves with epinephrine (alpha 2 and beta agonist), with isoproterenol (beta agonist) and epinephrine + propranolol and adenosine deaminase, were studied."( Lipolytic response of adipocytes to epinephrine in sedentary and exercise-trained subjects: sex-related differences.
Beauville, M; Crampes, F; Garrigues, M; Marceron, M; Riviere, D, 1989
)
0.28
" Dose-response relationships between insulin and intermediary metabolites were sought by analysis of variance applied to regression."( Use of combined oral contraceptive preparations alters the insulin sensitivity of fatty acid and ketone metabolism.
Nattrass, M; Singh, BM, 1989
)
0.28
" Standard dose-response curves were linear from 50 to 3000 pmol glycerol with less than 3% SD in triplicate measurements."( Radiometric assays for glycerol, glucose, and glycogen.
Bradley, DC; Kaslow, HR, 1989
)
0.83
" The dose-response relationships of the alpha 2- and beta-selective agents clonidine and isoproterenol were not appreciably changed by caloric restriction."( Adrenergic regulation of lipolysis in abdominal adipocytes of obese subjects during caloric restriction: reversal of catecholamine action caused by relief of endogenous inhibition.
Fischer, B; Kather, H; Schlierf, G; Wieland, E; Wirth, A, 1985
)
0.27
" The presence of insulin did not alter the relative sensitivities to glucagon of adipocytes from fed animals in different reproductive states, although all dose-response curves were shifted to the right."( Changes in the sensitivity to glucagon of lipolysis in adipocytes from pregnant and lactating rats.
Zammit, VA, 1988
)
0.27
"Transplacental exposure to the DNA alkylating agent N-methyl-N-nitrosourea on day 16 of gestation in CD-1 albino mice induces a degeneration of the retina, the severity of which depends upon the dosage level of the drug."( Biochemical characterization of retinal protein and phospholipid synthesis in mice exposed transplacentally to N-methyl-N-nitrosourea.
O'Brien, PJ; Smith, SB, 1988
)
0.27
" The insulin-glucose dose-response curve showed a significant left shift at 3 months with a further significant improvement at 12 months."( Following weight loss in massively obese patients correction of the insulin resistance of fat metabolism is delayed relative to the improvement in carbohydrate metabolism.
Baddeley, RM; Crase, J; Hale, PJ; Nattrass, M; Singh, BM, 1988
)
0.27
" Plasma free insulin profiles reflected the dosage patterns and there was no change in insulin metabolic clearance rate in pregnancy."( Observations on the metabolic basis for altered insulin dose distribution in diabetic pregnancy.
Frier, BM; Home, PD; Johnstone, FD; Steel, JM; Young, RJ,
)
0.13
" The metformin dosage was 1 g twice daily in 9 of the patients and 850 mg thrice daily in the 10th subject."( Mechanism of metformin action in non-insulin-dependent diabetes.
Disilvio, L; Featherbe, D; Hawa, MI; Jackson, RA; Jaspan, JB; Kurtz, AB; Sim, BM, 1987
)
0.27
" Due to its longer efficacy, glycerol provides an important supplement or alternative to sorbitol therapy, especially as the permitted maximum dosage would have to have been exceeded in a treatment consisting exclusively of sorbitol."( [Intracranial pressure-controlled treatment of brain edema with glycerin and sorbitol in intracerebral hemorrhage].
Brenner, M; Haass, A; Hamann, G; Harms, M; Kloss, R; Schimrigk, K, 1987
)
0.56
" The presence of Cremophor EL as an emulsifying agent in the parenteral dosage formulation of cyclosporine is a likely etiology for this acute adverse reaction."( Anaphylactoid reactions associated with parenteral cyclosporine use: possible role of Cremophor EL.
Burckart, GJ; Griffith, BP; Hardesty, RJ; Howrie, DL; Ptachcinski, RJ; Rosenthal, JT; Venkataramanan, R, 1985
)
0.27
"Nine men were studied during three 4-h cycling bouts to determine the effect of frequency and dosage of solid carbohydrate (CHO) feedings (86 g) on muscle glycogen utilization and exercise performance."( Effect of carbohydrate feeding frequencies and dosage on muscle glycogen use during exercise.
Costill, DL; Fielding, RA; Fink, WJ; Hargreaves, M; King, DS; Kovaleski, JE, 1985
)
0.27
" The dose-response curve of norepinephrine-stimulated lipolysis in rat adipocytes was not sigmoidal but biphasic in nature."( Bimodal effect of insulin on hormone-stimulated lipolysis: relation to intracellular 3',5'-cyclic adenylic acid and free fatty acid levels.
Angel, A; Desai, KS; Li, KC, 1973
)
0.25
" Diabetic patients treated with salbutamol should therefore be under close surveillance and have their insulin dosage increased."( [Metabolic risks of salbutamol in diabetic patients. A study using somatostatin (author's transl)].
Compagnie, MJ; Dellenbach, P; Schlienger, JL; Stephan, F, 1980
)
0.26
" The degree of 32PO4 incorporation into these phospholipids paralleled the dose-response curves for histamine release."( Enhanced phospholipid metabolism in rat mast cells stimulated to release histamine.
Schellenberg, RR, 1980
)
0.26
" Dose-response curves were determined for isoproterenol on cAMP levels, protein kinase activity and glycerol release."( Relationship among isoproterenol, cyclic AMP, cyclic AMP-dependent protein kinase and lipolysis in perfused fat cells.
Allen, DO; Long, KJ; Sengupta, K, 1981
)
0.48
" It is concluded that high dosed caffeine causes peripheral insulin resistance in the human being as well as in the experimental animal."( [Effect of caffeine on various metabolic parameters in vivo].
Förster, H; Sachs, M, 1984
)
0.27
" There were no further significant increases in mean plasma lipid levels if the infused dosage was increased to 3 or 4 g/kg a day."( Plasma lipid levels in preterm neonates receiving parenteral fat emulsions.
Brans, YW; Hilliard, JL; Hunter, MA; Shannon, DL, 1983
)
0.27
" For both tissue regions fasting induced a right-ward shift in the dose-response curve for the inhibitory effect of the alpha 2 agonist, clonidine, on theophylline-induced lipolysis, corresponding to a 10-fold decrease in sensitivity."( Influence of fasting on lipolytic response to adrenergic agonists and on adrenergic receptors in subcutaneous adipocytes.
Arner, P; Engfeldt, P; Kimura, H; Ostman, J; Wahrenberg, H, 1984
)
0.27
" In each instance, hemicholinium-3 causes a significant inhibition of control activity at a concentration of 30 microM, a dosage that causes complete photoreceptor outer segment degeneration in mammalian retinas."( Alteration of retinal choline metabolism in an experimental model for photoreceptor cell degeneration.
Anderson, RE; Pu, GA, 1983
)
0.27
" In untreated hyperthyroidism, there was a decreased sensitivity to the antilipolytic effect of insulin, since the dose-response curve was shifted to the right; 250 microU/ml insulin were required for 50% of the maximal effect compared to 25 microU/ml in the controls."( Changes in the effects of insulin on human adipose tissue metabolism in hyperthyroidism.
Arner, P; Ostman, J; Wennlund, A, 1981
)
0.26
"5 h after the second dose of glycerol, specific radioactivity(SRA) of glycerol and of [14C] an [3H] glucose were measured in plasma obtained from the three previously mentioned sites in dosed and undosed sheep."( The utilisation of glycerol by sheep.
Evans, J; Ford, EJ; Ranaweera, A, 1980
)
0.88
" As dose-response studies indicate, accumulations of PI and DAG are most susceptible to CPZ."( Effect of chlorpromazine on the synthesis of neutral lipids and phospholipids from [3H]glycerol in the primordial human placenta.
Heiczman, A; Tóth, M, 1995
)
0.51
" No differences were found in endurance performance between the three caffeine dosages which indicates that no dose-response relation of caffeine and endurance performance was found."( The effect of different dosages of caffeine on endurance performance time.
de Haan, A; Jeukendrup, AE; Pasman, WJ; van Baak, MA, 1995
)
0.29
" The dose-response curves for SSBs due to glycerol radicals are predominantly "one-hit" over the entire glycerol concentration range where they were observable (> or = 75 mM)."( Role of scavenger-derived radicals in the induction of double-strand and single-strand breaks in irradiated DNA.
Ayene, IS; Koch, CJ; Krisch, RE, 1995
)
0.56
"The pharmaceutical utility of silk fibroin as a possible material for an oral dosage form for elderly patients was investigated."( New oral dosage form for elderly patients: preparation and characterization of silk fibroin gel.
Hanawa, T; Hidaka, M; Ikoma, R; Sugihara, M; Tsuchiya, T; Watanabe, A, 1995
)
0.29
" The dosage form of FK480 is a soft capsule containing a solution of FK480 in a mixture of polyethylene glycol 400 (PEG 400) and glycerol to improve its bioavailability."( Mechanism of optical isomerization of (S)-N-[1-(2-fluorophenyl)-3,4,6,7- tetrahydro-4-oxopyrrolo[3,2,1-jk] [1,4]-benzodiazepine-3-yl]-1H- indole-2-carboxamide (FK480) in soft capsules containing polyethylene glycol 400 and glycerol.
Fukuyama, S; Kihara, N; Koda, S; Morokoshi, N; Nakashima, K; Yasuda, T, 1994
)
0.68
" Paclitaxel dissolved either in ethanol or ethanol plus cremophor EL, resulted in steep and almost identical dose-response curves for the parental lines ZR 75-1 and HS 578T, respectively, independent of the solvent used."( Paclitaxel-induced cytotoxicity--the effects of cremophor EL (castor oil) on two human breast cancer cell lines with acquired multidrug resistant phenotype and induced expression of the permeability glycoprotein.
Bergh, J; Fjällskog, ML; Frii, L, 1994
)
0.29
" Exposure times and dose-response relationships should be explored to optimize future clinical applications of this drug."( Analysis of exposure times and dose escalation of paclitaxel in ovarian cancer cell lines.
Adler, LM; Herzog, TJ; Mutch, DG; Rader, JS; Williams, S, 1994
)
0.29
" In this latter group, otitis media was induced by injecting glycerin into the middle ear clefts 1 months after birth, and the degree of inflammation was varied by administering or withholding antibiotics (cefamandole and dibekacin) and adjusting the dosage regimen."( The relationship between the degree of chronic middle ear inflammation and tympanic bulla pneumatization in the pig as animal model.
Ikarashi, F; Nakano, Y; Okura, T, 1994
)
0.29
" Concentration-response curves for activation of lipolysis by each agonist correlated well with the dose-response curves for activation of cAMP-dependent protein kinase (A-Kinase)."( Correlation of beta 3-adrenoceptor-induced activation of cyclic AMP-dependent protein kinase with activation of lipolysis in rat white adipocytes.
Cawthorne, MA; Kirkham, DM; Murphy, GJ; Young, P, 1993
)
0.29
" Incubation with 1 microM adrenaline and increasing doses of phenylisopropyladenosine (PIA) caused a rightward shift in the dose-response curve of adipocytes in five of the ten exercisers compared to litter-mate controls."( Exercise attenuates the anti-lipolytic effect of adenosine in adipocytes isolated from miniature swine.
Carey, GB; Sidmore, KA, 1994
)
0.29
" Clear inter-individual variations in the adipocyte lipolytic adrenoceptor sensitivity (pD2) for noradrenaline were observed in dose-response experiments (i."( Systolic blood pressure is related to catecholamine sensitivity in subcutaneous abdominal fat cells.
Hoffstedt, J; Lönnqvist, F; Reynisdottir, S, 1996
)
0.29
" The dose-response curves for both SSBs and DSBs in either air or nitrogen are predominantly linear when 75 or 750 mM glycerol is combined with 0-20 mM GSH."( Simulation of the cellular oxygen effect with an SV40 DNA model system using DNA strand breaks as an end point.
Ayene, IS; Koch, CJ; Krisch, RE, 1996
)
0.5
" dosage form of PSC 833, [3'-keto-Bmt1]-[Val2]-cyclosporin, contains CreEL and has been presumed to have the potentiation of the reversal activity of PSC 833."( Cremophor EL reversed multidrug resistance in vitro but not in tumor-bearing mouse models.
Itoh, Y; Naito, M; Nakayama, Y; Oh-hara, T; Tsuruo, T; Watanabe, T, 1996
)
0.29
"50 g/kg dosage gave evidence of ameliorating effects 14 days after treatment."( Distortion-product otoacoustic emissions and glycerol on the guinea pig hydropic ear.
Cianfrone, G; Cristofari, P; Magliulo, G; Musacchio, A; Petti, R; Vingolo, GM, 1997
)
0.56
" An aqueous acetonitrile (ACN) buffer containing sodium dodecyl sulfate (SDS) surfactant allows resolution of the 15 taxanes from each other and from the principal matrix ingredient in the injectable dosage form of the drug, Cremophor EL (polyethoxylated castor oil)."( Separation of paclitaxel and related taxanes by micellar electrokinetic capillary chromatography.
Locke, DC; Shao, LK, 1998
)
0.3
"Paclitaxel's optimal dosage and scheduling is currently not determined."( Cell line and schedule-dependent cytotoxicity of paclitaxel (Taxol): role of the solvent Cremophor EL/ethanol.
Cordes, N; Plasswilm, L,
)
0.13
" Rats were dosed with [1-14C]glycerol, [14C]polyglycerol and ([14C]polyglycerol)PGPR by gavage and their urine."( The fate of ingested glyceran esters of condensed castor oil fatty acids [polyglycerol polyricinoleate (PGPR)] in the rat.
Howes, D; James, CT; Wilson, R,
)
0.65
" Dose-response curves for adenosine inhibition of isoproterenol-stimulated lipolysis demonstrated that chronic culture with bST decreased adipose tissue responsiveness and sensitivity to adenosine."( Effect of somatotropin, insulin, and glucocorticoid on lipolysis in chronic cultures of adipose tissue from lactating cows.
Bauman, DE; Lanna, DP, 1999
)
0.3
" The compound is pharmaceutically formulated as a lyophilized product containing 500 microg active substance per dosage unit."( Compatibility and stability of aplidine, a novel marine-derived depsipeptide antitumor agent, in infusion devices, and its hemolytic and precipitation potential upon i.v. administration.
Beijnen, JH; Bouma, M; Bult, A; Henrar, RE; Manada, C; Nuijen, B, 1999
)
0.3
"The objective of this work is to study the interaction of a copolymer, poly methyl vinyl ether/maleic anhydride (PMV/MA) used in pharmaceutical dosage form and a phospholipid L-alpha-dimiristoyl phosphatidylcholine (DMPC) with the aim of developing a bioadhesive system."( Interaction of poly methyl vinyl ether/maleic anhydride-dimiristoyl phosphatidylcholine: a model bioadhesion study.
Ballesteros, MP; Castro, RM; Lastres, JL; Nuñez, JL, 2000
)
0.31
" When isoproterenol was perfused, a dose-response increase in glycerol production was induced in both tissues."( In vivo lipolysis in adipose tissue from two anatomical locations measured by microdialysis.
Macarulla, MT; Portillo, MP; Torres, MI; Villaro, JM, 2000
)
0.55
" Deletion of SGD1 results in loss of cell viability, while an increased dosage of SGD1 partially suppresses the osmosensitivity of pbs2 delta and hog1 delta mutants that are defective in the osmosignaling high osmolarity glycerol (HOG) mitogen-activated protein kinase pathway."( SGD1 encodes an essential nuclear protein of Saccharomyces cerevisiae that affects expression of the GPD1 gene for glycerol 3-phosphate dehydrogenase.
Adler, L; Akhtar, N; Corbett, AH; Larsson, K; Påhlman, AK, 2000
)
0.7
" The dose-response curve for L-750355-induced glycerolemia lies to the left of that for tachycardia."( L-750355, a human beta3-adrenoceptor agonist; in vitro pharmacology and profile of activity in vivo in the rhesus monkey.
Bach, T; Candelore, MR; Cascieri, MA; Cioffe, C; Deng, L; Fisher, MH; Forrest, MJ; Hegarty-Friscino, B; Hom, G; MacIntyre, E; Marko, O; Ok, HO; Strader, C; Szumiloski, J; Tota, L; Vicario, P; Weber, AE; Wyvratt, M, 2000
)
0.57
" The aim of the present study was to determine insulin dose-response characteristics of systemic, sc adipose tissue and muscle lipolysis in humans."( Suppression of systemic, intramuscular, and subcutaneous adipose tissue lipolysis by insulin in humans.
Becker, R; Grauer, P; Häring, H; Hauer, B; Jacob, S; Löblein, K; Nielsen, M; Renn, W; Stumvoll, M; Wahl, HG, 2000
)
0.31
" Dose-response curves conducted at 30-min incubation time showed that chlorpromazine potently inhibited labelling of diacylglycerol and diacyglycerol-derived lipids (triacyglycerol and phosphatidylcholine) by the 3H-labelled precursors."( Chlorpromazine and human platelet glycerolipid metabolism: precursor specificity and significance of drug-platelet interaction time.
Daasvatn, KO; Holmsen, H, 1999
)
0.79
" The pharmaceutical formulation consists of a lyophilized product containing 150 micrograms kahalalide F, 3 mg citric acid, 3 mg polysorbate 80, and 150 mg of sucrose per dosage unit, to be reconstituted with 3 mL of a mixture composed of Cremophor EL, ethanol, and water (5/5/90% v/v/v), resulting in a solution of pH 3 and to be further diluted in normal saline for infusion."( In vitro hemolysis and buffer capacity studies with the novel marine anticancer agent kahalalide F and its reconstitution vehicle cremophor EL/ethanol.
Beijnen, JH; Bouma, M; Bult, A; Jimeno, JM; Manada, C; Nuijen, B,
)
0.13
" Kahalalide F is pharmaceutically formulated as a lyophilized product containing 150 microg active substance per dosage unit."( Compatibility and stability of the investigational polypeptide marine anticancer agent kahalalide F in infusion devices.
Beijnen, JH; Bouma, M; Bult, A; Jimeno, JM; Lazaro, LL; Manada, C; Nuijen, B, 2001
)
0.31
" The steadily increasing radiation dosage that the spacecraft is experiencing is well beyond the original design parameters, and is contributing to a number of spacecraft problems and concerns."( Project Galileo: completing Europa, preparing for Io.
Cox, ZN; Erickson, JK; Paczkowski, BG; Sible, RW; Theilig, EE,
)
0.13
" dosing (17."( Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.
Buijs, D; Gelderblom, H; Nooter, K; Ouwens, L; Sparreboom, A; Stoter, G; van Zomeren, DM; Verweij, J, 2002
)
0.31
" For this purpose, the fractionating robot Probot was employed which enables both the on-line fractionation of the CE eluate on a MALDI target during the electrophoretic separation and the simultaneous dosage of the MALDI matrix solution."( Separation and first structure elucidation of Cremophor EL-components by hyphenated capillary electrophoresis and delayed extraction-matrix assisted laser desorption/ionization-time of flight-mass spectrometry.
Frahm, AW; Meyer, T; Waidelich, D, 2002
)
0.31
" Clinically relevant peripheral neurotoxicity tended to occur at around 1500 mg/m2 cumulative dosage at weekly doses > or =110 mg/m2."( Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation study.
Briasoulis, E; Haidou, C; Karavasilis, V; Pavlidis, N; Piperidou, C; Tzamakou, E, 2002
)
0.31
" In order to combine CE and MS the fractionating robot Probot was employed which enables both the online fractionation of the CE eluate on a MALDI target during the electrophoretic separation and the simultaneous dosage of the MALDI matrix."( Polyoxyethylene-Delta(9,11)-didehydrostearate and glycerol-polyoxyethylene-Delta(9,11)-didehydrostearate: two new components of the non-ionic emulsifier Cremophor EL.
Frahm, AW; Meyer, T; Waidelich, D, 2002
)
0.57
" The purpose of this study was to use a rat model to evaluate whether the pharmacokinetic interaction between OPT and PXL is dosing sequence-dependent."( Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.
Balcerzak, S; Chan, KK; D'Ambrosio, S; Grever, M; Kraut, EH; Liu, J, 2002
)
0.31
" The 24-h urinary elimination of total Pt increased in both combination groups, irrespective of the dosing sequence."( Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.
Balcerzak, S; Chan, KK; D'Ambrosio, S; Grever, M; Kraut, EH; Liu, J, 2002
)
0.31
"These results suggest that alterations in the pharmacokinetics of OPT by fPXL are dosing sequence-dependent and mainly caused by the formulation vehicle CrEL."( Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.
Balcerzak, S; Chan, KK; D'Ambrosio, S; Grever, M; Kraut, EH; Liu, J, 2002
)
0.31
" Insulin responsiveness of the lipolytic and lipogenic pathways was analyzed by dose-response experiments, giving evidence for the involvement of improved insulin responsiveness in the enhanced lipogenic and reduced lipolytic activities of adipocytes in early pregnancy."( Fat accumulation in the rat during early pregnancy is modulated by enhanced insulin responsiveness.
Cacho, J; Crespo-Solans, MD; del Campo, S; Herrera, E; Ramos, MP, 2003
)
0.32
" An increase in the dosage of phage particles, up to at least 5 x 10(7) phage particles per 100-mm dish, resulted in a linear increase in the number of transformants."( Phage particle-mediated gene transfer to cultured mammalian cells.
Hamada, Y; Hirose, S; Ishiura, M; Okada, Y; Suzuki, Y; Uchida, T, 1982
)
0.26
" A PTC4 cDNA that encodes a protein phosphatase belonging to the PP2C family was obtained as a high dosage suppressor of the lethality of Delta cnb1 Delta mpk1 strain."( Evidence for antagonistic regulation of cell growth by the calcineurin and high osmolarity glycerol pathways in Saccharomyces cerevisiae.
Hirata, D; Miyakawa, T; Shitamukai, A; Sonobe, S, 2004
)
0.54
" The gene dosage of in vitro evolved lycopene cyclase crtY2 significantly changed the carotenoid profile."( Investigation of factors influencing production of the monocyclic carotenoid torulene in metabolically engineered Escherichia coli.
Lee, PC; Mijts, BN; Schmidt-Dannert, C, 2004
)
0.32
" Glycerol was also successfully dosed using an internal reference, 1,5-pentanediol."( Characterization of European wine glycerol: stable carbon isotope approach.
Calderone, G; Guillou, C; Naulet, N; Reniero, F, 2004
)
1.51
" Additionally, 3-MCPD (5 mg/kg) significantly reduced sperm motility, copulation, fertility indices, and the number of live fetuses showed steep dose-response curves."( Mechanism of antifertility in male rats treated with 3-monochloro-1,2-propanediol (3-MCPD).
Chae, SY; Choi, KS; Choi, YW; Da Lee, R; Kim, SS; Kwack, SJ; Lee, BM; Lim, KJ; Park, KL; Rhee, GS; Seok, JH; Won, YH, 2004
)
0.32
"The aim of this study was to systematically obtain a model of factors that would yield an optimized self-nanoemulsified capsule dosage form (SNCDF) of a highly lipophilic model compound, Coenzyme Q10 (CoQ)."( Response surface methodology for optimization and characterization of limonene-based coenzyme Q10 self-nanoemulsified capsule dosage form.
Khan, MA; Nutan, MT; Palamakula, A, 2004
)
0.32
" Dose-response curves for glycerol and uracil indicated that weevil preference increased as sample concentration increased."( Chemically mediated host-plant selection by the milfoil weevil: a freshwater insect-plant interaction.
Gleason, FK; Marko, MD; Newman, RM, 2005
)
0.63
" Moreover, they release the requirement for dosage of pure oxygen and thereby can facilitate the scale-up of the production process."( Oxygen-limited control of methanol uptake for improved production of a single-chain antibody fragment with recombinant Pichia pastoris.
Hoffmann, F; Khatri, NK, 2006
)
0.33
" The incidence of grade 3 sensory neuropathy was higher in nab-paclitaxel recipients, reflecting the higher dosage of nab-paclitaxel, and improved with treatment interruption."( Albumin-bound Paclitaxel: in metastatic breast cancer.
Keating, GM; Robinson, DM, 2006
)
0.33
" Analysis of dose-response relations between plasma insulin and metabolites during insulin infusions showed that maximally insulin-suppressed concentrations of NEFA and glycerol were significantly greater in pregnant than in nonpregnant ewes but were unaffected by undernutrition."( Pregnancy but not moderate undernutrition attenuates insulin suppression of fat mobilization in sheep.
Bell, AW; Dunshea, FR; Ehrhardt, RA; Petterson, JA; Slepetis, R, 1994
)
0.48
" Only glycerol showed dose-response and effects potentially better than no treatment."( Anti-irritants I: Dose-response in acute irritation.
Andersen, F; Andersen, KE; Bindslev-Jensen, C; Fullerton, A; Hedegaard, K; Petersen, TK, 2006
)
0.81
" The dose-response effect of 4 alleged AI (nifedipine, (-)-alpha-bisabolol, canola oil and glycerol) was studied on experimentally induced acute irritation in healthy volunteers, and only glycerol showed dose-related response and effects potentially better than no treatment."( Anti-irritants II: Efficacy against cumulative irritation.
Andersen, F; Andersen, KE; Bindslev-Jensen, C; Fullerton, A; Hedegaard, K; Petersen, TK, 2006
)
0.55
" A minimum solvent dosage of 44-54 wt % of the reaction mixture was necessary to achieve high MAG yields of 47-56 wt %, within 20 min."( Evaluation of binary solvent mixtures for efficient monoacylglycerol production by continuous enzymatic glycerolysis.
Abildskov, J; Damstrup, ML; Jensen, AD; Kiil, S; Sparsø, FV; Xu, X, 2006
)
0.58
" One CAT was performed after a nicotine (NIC) dosing using a 21-mg transdermal patch, whereas the other CAT was performed after a placebo (PL) treatment."( The effects of nicotine on the metabolic and hormonal responses during acute cold exposure.
Blegen, M; Caine-Bish, N; Cheatham, CC; Glickman, EL; Kalinski, M; Kamimori, GH; Marcinkiewicz, JL; Otterstetter, R; Potkanowicz, ES, 2006
)
0.33
"The application of microcapsule for pharmaceutical dosage form for various drugs has received considerable attention in recent years due to its multiple advantages."( Microencapsulation of extract containing shikonin using gelatin-acacia coacervation method: a formaldehyde-free approach.
Cham, TM; Cheng, YH; Huang, YI; Tsai, TR; Yu, CC, 2007
)
0.34
" Animals were allocated to 1 of 4 treatment groups: 1) control, feed and water deprived for 48 h (n = 6); 2) transported, transported for 48 h (n = 6); 3) glycerol, dosed with glycerol (2 g/kg of BW) and then transported for 48 h (n = 6); and 4) betaine, dosed with betaine (0."( Physiological and metabolic effects of prophylactic treatment with the osmolytes glycerol and betaine on Bos indicus steers during long duration transportation.
Dobson, GP; Fitzpatrick, LA; Parker, AJ, 2007
)
0.76
" Lipid granules of KTZ prepared with Compritol 888 ATO could be proposed as a new KTZ solid dosage form with optimum dissolution and therapeutic characteristics."( In vitro release--in vivo microbiological and toxicological studies on ketoconazole lipid granules.
Ay, Z; Durmaz, G; Ertan, G; Gokce, EH; Gokce, G; Guneri, T; Hilmioglu, S; Metin, DY; Ozer, O; Ozyazici, M; Ozyurt, D; Pekcetin, C; Yalcin, A, 2007
)
0.34
") to the desired drug dosing concentration at the acceptable excipient level."( Solubilization and preformulation of poorly water soluble and hydrolysis susceptible N-epoxymethyl-1,8-naphthalimide (ENA) compound.
Dong, Y; Ng, WK; Surana, U; Tan, RB, 2008
)
0.35
" The effects depend on the dosage of agents, including volume and concentration, and decrease with the dosage of agents."( Short-term and long-term effects of optical clearing agents on blood vessels in chick chorioallantoic membrane.
Cui, H; Li, P; Luo, Q; Mao, Z; Zhang, J; Zhu, D,
)
0.13
" The droplet size and dissolution of optimal formulation were determined to prove that the dosage form is a useful delivery system for piroxicam."( [Design and in vitro evaluation of self-microemulsifying drug delivery systems for piroxicam].
Nie, SF; Pan, WS; Sun, JY; Wang, J; Wang, Y; Zhou, XT, 2008
)
0.35
" A surprising dose-response increase of erythroid cells is noted in cultures with the ester cannabinoids (in the absence of the cytokine erythropoietin), while a considerable dose-response augmentation of megakaryocytes is noted in cultures with the ethanolamide cannabinoids (in the presence of erythropoietin)."( Endocannabinoids as positive or negative factors in hematopoietic cell migration and differentiation.
Breuer, A; Fride, E; Mechoulam, R; Milman, G; Patinkin, D, 2008
)
0.35
" The influence of solubilizers on the aqueous solubility of the itraconazole, ketoconazole and miconazole was investigated in order to enhance their solubility for a possible parenteral dosage form."( Aqueous solvent system for the solubilization of azole compounds.
Antal, I; Klebovich, I; Kovács, K; Ludányi, K; Stampf, G, 2009
)
0.35
" and a spore form of Bacillus subtilis from nonprocessed bacteria to coated dosage forms (i."( Evaluation of the viability of Lactobacillus spp. after the production of different solid dosage forms.
Brachkova, MI; Duarte, A; Pinto, JF, 2009
)
0.35
" Benchmark dose analysis of the dose-response data for renal tubular hyperplasia in male and female rats exposed to 3-MCPD in drinking water for 2 years was conducted."( Toxicity value for 3-monochloropropane-1,2-diol using a benchmark dose methodology.
Hwang, M; Jang, DD; Kim, J; Yoo, TM; Yoon, E, 2009
)
0.35
" CT imaging and Raman spectroscopy are used to construct dose-response curves for irradiated gels varying in (i) initial total monomer (%T) and (ii) initial co-solvent concentration."( Effects of glycerol co-solvent on the rate and form of polymer gel dose response.
Berman, A; Hilts, M; Jirasek, A; McAuley, KB, 2009
)
0.74
" Findings attributable to Proliferol after 24 hours included dose-response elevations in alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, and creatine kinase, which returned to normal after 14 days."( Acute toxicity evaluation of proliferol: a dose-escalating, placebo-controlled study in swine.
Dagenais, S; Green, R; Hite, M; Mayer, J; Wooley, J,
)
0.13
"3 mOsm/l in the group of diabetic patients after the low and high dose, respectively, reflecting a dose-response relationship."( The effects of peroral glycerol on plasma osmolarity in diabetic patients and healthy individuals.
la Cour, M; Lund-Andersen, H; Sander, B; Thornit, DN, 2009
)
0.66
" Development of a novel semimechanistic pharmacodynamic model permitted quantitative hypothesis testing with the tumor volume progression data, and suggested the existence of a transient treatment effect that was consistent with sensitization or "priming" of tumors by more frequent L-pac dosing schedules."( Differential pharmacodynamic effects of paclitaxel formulations in an intracranial rat brain tumor model.
Harrold, JM; Mager, DE; Mazurchuk, RV; Straubinger, RM; Tamburlin, JH; Zhou, R, 2010
)
0.36
" The anti-cellulite effect was evaluated by the dosage of released glycerol and histological analysis of the hypodermis."( Ex vivo human skin evaluation of localized fat reduction and anti-aging effect by TriPollar radio frequency treatments.
Boisnic, S; Branchet, MC, 2010
)
0.6
"The number of mixed micellar (MM) drug products being introduced into the commercial pharmaceutical market is very limited although there is need for alternative dosage forms for poorly soluble active drug substances."( Mixed micelle formation with phosphatidylcholines: the influence of surfactants with different molecule structures.
Müller, BW; Rupp, C; Steckel, H, 2010
)
0.36
" Blood ammonia and blood and urine metabolites were compared after 7 days (steady state) of TID dosing on either drug, both dosed to deliver the same amount of phenylbutyric acid (PBA)."( Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control.
Beliveau, M; Berry, SA; Diaz, GA; Dickinson, K; Gargosky, S; Lee, B; Marier, JF; Martinez, A; Mauney, J; Mian, A; Mokhtarani, M; Rhead, W; Scharschmidt, BF; Shchelochkov, O, 2010
)
0.36
" Oral administration of the cultured yeast at a dosage of 130 mg/kg body weight/day for 6 days could significantly reduce the plasma glucose content in STZ-induced diabetic mice and keep their body weights in the normal range."( Effects of cultural medium and conditions on the proliferation and hypoglycemic activity of Saccharomyces pastorianus no. 54.
Lin, HT; Tsai, GJ; Wang, SH; Wu, CH; Wu, GJ, 2011
)
0.37
" No statistically significant differences were observed in plasma phenylacetic acid and PAGN exposure during dosing with GPB vs."( Ammonia control in children with urea cycle disorders (UCDs); phase 2 comparison of sodium phenylbutyrate and glycerol phenylbutyrate.
Beliveau, M; Diaz, GA; Dickinson, K; Feigenbaum, A; Jomphe, C; Lichter-Konecki, U; Marier, JF; Martinez, A; Mauney, J; Merritt, JL; Mokhtarani, M; Rhead, W; Scharschmidt, B, 2011
)
0.58
" In conclusion, the bioadhesive films formed from organic-inorganic hybrid gels possessed very good qualities for application on the skin and may provide a promising formulation for TDDS, especially when the patient acceptability from an aesthetic perspective of the dosage form is a prime consideration."( Bioadhesive film formed from a novel organic-inorganic hybrid gel for transdermal drug delivery system.
Deng, L; Dong, A; Du, X; Guo, R; Zhang, J; Zhang, R, 2011
)
0.37
"09 g) were repeatedly dosed with either [(13)C(3)]glycerol (14 mg/d for 4 d) or [(13)C(6)]glucose (15 mg/d for 3 d) into the chorio-allantoic fluid before blood and tissue collection."( Glycerol is a major substrate for glucose, glycogen, and nonessential amino acid synthesis in late-term chicken embryos.
Bequette, BJ; Sunny, NE, 2011
)
2.07
"The poor transport observed in a reconstituted system together with the high value of K(i) and the results of complementation study well explain the usual high dosage of this drug for the treatment of the urinary tract infections."( Interaction of fosfomycin with the glycerol 3-phosphate transporter of Escherichia coli.
Cappello, AR; Dolce, V; Iacopetta, D; Madeo, M; Martello, E; Santoro, A, 2011
)
0.65
"To compare physiochemical properties of mono-, di- and triglycerides of medium chain fatty acids for development of oral pharmaceutical dosage forms of poorly water-soluble drugs using phase diagrams, drug solubility, and drug dispersion experiments."( A comparative evaluation of mono-, di- and triglyceride of medium chain fatty acids by lipid/surfactant/water phase diagram, solubility determination and dispersion testing for application in pharmaceutical dosage form development.
Dalrymple, DM; Prajapati, HN; Serajuddin, AT, 2012
)
0.38
" This study evaluates several proliferant dosages develop an optimal dosage that maximizes cell and collagen regeneration."( Effect of prolotherapy on cellular proliferation and collagen deposition in MC3T3-E1 and patellar tendon fibroblast populations.
Brolinson, PG; Ekwueme, EC; Empson, YM; Freeman, JW; Paynter, DM, 2011
)
0.37
" Consequently, dosing strategies for these compounds could benefit from the development and application of molecular activity biomarkers to infer and distinguish between methanol- or glycerol-based denitrification in activated sludge."( Alcohol dehydrogenase expression as a biomarker of denitrification activity in activated sludge using methanol and glycerol as electron donors.
Chandran, K; Lu, H; Nuruzzaman, F; Ravindhar, J, 2011
)
0.77
"The carried out studies allowed to propose composition of stomatological dressing makes opportunity to ensure preferable physiochemicals features for dosage forms."( [The effect of the composition of stomatological dressings on Carbopol 971P and methylocelullose base on pharmaceutical availability of metronidazole].
Kida, D; Pluta, J, 2011
)
0.37
" The OG liposome formulation with the appropriate OG/lipid ratio and dosing level had greater efficacy than either conventional gel formulation and maintained this efficacy for at least 2 months."( Development of a liposome microbicide formulation for vaginal delivery of octylglycerol for HIV prevention.
Gupta, P; Isaacs, C; Moncla, BJ; Patton, D; Rohan, LC; Sassi, AB; Wang, L, 2012
)
0.61
" Compared with the results of our previous single factor experiment, although the values of diolein yield and 1,3-diolien/diolein could not be improved markedly, the enzyme dosage and the reaction medium were spared by 25% and 20%, respectively, which was a remarkable improvement of the enzymatic process."( Rational synthesis of 1,3-diolein by enzymatic esterification.
Du, W; Duan, ZQ; Liu, DH, 2012
)
0.38
"Eight subjects were dosed rectally with radiolabelled and gadolinium-labelled gels to simulate microbicide gel and seminal fluid."( Quantification of the spatial distribution of rectally applied surrogates for microbicide and semen in colon with SPECT and magnetic resonance imaging.
Bakshi, RP; Caffo, BS; Cao, YJ; Du, Y; Fuchs, EJ; Grohskopf, LA; Hendrix, CW; Khan, WA; Lee, LA; Li, L; Macura, K; Wahl, RL, 2012
)
0.38
" The pH value, dosages of polyaluminum chloride (PACl) and dosage of polyacrylamide (PAM) were considered to be the factors that can influence coagulation efficiency."( Removal of organic impurities in waste glycerol from biodiesel production process through the acidification and coagulation processes.
Musikavong, C; Suksaroj, C; Taweepreda, W; Xie, QG, 2012
)
0.65
" SOSM increased above baseline after dosing with glycerol but decreased after isosorbide, which difference was significant at 1, 2, and 4 h post-administration."( Effects of oral isosorbide and glycerol on intraocular pressure, serum osmolality, and blood glucose in normal dogs.
Cochrane, ZN; Felchle, LM; Kennard, G; Wasserman, NT, 2013
)
0.93
" However, its effectiveness from conventional dosage forms is limited due to its poor solubility and penetration into the SC."( Polyglycerol fatty acid ester surfactant-based microemulsions for targeted delivery of ceramide AP into the stratum corneum: formulation, characterisation, in vitro release and penetration investigation.
Metz, H; Neubert, RH; Sahle, FF; Wohlrab, J, 2012
)
0.94
"We have analyzed pharmacokinetic data for glycerol phenylbutyrate (also GT4P or HPN-100) and sodium phenylbutyrate with respect to possible dosing biomarkers in patients with urea cycle disorders (UCD)."( Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders.
Bart, S; Bartholomew, D; Bartley, J; Berquist, W; Berry, SA; Cederbaum, S; Coakley, DF; Diaz, GA; Dickinson, K; Dorrani, N; Feigenbaum, A; Gallagher, R; Harding, CO; Korson, MS; Kronn, D; Lee, B; Lemons, C; Lichter-Konecki, U; Longo, N; McCandless, SE; Merritt, JL; Mokhtarani, M; Moors, TL; Rhead, W; Scharschmidt, BF; Smith, W; Sreenath-Nagamani, S; Summar, M; Vockley, J; Zori, R, 2012
)
0.64
" It includes externalization of receptors, which is negatively regulated by HGF, and can explain the gradual increase in trough concentration during repeated dosing in monkeys."( Pharmacokinetic modeling of hepatocyte growth factor in experimental animals and humans.
Abe, T; Adachi, K; Fukuta, K; Kato, Y; Matsumoto, K; Nakamichi, N; Nakamura, T; Sano, K; Sugiura, T; Takahashi, S, 2013
)
0.39
" One such tool is the International Life Sciences Institute (ILSI) Key Events Dose-Response Framework (KEDRF)."( Application of the International Life Sciences Institute Key Events Dose-Response Framework to food contaminants.
Fenner-Crisp, PA, 2012
)
0.38
" These results have implications during dosage form design, testing, and for usage patient use."( In vitro investigation of the effect of ambient humidity on regional delivered dose with solution and suspension MDIs.
Church, T; Finlay, WH; Hoe, S; Lewis, D; Shemirani, FM; Vehring, R, 2013
)
0.39
" When dosing diluted g-phase previously treated by acidulation, very good removal efficiency of COD, stable biogas production and high share of methane in the biogas were observed at the organic loading rates of up to 12kg/(m(3)d)."( Long-term monodigestion of crude glycerol in a UASB reactor.
Bodík, I; Czölderová, M; Hutňan, M; Kolesárová, N, 2013
)
0.67
" GSK256073 was dosed 5 mg every 12 h before breakfast and supper (BID), 10 mg every 24 h before breakfast (QD), 25 mg BID and 50 mg QD."( GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus.
Byerly, RL; Dobbins, RL; Gao, FF; Le Monnier de Gouville, AC; Mahar, KM; Nachbaur, GJ; Napolitano, A; Shearn, SP, 2013
)
0.39
" Sustained suppression of non-esterified fatty acid (NEFA) and glycerol concentrations was observed with all GSK256073 doses throughout the 48-h dosing period."( GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus.
Byerly, RL; Dobbins, RL; Gao, FF; Le Monnier de Gouville, AC; Mahar, KM; Nachbaur, GJ; Napolitano, A; Shearn, SP, 2013
)
0.63
" Dose simulations demonstrated similar PAA exposure following mole-equivalent PBA dosing of both drugs and greater PAA exposure in younger patients based on BSA."( Population pharmacokinetic modeling and dosing simulations of nitrogen-scavenging compounds: disposition of glycerol phenylbutyrate and sodium phenylbutyrate in adult and pediatric patients with urea cycle disorders.
Berry, SA; Coakley, D; Diaz, GA; Dickinson, K; Lee, B; Lemons, C; Lichter-Konecki, U; Mokhtarani, M; Monteleone, JP; Rhead, W; Scharschmidt, BF, 2013
)
0.6
" Glycerine dosage can remedy the lowered specific biogas yield of sewage sludge in Flanders and consequently enhance green electricity production."( Co-digestion of glycerine and sewage sludge to optimise green electricity production.
De Gueldre, G; Hellinck, N; Maes, L; Van De Steene, B; Weemaes, M, 2013
)
0.39
" The plasma PAA:PAGN ratio is a functional measure of the rate of PAA metabolism and represents a useful dosing biomarker."( Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Bartley, J; Berquist, W; Berry, SA; Brown, RS; Coakley, D; Diaz, GA; Dickinson, K; Feigenbaum, A; Gallagher, R; Ghabril, M; Harding, C; Lee, B; Lemons, C; Lichter-Konecki, U; Longo, N; Mantry, P; McCandless, SE; Milikien, DA; Mokhtarani, M; Moors, T; Nagamani, SC; Norris, C; Rhead, W; Rockey, DC; Scharschmidt, BF; Schulze, A; Smith, W; Vierling, JM, 2013
)
0.39
"Modern solid multiparticulate drug forms (minitablets, pellets, granules) can provide the possibility of precise dosing or modified drug release or taste masking for medicines used in children."( Application properties of oral gels as media for administration of minitablets and pellets to paediatric patients.
Kluk, A; Sznitowska, M, 2014
)
0.4
"To screen suitable nasal dosage forms of Scutellaria baicalensis extract phospholipid complex."( [Study on formulation of Scutellaria baicalensis extract phospholipid complex nasal preparation].
Liu, JY; Shi, JH; Shi, YJ; Tang, M; Yang, M, 2013
)
0.39
"Mucoadhesive films containing curcumin-loaded nanoparticles were developed, aiming to prolong the residence time of the dosage form in the oral cavity and to increase drug absorption through the buccal mucosa."( Mucoadhesive films containing chitosan-coated nanoparticles: a new strategy for buccal curcumin release.
Borsali, R; Lemos-Senna, E; Mazzarino, L, 2014
)
0.4
" Glycerol dosing resulted in no change in apparent dewaterability, with both codigestion and control reactors returning values of 22%-24%."( Anaerobic codigestion of sewage sludge and glycerol, focusing on process kinetics, microbial dynamics and sludge dewaterability.
Astals, S; Batstone, DJ; Devadas, M; Jensen, PD; Lu, Y, 2014
)
1.58
"This study aimed to prepare and evaluate mucoadhesive sponges as dosage forms for delivering solid lipid nanoparticles."( Lyophilized sponges loaded with curcumin solid lipid nanoparticles for buccal delivery: Development and characterization.
Abdallah, OY; El-Massik, MA; Farid, RM; Hazzah, HA; Nasra, MM, 2015
)
0.42
"The reduction in symptoms following 3 months of open-label GPB dosing was similar in pediatric and adult patients and may be related to chemical structure and intrinsic characteristics of the product rather than its effect on ammonia control."( Self-reported treatment-associated symptoms among patients with urea cycle disorders participating in glycerol phenylbutyrate clinical trials.
Bartholomew, D; Bartley, J; Berquist, W; Berry, SA; Cederbaum, S; Coakley, DF; Diaz, GA; Dickinson, K; Feigenbaum, A; Gallagher, R; Harding, CO; Korson, MS; Kronn, D; Le Mons, C; Lee, BH; Lichter-Konecki, U; Longo, N; Marino, M; McCandless, SE; Merritt, JL; Mokhtarani, M; Nagamani, SC; Rhead, W; Scharschmidt, BF; Schulze, A; Smith, W; Vockley, J; Wong, D; Zori, R,
)
0.35
"Gelatin-based films with an immobilized enzyme designed for extending the stability of the protein in dry, non-powder configuration with precise dosing attributes were subjected to stress conditions of temperature and relative humidity."( Investigation of Film with β-Galactosidase Designed for Stabilization and Handling in Dry Configuration.
Liu, D; Otte, A; Pinal, R; Xiang, M; Zhang, L, 2015
)
0.42
" The results showed that compared with traditional liquefaction, the introduction of MUAT allowed the solvent dosage to be halved and shortened the liquefaction time from 60 to 20 min."( Rapid and solvent-saving liquefaction of woody biomass using microwave-ultrasonic assisted technology.
Fan, L; Liao, Y; Lu, Z; Wang, S; Wu, Z; Zhang, H; Zheng, D, 2016
)
0.43
" Given the frequency of haploinsufficiency, this observation suggests that conserved duplicate genes, even though minor cases of retained duplicates, do not exhibit a dosage effect in yeast, except for ribosomal proteins."( Yeast Interspecies Comparative Proteomics Reveals Divergence in Expression Profiles and Provides Insights into Proteome Resource Allocation and Evolutionary Roles of Gene Duplication.
Ishibashi, Y; Ito, H; Kito, K; Nohara, T; Ohnishi, M; Takeda, D, 2016
)
0.43
"00) following N-9 gel dosing and 20."( Feasibility of radiolabeled small molecule permeability as a quantitative measure of microbicide candidate toxicity.
Aung, WS; Bakshi, RP; Coleman, JS; Fuchs, E; Hendrix, CW; Marzinke, MA; Robinson, J; Spiegel, HML, 2016
)
0.43
" Emodin transport and metabolism were evaluated in Transwell-cultured MDCK1A1 cells after apical dosing of EMO-NE or control solution."( Cremophor EL-based nanoemulsion enhances transcellular permeation of emodin through glucuronidation reduction in UGT1A1-overexpressing MDCKII cells.
Dong, D; Lu, D; Wang, S; Wu, B; Zhang, T, 2016
)
0.43
" Thus, this montelukast sodium-loaded oral suspension, with bioequivalence to the commercial granules and excellent stability, could be a prospective dosage form for the treatment of asthma."( Novel montelukast sodium-loaded stable oral suspension bioequivalent to the commercial granules in rats.
Cho, KH; Choi, HG; Jin, SG; Kim, DS; Kim, DW; Kim, JO; Kim, KS; Kim, YH; Kim, YI; Kwon, TK; Li, DX; Park, JH; Woo, JS; Yong, CS; Yousaf, AM, 2016
)
0.43
"SCIT dosing and glycerin tables are useful tools to assist allergists with practice decisions that involve variable patient formulas and injection volumes and can help identify suitable conditions for treatment of patients presenting with diverse allergen sensitivities and specificity profiles."( Math-free guides for glycerin and allergens at variable subcutaneous injection volumes: How's my dosing? Update.
Converse, LM; Grier, TJ; Rekkerth, DJ; Renahan, KE, 2016
)
0.43
" Using zebrafish embryos and mice, we tested toxicity, iron removal efficacy with low dosing and the biodistribution of ultra-long circulating DFO (ULC-DFO) conjugates."( In vivo efficacy, toxicity and biodistribution of ultra-long circulating desferrioxamine based polymeric iron chelator.
Abbina, S; Hamilton, JL; Hatef, A; Imran Ul-Haq, M; Kalathottukaren, MT; Kizhakkedathu, JN; Lai, BF; Unniappan, S, 2016
)
0.43
" Isolated primary adipocytes were incubated with different RAS blockers (aliskiren, captopril and losartan) in vitro for 24 h and lipolysis, lipogenesis and glucose oxidation capacities were determined in dose-response assays to a β-adrenergic agonist and to insulin."( Renin-angiotensin system blockers regulate the metabolism of isolated fat cells in vitro.
Andreotti, S; Caminhotto, Rde O; Campaãa, AB; Lima, FB; Sertié, RA, 2016
)
0.43
"Many drugs are unavailable in suitable oral paediatric dosage forms, and pharmacists often have to compound drugs to provide paediatric patients with an acceptable formulation in the right dose."( Formulating a poorly water soluble drug into an oral solution suitable for paediatric patients; lorazepam as a model drug.
Eckhardt, M; Hanff, LM; Koch, BC; Postma, DJ; Smeets, OS; van der Velde, I; van der Vossen, AC; Vermes, A; Vulto, AG, 2017
)
0.46
"9 nmol/g), which persisted at 60 min after dosing (21."( Increased anaplerosis of the tricarboxylic acid cycle decreased meal size and energy intake of cows in the postpartum period.
Allen, MS; Gualdrón-Duarte, LB, 2017
)
0.46
"Transdermal administration of drugs represents an excellent alternative to conventional pharmaceutical dosage forms."( A Novel Chemical Enhancer Approach for Transdermal Drug Delivery with C
Hijikuro, I; Kadhum, WR; Sekiguchi, S; Sugibayashi, K; Todo, H, 2017
)
0.46
" Results confirmed that the proposed microemulsion system containing RLX could improve and control the drug release profile in comparison to conventional dosage form."( Preparation, characterization and in vitro evaluation of microemulsion of raloxifene hydrochloride.
Biriaee, A; Dehghani, F; Farhadian, N; Golmohammadzadeh, S; Khameneh, B, 2017
)
0.46
" Dose-response analyses did not reveal a clear lipolytic effect in both species."( Pterostilbene Inhibits Lipogenic Activity similar to Resveratrol or Caffeine but Differently Modulates Lipolysis in Adipocytes.
Belles, C; Briot, A; Carpéné, C; Fernández-Quintela, A; Gomez-Zorita, S; Portillo, MP, 2017
)
0.46
"In this study, the effect of mixing on volatile fatty acid (VFA) production and composition was investigated through running five identical bench-scale reactors that were filled with primary solid and dosed with either pure glycerol or biodiesel waste."( The effect of mixing on fermentation of primary solids, glycerol, and biodiesel waste.
Ghasemi, M; Randall, AA, 2018
)
0.91
"MTN-014 was a phase 1, cross-over, randomized sequence trial comparing the cross-compartment pharmacokinetics and pharmacodynamics of daily TFV reduced-glycerin 1% gel after 14 days each of rectal and vaginal application, with directly observed dosing and a 6-week washout period between phases."( Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing.
Balar, B; Dai, JY; Dezzutti, CS; Galaska, B; Hendrix, CW; Justman, JE; Kunjara Na Ayudhya, RP; Levy, L; Marzinke, MA; McGowan, I; Mushamiri, I; Nair, GL; Pan, Z; Piper, JM; Schwartz, JL, 2018
)
0.48
" TFV and TFV diphosphate (TFV-DP) were detected in most samples collected from the dosing compartment."( Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing.
Balar, B; Dai, JY; Dezzutti, CS; Galaska, B; Hendrix, CW; Justman, JE; Kunjara Na Ayudhya, RP; Levy, L; Marzinke, MA; McGowan, I; Mushamiri, I; Nair, GL; Pan, Z; Piper, JM; Schwartz, JL, 2018
)
0.48
" Although high TFV concentrations in the dosing compartment may be protective, low cross-compartment tissue concentrations are not likely to be protective."( Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing.
Balar, B; Dai, JY; Dezzutti, CS; Galaska, B; Hendrix, CW; Justman, JE; Kunjara Na Ayudhya, RP; Levy, L; Marzinke, MA; McGowan, I; Mushamiri, I; Nair, GL; Pan, Z; Piper, JM; Schwartz, JL, 2018
)
0.48
" Accordingly, ML-SNEP coated with Kollicoat Smartseal 30D and/or silicon dioxide could be an excellent dosage form that combine dual enhancement of CN solubilization and stabilization."( Stabilization benefits of single and multi-layer self-nanoemulsifying pellets: A poorly-water soluble model drug with hydrolytic susceptibility.
Abdel-Rahman, SI; Alanazi, FK; Shahba, AA, 2018
)
0.48
"The dosage of PVA17-88,ethanol and glycerin were used as factors, the film-forming properties,the release rate of strychnine and berberine hydrochloride in eight hours were adopted as indexes to optimize the molding process; the release rate and transdermal release were examined in vitro by using Franz diffusion cells."( [Multi-objective Simultaneous Optimization of Huang-ma Slow-release Membrane Spray Agent].
Chen, W; Gao, Q; Liu, M; Liu, X; Yang, M, 2016
)
0.43
" Covariate analyses indicated that age did not influence the PK parameters, with body surface area (BSA) being the most significant covariate, reinforcing current BSA based dosing recommendations as seen in older patients."( Pharmacokinetics of glycerol phenylbutyrate in pediatric patients 2 months to 2 years of age with urea cycle disorders.
Berry, SA; Diaz, GA; Dong, M; Ficicioglu, C; Harding, CO; Holt, RJ; Lichter-Konecki, U; Longo, N; McCandless, SE; Perdok, R; Robinson, B; Smith, WE; Vinks, AA; Vockley, J; Zori, R, 2018
)
0.8
" Highest motility was found in PVA 18 kDa with regardless of the dosage (P < 0."( Effect of polyvinyl alcohol on survival and function of angora buck spermatozoa following cryopreservation.
Daşkın, A; Tekin, K, 2019
)
0.51
" Growth deficiency of the gsp1-1894 cells on galactose medium was further suppressed by high dosage of the SIP2 DNA, which encodes the cytosolic β subunit of AMPK."( Altered metabolic regulation owing to gsp1 mutations encoding the nuclear small G protein in Saccharomyces cerevisiae.
Hayashi, N; Oki, M, 2020
)
0.56
" The latest strategies for the prevention of the sexual transmission of HIV have moved towards sustained-release dosage forms, so films may be an effective strategy that could also improve the patient's comfort."( Development of mucoadhesive vaginal films based on HPMC and zein as novel formulations to prevent sexual transmission of HIV.
Bedoya, LM; Cazorla-Luna, R; Martín-Illana, A; Notario-Pérez, F; Peña, J; Ruiz-Caro, R; Veiga, MD, 2019
)
0.51
"%, an enzyme dosage of 6 wt."( Highly Selective Synthesis of Monolaurin via Enzymatic Transesterification under Batch and Continuous Flow Conditions.
Chen, F; Liu, C; Xu, B; Zhang, G; Zhang, J; Zhao, F, 2019
)
0.51
"Safe application of water-insoluble acaricides requires fast release from solid dosage systems into aquatic environments."( Dextrin Nanocomposites as Matrices for Solid Dosage Forms.
Atanasova, M; Du Toit, EL; Emmambux, MN; Focke, WW; Oosthuizen, H; Phillips, J; Venter, JL; Wesley-Smith, J, 2020
)
0.56
" The objective of this study was to develop a tunable extruded 3D printing platform based on thermo-sensitive gelatin pastes to meet the needs of achieving different drug release characteristics with flexible dosing and design."( A tunable extruded 3D printing platform using thermo-sensitive pastes.
Ivone, R; Lin, X; Shen, J; Wang, X; Xie, L; Yang, G; Yang, Y, 2020
)
0.56
" Dexamethasone-loaded SLN were manufactured via melt-emulsification and high pressure homogenization in the dosage form of a lipid nanosuspension."( Novel approach for overcoming the stability challenges of lipid-based excipients. Part 3: Application of polyglycerol esters of fatty acids for the next generation of solid lipid nanoparticles.
Corzo, C; Lochmann, D; Meindl, C; Reyer, S; Salar-Behzadi, S, 2020
)
0.77
" Besides, the dosage should be much increased compared with the original molecule due to the increase in molecular weight."( [Conjugation to Branched Glycerol Oligomers, a Novel Strategy for Extremely Hydrophobic Agents].
Abe, S; Miyamoto, L; Nemoto, H; Tsuchiya, K, 2020
)
0.86
" Our results showed that ammonia excretion was not altered by dietary glycerol supplementation, and the highest glycerol dosage was associated with significant increases in amino acids and a decrease of ergogenic creatine in digesta metabolome."( Effect of glycerol feed-supplementation on seabass metabolism and gut microbiota.
Coelho, FJRC; Gomes, NCM; Louvado, A; Magnoni, L; Ozorio, ROA; Palma, M; Tavares, LC; Viegas, I, 2020
)
1.19
"The effects were independent of the dosage used."( Effectiveness of topical glyceryl trinitrate in treatment of tendinopathy - systematic review and meta-analysis.
Johansson, J; Juhola, J; Kemppi, V; Saltychev, M, 2022
)
0.72
"Our aim was to determine the surface free energy (SFE) of semi-solid dosage forms (SSDFs) by establishing a reproducible method for measuring the contact angle of liquids to SSDFs."( A Method for Measuring the Surface Free Energy of Topical Semi-solid Dosage Forms.
Fujii, M; Goto, Y; Hashizaki, K; Hoshii, Y; Ikeuchi, K; Imai, M; Taguchi, H, 2021
)
0.62
" Emodin and rhein showed greater inhibition than the other compounds; dosage at 50 μM reduced intracellular triglyceride (TG) by about 30% in the differentiated adipocytes."( Rhubarb hydroxyanthraquinones act as antiobesity agents to inhibit adipogenesis and enhance lipolysis.
Aljuffali, IA; Chen, WJ; Fang, JY; Hsu, CY; Huang, TH, 2022
)
0.72
" Crude glycerol dosage, yeast extract dosage and initial pH were the influencing factors playing a significant role in the malic acid synthesis."( Techno economic analysis of malic acid production using crude glycerol derived from waste cooking oil.
Bharathiraja, B; Iyyappan, J; Jayamuthunagai, J; Praveenkumar, R; Sreejith, R, 2022
)
1.42
" We present a case of CGKD that was initially misdiagnosed and died during treatment in our hospital in terms of improving our understanding of the clinical features and diagnosis of this disease, as well as highlighting the need for more precise dosing of corticosteroid replacement therapy."( Delayed diagnosis of complex glycerol kinase deficiency in a Chinese male infant: a case report.
Chen, Y; Liu, X; Su, Y; Sun, M; Tao, N; Xu, F, 2022
)
1.01
" According to the dose-response bioassays and room size chamber testing, the highest larvicidal, pupicidal and adulticidal activities were observed with D2, followed by D1 and negative control."( Effect of short-chain alcohols on the physicochemical properties of d-phenothrin emulsions and their insecticidal activity against Aedes aegypti.
Hasan, ZAA; Mohsin, SMN, 2023
)
0.91
" The optimized ultrasonic pretreatment conditions were: lard to GML mole ratio 3:1, enzyme dosage 6 %, ultrasonic temperature 80 °C, time 9 min, power 315 W."( Preparation and characterization of diacylglycerol via ultrasound-assisted enzyme-catalyzed transesterification of lard with glycerol monolaurate.
Diao, X; Guan, H; Jia, R; Liu, D; Sun, W; Wang, Y, 2023
)
1.17
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (374 Items)

ItemProcessFrequency
Snackscore-ingredient496
Sweet snackscore-ingredient389
Confectioneriescore-ingredient323
sucréscore-ingredient76
Biscuits and cakescore-ingredient53
Biscuits et gâteauxcore-ingredient49
Chewing gumcore-ingredient47
Sugar-free chewing gumcore-ingredient38
Gâteauxcore-ingredient37
Cakescore-ingredient34
Plant-based foods and beveragescore-ingredient31
Plant-based foodscore-ingredient30
Candiescore-ingredient25
Cocoa and its productscore-ingredient24
Confiseriescore-ingredient24
Biscuitscore-ingredient23
Dietary supplementscore-ingredient23
Cereals and potatoescore-ingredient21
Madeleinescore-ingredient21
Dessertscore-ingredient19
Chocolate candiescore-ingredient19
Barscore-ingredient16
Breadscore-ingredient13
Frozen foodscore-ingredient12
Frozen dessertscore-ingredient10
Aliments et boissons à base de végétauxcore-ingredient9
Bonbonscore-ingredient9
Cacao et dérivéscore-ingredient9
Chewing-gumcore-ingredient8
Cereal barscore-ingredient8
Cereals and their productscore-ingredient8
Aliments d'origine végétalecore-ingredient8
Barres protéinéescore-ingredient8
Compléments pour le Bodybuildingcore-ingredient8
Compléments alimentairescore-ingredient8
Mealscore-ingredient7
Chewing-gum sans sucrescore-ingredient7
Chocolatescore-ingredient7
Barrescore-ingredient7
Flatbreadscore-ingredient7
Zoete snackscore-ingredient7
en:candiescore-ingredient6
Céréales et pommes de terrecore-ingredient6
Snacks sucréscore-ingredient6
Surgeléscore-ingredient6
Confiseries chocolatéescore-ingredient6
Beveragescore-ingredient5
Pastriescore-ingredient5
Wrapscore-ingredient5
Wheat flatbreadscore-ingredient5
Gâteaux au chocolatcore-ingredient5
Bonbons de chocolatcore-ingredient5
Bars covered with chocolatecore-ingredient4
Painscore-ingredient4
Wheat breadscore-ingredient4
White breadscore-ingredient4
Arômescore-ingredient4
Additifs alimentairescore-ingredient4
Protein barscore-ingredient4
Bodybuilding supplementscore-ingredient4
Brodencore-ingredient4
Granen en aardappelscore-ingredient4
Plantaardige levensmiddelencore-ingredient4
Plantaardige levensmiddelen en drankencore-ingredient4
Zoetwarencore-ingredient4
Sodascore-ingredient3
Carbonated drinkscore-ingredient3
Pasta dishescore-ingredient3
Pastascore-ingredient3
Gumcore-ingredient3
Vegetable fatscore-ingredient3
Fatscore-ingredient3
Groceriescore-ingredient3
Condimentscore-ingredient3
Special breadscore-ingredient3
en:vitaminscore-ingredient3
Vitaminscore-ingredient3
en:confectioneriescore-ingredient3
Koekjescore-ingredient3
Koekjes en cakescore-ingredient3
Sandwichescore-ingredient3
Arômes pâtisseriecore-ingredient3
Quatre-quartscore-ingredient3
Pâtisseriescore-ingredient3
Chocolatscore-ingredient3
Assortiments de bonbons de chocolatcore-ingredient3
Madeleines au chocolatcore-ingredient3
Weizenbrotecore-ingredient3
Weißbrotecore-ingredient3
Fladenbrotecore-ingredient3
Brotecore-ingredient3
Getreide und Kartoffelncore-ingredient3
Pflanzliche Lebensmittelcore-ingredient3
Pflanzliche Lebensmittel und Getränkecore-ingredient3
Platte brodencore-ingredient3
Kauwgomcore-ingredient3
Candy canescore-ingredient2
Capsulescore-ingredient2
en:chocolate-biscuitscore-ingredient2
Cake mixescore-ingredient2
Dessert mixescore-ingredient2
Baking Mixescore-ingredient2
Pastry helperscore-ingredient2
Cooking helperscore-ingredient2
Dark chocolatescore-ingredient2
fr:Barres chocolatées à la noix de cococore-ingredient2
Chocolate biscuity barscore-ingredient2
Biscuits sabléscore-ingredient2
Puddingscore-ingredient2
Tortillas de blécore-ingredient2
Pains de blécore-ingredient2
Pains blancscore-ingredient2
Pains platscore-ingredient2
Crêpes et galettescore-ingredient2
en:Cereals and their productscore-ingredient2
en:Cereals and potatoescore-ingredient2
en:Plant-based foodscore-ingredient2
en:Plant-based foods and beveragescore-ingredient2
Noodlescore-ingredient2
Pitascore-ingredient2
Milk chocolate barcore-ingredient2
Milk chocolatescore-ingredient2
Vitamin waterscore-ingredient2
Crêpescore-ingredient2
Browniescore-ingredient2
Muffinscore-ingredient2
en:chocolate-cakescore-ingredient2
Biscuits fourréscore-ingredient2
Boissons sans alcoolcore-ingredient2
Boissonscore-ingredient2
Céréales et dérivéscore-ingredient2
Petit-déjeunerscore-ingredient2
Tartes sucréescore-ingredient2
Gâteaux fourréscore-ingredient2
Madeleines naturescore-ingredient2
Chocolats noirscore-ingredient2
Barres de céréalescore-ingredient2
Desserts glacéscore-ingredient2
Donutscore-ingredient2
Pains spéciauxcore-ingredient2
Food additivescore-ingredient2
Pound Cakecore-ingredient2
Weizenfladenbrotecore-ingredient2
Sugarscore-ingredient2
Sweetenerscore-ingredient2
en:dietary-supplementscore-ingredient2
en:Barscore-ingredient2
en:Cocoa and its productscore-ingredient2
en:Sweet snackscore-ingredient2
en:Snackscore-ingredient2
Édulcorantscore-ingredient2
Bonbons durscore-ingredient2
Graantortillascore-ingredient2
Graanbrodencore-ingredient2
Witte brodencore-ingredient2
Microwave mealscore-ingredient1
Assortments of biscuitscore-ingredient1
Biscuits and crackerscore-ingredient1
en:Flavoured milk chocolatescore-ingredient1
en:Flavoured chocolatescore-ingredient1
en:Assorted chocolate candiescore-ingredient1
Chocolates con lechecore-ingredient1
Bombonescore-ingredient1
Dulces de chocolatecore-ingredient1
Dulcescore-ingredient1
Cacao y sus productoscore-ingredient1
Snacks dulcescore-ingredient1
Botanascore-ingredient1
Soupscore-ingredient1
Canned fruitscore-ingredient1
Fruits based foodscore-ingredient1
Canned plant-based foodscore-ingredient1
Fruits and vegetables based foodscore-ingredient1
Canned foodscore-ingredient1
Sausagescore-ingredient1
Prepared meatscore-ingredient1
Meatscore-ingredient1
Meats and their productscore-ingredient1
Bircher-style muesliscore-ingredient1
Muesliscore-ingredient1
Breakfast cerealscore-ingredient1
Breakfastscore-ingredient1
en:gingerbreadscore-ingredient1
Dark chocolates with almondscore-ingredient1
Chocolates with almondscore-ingredient1
Christmas sweetscore-ingredient1
Christmas foods and drinkscore-ingredient1
Festive foodscore-ingredient1
Bars-covered-with-chocolatecore-ingredient1
en:biscuitscore-ingredient1
Biscuits secscore-ingredient1
Saucescore-ingredient1
Tortillascore-ingredient1
Galettescore-ingredient1
Tortillas de maïscore-ingredient1
Gum and mintscore-ingredient1
Plant-based beveragescore-ingredient1
en:Instant noodle soupscore-ingredient1
en:Instant noodlescore-ingredient1
en:Noodlescore-ingredient1
en:Dried products to be rehydratedcore-ingredient1
en:Pastascore-ingredient1
en:Dried productscore-ingredient1
Instant noodlescore-ingredient1
Dried products to be rehydratedcore-ingredient1
Dried productscore-ingredient1
Sandwichscore-ingredient1
Épicerie sucreecore-ingredient1
Low-sugar barcore-ingredient1
Gummy bearscore-ingredient1
Gummi candiescore-ingredient1
en:acid-gummy-candiescore-ingredient1
Yogurtscore-ingredient1
Fermented dairy dessertscore-ingredient1
Dairy dessertscore-ingredient1
Fermented milk productscore-ingredient1
Fermented foodscore-ingredient1
Dairiescore-ingredient1
wafflecore-ingredient1
Marshmallowscore-ingredient1
Chocolates with hazelnutscore-ingredient1
Payscore-ingredient1
Cheesecakescore-ingredient1
Waterscore-ingredient1
Beverages and beverages preparationscore-ingredient1
Crêpes and galettescore-ingredient1
en:chewing-gumcore-ingredient1
en:gumcore-ingredient1
Chocolate trufflescore-ingredient1
Assorted chocolatescore-ingredient1
Chocolate cakescore-ingredient1
Sushiscore-ingredient1
Sushis-and-makiscore-ingredient1
Bagel breadscore-ingredient1
en:sugar-free-chewing-gumcore-ingredient1
Muffins aux fruitscore-ingredient1
Christmas Puddingscore-ingredient1
Filled-sponge-cake-rollscore-ingredient1
Biscuits à la fraisecore-ingredient1
en:Plum cakescore-ingredient1
Cakes aux fruitscore-ingredient1
en:madeleinescore-ingredient1
édulcoréescore-ingredient1
Céréales fourréescore-ingredient1
Céréales extrudéescore-ingredient1
Céréales pour petit-déjeunercore-ingredient1
Tartelettes à la préparation de fruitscore-ingredient1
Tartes au citroncore-ingredient1
Tartelettescore-ingredient1
Tartescore-ingredient1
Tartes aux fruitscore-ingredient1
Crêpes fourrées aux fraisescore-ingredient1
Crêpes fourrées sucréescore-ingredient1
Crêpes fourréescore-ingredient1
Plats préparéscore-ingredient1
Fond de tartecore-ingredient1
Pâtes à tartecore-ingredient1
Nonnettescore-ingredient1
Xcore-ingredient1
Naturescore-ingredient1
Palmierscore-ingredient1
Biscuits feuilletéscore-ingredient1
Chocolats au cafécore-ingredient1
Chocolats noirs au cafécore-ingredient1
Barres de céréales aux fruits et fruits à coquescore-ingredient1
Barres de céréales au chocolatcore-ingredient1
Barres de céréales aux fruits à coquescore-ingredient1
Omelettes Norvégiennes glacéescore-ingredient1
Glaces et sorbetscore-ingredient1
Substitut nicotiniquecore-ingredient1
Feuilletés aux pommescore-ingredient1
en:Buiscuitcore-ingredient1
Filled biscuitscore-ingredient1
Madeleines longuescore-ingredient1
Barres chocolatéescore-ingredient1
fr:Pastilles à la menthecore-ingredient1
Beignets naturecore-ingredient1
Beignetscore-ingredient1
Chocolats noirs fourréscore-ingredient1
Chocolats noirs à l'orangecore-ingredient1
Chocolats fourréscore-ingredient1
Pains Burgercore-ingredient1
Chocolate dessertscore-ingredient1
en:wheat-flatbreadscore-ingredient1
Food coloringscore-ingredient1
Barres énergétiques protéinéescore-ingredient1
Barres énergétiquescore-ingredient1
Tortilla-Fladenbrotecore-ingredient1
Biscuit filled with fruit pastecore-ingredient1
Glaces à l'eaucore-ingredient1
Brown sugarscore-ingredient1
Biscuits au chocolatcore-ingredient1
Bakingcore-ingredient1
Cookies protéinéscore-ingredient1
Proteincore-ingredient1
whole wheat tortilla wrapcore-ingredient1
en:Chocolate candiescore-ingredient1
en:Breakfast cerealscore-ingredient1
en:Breakfastscore-ingredient1
Miels au chocolatcore-ingredient1
Mielscore-ingredient1
Produits d'élevagescore-ingredient1
Produits de la ruchecore-ingredient1
Produits à tartiner sucréscore-ingredient1
Produits à tartinercore-ingredient1
en:rock-candiescore-ingredient1
Pains d'épicescore-ingredient1
Pralinescore-ingredient1
Confiseries de fruits à coquescore-ingredient1
Fruits à coques et dérivéscore-ingredient1
Massepaincore-ingredient1
en:Fondantscore-ingredient1
en:Pastry helperscore-ingredient1
en:Cooking helperscore-ingredient1
pl:wysokobiałkowycore-ingredient1
pl:Batoncore-ingredient1
Génoises fourrées aux fruits et nappées de chocolatcore-ingredient1
en:Protein barscore-ingredient1
en:Bodybuilding supplementscore-ingredient1
en:Dietary supplementscore-ingredient1
Protecore-ingredient1
Products without glutencore-ingredient1
Products for specific dietscore-ingredient1
Specific productscore-ingredient1
Vins sans alcoolcore-ingredient1
Boissons gazeusescore-ingredient1
Vinscore-ingredient1
alcooliséescore-ingredient1
Open Beauty Factscore-ingredient1
Non food productscore-ingredient1
Halvascore-ingredient1
Pains précuitscore-ingredient1
Pains kebabcore-ingredient1
Cosmetiquecore-ingredient1
Blueberry muffinscore-ingredient1
Fruit muffinscore-ingredient1
Sukkercore-ingredient1
Sødemidlercore-ingredient1
Broodjescore-ingredient1
en:groceriescore-ingredient1
Chocolats au laitcore-ingredient1
Chocoladecakescore-ingredient1
Mjölkchokladcore-ingredient1
Chokladcore-ingredient1
Söta snackscore-ingredient1
Complément alimentairecore-ingredient1
Kits repascore-ingredient1
en:meal-kitscore-ingredient1
fr:Plat préparercore-ingredient1
en:Botanas Snacks dulces Galletas y pasteles Pasteles Magdalenascore-ingredient1
es:Reposteriacore-ingredient1
en:Beef jerkiescore-ingredient1
en:Dried meatscore-ingredient1
en:Meatscore-ingredient1
en:Meats and their productscore-ingredient1
Svačinycore-ingredient1
Croissantscore-ingredient1
Viennoiseriescore-ingredient1
Suikervrije kauwgomcore-ingredient1
Zoete dropcore-ingredient1
Dropcore-ingredient1
Snoepcore-ingredient1
Voedingssupplementencore-ingredient1
en:open-beauty-factscore-ingredient1
Voedingsadditiefcore-ingredient1
nl:Collageencore-ingredient1
Tortillacore-ingredient1
Groentetortillacore-ingredient1
Vegetables tortelliniscore-ingredient1
Tortellinicore-ingredient1
Stuffed pastascore-ingredient1
Chocolate Pound cakecore-ingredient1
Medicinecore-ingredient1
Syrupscore-ingredient1

Roles (9)

RoleDescription
osmolyteA solute used by a cell under water stress to maintain cell volume.
solventA liquid that can dissolve other substances (solutes) without any change in their chemical composition.
detergentA surfactant (or a mixture containing one or more surfactants) having cleaning properties in dilute solutions.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
algal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in algae including unicellular organisms like chlorella and diatoms to multicellular organisms like giant kelps and brown algae.
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
triolA chemical compound containing three hydroxy groups.
alditolA carbohydrate that is an acyclic polyol having the general formula HOCH2[CH(OH)]nCH2OH (formally derivable from an aldose by reduction of the carbonyl group).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3,108)

PathwayProteinsCompounds
Glycolysis6132
Transport of small molecules39295
Aquaporin-mediated transport1811
Passive transport by Aquaporins133
Transport of glycerol from adipocytes to the liver by Aquaporins21
Digestion and absorption1724
Digestion1223
Digestion of dietary lipid36
Hemostasis23944
Platelet activation, signaling and aggregation6315
Effects of PIP2 hydrolysis110
Arachidonate production from DAG16
Metabolism14961108
Carbohydrate metabolism173120
Glucose metabolism7642
Metabolism of lipids500463
Triglyceride metabolism1317
Triglyceride biosynthesis310
Triglyceride catabolism1013
Phospholipid metabolism12242
Glycerophospholipid biosynthesis7439
Acyl chain remodeling of DAG and TAG33
Synthesis of PG38
Signaling Pathways1269117
Signaling by GPCR24955
GPCR downstream signalling17252
G alpha (q) signalling events7928
Glycerolipid Metabolism1124
Galactose Metabolism1234
Galactosemia1234
Glycerol Kinase Deficiency1124
D-Glyceric Acidura1124
Familial Lipoprotein Lipase Deficiency1124
Inner Membrane Transport7862
Glycerol Metabolism3028
Glycerol Metabolism II2930
Glycerol Metabolism III (sn-Glycero-3-Phosphoethanolamine)3030
Glycerol Metabolism IV (Glycerophosphoglycerol)3030
Glycerol Metabolism V (Glycerophosphoserine)3030
phospholipid biosynthesis I (CL(18:2(9Z,12Z)/18:2(9Z,12Z)/18:2(9Z,12Z)/18:2(9Z,12Z)) )1324
phospholipid biosynthesis (CL(18:1(9Z)/18:1(9Z)/18:1(9Z)/19:0cycv8c))1321
phospholipid biosynthesis (CL(18:1/18:1/18:1/18:1))1222
phospholipid biosynthesis (CL(14:0/15:0cyclo/17:0cycw7c/14:0)1318
phospholipid biosynthesis CL(14:0/16:0/14:0/14:0)1320
Phospholipid Biosynthesis CL(14:0/16:0/14:0/18:1(9Z))1220
phospholipid biosynthesis CL(14:0/16:0/14:0/19:0cycv8c)1319
phospholipid biosynthesis CL(14:0/16:0/16:1(9Z)/14:0)1320
phospholipid biosynthesis CL(14:0/16:0/18:1(9Z)/14:0)1321
phospholipid biosynthesis CL(14:0/16:0/19:0cycv8c/14:0)1319
phospholipid biosynthesis CL(14:0/16:1(9Z)/14:0/16:1(9Z))1321
phospholipid biosynthesis CL(14:0/16:1(9Z)/14:0/18:1(9Z))1321
phospholipid biosynthesis CL(14:0/16:1(9Z)/14:0/19:0cycv8c)1319
phospholipid biosynthesis CL(14:0/16:1(9Z)/18:1(9Z)/14:0)1321
phospholipid biosynthesis CL(14:0/16:1(9Z)/19:0cycv8c/14:0)1319
phospholipid biosynthesis CL(14:0/18:1(9Z)/14:0/14:0)1321
phospholipid biosynthesis CL(14:0/18:1(9Z)/14:0/18:1(9Z))1321
phospholipid biosynthesis CL(14:0/18:1(9Z)/14:0/19:0cycv8c)1319
phospholipid biosynthesis CL(14:0/18:1(9Z)/17:0cycw7c/14:0)1319
phospholipid biosynthesis CL(14:0/18:1(9Z)/19:0cycv8c/14:0)1319
phospholipid biosynthesis CL(14:0/19:0cycv8c/14:0/17:0cycw7c)1319
phospholipid biosynthesis CL(14:0/19:0cycv8c/14:0/19:0cycv8c)1319
phospholipid biosynthesis CL(14:0/19:0cycv8c/17:0cycw7c/14:0)1319
phospholipid biosynthesis CL(15:0cyclo/14:0/14:0/17:0cycw7c)1319
phospholipid biosynthesis CL(15:0cyclo/14:0/16:1(9Z)/16:1(9Z))1321
phospholipid biosynthesis CL(15:0cyclo/14:0/19:0cycv8c/19:0cycv8c)1318
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/16:0/16:1(9Z))1322
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/16:1(9Z)/16:1(9Z))1323
phospholipid biosynthesis CL(15:0cyclo/16:0/16:1(9Z)/16:1(9Z))1323
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/14:0/16:1(9Z))1321
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/15:0cyclo/16:1(9Z))1323
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/16:1(9Z)/14:0)1321
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/16:1(9Z)/15:0cyclo)1323
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/16:1(9Z)/16:0)1323
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/16:1(9Z)/16:1(9Z))1324
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/16:1(9Z)/18:1(9Z))1322
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/16:1(9Z)/19:0cycv8c)1321
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/18:1(9Z)/16:1(9Z))1323
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/19:0cycv8c/16:1(9Z))1321
phospholipid biosynthesis CL(15:0cyclo/17:0cycw7c/14:0/14:0)1319
phospholipid biosynthesis CL(15:0cyclo/18:1(9Z)/16:1(9Z)/16:1(9Z))1322
phospholipid biosynthesis CL(15:0cyclo/18:1(9Z)/18:1(9Z)/19:0cycv8c)1320
phospholipid biosynthesis CL(15:0cyclo/18:1(9Z)/19:0cycv8c/18:1(9Z))1320
phospholipid biosynthesis CL(15:0cyclo/19:0cycv8c/14:0/19:0cycv8c)1320
phospholipid biosynthesis CL(15:0cyclo/19:0cycv8c/16:1(9Z)/16:1(9Z))1321
phospholipid biosynthesis CL(15:0cyclo/19:0cycv8c/18:1(9Z)/18:1(9Z))1320
phospholipid biosynthesis CL(16:0/14:0/14:0/14:0)1320
phospholipid biosynthesis CL(16:0/14:0/14:0/16:0)1321
phospholipid biosynthesis CL(16:0/14:0/14:0/16:1(9Z))1321
phospholipid biosynthesis CL(16:0/14:0/14:0/18:1(9Z))1321
phospholipid biosynthesis CL(16:0/14:0/14:0/19:0cycv8c)1319
phospholipid biosynthesis CL(16:0/14:0/16:0/14:0)1322
phospholipid biosynthesis CL(16:0/14:0/16:1(9Z)/14:0)1320
phospholipid biosynthesis CL(16:0/14:0/19:0cycv8c/14:0)1319
phospholipid biosynthesis CL(16:0/15:0cyclo/16:1(9Z)/16:1(9Z))1323
phospholipid biosynthesis CL(16:0/16:1(9Z)/16:1(9Z)/18:1(9Z))1324
phospholipid biosynthesisCL(16:0/16:1(9Z)/16:1(9Z)/19:0cycv8c)1321
phospholipid biosynthesis CL(16:0/16:1(9Z)/18:1(9Z)/16:1(9Z))1324
phospholipid biosynthesis CL(16:0/16:1(9Z)/19:0cycv8c/16:1(9Z))1321
phospholipid biosynthesis CL(16:0/18:1(9Z)/16:1(9Z)/16:1(9Z))1324
phospholipid biosynthesis CL(16:0/19:0cycv8c/14:0/14:0)1319
phospholipid biosynthesis CL(16:0/19:0cycv8c/16:1(9Z)/16:1(9Z))1321
phospholipid biosynthesis CL(16:1(9Z)/14:0/14:0/16:1(9Z))1321
phospholipid biosynthesis CL(16:1(9Z)/14:0/14:0/18:1(9Z))1321
phospholipid biosynthesis CL(16:1(9Z)/14:0/14:0/19:0cycv8c)1319
phospholipid biosynthesis CL(16:1(9Z)/14:0/16:1(9Z)/14:0)1322
phospholipid biosynthesis CL(16:1(9Z)/14:0/18:1(9Z)/14:0)1321
phospholipid biosynthesis CL(16:1(9Z)/14:0/19:0cycv8c/14:0)1319
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/14:0/16:1(9Z))1323
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/16:0/16:1(9Z))1323
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/16:1(9Z)/14:0)1323
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/16:1(9Z)/15:0cyclo)1323
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/16:1(9Z)/16:0)1323
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/16:1(9Z)/16:1(9Z))1323
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/16:1(9Z)/18:1(9Z))1322
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/16:1(9Z)/19:0cycv8c)1321
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/18:1(9Z)/16:1(9Z))1322
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/19:0cycv8c/16:1(9Z))1321
phospholipid biosynthesis CL(16:1(9Z)/16:0/16:1(9Z)/18:1(9Z))1324
phospholipid biosynthesis CL(16:1(9Z)/16:0/16:1(9Z)/19:0cycv8c)1321
phospholipid biosynthesis CL(16:1(9Z)/16:0/18:1(9Z)/16:1(9Z))1324
phospholipid biosynthesis CL(16:1(9Z)/16:0/19:0cycv8c/16:1(9Z))1321
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/14:0/14:0)1321
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/14:0/15:0cyclo)1321
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/14:0/18:1(9Z))1323
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/14:0/19:0cycv8c)1321
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/16:1(9Z)/18:1(9Z))1324
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/16:1(9Z)/19:0cycv8c)1321
phospholipid biosynthesis (CL(18:1(9Z)/15:0cyclo/18:1(9Z)/15:0cyclo))1015
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/18:1(9Z)/14:0)1323
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/18:1(9Z)/15:0cyclo)1323
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/18:1(9Z)/16:0)1324
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/18:1(9Z)/16:1(9Z))1324
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/18:1(9Z)/18:1(9Z))1325
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/18:1(9Z)/19:0cycv8c)1321
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/19:0cycv8c/14:0)1321
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/19:0cycv8c/15:0cyclo)1321
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/19:0cycv8c/16:0)1321
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/19:0cycv8c/16:1(9Z))1321
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/19:0cycv8c/18:1(9Z))1321
phospholipid biosynthesis CL(16:1(9Z)/16:1(9Z)/19:0cycv8c/19:0cycv8c)1221
phospholipid biosynthesis CL(16:1(9Z)/18:1(9Z)/14:0/14:0)1321
phospholipid biosynthesis CL(16:1(9Z)/18:1(9Z)/14:0/16:1(9Z))1323
phospholipid biosynthesis CL(16:1(9Z)/18:1(9Z)/16:1(9Z)/14:0)1323
phospholipid biosynthesis CL(16:1(9Z)/18:1(9Z)/16:1(9Z)/18:1(9Z))1324
phospholipid biosynthesis (CL(18:1(9Z)/16:0/18:1(9Z)/16:0))1018
phospholipid biosynthesis CL(16:1(9Z)/18:1(9Z)/16:1(9Z)/19:0cycv8c)1321
phospholipid biosynthesis CL(16:1(9Z)/18:1(9Z)/18:1(9Z)/16:1(9Z))1324
phospholipid biosynthesis CL(16:1(9Z)/18:1(9Z)/19:0cycv8c/16:1(9Z))1321
phospholipid biosynthesis CL(16:1(9Z)/19:0cycv8c/14:0/14:0)1319
phospholipid biosynthesis CL(16:1(9Z)/19:0cycv8c/14:0/16:1(9Z))1321
phospholipid biosynthesis (CL(18:1(9Z)/16:1(9Z)/18:1(9Z)/16:1(9Z)))1018
phospholipid biosynthesis CL(16:1(9Z)/19:0cycv8c/16:1(9Z)/14:0)1321
phospholipid biosynthesis CL(16:1(9Z)/19:0cycv8c/16:1(9Z)/19:0cycv8c)1221
phospholipid biosynthesis CL(16:1(9Z)/19:0cycv8c/19:0cycv8c/16:1(9Z))1221
phospholipid biosynthesis CL(17:0cycw7c/15:0cyclo/14:0/14:0)1319
phospholipid biosynthesis (CL(18:1(9Z)/15:0cyclo/14:0/15:0cyclo) 5)1014
phospholipid biosynthesis (CL(10:0(3-OH)/10:0/10:0(3-OH)/10:0))1014
phospholipid biosynthesis (CL(10:0(3-OH)/12:0(3-OH)/10:0(3-OH)/12:0(3-OH)))1014
phospholipid biosynthesis (CL(10:0(3-OH)/12:0/10:0(3-OH)/12:0))1014
phospholipid biosynthesis (CL(10:0(3-OH)/15:0cyclo/10:0(3-OH)/15:0cyclo))1014
phospholipid biosynthesis (CL(10:0(3-OH)/16:1(9Z)/10:0(3-OH)/16:1(9Z)))1014
phospholipid biosynthesis (CL(10:0(3-OH)/16:0/10:0(3-OH)/16:0))1014
phospholipid biosynthesis (CL(10:0(3-OH)/17:0cycw7c/10:0(3-OH)/17:0cycw7c))1014
phospholipid biosynthesis (CL(10:0(3-OH)/19:0cycv8c/10:0(3-OH)/19:0cycv8c))1014
phospholipid biosynthesis (CL(10:0(3-OH)/19:iso/10:0(3-OH)/19:iso))1013
phospholipid biosynthesis (CL(10:0/10:0(3-OH)/10:0/10:0(3-OH)))1014
phospholipid biosynthesis (CL(10:0/12:0(3-OH)/10:0/12:0(3-OH)))1014
phospholipid biosynthesis (CL(12:0(3-OH)/10:0(3-OH)/12:0(3-OH)/10:0(3-OH)))1014
phospholipid biosynthesis (CL(12:0(3-OH)/10:0/12:0(3-OH)/10:0))1014
phospholipid biosynthesis (CL(12:0(3-OH)/14:0(3-OH)/12:0(3-OH)/14:0(3-OH)))1014
phospholipid biosynthesis (CL(12:0(3-OH)/14:0/12:0(3-OH)/14:0))1014
phospholipid biosynthesis (CL(12:0(3-OH)/15:0/12:0(3-OH)/15:0))1014
phospholipid biosynthesis (CL(12:0(3-OH)/15:0cyclo/12:0(3-OH)/15:0cyclo))1014
phospholipid biosynthesis (CL(12:0(3-OH)/17:0cycw7c/12:0(3-OH)/17:0cycw7c))1014
phospholipid biosynthesis (CL(12:0(3-OH)/18:1(9Z)/12:0(3-OH)/18:1(9Z)))1014
phospholipid biosynthesis (CL(12:0(3-OH)/19:0cycv8c/12:0(3-OH)/19:0cycv8c))1014
phospholipid biosynthesis (CL(12:0(3-OH)/19:iso/12:0(3-OH)/19:iso))1014
phospholipid biosynthesis (CL(12:0/10:0(3-OH)/12:0/10:0(3-OH)))1014
phospholipid biosynthesis (CL(12:0/12:0/12:0/12:0))1014
phospholipid biosynthesis (CL(12:0/14:0(3-OH)/12:0/14:0(3-OH)))1014
phospholipid biosynthesis (CL(12:0/19:iso/12:0/19:iso))1015
phospholipid biosynthesis (CL(14:0(3-OH)/12:0(3-OH)/14:0(3-OH)/12:0(3-OH)))1014
phospholipid biosynthesis (CL(14:0(3-OH)/12:0/14:0(3-OH)/12:0))1014
phospholipid biosynthesis (CL(14:0(3-OH)/16:1(9Z)/14:0(3-OH)/16:1(9Z)))1014
phospholipid biosynthesis (CL(14:0(3-OH)/17:0cycw7c/14:0(3-OH)/17:0cycw7c))1014
phospholipid biosynthesis (CL(14:0/12:0(3-OH)/14:0/12:0(3-OH)))1014
phospholipid biosynthesis (CL(15:0/10:0(3-OH)/15:0/10:0(3-OH)))1014
phospholipid biosynthesis (CL(15:0/12:0(3-OH)/15:0/12:0(3-OH)))1014
phospholipid biosynthesis (CL(15:0cyclo/10:0(3-OH)/15:0cyclo/10:0(3-OH)))1014
phospholipid biosynthesis (CL(16:0/10:0(3-OH)/16:0/10:0(3-OH)))1014
phospholipid biosynthesis (CL(16:0/14:0(3-OH)/16:0/14:0(3-OH)))1014
phospholipid biosynthesis (CL(16:1(9Z)/14:0(3-OH)/16:1(9Z)/14:0(3-OH)))1014
phospholipid biosynthesis (CL(17:0cycw7c/10:0(3-OH)/17:0cycw7c/10:0(3-OH)))1014
phospholipid biosynthesis (CL(17:0cycw7c/12:0(3-OH)/17:0cycw7c/12:0(3-OH)))1014
phospholipid biosynthesis (CL(17:0cycw7c/19:iso/17:0cycw7c/19:iso))1014
phospholipid biosynthesis (CL(18:1(11Z)/19:0/18:1(11Z)/19:0))1120
phospholipid biosynthesis (CL(18:1(9Z)/12:0(3-OH)/18:1(9Z)/12:0(3-OH)))1014
phospholipid biosynthesis (CL(19:0/16:1(9Z)/19:0/16:1(9Z)))1014
phospholipid biosynthesis (CL(19:0/18:1(11Z)/19:0/18:1(11Z)))1019
phospholipid biosynthesis (CL(19:0cycv8c/10:0(3-OH)/19:0cycv8c/10:0(3-OH)))1014
phospholipid biosynthesis (CL(19:0cycv8c/12:0(3-OH)/19:0cycv8c/12:0(3-OH)))1014
phospholipid biosynthesis (CL(19:1(9Z)/16:1(9Z)/19:1(9Z)/16:1(9Z)))1014
phospholipid biosynthesis (CL(19:iso/10:0(3-OH)/19:iso/10:0(3-OH)))1014
phospholipid biosynthesis (CL(19:iso/10:0/19:iso/10:0))1015
phospholipid biosynthesis (CL(19:iso/12:0(3-OH)/19:iso/12:0(3-OH)))1014
phospholipid biosynthesis (CL(19:iso/12:0/19:iso/12:0))1015
phospholipid biosynthesis (CL(19:iso/14:0(3-OH)/19:iso/14:0(3-OH)))1014
phospholipid biosynthesis (CL(19:iso/14:0/19:iso/14:0))1015
phospholipid biosynthesis (CL(19:iso/19:iso/19:iso/19:iso))1015
phospholipid biosynthesis (CL(16:0/16:0/16:0/16:0))1018
phospholipid biosynthesis (CL(15:0cyclo/15:0cyclo/18:1(9Z)/16:0)) 14425991801015
phospholipid biosynthesis (CL(16:1(9Z)/19:0cycv8c/16:1(9Z)/19:0cycv8c))1015
phospholipid biosynthesis (CL(18:1(9Z)/16:1(9Z)/18:1(9Z)/16:1(9Z))) 21019
Triacylglycerol Metabolism1413
Triacylglycerol metabolism TG(10:0/10:0/10:0)149
Triacylglycerol metabolism TG(10:0/10:0/12:0)1411
Triacylglycerol metabolism TG(10:0/10:0/14:0)1411
Triacylglycerol metabolism TG(10:0/12:0/12:0)1412
Triacylglycerol metabolism TG(10:0/10:0/14:1(9Z))149
Triacylglycerol metabolism TG(10:0/10:0/16:0)1411
Triacylglycerol metabolism TG(10:0/12:0/14:0)1412
Triacylglycerol metabolism TG(12:0/12:0/12:0)1412
Triacylglycerol metabolism TG(10:0/10:0/16:1(9Z))149
Triacylglycerol metabolism TG(10:0/12:0/14:1(9Z))1410
Triacylglycerol metabolism TG(10:0/10:0/18:0)1411
Triacylglycerol metabolism TG(10:0/12:0/16:0)1412
Triacylglycerol metabolism TG(10:0/14:0/14:0)1412
Triacylglycerol metabolism TG(12:0/12:0/14:0)1413
Triacylglycerol metabolism TG(10:0/10:0/18:1(9Z))149
Triacylglycerol metabolism TG(10:0/12:0/16:1(9Z))1410
Triacylglycerol metabolism TG(10:0/14:0/14:1(9Z))1410
Triacylglycerol metabolism TG(12:0/12:0/14:1(9Z))1411
Triacylglycerol metabolism TG(10:0/10:0/20:0)1411
Triacylglycerol metabolism TG(10:0/12:0/18:0)1412
Triacylglycerol metabolism TG(10:0/14:0/16:0)1412
Triacylglycerol metabolism TG(10:0/15:0/15:0)1412
Triacylglycerol metabolism TG(12:0/12:0/16:0)1412
Triacylglycerol metabolism TG(12:0/14:0/14:0)1413
Triacylglycerol metabolism TG(10:0/10:0/20:1(13Z))149
Triacylglycerol metabolism TG(10:0/12:0/18:1(9Z))1410
Triacylglycerol metabolism TG(10:0/14:0/16:1(9Z))1410
Triacylglycerol metabolism TG(10:0/14:1(9Z)/16:0)1411
Triacylglycerol metabolism TG(10:0/15:0/15:1(9Z))1410
Triacylglycerol metabolism TG(12:0/12:0/16:1(9Z))1411
Triacylglycerol metabolism TG(12:0/14:0/14:1(9Z))1411
Triacylglycerol metabolism TG(10:0/14:1(9Z)/16:1(9Z))1410
Triacylglycerol metabolism TG(10:0/15:1(9Z)/15:1(9Z))1410
Triacylglycerol metabolism TG(12:0/14:1(9Z)/14:1(9Z))1411
Triacylglycerol metabolism TG(10:0/10:0/22:0)1411
Triacylglycerol metabolism TG(10:0/12:0/20:0)1412
Triacylglycerol metabolism TG(10:0/14:0/18:0)1412
Triacylglycerol metabolism TG(10:0/16:0/16:0)1412
Triacylglycerol metabolism TG(12:0/12:0/18:0)1413
Triacylglycerol metabolism TG(12:0/14:0/16:0)1412
Triacylglycerol metabolism TG(12:0/15:0/15:0)1413
Triacylglycerol metabolism TG(14:0/14:0/14:0)1412
Triacylglycerol metabolism TG(10:0/10:0/22:1(13Z))1410
Triacylglycerol metabolism TG(10:0/12:0/20:1(13Z))1410
Triacylglycerol metabolism TG(10:0/14:0/18:1(9Z))1410
Triacylglycerol metabolism TG(10:0/14:1(9Z)/18:0)1411
Triacylglycerol metabolism TG(10:0/16:0/16:1(9Z))1410
Triacylglycerol metabolism TG(12:0/12:0/18:1(9Z))1411
Triacylglycerol metabolism TG(12:0/14:0/16:1(9Z))1411
Triacylglycerol metabolism TG(12:0/14:1(9Z)/16:0)1411
Triacylglycerol metabolism TG(12:0/15:0/15:1(9Z))1411
Triacylglycerol metabolism TG(14:0/14:0/14:1(9Z))1412
Triacylglycerol metabolism TG(10:0/14:1(9Z)/18:1(9Z))1410
Triacylglycerol metabolism TG(10:0/16:1(9Z)/16:1(9Z))1410
Triacylglycerol metabolism TG(12:0/14:1(9Z)/16:1(9Z))1411
Triacylglycerol metabolism TG(12:0/15:1(9Z)/15:1(9Z))1411
Triacylglycerol metabolism TG(14:0/14:1(9Z)/14:1(9Z))1412
Triacylglycerol metabolism TG(14:1(9Z)/14:1(9Z)/14:1(9Z))1412
Triacylglycerol metabolism TG(10:0/15:0/18:0)1412
Triacylglycerol metabolism TG(12:0/15:0/16:0)1412
Triacylglycerol metabolism TG(14:0/14:0/15:0)1412
Triacylglycerol metabolism TG(10:0/10:0/23:1(9Z))149
Triacylglycerol metabolism TG(10:0/15:0/18:1(9Z))1410
Triacylglycerol metabolism TG(10:0/15:1(9Z)/18:0)1410
Triacylglycerol metabolism TG(12:0/15:0/16:1(9Z))1411
Triacylglycerol metabolism TG(12:0/15:1(9Z)/16:0)1411
Triacylglycerol metabolism TG(14:0/14:0/15:1(9Z))1410
Triacylglycerol metabolism TG(14:0/14:1(9Z)/15:0)1412
Triacylglycerol metabolism TG(10:0/15:1(9Z)/18:1(9Z))1410
Triacylglycerol metabolism TG(12:0/15:1(9Z)/16:1(9Z))1411
Triacylglycerol metabolism TG(14:0/14:1(9Z)/15:1(9Z))1410
Triacylglycerol metabolism TG(14:1(9Z)/14:1(9Z)/15:0)1411
Triacylglycerol metabolism TG(10:0/10:0/24:0)149
Triacylglycerol metabolism TG(10:0/12:0/22:0)1412
Triacylglycerol metabolism TG(10:0/14:0/20:0)1412
Triacylglycerol metabolism TG(10:0/16:0/18:0)1412
Triacylglycerol metabolism TG(12:0/12:0/20:0)1413
Triacylglycerol metabolism TG(12:0/14:0/18:0)1413
Triacylglycerol metabolism TG(12:0/16:0/16:0)1412
Triacylglycerol metabolism TG(14:0/14:0/16:0)1412
Triacylglycerol metabolism TG(14:0/15:0/15:0)1412
Triacylglycerol metabolism TG(10:0/10:0/24:1(15Z))1410
Triacylglycerol metabolism TG(10:0/12:0/22:1(13Z))1411
Triacylglycerol metabolism TG(10:0/14:0/20:1(13Z))1410
Triacylglycerol metabolism TG(10:0/14:1(9Z)/20:0)1411
Triacylglycerol metabolism TG(10:0/16:0/18:1(9Z))1410
Triacylglycerol metabolism TG(10:0/16:1(9Z)/18:0)1411
Triacylglycerol metabolism TG(12:0/12:0/20:1(13Z))1411
Triacylglycerol metabolism TG(12:0/14:0/18:1(9Z))1411
Triacylglycerol metabolism TG(12:0/14:1(9Z)/18:0)1412
Triacylglycerol metabolism TG(12:0/16:0/16:1(9Z))1411
Triacylglycerol metabolism TG(14:0/14:0/16:1(9Z))1412
Triacylglycerol metabolism TG(14:0/14:1(9Z)/16:0)1412
Triacylglycerol metabolism TG(14:0/15:0/15:1(9Z))1410
Triacylglycerol metabolism TG(14:1(9Z)/15:0/15:0)1411
Triacylglycerol metabolism TG(10:0/14:1(9Z)/20:1(13Z))1410
Triacylglycerol metabolism TG(10:0/16:1(9Z)/18:1(9Z))1410
Triacylglycerol metabolism TG(12:0/14:1(9Z)/18:1(9Z))1411
Triacylglycerol metabolism TG(12:0/16:1(9Z)/16:1(9Z))1411
Triacylglycerol metabolism TG(14:0/14:1(9Z)/16:1(9Z))1412
Triacylglycerol metabolism TG(14:0/15:1(9Z)/15:1(9Z))1410
Triacylglycerol metabolism TG(14:1(9Z)/14:1(9Z)/16:0)1411
Triacylglycerol metabolism TG(14:1(9Z)/15:0/15:1(9Z))1410
Triacylglycerol metabolism TG(10:0/10:0/25:0)149
Triacylglycerol metabolism TG(10:0/15:0/20:0)1412
Triacylglycerol metabolism TG(12:0/15:0/18:0)1413
Triacylglycerol metabolism TG(14:0/15:0/16:0)1412
Triacylglycerol metabolism TG(15:0/15:0/15:0)1412
Triacylglycerol metabolism TG(10:0/10:0/25:1(15Z))1410
Triacylglycerol metabolism TG(10:0/12:0/23:1(9Z))1410
Triacylglycerol metabolism TG(10:0/15:0/20:1(13Z))1410
Triacylglycerol metabolism TG(10:0/15:1(9Z)/20:0)1410
Triacylglycerol metabolism TG(12:0/15:0/18:1(9Z))1411
Triacylglycerol metabolism TG(12:0/15:1(9Z)/18:0)1411
Triacylglycerol metabolism TG(14:0/15:0/16:1(9Z))1412
Triacylglycerol metabolism TG(14:0/15:1(9Z)/16:0)1410
Triacylglycerol metabolism TG(14:1(9Z)/15:0/16:0)1411
Triacylglycerol metabolism TG(15:0/15:0/15:1(9Z))1410
Triacylglycerol metabolism TG(10:0/15:1(9Z)/20:1(13Z))1410
Triacylglycerol metabolism TG(12:0/15:1(9Z)/18:1(9Z))1411
Triacylglycerol metabolism TG(14:0/15:1(9Z)/16:1(9Z))1410
Triacylglycerol metabolism TG(14:1(9Z)/15:0/16:1(9Z))1412
Triacylglycerol metabolism TG(14:1(9Z)/15:1(9Z)/16:0)1410
Triacylglycerol metabolism TG(15:0/15:1(9Z)/15:1(9Z))1410
Triacylglycerol metabolism TG(14:1(9Z)/15:1(9Z)/16:1(9Z))1410
Triacylglycerol metabolism TG(15:1(9Z)/15:1(9Z)/15:1(9Z))1410
Triacylglycerol metabolism TG(10:0/10:0/26:0)149
Triacylglycerol metabolism TG(10:0/12:0/24:0)1410
Triacylglycerol metabolism TG(10:0/14:0/22:0)1412
Triacylglycerol metabolism TG(10:0/16:0/20:0)1412
Triacylglycerol metabolism TG(10:0/18:0/18:0)1412
Triacylglycerol metabolism TG(12:0/12:0/22:0)1413
Triacylglycerol metabolism TG(12:0/14:0/20:0)1413
Triacylglycerol metabolism TG(12:0/16:0/18:0)1413
Triacylglycerol metabolism TG(14:0/14:0/18:0)1412
Triacylglycerol metabolism TG(14:0/16:0/16:0)1412
Triacylglycerol metabolism TG(15:0/15:0/16:0)1412
Triacylglycerol metabolism TG(10:0/10:0/26:1(5Z))1410
Triacylglycerol metabolism TG(10:0/12:0/24:1(15Z))1411
Triacylglycerol metabolism TG(10:0/14:0/22:1(13Z))1411
Triacylglycerol metabolism TG(10:0/14:1(9Z)/22:0)1411
Triacylglycerol metabolism TG(10:0/16:0/20:1(13Z))1410
Triacylglycerol metabolism TG(10:0/16:1(9Z)/20:0)1411
Triacylglycerol metabolism TG(10:0/18:0/18:1(9Z))1410
Triacylglycerol metabolism TG(12:0/12:0/22:1(13Z))1411
Triacylglycerol metabolism TG(12:0/14:0/20:1(13Z))1411
Triacylglycerol metabolism TG(12:0/14:1(9Z)/20:0)1412
Triacylglycerol metabolism TG(12:0/16:0/18:1(9Z))1411
Triacylglycerol metabolism TG(12:0/16:1(9Z)/18:0)1412
Triacylglycerol metabolism TG(14:0/14:0/18:1(9Z))1412
Triacylglycerol metabolism TG(14:0/14:1(9Z)/18:0)1412
Triacylglycerol metabolism TG(14:0/16:0/16:1(9Z))1412
Triacylglycerol metabolism TG(14:1(9Z)/16:0/16:0)1411
Triacylglycerol metabolism TG(15:0/15:0/16:1(9Z))1412
Triacylglycerol metabolism TG(15:0/15:1(9Z)/16:0)1410
Triacylglycerol metabolism TG(10:0/14:1(9Z)/22:1(13Z))1410
Triacylglycerol metabolism TG(10:0/16:1(9Z)/20:1(13Z))1410
Triacylglycerol metabolism TG(10:0/18:1(9Z)/18:1(9Z))1410
Triacylglycerol metabolism TG(12:0/14:1(9Z)/20:1(13Z))1411
Triacylglycerol metabolism TG(12:0/16:1(9Z)/18:1(9Z))1411
Triacylglycerol metabolism TG(14:0/14:1(9Z)/18:1(9Z))1412
Triacylglycerol metabolism TG(14:0/16:1(9Z)/16:1(9Z))1412
Triacylglycerol metabolism TG(14:1(9Z)/14:1(9Z)/18:0)1411
Triacylglycerol metabolism TG(14:1(9Z)/16:0/16:1(9Z))1412
Triacylglycerol metabolism TG(15:0/15:1(9Z)/16:1(9Z))1410
Triacylglycerol metabolism TG(15:1(9Z)/15:1(9Z)/16:0)1410
Triacylglycerol metabolism TG(10:0/10:0/27:0)149
Triacylglycerol metabolism TG(10:0/12:0/25:0)1410
Triacylglycerol metabolism TG(10:0/15:0/22:0)1412
Triacylglycerol metabolism TG(12:0/15:0/20:0)1413
Triacylglycerol metabolism TG(14:0/15:0/18:0)1412
Triacylglycerol metabolism TG(15:0/16:0/16:0)1412
Triacylglycerol metabolism TG(10:0/10:0/28:0)149
Triacylglycerol metabolism TG(10:0/12:0/26:0)1410
Triacylglycerol metabolism TG(10:0/14:0/24:0)1410
Triacylglycerol metabolism TG(10:0/16:0/22:0)1412
Triacylglycerol metabolism TG(10:0/18:0/20:0)1412
Triacylglycerol metabolism TG(12:0/12:0/24:0)1411
Triacylglycerol metabolism TG(12:0/14:0/22:0)1413
Triacylglycerol metabolism TG(12:0/16:0/20:0)1413
Triacylglycerol metabolism TG(12:0/18:0/18:0)1413
Triacylglycerol metabolism TG(14:0/14:0/20:0)1412
Triacylglycerol metabolism TG(14:0/16:0/18:0)1412
Triacylglycerol metabolism TG(15:0/15:0/18:0)1412
Triacylglycerol metabolism TG(16:0/16:0/16:0)1413
Triacylglycerol metabolism TG(10:0/10:0/29:0)149
Triacylglycerol metabolism TG(10:0/12:0/27:0)1410
Triacylglycerol metabolism TG(10:0/14:0/25:0)1410
Triacylglycerol metabolism TG(10:0/15:0/24:0)1410
Triacylglycerol metabolism TG(12:0/12:0/25:0)1410
Triacylglycerol metabolism TG(12:0/15:0/22:0)1413
Triacylglycerol metabolism TG(14:0/15:0/20:0)1412
Triacylglycerol metabolism TG(15:0/16:0/18:0)1412
Triacylglycerol metabolism TG(10:0/10:0/30:0)149
Triacylglycerol metabolism TG(10:0/12:0/28:0)1410
Triacylglycerol metabolism TG(10:0/14:0/26:0)1410
Triacylglycerol metabolism TG(10:0/15:0/25:0)1410
Triacylglycerol metabolism TG(10:0/16:0/24:0)1410
Triacylglycerol metabolism TG(10:0/18:0/22:0)1412
Triacylglycerol metabolism TG(10:0/20:0/20:0)1412
Triacylglycerol metabolism TG(12:0/12:0/26:0)1411
Triacylglycerol metabolism TG(12:0/14:0/24:0)1411
Triacylglycerol metabolism TG(12:0/16:0/22:0)1413
Triacylglycerol metabolism TG(12:0/18:0/20:0)1413
Triacylglycerol metabolism TG(14:0/14:0/22:0)1412
Triacylglycerol metabolism TG(14:0/16:0/20:0)1412
Triacylglycerol metabolism TG(14:0/18:0/18:0)1412
Triacylglycerol metabolism TG(15:0/15:0/20:0)1412
Triacylglycerol metabolism TG(16:0/16:0/18:0)1412
Triacylglycerol metabolism TG(10:0/12:0/29:0)1410
Triacylglycerol metabolism TG(10:0/14:0/27:0)1410
Triacylglycerol metabolism TG(10:0/15:0/26:0)1410
Triacylglycerol metabolism TG(10:0/16:0/25:0)1410
Triacylglycerol metabolism TG(12:0/12:0/27:0)1410
Triacylglycerol metabolism TG(12:0/14:0/25:0)1411
Triacylglycerol metabolism TG(12:0/15:0/24:0)1411
Triacylglycerol metabolism TG(14:0/15:0/22:0)1412
Triacylglycerol metabolism TG(15:0/16:0/20:0)1412
Triacylglycerol metabolism TG(15:0/18:0/18:0)1413
Triacylglycerol metabolism TG(10:0/12:0/30:0)1410
Triacylglycerol metabolism TG(10:0/14:0/28:0)1410
Triacylglycerol metabolism TG(10:0/15:0/27:0)1410
Triacylglycerol metabolism TG(10:0/16:0/26:0)1410
Triacylglycerol metabolism TG(10:0/18:0/24:0)1410
Triacylglycerol metabolism TG(10:0/20:0/22:0)1412
Triacylglycerol metabolism TG(12:0/12:0/28:0)1411
Triacylglycerol metabolism TG(12:0/14:0/26:0)1411
Triacylglycerol metabolism TG(12:0/15:0/25:0)1411
Triacylglycerol metabolism TG(12:0/16:0/24:0)1411
Triacylglycerol metabolism TG(12:0/18:0/22:0)1413
Triacylglycerol metabolism TG(12:0/20:0/20:0)1413
Triacylglycerol metabolism TG(14:0/14:0/24:0)1412
Triacylglycerol metabolism TG(14:0/16:0/22:0)1412
Triacylglycerol metabolism TG(14:0/18:0/20:0)1412
Triacylglycerol metabolism TG(15:0/15:0/22:0)1412
Triacylglycerol metabolism TG(16:0/16:0/20:0)1413
Triacylglycerol metabolism TG(16:0/18:0/18:0)1412
Triacylglycerol metabolism TG(10:0/14:0/29:0)1410
Triacylglycerol metabolism TG(10:0/15:0/28:0)1410
Triacylglycerol metabolism TG(10:0/16:0/27:0)1410
Triacylglycerol metabolism TG(10:0/18:0/25:0)1410
Triacylglycerol metabolism TG(12:0/12:0/29:0)1410
Triacylglycerol metabolism TG(12:0/14:0/27:0)1411
Triacylglycerol metabolism TG(12:0/15:0/26:0)1411
Triacylglycerol metabolism TG(12:0/16:0/25:0)1410
Triacylglycerol metabolism TG(14:0/14:0/25:0)1410
Triacylglycerol metabolism TG(14:0/15:0/24:0)1412
Triacylglycerol metabolism TG(15:0/16:0/22:0)1412
Triacylglycerol metabolism TG(15:0/18:0/20:0)1413
Triacylglycerol metabolism TG(10:0/14:0/30:0)1410
Triacylglycerol metabolism TG(10:0/15:0/29:0)1410
Triacylglycerol metabolism TG(10:0/16:0/28:0)1410
Triacylglycerol metabolism TG(10:0/18:0/26:0)1410
Triacylglycerol metabolism TG(10:0/20:0/24:0)1410
Triacylglycerol metabolism TG(10:0/22:0/22:0)1413
Triacylglycerol metabolism TG(12:0/12:0/30:0)1411
Triacylglycerol metabolism TG(12:0/14:0/28:0)1411
Triacylglycerol metabolism TG(12:0/15:0/27:0)1411
Triacylglycerol metabolism TG(12:0/16:0/26:0)1411
Triacylglycerol metabolism TG(12:0/18:0/24:0)1411
Triacylglycerol metabolism TG(12:0/20:0/22:0)1413
Triacylglycerol metabolism TG(14:0/14:0/26:0)1410
Triacylglycerol metabolism TG(14:0/15:0/25:0)1410
Triacylglycerol metabolism TG(14:0/16:0/24:0)1412
Triacylglycerol metabolism TG(14:0/18:0/22:0)1412
Triacylglycerol metabolism TG(14:0/20:0/20:0)1413
Triacylglycerol metabolism TG(15:0/15:0/24:0)1412
Triacylglycerol metabolism TG(16:0/16:0/22:0)1414
Triacylglycerol metabolism TG(16:0/18:0/20:0)1412
Triacylglycerol metabolism TG(18:0/18:0/18:0)1414
Triacylglycerol metabolism TG(10:0/15:0/30:0)1410
Triacylglycerol metabolism TG(10:0/16:0/29:0)1410
Triacylglycerol metabolism TG(10:0/18:0/27:0)1410
Triacylglycerol metabolism TG(10:0/20:0/25:0)1410
Triacylglycerol metabolism TG(12:0/14:0/29:0)1411
Triacylglycerol metabolism TG(12:0/15:0/28:0)1411
Triacylglycerol metabolism TG(12:0/16:0/27:0)1410
Triacylglycerol metabolism TG(12:0/18:0/25:0)1411
Triacylglycerol metabolism TG(14:0/14:0/27:0)1410
Triacylglycerol metabolism TG(14:0/15:0/26:0)1410
Triacylglycerol metabolism TG(14:0/16:0/25:0)1410
Triacylglycerol metabolism TG(15:0/15:0/25:0)1410
Triacylglycerol metabolism TG(15:0/16:0/24:0)1412
Triacylglycerol metabolism TG(15:0/18:0/22:0)1413
Triacylglycerol metabolism TG(15:0/20:0/20:0)1413
Triacylglycerol metabolism TG(10:0/16:0/30:0)1410
Triacylglycerol metabolism TG(10:0/18:0/28:0)1410
Triacylglycerol metabolism TG(10:0/20:0/26:0)1410
Triacylglycerol metabolism TG(10:0/22:0/24:0)1411
Triacylglycerol metabolism TG(12:0/14:0/30:0)1411
Triacylglycerol metabolism TG(12:0/15:0/29:0)1411
Triacylglycerol metabolism TG(12:0/16:0/28:0)1411
Triacylglycerol metabolism TG(12:0/18:0/26:0)1411
Triacylglycerol metabolism TG(12:0/20:0/24:0)1411
Triacylglycerol metabolism TG(12:0/22:0/22:0)1414
Triacylglycerol metabolism TG(14:0/14:0/28:0)1410
Triacylglycerol metabolism TG(14:0/15:0/27:0)1410
Triacylglycerol metabolism TG(14:0/16:0/26:0)1410
Triacylglycerol metabolism TG(14:0/18:0/24:0)1412
Triacylglycerol metabolism TG(14:0/20:0/22:0)1413
Triacylglycerol metabolism TG(15:0/15:0/26:0)1410
Triacylglycerol metabolism TG(15:0/16:0/25:0)1410
Triacylglycerol metabolism TG(16:0/16:0/24:0)1414
Triacylglycerol metabolism TG(16:0/18:0/22:0)1413
Triacylglycerol metabolism TG(16:0/20:0/20:0)1413
Triacylglycerol metabolism TG(18:0/18:0/20:0)1413
Triacylglycerol metabolism TG(10:0/18:0/29:0)1410
Triacylglycerol metabolism TG(10:0/20:0/27:0)1410
Triacylglycerol metabolism TG(10:0/22:0/25:0)1411
Triacylglycerol metabolism TG(12:0/15:0/30:0)1411
Triacylglycerol metabolism TG(12:0/16:0/29:0)1410
Triacylglycerol metabolism TG(12:0/18:0/27:0)1411
Triacylglycerol metabolism TG(12:0/20:0/25:0)1411
Triacylglycerol metabolism TG(14:0/14:0/29:0)1410
Triacylglycerol metabolism TG(14:0/15:0/28:0)1410
Triacylglycerol metabolism TG(14:0/16:0/27:0)1410
Triacylglycerol metabolism TG(14:0/18:0/25:0)1410
Triacylglycerol metabolism TG(15:0/15:0/27:0)1410
Triacylglycerol metabolism TG(15:0/16:0/26:0)1410
Triacylglycerol metabolism TG(15:0/18:0/24:0)1413
Triacylglycerol metabolism TG(15:0/20:0/22:0)1413
Triacylglycerol metabolism TG(16:0/16:0/25:0)1412
Triacylglycerol Degradation56
Triacylglycerol Degradation TG(16:0/16:0/16:0)511
Triacylglycerol Degradation TG(16:0/16:0/18:0)512
Triacylglycerol Degradation TG(16:0/16:0/18:1(9Z))512
Triacylglycerol Degradation TG(16:0/16:0/18:1(11Z))512
Triacylglycerol Degradation TG(16:0/16:0/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(16:0/16:0/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(16:0/16:0/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(16:0/16:0/20:0)512
Triacylglycerol Degradation TG(16:0/16:0/20:1(11Z))512
Triacylglycerol Degradation TG(16:0/16:0/20:1(13Z))511
Triacylglycerol Degradation TG(16:0/16:0/22:0)512
Triacylglycerol Degradation TG(16:0/16:0/22:1(13Z))512
Triacylglycerol Degradation TG(16:0/18:0/16:0)512
Triacylglycerol Degradation TG(16:0/18:0/18:0)512
Triacylglycerol Degradation TG(16:0/18:0/18:1(9Z))513
Triacylglycerol Degradation TG(16:0/18:0/18:1(11Z))513
Triacylglycerol Degradation TG(16:0/18:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(16:0/18:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(16:0/18:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(16:0/18:0/20:0)513
Triacylglycerol Degradation TG(16:0/18:0/20:1(11Z))513
Triacylglycerol Degradation TG(16:0/18:0/20:1(13Z))512
Triacylglycerol Degradation TG(16:0/18:0/22:0)513
Triacylglycerol Degradation TG(16:0/18:0/22:1(13Z))513
Triacylglycerol Degradation TG(16:0/18:1(9Z)/16:0)512
Triacylglycerol Degradation TG(16:0/18:1(9Z)/18:0)513
Triacylglycerol Degradation TG(16:0/18:1(9Z)/18:1(9Z))512
Triacylglycerol Degradation TG(16:0/18:1(9Z)/18:1(11Z))513
Triacylglycerol Degradation TG(16:0/18:1(9Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(16:0/18:1(9Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(16:0/18:1(9Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(16:0/18:1(9Z)/20:0)513
Triacylglycerol Degradation TG(16:0/18:1(9Z)/20:1(11Z))513
Triacylglycerol Degradation TG(16:0/18:1(9Z)/20:1(13Z))512
Triacylglycerol Degradation TG(16:0/18:1(9Z)/22:0)513
Triacylglycerol Degradation TG(16:0/18:1(9Z)/22:1(13Z))513
Triacylglycerol Degradation TG(16:0/18:1(11Z)/16:0)512
Triacylglycerol Degradation TG(16:0/18:1(11Z)/18:0)513
Triacylglycerol Degradation TG(16:0/18:1(11Z)/18:1(9Z))513
Triacylglycerol Degradation TG(16:0/18:1(11Z)/18:1(11Z))512
Triacylglycerol Degradation TG(16:0/18:1(11Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(16:0/18:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(16:0/18:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(16:0/18:1(11Z)/20:0)513
Triacylglycerol Degradation TG(16:0/18:1(11Z)/20:1(11Z))513
Triacylglycerol Degradation TG(16:0/18:1(11Z)/20:1(13Z))512
Triacylglycerol Degradation TG(16:0/18:1(11Z)/22:0)513
Triacylglycerol Degradation TG(16:0/18:1(11Z)/22:1(13Z))513
Triacylglycerol Degradation TG(16:0/18:2(9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(16:0/18:2(9Z,12Z)/18:0)513
Triacylglycerol Degradation TG(16:0/18:2(9Z,12Z)/18:1(9Z))513
Triacylglycerol Degradation TG(16:0/18:2(9Z,12Z)/18:1(11Z))513
Triacylglycerol Degradation TG(16:0/18:2(9Z,12Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(16:0/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(16:0/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(16:0/18:2(9Z,12Z)/20:0)513
Triacylglycerol Degradation TG(16:0/18:2(9Z,12Z)/20:1(11Z))513
Triacylglycerol Degradation TG(16:0/18:2(9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(16:0/18:2(9Z,12Z)/22:0)513
Triacylglycerol Degradation TG(16:0/18:2(9Z,12Z)/22:1(13Z))513
Triacylglycerol Degradation TG(16:0/18:3(6Z,9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(16:0/18:3(6Z,9Z,12Z)/18:0)513
Triacylglycerol Degradation TG(16:0/18:3(6Z,9Z,12Z)/18:1(9Z))513
Triacylglycerol Degradation TG(16:0/18:3(6Z,9Z,12Z)/18:1(11Z))513
Triacylglycerol Degradation TG(16:0/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(16:0/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(16:0/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(16:0/18:3(6Z,9Z,12Z)/20:0)513
Triacylglycerol Degradation TG(16:0/18:3(6Z,9Z,12Z)/20:1(11Z))513
Triacylglycerol Degradation TG(16:0/18:3(6Z,9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(16:0/18:3(6Z,9Z,12Z)/22:0)513
Triacylglycerol Degradation TG(16:0/18:3(6Z,9Z,12Z)/22:1(13Z))513
Triacylglycerol Degradation TG(16:0/18:3(9Z,12Z,15Z)/16:0)512
Triacylglycerol Degradation TG(16:0/18:3(9Z,12Z,15Z)/18:0)513
Triacylglycerol Degradation TG(16:0/18:3(9Z,12Z,15Z)/18:1(9Z))513
Triacylglycerol Degradation TG(16:0/18:3(9Z,12Z,15Z)/18:1(11Z))513
Triacylglycerol Degradation TG(16:0/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(16:0/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(16:0/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(16:0/18:3(9Z,12Z,15Z)/20:0)513
Triacylglycerol Degradation TG(16:0/18:3(9Z,12Z,15Z)/20:1(11Z))513
Triacylglycerol Degradation TG(16:0/18:3(9Z,12Z,15Z)/20:1(13Z))512
Triacylglycerol Degradation TG(16:0/18:3(9Z,12Z,15Z)/22:0)513
Triacylglycerol Degradation TG(16:0/18:3(9Z,12Z,15Z)/22:1(13Z))513
Triacylglycerol Degradation TG(16:0/20:0/16:0)512
Triacylglycerol Degradation TG(16:0/20:0/18:0)513
Triacylglycerol Degradation TG(16:0/20:0/18:1(9Z))513
Triacylglycerol Degradation TG(16:0/20:0/18:1(11Z))513
Triacylglycerol Degradation TG(16:0/20:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(16:0/20:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(16:0/20:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(16:0/20:0/20:0)512
Triacylglycerol Degradation TG(16:0/20:0/20:1(11Z))513
Triacylglycerol Degradation TG(16:0/20:0/20:1(13Z))512
Triacylglycerol Degradation TG(16:0/20:0/22:0)513
Triacylglycerol Degradation TG(16:0/20:0/22:1(13Z))513
Triacylglycerol Degradation TG(16:0/20:1(11Z)/16:0)512
Triacylglycerol Degradation TG(16:0/20:1(11Z)/18:0)513
Triacylglycerol Degradation TG(16:0/20:1(11Z)/18:1(9Z))513
Triacylglycerol Degradation TG(16:0/20:1(11Z)/18:1(11Z))513
Triacylglycerol Degradation TG(16:0/20:1(11Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(16:0/20:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(16:0/20:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(16:0/20:1(11Z)/20:0)513
Triacylglycerol Degradation TG(16:0/20:1(11Z)/20:1(11Z))512
Triacylglycerol Degradation TG(16:0/20:1(11Z)/20:1(13Z))512
Triacylglycerol Degradation TG(16:0/20:1(11Z)/22:0)513
Triacylglycerol Degradation TG(16:0/20:1(11Z)/22:1(13Z))513
Triacylglycerol Degradation TG(16:0/20:1(13Z)/16:0)58
Triacylglycerol Degradation TG(16:0/20:1(13Z)/18:0)59
Triacylglycerol Degradation TG(16:0/20:1(13Z)/18:1(9Z))59
Triacylglycerol Degradation TG(16:0/20:1(13Z)/18:1(11Z))59
Triacylglycerol Degradation TG(16:0/20:1(13Z)/18:2(9Z,12Z))59
Triacylglycerol Degradation TG(16:0/20:1(13Z)/18:3(6Z,9Z,12Z))59
Triacylglycerol Degradation TG(16:0/20:1(13Z)/18:3(9Z,12Z,15Z))59
Triacylglycerol Degradation TG(16:0/20:1(13Z)/20:0)59
Triacylglycerol Degradation TG(16:0/20:1(13Z)/20:1(11Z))59
Triacylglycerol Degradation TG(16:0/20:1(13Z)/20:1(13Z))58
Triacylglycerol Degradation TG(16:0/20:1(13Z)/22:0)59
Triacylglycerol Degradation TG(16:0/20:1(13Z)/22:1(13Z))59
Triacylglycerol Degradation TG(16:0/22:0/16:0)512
Triacylglycerol Degradation TG(16:0/22:0/18:0)513
Triacylglycerol Degradation TG(16:0/22:0/18:1(9Z))513
Triacylglycerol Degradation TG(16:0/22:0/18:1(11Z))513
Triacylglycerol Degradation TG(16:0/22:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(16:0/22:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(16:0/22:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(16:0/22:0/20:0)513
Triacylglycerol Degradation TG(16:0/22:0/20:1(11Z))513
Triacylglycerol Degradation TG(16:0/22:0/20:1(13Z))512
Triacylglycerol Degradation TG(16:0/22:0/22:0)512
Triacylglycerol Degradation TG(16:0/22:0/22:1(13Z))513
Triacylglycerol Degradation TG(16:0/22:1(13Z)/16:0)512
Triacylglycerol Degradation TG(16:0/22:1(13Z)/18:0)513
Triacylglycerol Degradation TG(16:0/22:1(13Z)/18:1(9Z))513
Triacylglycerol Degradation TG(16:0/22:1(13Z)/18:1(11Z))513
Triacylglycerol Degradation TG(16:0/22:1(13Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(16:0/22:1(13Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(16:0/22:1(13Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(16:0/22:1(13Z)/20:0)513
Triacylglycerol Degradation TG(16:0/22:1(13Z)/20:1(11Z))513
Triacylglycerol Degradation TG(16:0/22:1(13Z)/20:1(13Z))512
Triacylglycerol Degradation TG(16:0/22:1(13Z)/22:0)513
Triacylglycerol Degradation TG(16:0/22:1(13Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:0/16:0/16:0)511
Triacylglycerol Degradation TG(18:0/16:0/18:0)512
Triacylglycerol Degradation TG(18:0/16:0/18:1(9Z))513
Triacylglycerol Degradation TG(18:0/16:0/18:1(11Z))513
Triacylglycerol Degradation TG(18:0/16:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:0/16:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:0/16:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:0/16:0/20:0)513
Triacylglycerol Degradation TG(18:0/16:0/20:1(11Z))513
Triacylglycerol Degradation TG(18:0/16:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:0/16:0/22:0)513
Triacylglycerol Degradation TG(18:0/16:0/22:1(13Z))513
Triacylglycerol Degradation TG(18:0/18:0/16:0)512
Triacylglycerol Degradation TG(18:0/18:0/18:0)511
Triacylglycerol Degradation TG(18:0/18:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:0/18:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:0/18:0/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:0/18:0/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:0/18:0/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:0/18:0/20:0)512
Triacylglycerol Degradation TG(18:0/18:0/20:1(11Z))512
Triacylglycerol Degradation TG(18:0/18:0/20:1(13Z))511
Triacylglycerol Degradation TG(18:0/18:0/22:0)512
Triacylglycerol Degradation TG(18:0/18:0/22:1(13Z))512
Triacylglycerol Degradation TG(18:0/18:1(9Z)/16:0)512
Triacylglycerol Degradation TG(18:0/18:1(9Z)/18:0)512
Triacylglycerol Degradation TG(18:0/18:1(9Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:0/18:1(9Z)/18:1(11Z))513
Triacylglycerol Degradation TG(18:0/18:1(9Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:0/18:1(9Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:0/18:1(9Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:0/18:1(9Z)/20:0)513
Triacylglycerol Degradation TG(18:0/18:1(9Z)/20:1(11Z))513
Triacylglycerol Degradation TG(18:0/18:1(9Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:0/18:1(9Z)/22:0)513
Triacylglycerol Degradation TG(18:0/18:1(9Z)/22:1(13Z))513
Triacylglycerol Degradation TG(18:0/18:1(11Z)/16:0)512
Triacylglycerol Degradation TG(18:0/18:1(11Z)/18:0)512
Triacylglycerol Degradation TG(18:0/18:1(11Z)/18:1(9Z))513
Triacylglycerol Degradation TG(18:0/18:1(11Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:0/18:1(11Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:0/18:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:0/18:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:0/18:1(11Z)/20:0)513
Triacylglycerol Degradation TG(18:0/18:1(11Z)/20:1(11Z))513
Triacylglycerol Degradation TG(18:0/18:1(11Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:0/18:1(11Z)/22:0)513
Triacylglycerol Degradation TG(18:0/18:1(11Z)/22:1(13Z))513
Triacylglycerol Degradation TG(18:0/18:2(9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(18:0/18:2(9Z,12Z)/18:0)512
Triacylglycerol Degradation TG(18:0/18:2(9Z,12Z)/18:1(9Z))513
Triacylglycerol Degradation TG(18:0/18:2(9Z,12Z)/18:1(11Z))513
Triacylglycerol Degradation TG(18:0/18:2(9Z,12Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:0/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:0/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:0/18:2(9Z,12Z)/20:0)513
Triacylglycerol Degradation TG(18:0/18:2(9Z,12Z)/20:1(11Z))513
Triacylglycerol Degradation TG(18:0/18:2(9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:0/18:2(9Z,12Z)/22:0)513
Triacylglycerol Degradation TG(18:0/18:2(9Z,12Z)/22:1(13Z))513
Triacylglycerol Degradation TG(18:0/18:3(6Z,9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(18:0/18:3(6Z,9Z,12Z)/18:0)512
Triacylglycerol Degradation TG(18:0/18:3(6Z,9Z,12Z)/18:1(9Z))513
Triacylglycerol Degradation TG(18:0/18:3(6Z,9Z,12Z)/18:1(11Z))513
Triacylglycerol Degradation TG(18:0/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:0/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:0/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:0/18:3(6Z,9Z,12Z)/20:0)513
Triacylglycerol Degradation TG(18:0/18:3(6Z,9Z,12Z)/20:1(11Z))513
Triacylglycerol Degradation TG(18:0/18:3(6Z,9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:0/18:3(6Z,9Z,12Z)/22:0)513
Triacylglycerol Degradation TG(18:0/18:3(6Z,9Z,12Z)/22:1(13Z))513
Triacylglycerol Degradation TG(18:0/18:3(9Z,12Z,15Z)/16:0)512
Triacylglycerol Degradation TG(18:0/18:3(9Z,12Z,15Z)/18:0)512
Triacylglycerol Degradation TG(18:0/18:3(9Z,12Z,15Z)/18:1(9Z))513
Triacylglycerol Degradation TG(18:0/18:3(9Z,12Z,15Z)/18:1(11Z))513
Triacylglycerol Degradation TG(18:0/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:0/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:0/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:0/18:3(9Z,12Z,15Z)/20:0)513
Triacylglycerol Degradation TG(18:0/18:3(9Z,12Z,15Z)/20:1(11Z))513
Triacylglycerol Degradation TG(18:0/18:3(9Z,12Z,15Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:0/18:3(9Z,12Z,15Z)/22:0)513
Triacylglycerol Degradation TG(18:0/18:3(9Z,12Z,15Z)/22:1(13Z))513
Triacylglycerol Degradation TG(18:0/20:0/16:0)513
Triacylglycerol Degradation TG(18:0/20:0/18:0)512
Triacylglycerol Degradation TG(18:0/20:0/18:1(9Z))513
Triacylglycerol Degradation TG(18:0/20:0/18:1(11Z))513
Triacylglycerol Degradation TG(18:0/20:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:0/20:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:0/20:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:0/20:0/20:0)512
Triacylglycerol Degradation TG(18:0/20:0/20:1(11Z))513
Triacylglycerol Degradation TG(18:0/20:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:0/20:0/22:0)513
Triacylglycerol Degradation TG(18:0/20:0/22:1(13Z))513
Triacylglycerol Degradation TG(18:0/20:1(11Z)/16:0)512
Triacylglycerol Degradation TG(18:0/20:1(11Z)/18:0)512
Triacylglycerol Degradation TG(18:0/20:1(11Z)/18:1(9Z))513
Triacylglycerol Degradation TG(18:0/20:1(11Z)/18:1(11Z))513
Triacylglycerol Degradation TG(18:0/20:1(11Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:0/20:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:0/20:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:0/20:1(11Z)/20:0)513
Triacylglycerol Degradation TG(18:0/20:1(11Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:0/20:1(11Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:0/20:1(11Z)/22:0)513
Triacylglycerol Degradation TG(18:0/20:1(11Z)/22:1(13Z))513
Triacylglycerol Degradation TG(18:0/20:1(13Z)/16:0)59
Triacylglycerol Degradation TG(18:0/20:1(13Z)/18:0)58
Triacylglycerol Degradation TG(18:0/20:1(13Z)/18:1(9Z))59
Triacylglycerol Degradation TG(18:0/20:1(13Z)/18:1(11Z))59
Triacylglycerol Degradation TG(18:0/20:1(13Z)/18:2(9Z,12Z))59
Triacylglycerol Degradation TG(18:0/20:1(13Z)/18:3(6Z,9Z,12Z))59
Triacylglycerol Degradation TG(18:0/20:1(13Z)/18:3(9Z,12Z,15Z))59
Triacylglycerol Degradation TG(18:0/20:1(13Z)/20:0)59
Triacylglycerol Degradation TG(18:0/20:1(13Z)/20:1(11Z))59
Triacylglycerol Degradation TG(18:0/20:1(13Z)/20:1(13Z))58
Triacylglycerol Degradation TG(18:0/20:1(13Z)/22:0)59
Triacylglycerol Degradation TG(18:0/20:1(13Z)/22:1(13Z))59
Triacylglycerol Degradation TG(18:0/22:0/16:0)513
Triacylglycerol Degradation TG(18:0/22:0/18:0)512
Triacylglycerol Degradation TG(18:0/22:0/18:1(9Z))513
Triacylglycerol Degradation TG(18:0/22:0/18:1(11Z))513
Triacylglycerol Degradation TG(18:0/22:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:0/22:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:0/22:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:0/22:0/20:0)513
Triacylglycerol Degradation TG(18:0/22:0/20:1(11Z))513
Triacylglycerol Degradation TG(18:0/22:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:0/22:0/22:0)512
Triacylglycerol Degradation TG(18:0/22:0/22:1(13Z))513
Triacylglycerol Degradation TG(18:0/22:1(13Z)/16:0)512
Triacylglycerol Degradation TG(18:0/22:1(13Z)/18:0)512
Triacylglycerol Degradation TG(18:0/22:1(13Z)/18:1(9Z))513
Triacylglycerol Degradation TG(18:0/22:1(13Z)/18:1(11Z))513
Triacylglycerol Degradation TG(18:0/22:1(13Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:0/22:1(13Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:0/22:1(13Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:0/22:1(13Z)/20:0)513
Triacylglycerol Degradation TG(18:0/22:1(13Z)/20:1(11Z))513
Triacylglycerol Degradation TG(18:0/22:1(13Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:0/22:1(13Z)/22:0)513
Triacylglycerol Degradation TG(18:0/22:1(13Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:1(9Z)/16:0/16:0)511
Triacylglycerol Degradation TG(18:1(9Z)/16:0/18:0)512
Triacylglycerol Degradation TG(18:1(9Z)/16:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:1(9Z)/16:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(9Z)/16:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/16:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/16:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(9Z)/16:0/20:0)512
Triacylglycerol Degradation TG(18:1(9Z)/16:0/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(9Z)/16:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(9Z)/16:0/22:0)512
Triacylglycerol Degradation TG(18:1(9Z)/16:0/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:0/16:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:0/18:0)511
Triacylglycerol Degradation TG(18:1(9Z)/18:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:0/20:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:0/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:0/22:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:0/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:1(9Z)/16:0)511
Triacylglycerol Degradation TG(18:1(9Z)/18:1(9Z)/18:0)511
Triacylglycerol Degradation TG(18:1(9Z)/18:1(9Z)/18:1(9Z))511
Triacylglycerol Degradation TG(18:1(9Z)/18:1(9Z)/18:1(11Z))511
Triacylglycerol Degradation TG(18:1(9Z)/18:1(9Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:1(9Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:1(9Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:1(9Z)/20:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:1(9Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:1(9Z)/20:1(13Z))511
Triacylglycerol Degradation TG(18:1(9Z)/18:1(9Z)/22:0)511
Triacylglycerol Degradation TG(18:1(9Z)/18:1(9Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:1(11Z)/16:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:1(11Z)/18:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:1(11Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:1(11Z)/18:1(11Z))511
Triacylglycerol Degradation TG(18:1(9Z)/18:1(11Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:1(11Z)/20:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:1(11Z)/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:1(11Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:1(11Z)/22:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:1(11Z)/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:2(9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:2(9Z,12Z)/18:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:2(9Z,12Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:2(9Z,12Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:2(9Z,12Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:2(9Z,12Z)/20:0)513
Triacylglycerol Degradation TG(18:1(9Z)/18:2(9Z,12Z)/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:2(9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:2(9Z,12Z)/22:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:2(9Z,12Z)/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/18:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/20:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/22:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/16:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/18:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/20:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/22:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(9Z)/20:0/16:0)512
Triacylglycerol Degradation TG(18:1(9Z)/20:0/18:0)512
Triacylglycerol Degradation TG(18:1(9Z)/20:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:1(9Z)/20:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(9Z)/20:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/20:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/20:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(9Z)/20:0/20:0)512
Triacylglycerol Degradation TG(18:1(9Z)/20:0/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(9Z)/20:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(9Z)/20:0/22:0)512
Triacylglycerol Degradation TG(18:1(9Z)/20:0/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(9Z)/20:1(11Z)/16:0)512
Triacylglycerol Degradation TG(18:1(9Z)/20:1(11Z)/18:0)512
Triacylglycerol Degradation TG(18:1(9Z)/20:1(11Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:1(9Z)/20:1(11Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(9Z)/20:1(11Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/20:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/20:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(9Z)/20:1(11Z)/20:0)512
Triacylglycerol Degradation TG(18:1(9Z)/20:1(11Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:1(9Z)/20:1(11Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(9Z)/20:1(11Z)/22:0)512
Triacylglycerol Degradation TG(18:1(9Z)/20:1(11Z)/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(9Z)/20:1(13Z)/16:0)59
Triacylglycerol Degradation TG(18:1(9Z)/20:1(13Z)/18:0)59
Triacylglycerol Degradation TG(18:1(9Z)/20:1(13Z)/18:1(9Z))58
Triacylglycerol Degradation TG(18:1(9Z)/20:1(13Z)/18:1(11Z))59
Triacylglycerol Degradation TG(18:1(9Z)/20:1(13Z)/18:2(9Z,12Z))59
Triacylglycerol Degradation TG(18:1(9Z)/20:1(13Z)/18:3(6Z,9Z,12Z))59
Triacylglycerol Degradation TG(18:1(9Z)/20:1(13Z)/18:3(9Z,12Z,15Z))59
Triacylglycerol Degradation TG(18:1(9Z)/20:1(13Z)/20:0)59
Triacylglycerol Degradation TG(18:1(9Z)/20:1(13Z)/20:1(11Z))59
Triacylglycerol Degradation TG(18:1(9Z)/20:1(13Z)/20:1(13Z))58
Triacylglycerol Degradation TG(18:1(9Z)/20:1(13Z)/22:0)59
Triacylglycerol Degradation TG(18:1(9Z)/20:1(13Z)/22:1(13Z))59
Triacylglycerol Degradation TG(18:1(9Z)/22:0/16:0)512
Triacylglycerol Degradation TG(18:1(9Z)/22:0/18:0)512
Triacylglycerol Degradation TG(18:1(9Z)/22:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:1(9Z)/22:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(9Z)/22:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/22:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/22:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(9Z)/22:0/20:0)512
Triacylglycerol Degradation TG(18:1(9Z)/22:0/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(9Z)/22:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(9Z)/22:0/22:0)511
Triacylglycerol Degradation TG(18:1(9Z)/22:0/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(9Z)/22:1(13Z)/16:0)512
Triacylglycerol Degradation TG(18:1(9Z)/22:1(13Z)/18:0)512
Triacylglycerol Degradation TG(18:1(9Z)/22:1(13Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:1(9Z)/22:1(13Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(9Z)/22:1(13Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/22:1(13Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/22:1(13Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(9Z)/22:1(13Z)/20:0)512
Triacylglycerol Degradation TG(18:1(9Z)/22:1(13Z)/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(9Z)/22:1(13Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(9Z)/22:1(13Z)/22:0)512
Triacylglycerol Degradation TG(18:1(9Z)/22:1(13Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:1(11Z)/16:0/16:0)511
Triacylglycerol Degradation TG(18:1(11Z)/16:0/18:0)512
Triacylglycerol Degradation TG(18:1(11Z)/16:0/18:1(9Z))513
Triacylglycerol Degradation TG(18:1(11Z)/16:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(11Z)/16:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/16:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/16:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(11Z)/16:0/20:0)512
Triacylglycerol Degradation TG(18:1(11Z)/16:0/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(11Z)/16:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(11Z)/16:0/22:0)512
Triacylglycerol Degradation TG(18:1(11Z)/16:0/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:0/16:0)512
Triacylglycerol Degradation TG(18:1(11Z)/18:0/18:0)511
Triacylglycerol Degradation TG(18:1(11Z)/18:0/18:1(9Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(11Z)/18:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:0/20:0)512
Triacylglycerol Degradation TG(18:1(11Z)/18:0/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(11Z)/18:0/22:0)512
Triacylglycerol Degradation TG(18:1(11Z)/18:0/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:1(9Z)/16:0)512
Triacylglycerol Degradation TG(18:1(11Z)/18:1(9Z)/18:0)512
Triacylglycerol Degradation TG(18:1(11Z)/18:1(9Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:1(11Z)/18:1(9Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(11Z)/18:1(9Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:1(9Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:1(9Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:1(9Z)/20:0)512
Triacylglycerol Degradation TG(18:1(11Z)/18:1(9Z)/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:1(9Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(11Z)/18:1(9Z)/22:0)512
Triacylglycerol Degradation TG(18:1(11Z)/18:1(9Z)/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:1(11Z)/16:0)511
Triacylglycerol Degradation TG(18:1(11Z)/18:1(11Z)/18:0)511
Triacylglycerol Degradation TG(18:1(11Z)/18:1(11Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:1(11Z)/18:1(11Z)/18:1(11Z))511
Triacylglycerol Degradation TG(18:1(11Z)/18:1(11Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:1(11Z)/18:1(11Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:1(11Z)/18:1(11Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:1(11Z)/18:1(11Z)/20:0)511
Triacylglycerol Degradation TG(18:1(11Z)/18:1(11Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:1(11Z)/18:1(11Z)/20:1(13Z))511
Triacylglycerol Degradation TG(18:1(11Z)/18:1(11Z)/22:0)511
Triacylglycerol Degradation TG(18:1(11Z)/18:1(11Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:1(11Z)/18:2(9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(18:1(11Z)/18:2(9Z,12Z)/18:0)512
Triacylglycerol Degradation TG(18:1(11Z)/18:2(9Z,12Z)/18:1(9Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:2(9Z,12Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(11Z)/18:2(9Z,12Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:1(11Z)/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:2(9Z,12Z)/20:0)512
Triacylglycerol Degradation TG(18:1(11Z)/18:2(9Z,12Z)/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:2(9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(11Z)/18:2(9Z,12Z)/22:0)512
Triacylglycerol Degradation TG(18:1(11Z)/18:2(9Z,12Z)/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:3(6Z,9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(18:1(11Z)/18:3(6Z,9Z,12Z)/18:0)512
Triacylglycerol Degradation TG(18:1(11Z)/18:3(6Z,9Z,12Z)/18:1(9Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:3(6Z,9Z,12Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(11Z)/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:1(11Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:3(6Z,9Z,12Z)/20:0)512
Triacylglycerol Degradation TG(18:1(11Z)/18:3(6Z,9Z,12Z)/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:3(6Z,9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(11Z)/18:3(6Z,9Z,12Z)/22:0)512
Triacylglycerol Degradation TG(18:1(11Z)/18:3(6Z,9Z,12Z)/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:3(9Z,12Z,15Z)/16:0)512
Triacylglycerol Degradation TG(18:1(11Z)/18:3(9Z,12Z,15Z)/18:0)512
Triacylglycerol Degradation TG(18:1(11Z)/18:3(9Z,12Z,15Z)/18:1(9Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:3(9Z,12Z,15Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(11Z)/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:1(11Z)/18:3(9Z,12Z,15Z)/20:0)512
Triacylglycerol Degradation TG(18:1(11Z)/18:3(9Z,12Z,15Z)/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:3(9Z,12Z,15Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(11Z)/18:3(9Z,12Z,15Z)/22:0)512
Triacylglycerol Degradation TG(18:1(11Z)/18:3(9Z,12Z,15Z)/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(11Z)/20:0/16:0)512
Triacylglycerol Degradation TG(18:1(11Z)/20:0/18:0)512
Triacylglycerol Degradation TG(18:1(11Z)/20:0/18:1(9Z))513
Triacylglycerol Degradation TG(18:1(11Z)/20:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(11Z)/20:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/20:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/20:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(11Z)/20:0/20:0)511
Triacylglycerol Degradation TG(18:1(11Z)/20:0/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(11Z)/20:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(11Z)/20:0/22:0)512
Triacylglycerol Degradation TG(18:1(11Z)/20:0/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(11Z)/20:1(11Z)/16:0)512
Triacylglycerol Degradation TG(18:1(11Z)/20:1(11Z)/18:0)512
Triacylglycerol Degradation TG(18:1(11Z)/20:1(11Z)/18:1(9Z))513
Triacylglycerol Degradation TG(18:1(11Z)/20:1(11Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(11Z)/20:1(11Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/20:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/20:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(11Z)/20:1(11Z)/20:0)512
Triacylglycerol Degradation TG(18:1(11Z)/20:1(11Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:1(11Z)/20:1(11Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(11Z)/20:1(11Z)/22:0)512
Triacylglycerol Degradation TG(18:1(11Z)/20:1(11Z)/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(11Z)/20:1(13Z)/16:0)59
Triacylglycerol Degradation TG(18:1(11Z)/20:1(13Z)/18:0)59
Triacylglycerol Degradation TG(18:1(11Z)/20:1(13Z)/18:1(9Z))59
Triacylglycerol Degradation TG(18:1(11Z)/20:1(13Z)/18:1(11Z))58
Triacylglycerol Degradation TG(18:1(11Z)/20:1(13Z)/18:2(9Z,12Z))59
Triacylglycerol Degradation TG(18:1(11Z)/20:1(13Z)/18:3(6Z,9Z,12Z))59
Triacylglycerol Degradation TG(18:1(11Z)/20:1(13Z)/18:3(9Z,12Z,15Z))59
Triacylglycerol Degradation TG(18:1(11Z)/20:1(13Z)/20:0)59
Triacylglycerol Degradation TG(18:1(11Z)/20:1(13Z)/20:1(11Z))59
Triacylglycerol Degradation TG(18:1(11Z)/20:1(13Z)/20:1(13Z))58
Triacylglycerol Degradation TG(18:1(11Z)/20:1(13Z)/22:0)59
Triacylglycerol Degradation TG(18:1(11Z)/20:1(13Z)/22:1(13Z))59
Triacylglycerol Degradation TG(18:1(11Z)/22:0/16:0)512
Triacylglycerol Degradation TG(18:1(11Z)/22:0/18:0)512
Triacylglycerol Degradation TG(18:1(11Z)/22:0/18:1(9Z))513
Triacylglycerol Degradation TG(18:1(11Z)/22:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(11Z)/22:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/22:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/22:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(11Z)/22:0/20:0)512
Triacylglycerol Degradation TG(18:1(11Z)/22:0/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(11Z)/22:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(11Z)/22:0/22:0)511
Triacylglycerol Degradation TG(18:1(11Z)/22:0/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(11Z)/22:1(13Z)/16:0)512
Triacylglycerol Degradation TG(18:1(11Z)/22:1(13Z)/18:0)512
Triacylglycerol Degradation TG(18:1(11Z)/22:1(13Z)/18:1(9Z))513
Triacylglycerol Degradation TG(18:1(11Z)/22:1(13Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(11Z)/22:1(13Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/22:1(13Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/22:1(13Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(11Z)/22:1(13Z)/20:0)512
Triacylglycerol Degradation TG(18:1(11Z)/22:1(13Z)/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(11Z)/22:1(13Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(11Z)/22:1(13Z)/22:0)512
Triacylglycerol Degradation TG(18:1(11Z)/22:1(13Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/16:0/16:0)511
Triacylglycerol Degradation TG(18:2(9Z,12Z)/16:0/18:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/16:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/16:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/16:0/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/16:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/16:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/16:0/20:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/16:0/20:1(11Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/16:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/16:0/22:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/16:0/22:1(13Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:0/16:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:0/18:0)511
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:0/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:0/20:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:0/20:1(11Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:0/22:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:0/22:1(13Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(9Z)/16:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(9Z)/18:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(9Z)/18:1(9Z))511
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(9Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(9Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(9Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(9Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(9Z)/20:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(9Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(9Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(9Z)/22:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(9Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(11Z)/16:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(11Z)/18:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(11Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(11Z)/18:1(11Z))511
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(11Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(11Z)/20:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(11Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(11Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(11Z)/22:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(11Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:2(9Z,12Z)/16:0)511
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:2(9Z,12Z)/18:0)511
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:2(9Z,12Z)/18:1(9Z))511
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:2(9Z,12Z)/18:1(11Z))511
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:2(9Z,12Z)/18:2(9Z,12Z))511
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:2(9Z,12Z)/20:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:2(9Z,12Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:2(9Z,12Z)/20:1(13Z))511
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:2(9Z,12Z)/22:0)511
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:2(9Z,12Z)/22:1(13Z))511
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/18:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/20:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/22:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/16:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/18:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/20:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/22:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:0/16:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:0/18:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:0/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:0/20:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:0/20:1(11Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:0/22:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:0/22:1(13Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:1(11Z)/16:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:1(11Z)/18:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:1(11Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:1(11Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:1(11Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:1(11Z)/20:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:1(11Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:1(11Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:1(11Z)/22:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:1(11Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:1(13Z)/16:0)59
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:1(13Z)/18:0)59
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:1(13Z)/18:1(9Z))59
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:1(13Z)/18:1(11Z))59
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:1(13Z)/18:2(9Z,12Z))58
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:1(13Z)/18:3(6Z,9Z,12Z))59
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:1(13Z)/18:3(9Z,12Z,15Z))59
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:1(13Z)/20:0)59
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:1(13Z)/20:1(11Z))59
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:1(13Z)/20:1(13Z))58
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:1(13Z)/22:0)59
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:1(13Z)/22:1(13Z))59
Triacylglycerol Degradation TG(18:2(9Z,12Z)/22:0/16:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/22:0/18:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/22:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/22:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/22:0/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/22:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/22:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/22:0/20:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/22:0/20:1(11Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/22:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/22:0/22:0)511
Triacylglycerol Degradation TG(18:2(9Z,12Z)/22:0/22:1(13Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/22:1(13Z)/16:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/22:1(13Z)/18:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/22:1(13Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/22:1(13Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/22:1(13Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/22:1(13Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/22:1(13Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/22:1(13Z)/20:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/22:1(13Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/22:1(13Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/22:1(13Z)/22:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/22:1(13Z)/22:1(13Z))511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/16:0)511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/18:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/20:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/22:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:0/16:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:0/18:0)511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:0/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:0/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:0/20:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:0/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:0/22:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:0/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/16:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/18:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/18:1(9Z))511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/20:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/22:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(11Z)/16:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(11Z)/18:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(11Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(11Z)/18:1(11Z))511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(11Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(11Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(11Z)/20:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(11Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(11Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(11Z)/22:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(11Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/18:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/18:2(9Z,12Z))511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/20:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/22:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/16:0)511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/18:0)511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/18:1(9Z))511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/18:1(11Z))511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/20:0)511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/20:1(11Z))511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/20:1(13Z))511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/22:0)511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/22:1(13Z))511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/16:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/18:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/20:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/22:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:0/16:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:0/18:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:0/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:0/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:0/20:0)511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:0/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:0/22:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:0/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(11Z)/16:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(11Z)/18:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(11Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(11Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(11Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(11Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(11Z)/20:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(11Z)/20:1(11Z))511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(11Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(11Z)/22:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(11Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(13Z)/16:0)59
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(13Z)/18:0)59
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(13Z)/18:1(9Z))59
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(13Z)/18:1(11Z))59
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(13Z)/18:2(9Z,12Z))59
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(13Z)/18:3(6Z,9Z,12Z))58
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(13Z)/18:3(9Z,12Z,15Z))59
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(13Z)/20:0)59
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(13Z)/20:1(11Z))59
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(13Z)/20:1(13Z))58
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(13Z)/22:0)59
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(13Z)/22:1(13Z))59
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:0/16:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:0/18:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:0/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:0/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:0/20:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:0/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:0/22:0)511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:0/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:1(13Z)/16:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:1(13Z)/18:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:1(13Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:1(13Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:1(13Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:1(13Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:1(13Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:1(13Z)/20:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:1(13Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:1(13Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:1(13Z)/22:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:1(13Z)/22:1(13Z))511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/16:0)511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/18:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/20:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/22:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:0/16:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:0/18:0)511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:0/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:0/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:0/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:0/20:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:0/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:0/22:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:0/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/16:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/18:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/18:1(9Z))511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/20:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/22:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(11Z)/16:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(11Z)/18:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(11Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(11Z)/18:1(11Z))511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(11Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(11Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(11Z)/20:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(11Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(11Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(11Z)/22:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(11Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/18:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/18:2(9Z,12Z))511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/20:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/22:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/18:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/20:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/22:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/16:0)511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/18:0)511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/18:1(9Z))511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/18:1(11Z))511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/20:0)511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/20:1(11Z))511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/20:1(13Z))511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/22:0)511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/22:1(13Z))511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:0/16:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:0/18:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:0/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:0/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:0/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:0/20:0)511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:0/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:0/22:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:0/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(11Z)/16:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(11Z)/18:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(11Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(11Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(11Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(11Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(11Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(11Z)/20:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(11Z)/20:1(11Z))511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(11Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(11Z)/22:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(11Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(13Z)/16:0)59
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(13Z)/18:0)59
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(13Z)/18:1(9Z))59
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(13Z)/18:1(11Z))59
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(13Z)/18:2(9Z,12Z))59
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(13Z)/18:3(6Z,9Z,12Z))59
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(13Z)/18:3(9Z,12Z,15Z))58
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(13Z)/20:0)59
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(13Z)/20:1(11Z))59
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(13Z)/20:1(13Z))58
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(13Z)/22:0)59
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(13Z)/22:1(13Z))59
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:0/16:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:0/18:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:0/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:0/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:0/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:0/20:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:0/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:0/22:0)511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:0/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:1(13Z)/16:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:1(13Z)/18:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:1(13Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:1(13Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:1(13Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:1(13Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:1(13Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:1(13Z)/20:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:1(13Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:1(13Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:1(13Z)/22:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:1(13Z)/22:1(13Z))511
Triacylglycerol Degradation TG(20:0/16:0/16:0)511
Triacylglycerol Degradation TG(20:0/16:0/18:0)513
Triacylglycerol Degradation TG(20:0/16:0/18:1(9Z))513
Triacylglycerol Degradation TG(20:0/16:0/18:1(11Z))513
Triacylglycerol Degradation TG(20:0/16:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(20:0/16:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:0/16:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:0/16:0/20:0)512
Triacylglycerol Degradation TG(20:0/16:0/20:1(11Z))513
Triacylglycerol Degradation TG(20:0/16:0/20:1(13Z))512
Triacylglycerol Degradation TG(20:0/16:0/22:0)513
Triacylglycerol Degradation TG(20:0/16:0/22:1(13Z))513
Triacylglycerol Degradation TG(20:0/18:0/16:0)512
Triacylglycerol Degradation TG(20:0/18:0/18:0)511
Triacylglycerol Degradation TG(20:0/18:0/18:1(9Z))513
Triacylglycerol Degradation TG(20:0/18:0/18:1(11Z))513
Triacylglycerol Degradation TG(20:0/18:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(20:0/18:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:0/18:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:0/18:0/20:0)512
Triacylglycerol Degradation TG(20:0/18:0/20:1(11Z))513
Triacylglycerol Degradation TG(20:0/18:0/20:1(13Z))512
Triacylglycerol Degradation TG(20:0/18:0/22:0)513
Triacylglycerol Degradation TG(20:0/18:0/22:1(13Z))513
Triacylglycerol Degradation TG(20:0/18:1(9Z)/16:0)512
Triacylglycerol Degradation TG(20:0/18:1(9Z)/18:0)512
Triacylglycerol Degradation TG(20:0/18:1(9Z)/18:1(9Z))512
Triacylglycerol Degradation TG(20:0/18:1(9Z)/18:1(11Z))513
Triacylglycerol Degradation TG(20:0/18:1(9Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(20:0/18:1(9Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:0/18:1(9Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:0/18:1(9Z)/20:0)512
Triacylglycerol Degradation TG(20:0/18:1(9Z)/20:1(11Z))513
Triacylglycerol Degradation TG(20:0/18:1(9Z)/20:1(13Z))512
Triacylglycerol Degradation TG(20:0/18:1(9Z)/22:0)513
Triacylglycerol Degradation TG(20:0/18:1(9Z)/22:1(13Z))513
Triacylglycerol Degradation TG(20:0/18:1(11Z)/16:0)512
Triacylglycerol Degradation TG(20:0/18:1(11Z)/18:0)512
Triacylglycerol Degradation TG(20:0/18:1(11Z)/18:1(9Z))513
Triacylglycerol Degradation TG(20:0/18:1(11Z)/18:1(11Z))512
Triacylglycerol Degradation TG(20:0/18:1(11Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(20:0/18:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:0/18:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:0/18:1(11Z)/20:0)512
Triacylglycerol Degradation TG(20:0/18:1(11Z)/20:1(11Z))513
Triacylglycerol Degradation TG(20:0/18:1(11Z)/20:1(13Z))512
Triacylglycerol Degradation TG(20:0/18:1(11Z)/22:0)513
Triacylglycerol Degradation TG(20:0/18:1(11Z)/22:1(13Z))513
Triacylglycerol Degradation TG(20:0/18:2(9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(20:0/18:2(9Z,12Z)/18:0)512
Triacylglycerol Degradation TG(20:0/18:2(9Z,12Z)/18:1(9Z))513
Triacylglycerol Degradation TG(20:0/18:2(9Z,12Z)/18:1(11Z))513
Triacylglycerol Degradation TG(20:0/18:2(9Z,12Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(20:0/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:0/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:0/18:2(9Z,12Z)/20:0)512
Triacylglycerol Degradation TG(20:0/18:2(9Z,12Z)/20:1(11Z))513
Triacylglycerol Degradation TG(20:0/18:2(9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(20:0/18:2(9Z,12Z)/22:0)513
Triacylglycerol Degradation TG(20:0/18:2(9Z,12Z)/22:1(13Z))513
Triacylglycerol Degradation TG(20:0/18:3(6Z,9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(20:0/18:3(6Z,9Z,12Z)/18:0)512
Triacylglycerol Degradation TG(20:0/18:3(6Z,9Z,12Z)/18:1(9Z))513
Triacylglycerol Degradation TG(20:0/18:3(6Z,9Z,12Z)/18:1(11Z))513
Triacylglycerol Degradation TG(20:0/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(20:0/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(20:0/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:0/18:3(6Z,9Z,12Z)/20:0)512
Triacylglycerol Degradation TG(20:0/18:3(6Z,9Z,12Z)/20:1(11Z))513
Triacylglycerol Degradation TG(20:0/18:3(6Z,9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(20:0/18:3(6Z,9Z,12Z)/22:0)513
Triacylglycerol Degradation TG(20:0/18:3(6Z,9Z,12Z)/22:1(13Z))513
Triacylglycerol Degradation TG(20:0/18:3(9Z,12Z,15Z)/16:0)512
Triacylglycerol Degradation TG(20:0/18:3(9Z,12Z,15Z)/18:0)512
Triacylglycerol Degradation TG(20:0/18:3(9Z,12Z,15Z)/18:1(9Z))513
Triacylglycerol Degradation TG(20:0/18:3(9Z,12Z,15Z)/18:1(11Z))513
Triacylglycerol Degradation TG(20:0/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(20:0/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:0/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(20:0/18:3(9Z,12Z,15Z)/20:0)512
Triacylglycerol Degradation TG(20:0/18:3(9Z,12Z,15Z)/20:1(11Z))513
Triacylglycerol Degradation TG(20:0/18:3(9Z,12Z,15Z)/20:1(13Z))512
Triacylglycerol Degradation TG(20:0/18:3(9Z,12Z,15Z)/22:0)513
Triacylglycerol Degradation TG(20:0/18:3(9Z,12Z,15Z)/22:1(13Z))513
Triacylglycerol Degradation TG(20:0/20:0/16:0)511
Triacylglycerol Degradation TG(20:0/20:0/18:0)511
Triacylglycerol Degradation TG(20:0/20:0/18:1(9Z))512
Triacylglycerol Degradation TG(20:0/20:0/18:1(11Z))512
Triacylglycerol Degradation TG(20:0/20:0/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(20:0/20:0/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(20:0/20:0/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(20:0/20:0/20:0)511
Triacylglycerol Degradation TG(20:0/20:0/20:1(11Z))512
Triacylglycerol Degradation TG(20:0/20:0/20:1(13Z))511
Triacylglycerol Degradation TG(20:0/20:0/22:0)512
Triacylglycerol Degradation TG(20:0/20:0/22:1(13Z))512
Triacylglycerol Degradation TG(20:0/20:1(11Z)/16:0)512
Triacylglycerol Degradation TG(20:0/20:1(11Z)/18:0)512
Triacylglycerol Degradation TG(20:0/20:1(11Z)/18:1(9Z))513
Triacylglycerol Degradation TG(20:0/20:1(11Z)/18:1(11Z))513
Triacylglycerol Degradation TG(20:0/20:1(11Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(20:0/20:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:0/20:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:0/20:1(11Z)/20:0)512
Triacylglycerol Degradation TG(20:0/20:1(11Z)/20:1(11Z))512
Triacylglycerol Degradation TG(20:0/20:1(11Z)/20:1(13Z))512
Triacylglycerol Degradation TG(20:0/20:1(11Z)/22:0)513
Triacylglycerol Degradation TG(20:0/20:1(11Z)/22:1(13Z))513
Triacylglycerol Degradation TG(20:0/20:1(13Z)/16:0)59
Triacylglycerol Degradation TG(20:0/20:1(13Z)/18:0)59
Triacylglycerol Degradation TG(20:0/20:1(13Z)/18:1(9Z))59
Triacylglycerol Degradation TG(20:0/20:1(13Z)/18:1(11Z))59
Triacylglycerol Degradation TG(20:0/20:1(13Z)/18:2(9Z,12Z))59
Triacylglycerol Degradation TG(20:0/20:1(13Z)/18:3(6Z,9Z,12Z))59
Triacylglycerol Degradation TG(20:0/20:1(13Z)/18:3(9Z,12Z,15Z))59
Triacylglycerol Degradation TG(20:0/20:1(13Z)/20:0)58
Triacylglycerol Degradation TG(20:0/20:1(13Z)/20:1(11Z))59
Triacylglycerol Degradation TG(20:0/20:1(13Z)/20:1(13Z))58
Triacylglycerol Degradation TG(20:0/20:1(13Z)/22:0)59
Triacylglycerol Degradation TG(20:0/20:1(13Z)/22:1(13Z))59
Triacylglycerol Degradation TG(20:0/22:0/16:0)513
Triacylglycerol Degradation TG(20:0/22:0/18:0)513
Triacylglycerol Degradation TG(20:0/22:0/18:1(9Z))513
Triacylglycerol Degradation TG(20:0/22:0/18:1(11Z))513
Triacylglycerol Degradation TG(20:0/22:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(20:0/22:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:0/22:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:0/22:0/20:0)512
Triacylglycerol Degradation TG(20:0/22:0/20:1(11Z))513
Triacylglycerol Degradation TG(20:0/22:0/20:1(13Z))512
Triacylglycerol Degradation TG(20:0/22:0/22:0)512
Triacylglycerol Degradation TG(20:0/22:0/22:1(13Z))513
Triacylglycerol Degradation TG(20:0/22:1(13Z)/16:0)512
Triacylglycerol Degradation TG(20:0/22:1(13Z)/18:0)512
Triacylglycerol Degradation TG(20:0/22:1(13Z)/18:1(9Z))513
Triacylglycerol Degradation TG(20:0/22:1(13Z)/18:1(11Z))513
Triacylglycerol Degradation TG(20:0/22:1(13Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(20:0/22:1(13Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:0/22:1(13Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:0/22:1(13Z)/20:0)512
Triacylglycerol Degradation TG(20:0/22:1(13Z)/20:1(11Z))513
Triacylglycerol Degradation TG(20:0/22:1(13Z)/20:1(13Z))512
Triacylglycerol Degradation TG(20:0/22:1(13Z)/22:0)513
Triacylglycerol Degradation TG(20:0/22:1(13Z)/22:1(13Z))512
Triacylglycerol Degradation TG(20:1(11Z)/16:0/16:0)511
Triacylglycerol Degradation TG(20:1(11Z)/16:0/18:0)512
Triacylglycerol Degradation TG(20:1(11Z)/16:0/18:1(9Z))512
Triacylglycerol Degradation TG(20:1(11Z)/16:0/18:1(11Z))512
Triacylglycerol Degradation TG(20:1(11Z)/16:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/16:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/16:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:1(11Z)/16:0/20:0)512
Triacylglycerol Degradation TG(20:1(11Z)/16:0/20:1(11Z))512
Triacylglycerol Degradation TG(20:1(11Z)/16:0/20:1(13Z))512
Triacylglycerol Degradation TG(20:1(11Z)/16:0/22:0)512
Triacylglycerol Degradation TG(20:1(11Z)/16:0/22:1(13Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:0/16:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:0/18:0)511
Triacylglycerol Degradation TG(20:1(11Z)/18:0/18:1(9Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:0/18:1(11Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:0/20:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:0/20:1(11Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:0/20:1(13Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:0/22:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:0/22:1(13Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:1(9Z)/16:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:1(9Z)/18:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:1(9Z)/18:1(9Z))511
Triacylglycerol Degradation TG(20:1(11Z)/18:1(9Z)/18:1(11Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:1(9Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:1(9Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:1(9Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:1(9Z)/20:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:1(9Z)/20:1(11Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:1(9Z)/20:1(13Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:1(9Z)/22:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:1(9Z)/22:1(13Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:1(11Z)/16:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:1(11Z)/18:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:1(11Z)/18:1(9Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:1(11Z)/18:1(11Z))511
Triacylglycerol Degradation TG(20:1(11Z)/18:1(11Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:1(11Z)/20:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:1(11Z)/20:1(11Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:1(11Z)/20:1(13Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:1(11Z)/22:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:1(11Z)/22:1(13Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:2(9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:2(9Z,12Z)/18:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:2(9Z,12Z)/18:1(9Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:2(9Z,12Z)/18:1(11Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:2(9Z,12Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:2(9Z,12Z)/20:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:2(9Z,12Z)/20:1(11Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:2(9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:2(9Z,12Z)/22:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:2(9Z,12Z)/22:1(13Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:3(6Z,9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(6Z,9Z,12Z)/18:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(6Z,9Z,12Z)/18:1(9Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(6Z,9Z,12Z)/18:1(11Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:3(6Z,9Z,12Z)/20:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(6Z,9Z,12Z)/20:1(11Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(6Z,9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(6Z,9Z,12Z)/22:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(6Z,9Z,12Z)/22:1(13Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:3(9Z,12Z,15Z)/16:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(9Z,12Z,15Z)/18:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(9Z,12Z,15Z)/18:1(9Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(9Z,12Z,15Z)/18:1(11Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(9Z,12Z,15Z)/20:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(9Z,12Z,15Z)/20:1(11Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(9Z,12Z,15Z)/20:1(13Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(9Z,12Z,15Z)/22:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(9Z,12Z,15Z)/22:1(13Z))513
Triacylglycerol Degradation TG(20:1(11Z)/20:0/16:0)512
Triacylglycerol Degradation TG(20:1(11Z)/20:0/18:0)512
Triacylglycerol Degradation TG(20:1(11Z)/20:0/18:1(9Z))512
Triacylglycerol Degradation TG(20:1(11Z)/20:0/18:1(11Z))512
Triacylglycerol Degradation TG(20:1(11Z)/20:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/20:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/20:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:1(11Z)/20:0/20:0)511
Triacylglycerol Degradation TG(20:1(11Z)/20:0/20:1(11Z))512
Triacylglycerol Degradation TG(20:1(11Z)/20:0/20:1(13Z))512
Triacylglycerol Degradation TG(20:1(11Z)/20:0/22:0)512
Triacylglycerol Degradation TG(20:1(11Z)/20:0/22:1(13Z))513
Triacylglycerol Degradation TG(20:1(11Z)/20:1(11Z)/16:0)511
Triacylglycerol Degradation TG(20:1(11Z)/20:1(11Z)/18:0)511
Triacylglycerol Degradation TG(20:1(11Z)/20:1(11Z)/18:1(9Z))511
Triacylglycerol Degradation TG(20:1(11Z)/20:1(11Z)/18:1(11Z))511
Triacylglycerol Degradation TG(20:1(11Z)/20:1(11Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(20:1(11Z)/20:1(11Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(20:1(11Z)/20:1(11Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(20:1(11Z)/20:1(11Z)/20:0)511
Triacylglycerol Degradation TG(20:1(11Z)/20:1(11Z)/20:1(11Z))511
Triacylglycerol Degradation TG(20:1(11Z)/20:1(11Z)/20:1(13Z))511
Triacylglycerol Degradation TG(20:1(11Z)/20:1(11Z)/22:0)511
Triacylglycerol Degradation TG(20:1(11Z)/20:1(11Z)/22:1(13Z))512
Triacylglycerol Degradation TG(20:1(11Z)/20:1(13Z)/16:0)59
Triacylglycerol Degradation TG(20:1(11Z)/20:1(13Z)/18:0)59
Triacylglycerol Degradation TG(20:1(11Z)/20:1(13Z)/18:1(9Z))59
Triacylglycerol Degradation TG(20:1(11Z)/20:1(13Z)/18:1(11Z))59
Triacylglycerol Degradation TG(20:1(11Z)/20:1(13Z)/18:2(9Z,12Z))59
Triacylglycerol Degradation TG(20:1(11Z)/20:1(13Z)/18:3(6Z,9Z,12Z))59
Triacylglycerol Degradation TG(20:1(11Z)/20:1(13Z)/18:3(9Z,12Z,15Z))59
Triacylglycerol Degradation TG(20:1(11Z)/20:1(13Z)/20:0)59
Triacylglycerol Degradation TG(20:1(11Z)/20:1(13Z)/20:1(11Z))58
Triacylglycerol Degradation TG(20:1(11Z)/20:1(13Z)/20:1(13Z))58
Triacylglycerol Degradation TG(20:1(11Z)/20:1(13Z)/22:0)59
Triacylglycerol Degradation TG(20:1(11Z)/20:1(13Z)/22:1(13Z))59
Triacylglycerol Degradation TG(20:1(11Z)/22:0/16:0)512
Triacylglycerol Degradation TG(20:1(11Z)/22:0/18:0)512
Triacylglycerol Degradation TG(20:1(11Z)/22:0/18:1(9Z))512
Triacylglycerol Degradation TG(20:1(11Z)/22:0/18:1(11Z))512
Triacylglycerol Degradation TG(20:1(11Z)/22:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/22:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/22:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:1(11Z)/22:0/20:0)512
Triacylglycerol Degradation TG(20:1(11Z)/22:0/20:1(11Z))512
Triacylglycerol Degradation TG(20:1(11Z)/22:0/20:1(13Z))512
Triacylglycerol Degradation TG(20:1(11Z)/22:0/22:0)511
Triacylglycerol Degradation TG(20:1(11Z)/22:0/22:1(13Z))513
Triacylglycerol Degradation TG(20:1(11Z)/22:1(13Z)/16:0)512
Triacylglycerol Degradation TG(20:1(11Z)/22:1(13Z)/18:0)512
Triacylglycerol Degradation TG(20:1(11Z)/22:1(13Z)/18:1(9Z))512
Triacylglycerol Degradation TG(20:1(11Z)/22:1(13Z)/18:1(11Z))512
Triacylglycerol Degradation TG(20:1(11Z)/22:1(13Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/22:1(13Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/22:1(13Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:1(11Z)/22:1(13Z)/20:0)512
Triacylglycerol Degradation TG(20:1(11Z)/22:1(13Z)/20:1(11Z))512
Triacylglycerol Degradation TG(20:1(11Z)/22:1(13Z)/20:1(13Z))512
Triacylglycerol Degradation TG(20:1(11Z)/22:1(13Z)/22:0)512
Triacylglycerol Degradation TG(20:1(11Z)/22:1(13Z)/22:1(13Z))512
Triacylglycerol Degradation TG(20:1(13Z)/16:0/16:0)510
Triacylglycerol Degradation TG(20:1(13Z)/16:0/18:0)511
Triacylglycerol Degradation TG(20:1(13Z)/16:0/18:1(9Z))511
Triacylglycerol Degradation TG(20:1(13Z)/16:0/18:1(11Z))511
Triacylglycerol Degradation TG(20:1(13Z)/16:0/18:2(9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/16:0/18:3(6Z,9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/16:0/18:3(9Z,12Z,15Z))511
Triacylglycerol Degradation TG(20:1(13Z)/16:0/20:0)511
Triacylglycerol Degradation TG(20:1(13Z)/16:0/20:1(11Z))511
Triacylglycerol Degradation TG(20:1(13Z)/16:0/20:1(13Z))510
Triacylglycerol Degradation TG(20:1(13Z)/16:0/22:0)511
Triacylglycerol Degradation TG(20:1(13Z)/16:0/22:1(13Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:0/16:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:0/18:0)510
Triacylglycerol Degradation TG(20:1(13Z)/18:0/18:1(9Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:0/18:1(11Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:0/18:2(9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:0/18:3(6Z,9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:0/18:3(9Z,12Z,15Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:0/20:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:0/20:1(11Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:0/20:1(13Z))510
Triacylglycerol Degradation TG(20:1(13Z)/18:0/22:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:0/22:1(13Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(9Z)/16:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(9Z)/18:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(9Z)/18:1(9Z))510
Triacylglycerol Degradation TG(20:1(13Z)/18:1(9Z)/18:1(11Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(9Z)/18:2(9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(9Z)/18:3(6Z,9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(9Z)/18:3(9Z,12Z,15Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(9Z)/20:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(9Z)/20:1(11Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(9Z)/20:1(13Z))510
Triacylglycerol Degradation TG(20:1(13Z)/18:1(9Z)/22:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(9Z)/22:1(13Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(11Z)/16:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(11Z)/18:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(11Z)/18:1(9Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(11Z)/18:1(11Z))510
Triacylglycerol Degradation TG(20:1(13Z)/18:1(11Z)/18:2(9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(11Z)/18:3(6Z,9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(11Z)/18:3(9Z,12Z,15Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(11Z)/20:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(11Z)/20:1(11Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(11Z)/20:1(13Z))510
Triacylglycerol Degradation TG(20:1(13Z)/18:1(11Z)/22:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(11Z)/22:1(13Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:2(9Z,12Z)/16:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:2(9Z,12Z)/18:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:2(9Z,12Z)/18:1(9Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:2(9Z,12Z)/18:1(11Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:2(9Z,12Z)/18:2(9Z,12Z))510
Triacylglycerol Degradation TG(20:1(13Z)/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:2(9Z,12Z)/20:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:2(9Z,12Z)/20:1(11Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:2(9Z,12Z)/20:1(13Z))510
Triacylglycerol Degradation TG(20:1(13Z)/18:2(9Z,12Z)/22:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:2(9Z,12Z)/22:1(13Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(6Z,9Z,12Z)/16:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(6Z,9Z,12Z)/18:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(6Z,9Z,12Z)/18:1(9Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(6Z,9Z,12Z)/18:1(11Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))510
Triacylglycerol Degradation TG(20:1(13Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(6Z,9Z,12Z)/20:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(6Z,9Z,12Z)/20:1(11Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(6Z,9Z,12Z)/20:1(13Z))510
Triacylglycerol Degradation TG(20:1(13Z)/18:3(6Z,9Z,12Z)/22:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(6Z,9Z,12Z)/22:1(13Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(9Z,12Z,15Z)/16:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(9Z,12Z,15Z)/18:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(9Z,12Z,15Z)/18:1(9Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(9Z,12Z,15Z)/18:1(11Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))510
Triacylglycerol Degradation TG(20:1(13Z)/18:3(9Z,12Z,15Z)/20:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(9Z,12Z,15Z)/20:1(11Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(9Z,12Z,15Z)/20:1(13Z))510
Triacylglycerol Degradation TG(20:1(13Z)/18:3(9Z,12Z,15Z)/22:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(9Z,12Z,15Z)/22:1(13Z))511
Triacylglycerol Degradation TG(20:1(13Z)/20:0/16:0)511
Triacylglycerol Degradation TG(20:1(13Z)/20:0/18:0)511
Triacylglycerol Degradation TG(20:1(13Z)/20:0/18:1(9Z))511
Triacylglycerol Degradation TG(20:1(13Z)/20:0/18:1(11Z))511
Triacylglycerol Degradation TG(20:1(13Z)/20:0/18:2(9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/20:0/18:3(6Z,9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/20:0/18:3(9Z,12Z,15Z))511
Triacylglycerol Degradation TG(20:1(13Z)/20:0/20:0)510
Triacylglycerol Degradation TG(20:1(13Z)/20:0/20:1(11Z))511
Triacylglycerol Degradation TG(20:1(13Z)/20:0/20:1(13Z))510
Triacylglycerol Degradation TG(20:1(13Z)/20:0/22:0)511
Triacylglycerol Degradation TG(20:1(13Z)/20:0/22:1(13Z))511
Triacylglycerol Degradation TG(20:1(13Z)/20:1(11Z)/16:0)511
Triacylglycerol Degradation TG(20:1(13Z)/20:1(11Z)/18:0)511
Triacylglycerol Degradation TG(20:1(13Z)/20:1(11Z)/18:1(9Z))511
Triacylglycerol Degradation TG(20:1(13Z)/20:1(11Z)/18:1(11Z))511
Triacylglycerol Degradation TG(20:1(13Z)/20:1(11Z)/18:2(9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/20:1(11Z)/18:3(6Z,9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/20:1(11Z)/18:3(9Z,12Z,15Z))511
Triacylglycerol Degradation TG(20:1(13Z)/20:1(11Z)/20:0)511
Triacylglycerol Degradation TG(20:1(13Z)/20:1(11Z)/20:1(11Z))510
Triacylglycerol Degradation TG(20:1(13Z)/20:1(11Z)/20:1(13Z))510
Triacylglycerol Degradation TG(20:1(13Z)/20:1(11Z)/22:0)511
Triacylglycerol Degradation TG(20:1(13Z)/20:1(11Z)/22:1(13Z))511
Triacylglycerol Degradation TG(20:1(13Z)/20:1(13Z)/16:0)58
Triacylglycerol Degradation TG(20:1(13Z)/20:1(13Z)/18:0)58
Triacylglycerol Degradation TG(20:1(13Z)/20:1(13Z)/18:1(9Z))58
Triacylglycerol Degradation TG(20:1(13Z)/20:1(13Z)/18:1(11Z))58
Triacylglycerol Degradation TG(20:1(13Z)/20:1(13Z)/18:2(9Z,12Z))58
Triacylglycerol Degradation TG(20:1(13Z)/20:1(13Z)/18:3(6Z,9Z,12Z))58
Triacylglycerol Degradation TG(20:1(13Z)/20:1(13Z)/18:3(9Z,12Z,15Z))58
Triacylglycerol Degradation TG(20:1(13Z)/20:1(13Z)/20:0)58
Triacylglycerol Degradation TG(20:1(13Z)/20:1(13Z)/20:1(11Z))58
Triacylglycerol Degradation TG(20:1(13Z)/20:1(13Z)/20:1(13Z))57
Triacylglycerol Degradation TG(20:1(13Z)/20:1(13Z)/22:0)58
Triacylglycerol Degradation TG(20:1(13Z)/20:1(13Z)/22:1(13Z))58
Triacylglycerol Degradation TG(20:1(13Z)/22:0/16:0)511
Triacylglycerol Degradation TG(20:1(13Z)/22:0/18:0)511
Triacylglycerol Degradation TG(20:1(13Z)/22:0/18:1(9Z))511
Triacylglycerol Degradation TG(20:1(13Z)/22:0/18:1(11Z))511
Triacylglycerol Degradation TG(20:1(13Z)/22:0/18:2(9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/22:0/18:3(6Z,9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/22:0/18:3(9Z,12Z,15Z))511
Triacylglycerol Degradation TG(20:1(13Z)/22:0/20:0)511
Triacylglycerol Degradation TG(20:1(13Z)/22:0/20:1(11Z))511
Triacylglycerol Degradation TG(20:1(13Z)/22:0/20:1(13Z))510
Triacylglycerol Degradation TG(20:1(13Z)/22:0/22:0)510
Triacylglycerol Degradation TG(20:1(13Z)/22:0/22:1(13Z))511
Triacylglycerol Degradation TG(20:1(13Z)/22:1(13Z)/16:0)511
Triacylglycerol Degradation TG(20:1(13Z)/22:1(13Z)/18:0)511
Triacylglycerol Degradation TG(20:1(13Z)/22:1(13Z)/18:1(9Z))511
Triacylglycerol Degradation TG(20:1(13Z)/22:1(13Z)/18:1(11Z))511
Triacylglycerol Degradation TG(20:1(13Z)/22:1(13Z)/18:2(9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/22:1(13Z)/18:3(6Z,9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/22:1(13Z)/18:3(9Z,12Z,15Z))511
Triacylglycerol Degradation TG(20:1(13Z)/22:1(13Z)/20:0)511
Triacylglycerol Degradation TG(20:1(13Z)/22:1(13Z)/20:1(11Z))511
Triacylglycerol Degradation TG(20:1(13Z)/22:1(13Z)/20:1(13Z))510
Triacylglycerol Degradation TG(20:1(13Z)/22:1(13Z)/22:0)511
Triacylglycerol Degradation TG(20:1(13Z)/22:1(13Z)/22:1(13Z))510
Triacylglycerol Degradation TG(22:0/16:0/16:0)512
Triacylglycerol Degradation TG(22:0/16:0/18:0)513
Triacylglycerol Degradation TG(22:0/16:0/18:1(9Z))513
Triacylglycerol Degradation TG(22:0/16:0/18:1(11Z))513
Triacylglycerol Degradation TG(22:0/16:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(22:0/16:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:0/16:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:0/16:0/20:0)513
Triacylglycerol Degradation TG(22:0/16:0/20:1(11Z))513
Triacylglycerol Degradation TG(22:0/16:0/20:1(13Z))512
Triacylglycerol Degradation TG(22:0/16:0/22:0)512
Triacylglycerol Degradation TG(22:0/16:0/22:1(13Z))513
Triacylglycerol Degradation TG(22:0/18:0/16:0)513
Triacylglycerol Degradation TG(22:0/18:0/18:0)512
Triacylglycerol Degradation TG(22:0/18:0/18:1(9Z))513
Triacylglycerol Degradation TG(22:0/18:0/18:1(11Z))513
Triacylglycerol Degradation TG(22:0/18:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(22:0/18:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:0/18:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:0/18:0/20:0)513
Triacylglycerol Degradation TG(22:0/18:0/20:1(11Z))513
Triacylglycerol Degradation TG(22:0/18:0/20:1(13Z))512
Triacylglycerol Degradation TG(22:0/18:0/22:0)512
Triacylglycerol Degradation TG(22:0/18:0/22:1(13Z))513
Triacylglycerol Degradation TG(22:0/18:1(9Z)/16:0)512
Triacylglycerol Degradation TG(22:0/18:1(9Z)/18:0)512
Triacylglycerol Degradation TG(22:0/18:1(9Z)/18:1(9Z))512
Triacylglycerol Degradation TG(22:0/18:1(9Z)/18:1(11Z))513
Triacylglycerol Degradation TG(22:0/18:1(9Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(22:0/18:1(9Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:0/18:1(9Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:0/18:1(9Z)/20:0)512
Triacylglycerol Degradation TG(22:0/18:1(9Z)/20:1(11Z))513
Triacylglycerol Degradation TG(22:0/18:1(9Z)/20:1(13Z))512
Triacylglycerol Degradation TG(22:0/18:1(9Z)/22:0)512
Triacylglycerol Degradation TG(22:0/18:1(9Z)/22:1(13Z))513
Triacylglycerol Degradation TG(22:0/18:1(11Z)/16:0)512
Triacylglycerol Degradation TG(22:0/18:1(11Z)/18:0)512
Triacylglycerol Degradation TG(22:0/18:1(11Z)/18:1(9Z))513
Triacylglycerol Degradation TG(22:0/18:1(11Z)/18:1(11Z))512
Triacylglycerol Degradation TG(22:0/18:1(11Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(22:0/18:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:0/18:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:0/18:1(11Z)/20:0)512
Triacylglycerol Degradation TG(22:0/18:1(11Z)/20:1(11Z))513
Triacylglycerol Degradation TG(22:0/18:1(11Z)/20:1(13Z))512
Triacylglycerol Degradation TG(22:0/18:1(11Z)/22:0)512
Triacylglycerol Degradation TG(22:0/18:1(11Z)/22:1(13Z))513
Triacylglycerol Degradation TG(22:0/18:2(9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(22:0/18:2(9Z,12Z)/18:0)512
Triacylglycerol Degradation TG(22:0/18:2(9Z,12Z)/18:1(9Z))513
Triacylglycerol Degradation TG(22:0/18:2(9Z,12Z)/18:1(11Z))513
Triacylglycerol Degradation TG(22:0/18:2(9Z,12Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(22:0/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:0/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:0/18:2(9Z,12Z)/20:0)512
Triacylglycerol Degradation TG(22:0/18:2(9Z,12Z)/20:1(11Z))513
Triacylglycerol Degradation TG(22:0/18:2(9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(22:0/18:2(9Z,12Z)/22:0)512
Triacylglycerol Degradation TG(22:0/18:2(9Z,12Z)/22:1(13Z))513
Triacylglycerol Degradation TG(22:0/18:3(6Z,9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(22:0/18:3(6Z,9Z,12Z)/18:0)512
Triacylglycerol Degradation TG(22:0/18:3(6Z,9Z,12Z)/18:1(9Z))513
Triacylglycerol Degradation TG(22:0/18:3(6Z,9Z,12Z)/18:1(11Z))513
Triacylglycerol Degradation TG(22:0/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(22:0/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(22:0/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:0/18:3(6Z,9Z,12Z)/20:0)512
Triacylglycerol Degradation TG(22:0/18:3(6Z,9Z,12Z)/20:1(11Z))513
Triacylglycerol Degradation TG(22:0/18:3(6Z,9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(22:0/18:3(6Z,9Z,12Z)/22:0)512
Triacylglycerol Degradation TG(22:0/18:3(6Z,9Z,12Z)/22:1(13Z))513
Triacylglycerol Degradation TG(22:0/18:3(9Z,12Z,15Z)/16:0)512
Triacylglycerol Degradation TG(22:0/18:3(9Z,12Z,15Z)/18:0)512
Triacylglycerol Degradation TG(22:0/18:3(9Z,12Z,15Z)/18:1(9Z))513
Triacylglycerol Degradation TG(22:0/18:3(9Z,12Z,15Z)/18:1(11Z))513
Triacylglycerol Degradation TG(22:0/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(22:0/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:0/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(22:0/18:3(9Z,12Z,15Z)/20:0)512
Triacylglycerol Degradation TG(22:0/18:3(9Z,12Z,15Z)/20:1(11Z))513
Triacylglycerol Degradation TG(22:0/18:3(9Z,12Z,15Z)/20:1(13Z))512
Triacylglycerol Degradation TG(22:0/18:3(9Z,12Z,15Z)/22:0)512
Triacylglycerol Degradation TG(22:0/18:3(9Z,12Z,15Z)/22:1(13Z))513
Triacylglycerol Degradation TG(22:0/20:0/16:0)513
Triacylglycerol Degradation TG(22:0/20:0/18:0)513
Triacylglycerol Degradation TG(22:0/20:0/18:1(9Z))513
Triacylglycerol Degradation TG(22:0/20:0/18:1(11Z))513
Triacylglycerol Degradation TG(22:0/20:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(22:0/20:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:0/20:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:0/20:0/20:0)512
Triacylglycerol Degradation TG(22:0/20:0/20:1(11Z))513
Triacylglycerol Degradation TG(22:0/20:0/20:1(13Z))512
Triacylglycerol Degradation TG(22:0/20:0/22:0)512
Triacylglycerol Degradation TG(22:0/20:0/22:1(13Z))513
Triacylglycerol Degradation TG(22:0/20:1(11Z)/16:0)512
Triacylglycerol Degradation TG(22:0/20:1(11Z)/18:0)512
Triacylglycerol Degradation TG(22:0/20:1(11Z)/18:1(9Z))513
Triacylglycerol Degradation TG(22:0/20:1(11Z)/18:1(11Z))513
Triacylglycerol Degradation TG(22:0/20:1(11Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(22:0/20:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:0/20:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:0/20:1(11Z)/20:0)512
Triacylglycerol Degradation TG(22:0/20:1(11Z)/20:1(11Z))512
Triacylglycerol Degradation TG(22:0/20:1(11Z)/20:1(13Z))512
Triacylglycerol Degradation TG(22:0/20:1(11Z)/22:0)512
Triacylglycerol Degradation TG(22:0/20:1(11Z)/22:1(13Z))513
Triacylglycerol Degradation TG(22:0/20:1(13Z)/16:0)59
Triacylglycerol Degradation TG(22:0/20:1(13Z)/18:0)59
Triacylglycerol Degradation TG(22:0/20:1(13Z)/18:1(9Z))59
Triacylglycerol Degradation TG(22:0/20:1(13Z)/18:1(11Z))59
Triacylglycerol Degradation TG(22:0/20:1(13Z)/18:2(9Z,12Z))59
Triacylglycerol Degradation TG(22:0/20:1(13Z)/18:3(6Z,9Z,12Z))59
Triacylglycerol Degradation TG(22:0/20:1(13Z)/18:3(9Z,12Z,15Z))59
Triacylglycerol Degradation TG(22:0/20:1(13Z)/20:0)59
Triacylglycerol Degradation TG(22:0/20:1(13Z)/20:1(11Z))59
Triacylglycerol Degradation TG(22:0/20:1(13Z)/20:1(13Z))58
Triacylglycerol Degradation TG(22:0/20:1(13Z)/22:0)58
Triacylglycerol Degradation TG(22:0/20:1(13Z)/22:1(13Z))59
Triacylglycerol Degradation TG(22:0/22:0/16:0)512
Triacylglycerol Degradation TG(22:0/22:0/18:0)512
Triacylglycerol Degradation TG(22:0/22:0/18:1(9Z))512
Triacylglycerol Degradation TG(22:0/22:0/18:1(11Z))512
Triacylglycerol Degradation TG(22:0/22:0/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(22:0/22:0/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(22:0/22:0/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(22:0/22:0/20:0)512
Triacylglycerol Degradation TG(22:0/22:0/20:1(11Z))512
Triacylglycerol Degradation TG(22:0/22:0/20:1(13Z))511
Triacylglycerol Degradation TG(22:0/22:0/22:0)511
Triacylglycerol Degradation TG(22:0/22:0/22:1(13Z))512
Triacylglycerol Degradation TG(22:0/22:1(13Z)/16:0)512
Triacylglycerol Degradation TG(22:0/22:1(13Z)/18:0)512
Triacylglycerol Degradation TG(22:0/22:1(13Z)/18:1(9Z))513
Triacylglycerol Degradation TG(22:0/22:1(13Z)/18:1(11Z))513
Triacylglycerol Degradation TG(22:0/22:1(13Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(22:0/22:1(13Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:0/22:1(13Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:0/22:1(13Z)/20:0)512
Triacylglycerol Degradation TG(22:0/22:1(13Z)/20:1(11Z))513
Triacylglycerol Degradation TG(22:0/22:1(13Z)/20:1(13Z))512
Triacylglycerol Degradation TG(22:0/22:1(13Z)/22:0)512
Triacylglycerol Degradation TG(22:0/22:1(13Z)/22:1(13Z))512
Triacylglycerol Degradation TG(22:1(13Z)/16:0/16:0)511
Triacylglycerol Degradation TG(22:1(13Z)/16:0/18:0)512
Triacylglycerol Degradation TG(22:1(13Z)/16:0/18:1(9Z))512
Triacylglycerol Degradation TG(22:1(13Z)/16:0/18:1(11Z))512
Triacylglycerol Degradation TG(22:1(13Z)/16:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/16:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/16:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:1(13Z)/16:0/20:0)512
Triacylglycerol Degradation TG(22:1(13Z)/16:0/20:1(11Z))512
Triacylglycerol Degradation TG(22:1(13Z)/16:0/20:1(13Z))512
Triacylglycerol Degradation TG(22:1(13Z)/16:0/22:0)512
Triacylglycerol Degradation TG(22:1(13Z)/16:0/22:1(13Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:0/16:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:0/18:0)511
Triacylglycerol Degradation TG(22:1(13Z)/18:0/18:1(9Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:0/18:1(11Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:0/20:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:0/20:1(11Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:0/20:1(13Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:0/22:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:0/22:1(13Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:1(9Z)/16:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:1(9Z)/18:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:1(9Z)/18:1(9Z))511
Triacylglycerol Degradation TG(22:1(13Z)/18:1(9Z)/18:1(11Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:1(9Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:1(9Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:1(9Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:1(9Z)/20:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:1(9Z)/20:1(11Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:1(9Z)/22:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:1(9Z)/22:1(13Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:1(11Z)/16:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:1(11Z)/18:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:1(11Z)/18:1(9Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:1(11Z)/18:1(11Z))511
Triacylglycerol Degradation TG(22:1(13Z)/18:1(11Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:1(11Z)/20:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:1(11Z)/20:1(11Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:1(11Z)/20:1(13Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:1(11Z)/22:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:1(11Z)/22:1(13Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:2(9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:2(9Z,12Z)/18:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:2(9Z,12Z)/18:1(9Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:2(9Z,12Z)/18:1(11Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:2(9Z,12Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:2(9Z,12Z)/20:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:2(9Z,12Z)/20:1(11Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:2(9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:2(9Z,12Z)/22:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:2(9Z,12Z)/22:1(13Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(6Z,9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(6Z,9Z,12Z)/18:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(6Z,9Z,12Z)/18:1(9Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(6Z,9Z,12Z)/18:1(11Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:3(6Z,9Z,12Z)/20:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(6Z,9Z,12Z)/20:1(11Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(6Z,9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(6Z,9Z,12Z)/22:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(6Z,9Z,12Z)/22:1(13Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(9Z,12Z,15Z)/16:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(9Z,12Z,15Z)/18:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(9Z,12Z,15Z)/18:1(9Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(9Z,12Z,15Z)/18:1(11Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(9Z,12Z,15Z)/20:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(9Z,12Z,15Z)/20:1(11Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(9Z,12Z,15Z)/20:1(13Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(9Z,12Z,15Z)/22:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(9Z,12Z,15Z)/22:1(13Z))512
Triacylglycerol Degradation TG(22:1(13Z)/20:0/16:0)512
Triacylglycerol Degradation TG(22:1(13Z)/20:0/18:0)512
Triacylglycerol Degradation TG(22:1(13Z)/20:0/18:1(9Z))512
Triacylglycerol Degradation TG(22:1(13Z)/20:0/18:1(11Z))512
Triacylglycerol Degradation TG(22:1(13Z)/20:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/20:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/20:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:1(13Z)/20:0/20:0)511
Triacylglycerol Degradation TG(22:1(13Z)/20:0/20:1(11Z))512
Triacylglycerol Degradation TG(22:1(13Z)/20:0/20:1(13Z))512
Triacylglycerol Degradation TG(22:1(13Z)/20:0/22:0)512
Triacylglycerol Degradation TG(22:1(13Z)/20:0/22:1(13Z))512
Triacylglycerol Degradation TG(22:1(13Z)/20:1(11Z)/16:0)512
Triacylglycerol Degradation TG(22:1(13Z)/20:1(11Z)/18:0)512
Triacylglycerol Degradation TG(22:1(13Z)/20:1(11Z)/18:1(9Z))512
Triacylglycerol Degradation TG(22:1(13Z)/20:1(11Z)/18:1(11Z))512
Triacylglycerol Degradation TG(22:1(13Z)/20:1(11Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/20:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/20:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:1(13Z)/20:1(11Z)/20:0)512
Triacylglycerol Degradation TG(22:1(13Z)/20:1(11Z)/20:1(11Z))511
Triacylglycerol Degradation TG(22:1(13Z)/20:1(11Z)/20:1(13Z))512
Triacylglycerol Degradation TG(22:1(13Z)/20:1(11Z)/22:0)512
Triacylglycerol Degradation TG(22:1(13Z)/20:1(11Z)/22:1(13Z))512
Triacylglycerol Degradation TG(22:1(13Z)/20:1(13Z)/16:0)59
Triacylglycerol Degradation TG(22:1(13Z)/20:1(13Z)/18:0)59
Triacylglycerol Degradation TG(22:1(13Z)/20:1(13Z)/18:1(9Z))59
Triacylglycerol Degradation TG(22:1(13Z)/20:1(13Z)/18:1(11Z))59
Triacylglycerol Degradation TG(22:1(13Z)/20:1(13Z)/18:2(9Z,12Z))59
Triacylglycerol Degradation TG(22:1(13Z)/20:1(13Z)/18:3(6Z,9Z,12Z))59
Triacylglycerol Degradation TG(22:1(13Z)/20:1(13Z)/18:3(9Z,12Z,15Z))59
Triacylglycerol Degradation TG(22:1(13Z)/20:1(13Z)/20:0)59
Triacylglycerol Degradation TG(22:1(13Z)/20:1(13Z)/20:1(11Z))59
Triacylglycerol Degradation TG(22:1(13Z)/20:1(13Z)/20:1(13Z))58
Triacylglycerol Degradation TG(22:1(13Z)/20:1(13Z)/22:0)59
Triacylglycerol Degradation TG(22:1(13Z)/20:1(13Z)/22:1(13Z))58
Triacylglycerol Degradation TG(22:1(13Z)/22:0/16:0)512
Triacylglycerol Degradation TG(22:1(13Z)/22:0/18:0)512
Triacylglycerol Degradation TG(22:1(13Z)/22:0/18:1(9Z))512
Triacylglycerol Degradation TG(22:1(13Z)/22:0/18:1(11Z))512
Triacylglycerol Degradation TG(22:1(13Z)/22:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/22:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/22:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:1(13Z)/22:0/20:0)512
Triacylglycerol Degradation TG(22:1(13Z)/22:0/20:1(11Z))512
Triacylglycerol Degradation TG(22:1(13Z)/22:0/20:1(13Z))512
Triacylglycerol Degradation TG(22:1(13Z)/22:0/22:0)511
Triacylglycerol Degradation TG(22:1(13Z)/22:0/22:1(13Z))512
Triacylglycerol Degradation TG(22:1(13Z)/22:1(13Z)/16:0)511
Triacylglycerol Degradation TG(22:1(13Z)/22:1(13Z)/18:0)511
Triacylglycerol Degradation TG(22:1(13Z)/22:1(13Z)/18:1(9Z))511
Triacylglycerol Degradation TG(22:1(13Z)/22:1(13Z)/18:1(11Z))511
Triacylglycerol Degradation TG(22:1(13Z)/22:1(13Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(22:1(13Z)/22:1(13Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(22:1(13Z)/22:1(13Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(22:1(13Z)/22:1(13Z)/20:0)511
Triacylglycerol Degradation TG(22:1(13Z)/22:1(13Z)/20:1(11Z))511
Triacylglycerol Degradation TG(22:1(13Z)/22:1(13Z)/20:1(13Z))511
Triacylglycerol Degradation TG(22:1(13Z)/22:1(13Z)/22:0)511
Triacylglycerol Degradation TG(22:1(13Z)/22:1(13Z)/22:1(13Z))511
Triacylglycerol Degradation TG(22:1(13Z)/18:1(9Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(11Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))512
monoacylglycerol metabolism (yeast)012
glycerol degradation I17
triacylglycerol degradation95
Thyroid hormones production and peripheral downstream signaling effects2216
Phospholipid Biosynthesis CL(18:2(9Z,12Z)/18:2(9Z,12Z)/18:2(9Z,12Z)/18:2(9Z,12Z))324
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/18:1(9Z)/19:0cycw7)321
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/18:1(9Z)/18:1(9Z))323
Phospholipid Biosynthesis CL(14:0/15:0cycw5/14:0/17:0cycw7)316
Phospholipid Biosynthesis CL(14:0/15:0cycw5/17:0cycw7/14:0)316
Phospholipid Biosynthesis CL(14:0/16:0/14:0/14:0)321
Phospholipid Biosynthesis CL(14:0/16:0/14:0/16:0)320
Phospholipid Biosynthesis CL(14:0/16:0/14:0/19:0cycw7)320
Phospholipid Biosynthesis CL(14:0/16:0/16:1(9Z)/14:0)320
Phospholipid Biosynthesis CL(14:0/16:0/18:1(9Z)/14:0)320
Phospholipid Biosynthesis CL(14:0/16:0/19:0cycw7/14:0)320
Phospholipid Biosynthesis CL(14:0/16:1(9Z)/14:0/16:1(9Z))319
Phospholipid Biosynthesis CL(14:0/16:1(9Z)/14:0/18:1(9Z))319
Phospholipid Biosynthesis CL(14:0/16:1(9Z)/14:0/19:0cycw7)319
Phospholipid Biosynthesis CL(14:0/16:1(9Z)/18:1(9Z)/14:0)319
Phospholipid Biosynthesis CL(14:0/16:1(9Z)/19:0cycw7/14:0)319
Phospholipid Biosynthesis CL(14:0/18:1(9Z)/14:0/14:0)320
Phospholipid Biosynthesis CL(14:0/18:1(9Z)/14:0/17:0cycw7)319
Phospholipid Biosynthesis CL(14:0/18:1(9Z)/14:0/18:1(9Z))319
Phospholipid Biosynthesis CL(14:0/18:1(9Z)/14:0/19:0cycw7)319
Phospholipid Biosynthesis CL(14:0/18:1(9Z)/17:0cycw7/14:0)319
Phospholipid Biosynthesis CL(14:0/18:1(9Z)/19:0cycw7/14:0)319
Phospholipid Biosynthesis CL(14:0/19:0cycw7/14:0/17:0cycw7)316
Phospholipid Biosynthesis CL(14:0/19:0cycw7/14:0/19:0cycw7)316
Phospholipid Biosynthesis CL(14:0/19:0cycw7/17:0cycw7/14:0)316
Phospholipid Biosynthesis CL(15:0cycw5/14:0/14:0/17:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/14:0/16:1(9Z)/16:1(9Z))318
Phospholipid Biosynthesis CL(15:0cycw5/14:0/17:0cycw7/14:0)316
Phospholipid Biosynthesis CL(15:0cycw5/14:0/17:0cycw7/17:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/14:0/18:1(9Z)/18:1(9Z))318
Phospholipid Biosynthesis CL(15:0cycw5/14:0/19:0cycw7/19:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/14:0/16:0)316
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/14:0/16:1(9Z))315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/14:0/18:1(9Z))315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/14:0/19:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/16:0/16:1(9Z))317
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/15:0cycw5/18:1(9Z))315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/15:0cycw5/19:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/16:0/14:0)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/16:0/17:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/16:1(9Z)/16:1(9Z))317
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/16:0/18:1(9Z))318
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/16:0/19:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/16:1(9Z)/14:0)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/16:1(9Z)/16:0)317
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/16:1(9Z)/17:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/16:1(9Z)/18:1(9Z))317
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/16:1(9Z)/19:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/17:0cycw7/16:0)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/17:0cycw7/16:1(9Z))315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/17:0cycw7/17:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/17:0cycw7/18:1(9Z))315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/17:0cycw7/19:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/18:1(9Z)/14:0)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/18:1(9Z)/15:0cycw5)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/18:1(9Z)/16:1(9Z))317
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/18:1(9Z)/17:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/18:1(9Z)/18:1(9Z))317
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/18:1(9Z)/19:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/19:0cycw7/14:0)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/19:0cycw7/15:0cycw5)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/19:0cycw7/16:0)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/19:0cycw7/16:1(9Z))315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/19:0cycw7/17:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/19:0cycw7/18:1(9Z))315
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/19:0cycw7/19:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/16:0/14:0/15:0cycw5)316
Phospholipid Biosynthesis CL(15:0cycw5/16:0/15:0cycw5/14:0)316
Phospholipid Biosynthesis CL(15:0cycw5/16:0/15:0cycw5/16:1(9Z))316
Phospholipid Biosynthesis CL(15:0cycw5/16:0/15:0cycw5/17:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/16:0/15:0cycw5/18:1(9Z))316
Phospholipid Biosynthesis CL(15:0cycw5/16:0/15:0cycw5/19:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/16:0/16:0/16:0)319
Phospholipid Biosynthesis CL(15:0cycw5/16:0/17:0cycw7/15:0cycw5)316
Phospholipid Biosynthesis CL(15:0cycw5/16:0/16:0/16:1(9Z))318
Phospholipid Biosynthesis CL(15:0cycw5/16:0/16:0/17:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/16:0/16:0/18:1(9Z))319
Phospholipid Biosynthesis CL(15:0cycw5/16:0/16:0/19:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/16:0/16:1(9Z)/16:0)318
Phospholipid Biosynthesis CL(15:0cycw5/16:0/16:1(9Z)/15:0cycw5)316
Phospholipid Biosynthesis CL(15:0cycw5/16:0/16:1(9Z)/16:1(9Z))318
Phospholipid Biosynthesis CL(15:0cycw5/16:0/17:0cycw7/16:0)316
Phospholipid Biosynthesis CL(15:0cycw5/16:0/17:0cycw7/17:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/16:0/18:1(9Z)/15:0cycw5)316
Phospholipid Biosynthesis CL(15:0cycw5/16:0/18:1(9Z)/16:0)319
Phospholipid Biosynthesis CL(15:0cycw5/16:0/18:1(9Z)/18:1(9Z))318
Phospholipid Biosynthesis CL(15:0cycw5/16:0/19:0cycw7/15:0cycw5)316
Phospholipid Biosynthesis CL(15:0cycw5/16:0/19:0cycw7/16:0)316
Phospholipid Biosynthesis CL(15:0cycw5/16:0/19:0cycw7/19:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/14:0/15:0cycw5)316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/14:0/16:1(9Z))316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/15:0cycw5/14:0)316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/15:0cycw5/16:1(9Z))316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/15:0cycw5/17:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/15:0cycw5/18:1(9Z))316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/15:0cycw5/19:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/16:0/16:0)319
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/16:0/16:1(9Z))318
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/16:1(9Z)/14:0)316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/16:1(9Z)/15:0cycw5)316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/16:1(9Z)/16:0)318
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/16:1(9Z)/16:1(9Z))318
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/16:1(9Z)/17:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/16:1(9Z)/18:1(9Z))318
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/16:1(9Z)/19:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/17:0cycw7/15:0cycw5)316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/17:0cycw7/16:1(9Z))316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/17:0cycw7/17:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/18:1(9Z)/15:0cycw5)316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/18:1(9Z)/16:1(9Z))318
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/18:1(9Z)/18:1(9Z))318
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/19:0cycw7/15:0cycw5)316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/19:0cycw7/16:1(9Z))316
Phospholipid Biosynthesis CL(15:0cycw5/16:1(9Z)/19:0cycw7/19:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/14:0/14:0)316
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/14:0/17:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/15:0cycw5/17:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/16:0/16:0)318
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/16:0/17:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/16:1(9Z)/16:1(9Z))317
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/16:1(9Z)/17:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/17:0cycw7/14:0)315
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/17:0cycw7/15:0cycw5)315
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/17:0cycw7/16:0)315
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/17:0cycw7/16:1(9Z))315
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/17:0cycw7/17:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/17:0cycw7/18:1(9Z))315
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/17:0cycw7/19:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/18:1(9Z)/17:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/18:1(9Z)/18:1(9Z))317
Phospholipid Biosynthesis CL(15:0cycw5/17:0cycw7/19:0cycw7/17:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/14:0/15:0cycw5)316
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/14:0/18:1(9Z))316
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/15:0cycw5/14:0)316
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/15:0cycw5/17:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/15:0cycw5/18:1(9Z))316
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/15:0cycw5/19:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/16:0/16:0)319
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/16:0/18:1(9Z))319
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/16:1(9Z)/16:1(9Z))318
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/16:1(9Z)/18:1(9Z))318
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/17:0cycw7/15:0cycw5)316
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/17:0cycw7/17:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/17:0cycw7/18:1(9Z))316
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/18:1(9Z)/14:0)316
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/18:1(9Z)/15:0cycw5)316
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/18:1(9Z)/16:0)319
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/18:1(9Z)/16:1(9Z))318
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/18:1(9Z)/17:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/18:1(9Z)/18:1(9Z))318
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/18:1(9Z)/19:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/19:0cycw7/15:0cycw5)316
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/19:0cycw7/18:1(9Z))316
Phospholipid Biosynthesis CL(15:0cycw5/18:1(9Z)/19:0cycw7/19:0cycw7)316
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/14:0/15:0cycw5)315
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/14:0/19:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/15:0cycw5/14:0)315
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/19:0cycw7/15:0cycw5)321
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/15:0cycw5/17:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/15:0cycw5/19:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/16:0/16:0)318
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/16:0/19:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/16:1(9Z)/16:1(9Z))317
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/16:1(9Z)/19:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/17:0cycw7/15:0cycw5)315
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/19:0cycw7/16:0)321
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/17:0cycw7/17:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/18:1(9Z)/18:1(9Z))317
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/18:1(9Z)/19:0cycw7)315
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/19:0cycw7/14:0)315
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/19:0cycw7/15:0cycw5)315
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/19:0cycw7/16:0)315
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/19:0cycw7/16:1(9Z))315
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/19:0cycw7/18:1(9Z))315
Phospholipid Biosynthesis CL(15:0cycw5/19:0cycw7/19:0cycw7/19:0cycw7)315
Phospholipid Biosynthesis CL(16:0/14:0/14:0/14:0)322
Phospholipid Biosynthesis CL(16:0/14:0/14:0/16:0)322
Phospholipid Biosynthesis CL(16:0/14:0/14:0/16:1(9Z))321
Phospholipid Biosynthesis CL(16:0/14:0/14:0/18:1(9Z))321
Phospholipid Biosynthesis CL(16:0/14:0/14:0/19:0cycw7)321
Phospholipid Biosynthesis CL(16:0/14:0/16:0/14:0)321
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/19:0cycw7/17:0cycw7)321
Phospholipid Biosynthesis CL(18:1(9Z)/19:0cycw7/14:0/14:0)318
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/19:0cycw7/16:1(9Z))321
Phospholipid Biosynthesis CL(16:0/14:0/16:1(9Z)/14:0)321
Phospholipid Biosynthesis CL(16:0/14:0/16:1(9Z)/16:1(9Z))323
Phospholipid Biosynthesis CL(16:0/14:0/17:0cycw7/17:0cycw7)321
Phospholipid Biosynthesis CL(16:0/14:0/18:1(9Z)/14:0)321
Phospholipid Biosynthesis CL(16:0/14:0/18:1(9Z)/18:1(9Z))323
Phospholipid Biosynthesis CL(16:0/14:0/19:0cycw7/14:0)321
Phospholipid Biosynthesis CL(16:0/14:0/19:0cycw7/19:0cycw7)321
Phospholipid Biosynthesis CL(16:0/15:0cycw5/14:0/15:0cycw5)317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/15:0cycw5/14:0)317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/15:0cycw5/16:1(9Z))317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/15:0cycw5/17:0cycw7)317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/15:0cycw5/18:1(9Z))317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/15:0cycw5/19:0cycw7)317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/16:0/16:0)320
Phospholipid Biosynthesis CL(16:0/15:0cycw5/16:0/16:1(9Z))319
Phospholipid Biosynthesis CL(16:0/15:0cycw5/16:0/17:0cycw7)317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/16:0/18:1(9Z))320
Phospholipid Biosynthesis CL(16:0/15:0cycw5/16:0/19:0cycw7)317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/16:1(9Z)/15:0cycw5)317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/16:1(9Z)/16:0)319
Phospholipid Biosynthesis CL(18:1(9Z)/19:0cycw7/14:0/18:1(9Z))317
Phospholipid Biosynthesis CL(18:1(9Z)/19:0cycw7/14:0/19:0cycw7)317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/16:1(9Z)/16:1(9Z))319
Phospholipid Biosynthesis CL(16:0/15:0cycw5/17:0cycw7/15:0cycw5)317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/17:0cycw7/16:0)317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/17:0cycw7/17:0cycw7)317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/18:1(9Z)/15:0cycw5)317
Phospholipid Biosynthesis CL(18:1(9Z)/19:0cycw7/17:0cycw7/17:0cycw7)317
Phospholipid Biosynthesis CL(18:1(9Z)/19:0cycw7/17:0cycw7/18:1(9Z))317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/18:1(9Z)/16:0)320
Phospholipid Biosynthesis CL(16:0/15:0cycw5/18:1(9Z)/18:1(9Z))319
Phospholipid Biosynthesis CL(18:1(9Z)/19:0cycw7/18:1(9Z)/14:0)317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/19:0cycw7/15:0cycw5)317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/19:0cycw7/16:0)317
Phospholipid Biosynthesis CL(16:0/15:0cycw5/19:0cycw7/19:0cycw7)317
Phospholipid Biosynthesis CL(18:1(9Z)/19:0cycw7/18:1(9Z)/17:0cycw7)317
Phospholipid Biosynthesis CL(18:1(9Z)/19:0cycw7/19:0cycw7/14:0)317
Phospholipid Biosynthesis CL(16:0/16:0/14:0/14:0)323
Phospholipid Biosynthesis CL(19:0cycw7/14:0/14:0/17:0cycw7)316
Phospholipid Biosynthesis CL(16:0/16:0/14:0/16:1(9Z))322
Phospholipid Biosynthesis CL(19:0cycw7/14:0/14:0/19:0cycw7)316
Phospholipid Biosynthesis CL(16:0/16:0/14:0/17:0cycw7)322
Phospholipid Biosynthesis CL(16:0/16:0/14:0/18:1(9Z))322
Phospholipid Biosynthesis CL(16:0/16:0/14:0/19:0cycw7)322
Phospholipid Biosynthesis CL(16:0/16:0/16:0/17:0cycw7)322
Phospholipid Biosynthesis CL(16:0/16:0/16:0/18:1(9Z))326
Phospholipid Biosynthesis CL(16:0/16:0/16:0/19:0cycw7)322
Phospholipid Biosynthesis CL(16:0/16:0/16:1(9Z)/14:0)322
Phospholipid Biosynthesis CL(16:0/16:0/16:1(9Z)/15:0cycw5)322
Phospholipid Biosynthesis CL(19:0cycw7/14:0/17:0cycw7/14:0)316
Phospholipid Biosynthesis CL(19:0cycw7/14:0/17:0cycw7/17:0cycw7)316
Phospholipid Biosynthesis CL(16:0/16:0/16:1(9Z)/16:0)325
Phospholipid Biosynthesis CL(16:0/16:0/16:1(9Z)/16:1(9Z))325
Phospholipid Biosynthesis CL(16:0/16:0/18:1(9Z)/14:0)322
Phospholipid Biosynthesis CL(16:0/16:0/16:1(9Z)/17:0cycw7)322
Phospholipid Biosynthesis CL(16:0/16:0/16:1(9Z)/18:1(9Z))325
Phospholipid Biosynthesis CL(16:0/16:0/16:1(9Z)/19:0cycw7)322
Phospholipid Biosynthesis CL(16:0/16:0/17:0cycw7/14:0)322
Phospholipid Biosynthesis CL(16:0/16:0/17:0cycw7/15:0cycw5)322
Phospholipid Biosynthesis CL(16:0/16:0/17:0cycw7/16:0)322
Phospholipid Biosynthesis CL(16:0/16:0/17:0cycw7/16:1(9Z))322
Phospholipid Biosynthesis CL(16:0/16:0/17:0cycw7/17:0cycw7)322
Phospholipid Biosynthesis CL(19:0cycw7/14:0/19:0cycw7/14:0)316
Phospholipid Biosynthesis CL(19:0cycw7/15:0cycw5/14:0/15:0cycw5)315
Phospholipid Biosynthesis CL(16:0/16:0/17:0cycw7/18:1(9Z))322
Phospholipid Biosynthesis CL(16:0/16:0/17:0cycw7/19:0cycw7)322
Phospholipid Biosynthesis CL(16:0/16:0/18:1(9Z)/15:0cycw5)322
Phospholipid Biosynthesis CL(16:0/16:0/18:1(9Z)/16:0)326
Phospholipid Biosynthesis CL(16:0/16:0/18:1(9Z)/16:1(9Z))325
Phospholipid Biosynthesis CL(16:0/16:0/18:1(9Z)/17:0cycw7)322
Phospholipid Biosynthesis CL(16:0/16:0/18:1(9Z)/18:1(9Z))325
Phospholipid Biosynthesis CL(16:0/16:0/18:1(9Z)/19:0cycw7)322
Phospholipid Biosynthesis CL(16:0/16:0/19:0cycw7/14:0)322
Phospholipid Biosynthesis CL(16:0/16:0/19:0cycw7/15:0cycw5)322
Phospholipid Biosynthesis CL(16:0/16:0/19:0cycw7/16:0)322
Phospholipid Biosynthesis CL(16:0/16:0/19:0cycw7/16:1(9Z))322
Phospholipid Biosynthesis CL(16:0/16:0/19:0cycw7/17:0cycw7)322
Phospholipid Biosynthesis CL(16:0/16:0/19:0cycw7/18:1(9Z))322
Phospholipid Biosynthesis CL(19:0cycw7/15:0cycw5/14:0/19:0cycw7)315
Phospholipid Biosynthesis CL(19:0cycw7/15:0cycw5/15:0cycw5/14:0)315
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/14:0/14:0)322
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/14:0/16:0)322
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/14:0/16:1(9Z))321
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/16:0/14:0)321
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/16:0/16:1(9Z))323
Phospholipid Biosynthesis CL(19:0cycw7/15:0cycw5/15:0cycw5/17:0cycw7)315
Phospholipid Biosynthesis CL(19:0cycw7/15:0cycw5/16:0/19:0cycw7)315
Phospholipid Biosynthesis CL(19:0cycw7/15:0cycw5/16:1(9Z)/19:0cycw7)315
Phospholipid Biosynthesis CL(19:0cycw7/15:0cycw5/17:0cycw7/15:0cycw5)315
Phospholipid Biosynthesis CL(19:0cycw7/15:0cycw5/17:0cycw7/17:0cycw7)315
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/16:0/17:0cycw7)321
Phospholipid Biosynthesis CL(19:0cycw7/15:0cycw5/18:1(9Z)/19:0cycw7)315
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/16:0/18:1(9Z))325
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/16:0/19:0cycw7)321
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/16:1(9Z)/14:0)321
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/16:1(9Z)/16:0)324
Phospholipid Biosynthesis CL(19:0cycw7/15:0cycw5/19:0cycw7/14:0)315
Phospholipid Biosynthesis CL(19:0cycw7/15:0cycw5/19:0cycw7/15:0cycw5)315
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/16:1(9Z)/16:1(9Z))324
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/16:1(9Z)/17:0cycw7)321
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/16:1(9Z)/18:1(9Z))324
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/16:1(9Z)/19:0cycw7)321
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/17:0cycw7/16:0)321
Phospholipid Biosynthesis CL(19:0cycw7/15:0cycw5/19:0cycw7/16:0)315
Phospholipid Biosynthesis CL(19:0cycw7/15:0cycw5/19:0cycw7/16:1(9Z))315
Phospholipid Biosynthesis CL(19:0cycw7/15:0cycw5/19:0cycw7/18:1(9Z))315
Phospholipid Biosynthesis CL(19:0cycw7/15:0cycw5/19:0cycw7/19:0cycw7)315
Phospholipid Biosynthesis CL(19:0cycw7/16:0/14:0/14:0)317
Phospholipid Biosynthesis CL(19:0cycw7/16:0/14:0/16:0)317
Phospholipid Biosynthesis CL(19:0cycw7/16:0/14:0/19:0cycw7)316
Phospholipid Biosynthesis CL(19:0cycw7/16:0/16:0/14:0)316
Phospholipid Biosynthesis CL(19:0cycw7/16:0/16:0/17:0cycw7)316
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/17:0cycw7/16:1(9Z))321
Phospholipid Biosynthesis CL(19:0cycw7/16:0/16:1(9Z)/19:0cycw7)316
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/17:0cycw7/17:0cycw7)321
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/18:1(9Z)/16:0)325
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/18:1(9Z)/16:1(9Z))324
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/18:1(9Z)/18:1(9Z))324
Phospholipid Biosynthesis CL(19:0cycw7/16:0/17:0cycw7/16:0)316
Phospholipid Biosynthesis CL(19:0cycw7/16:0/17:0cycw7/17:0cycw7)316
Phospholipid Biosynthesis CL(19:0cycw7/16:0/17:0cycw7/19:0cycw7)316
Phospholipid Biosynthesis CL(19:0cycw7/16:0/18:1(9Z)/19:0cycw7)316
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/19:0cycw7/16:0)321
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/19:0cycw7/16:1(9Z))321
Phospholipid Biosynthesis CL(16:0/16:1(9Z)/19:0cycw7/19:0cycw7)321
Phospholipid Biosynthesis CL(16:0/17:0cycw7/14:0/16:0)318
Phospholipid Biosynthesis CL(16:0/17:0cycw7/14:0/17:0cycw7)317
Phospholipid Biosynthesis CL(19:0cycw7/16:0/19:0cycw7/14:0)316
Phospholipid Biosynthesis CL(19:0cycw7/16:0/19:0cycw7/16:1(9Z))316
Phospholipid Biosynthesis CL(16:0/17:0cycw7/16:0/14:0)317
Phospholipid Biosynthesis CL(16:0/17:0cycw7/16:0/17:0cycw7)317
Phospholipid Biosynthesis CL(16:0/17:0cycw7/16:1(9Z)/16:1(9Z))319
Phospholipid Biosynthesis CL(16:0/17:0cycw7/16:1(9Z)/17:0cycw7)317
Phospholipid Biosynthesis CL(16:0/17:0cycw7/17:0cycw7/14:0)317
Phospholipid Biosynthesis CL(16:0/17:0cycw7/17:0cycw7/16:1(9Z))317
Phospholipid Biosynthesis CL(16:0/17:0cycw7/17:0cycw7/18:1(9Z))317
Phospholipid Biosynthesis CL(16:0/17:0cycw7/17:0cycw7/19:0cycw7)317
Phospholipid Biosynthesis CL(16:0/17:0cycw7/18:1(9Z)/17:0cycw7)317
Phospholipid Biosynthesis CL(16:0/17:0cycw7/17:0cycw7/17:0cycw7)317
Phospholipid Biosynthesis CL(16:0/17:0cycw7/18:1(9Z)/18:1(9Z))319
Phospholipid Biosynthesis CL(16:0/17:0cycw7/19:0cycw7/17:0cycw7)317
Phospholipid Biosynthesis CL(16:0/17:0cycw7/19:0cycw7/19:0cycw7)317
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/14:0/14:0)324
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/14:0/16:0)324
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/14:0/18:1(9Z))323
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/16:0/14:0)323
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/16:0/17:0cycw7)323
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/16:0/18:1(9Z))325
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/16:0/19:0cycw7)323
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/16:1(9Z)/16:1(9Z))326
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/16:1(9Z)/18:1(9Z))326
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/17:0cycw7/16:0)323
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/17:0cycw7/17:0cycw7)323
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/17:0cycw7/18:1(9Z))323
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/18:1(9Z)/14:0)323
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/18:1(9Z)/16:0)327
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/18:1(9Z)/16:1(9Z))326
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/18:1(9Z)/17:0cycw7)323
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/18:1(9Z)/18:1(9Z))326
Phospholipid Biosynthesis CL(19:0cycw7/16:0/19:0cycw7/17:0cycw7)316
Phospholipid Biosynthesis CL(19:0cycw7/16:0/19:0cycw7/18:1(9Z))316
Phospholipid Biosynthesis CL(19:0cycw7/16:1(9Z)/14:0/14:0)317
Phospholipid Biosynthesis CL(19:0cycw7/16:1(9Z)/14:0/16:1(9Z))316
Phospholipid Biosynthesis CL(19:0cycw7/16:1(9Z)/14:0/19:0cycw7)316
Phospholipid Biosynthesis CL(19:0cycw7/16:1(9Z)/16:1(9Z)/14:0)316
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/18:1(9Z)/19:0cycw7)323
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/19:0cycw7/16:0)323
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/19:0cycw7/18:1(9Z))323
Phospholipid Biosynthesis CL(16:0/18:1(9Z)/19:0cycw7/19:0cycw7)323
Phospholipid Biosynthesis CL(16:0/19:0cycw7/14:0/14:0)318
Phospholipid Biosynthesis CL(19:0cycw7/16:1(9Z)/16:1(9Z)/17:0cycw7)316
Phospholipid Biosynthesis CL(19:0cycw7/16:1(9Z)/17:0cycw7/16:1(9Z))316
Phospholipid Biosynthesis CL(19:0cycw7/16:1(9Z)/17:0cycw7/17:0cycw7)316
Phospholipid Biosynthesis CL(19:0cycw7/16:1(9Z)/17:0cycw7/19:0cycw7)316
Phospholipid Biosynthesis CL(19:0cycw7/16:1(9Z)/18:1(9Z)/19:0cycw7)316
Phospholipid Biosynthesis CL(19:0cycw7/16:1(9Z)/19:0cycw7/14:0)316
Phospholipid Biosynthesis CL(16:0/19:0cycw7/14:0/16:0)318
Phospholipid Biosynthesis CL(16:0/19:0cycw7/14:0/19:0cycw7)317
Phospholipid Biosynthesis CL(16:0/19:0cycw7/16:0/14:0)317
Phospholipid Biosynthesis CL(16:0/19:0cycw7/16:0/17:0cycw7)317
Phospholipid Biosynthesis CL(16:0/19:0cycw7/16:1(9Z)/16:1(9Z))319
Phospholipid Biosynthesis CL(19:0cycw7/16:1(9Z)/19:0cycw7/16:1(9Z))316
Phospholipid Biosynthesis CL(19:0cycw7/16:1(9Z)/19:0cycw7/17:0cycw7)316
Phospholipid Biosynthesis CL(19:0cycw7/16:1(9Z)/19:0cycw7/18:1(9Z))316
Phospholipid Biosynthesis CL(19:0cycw7/17:0cycw7/14:0/14:0)316
Phospholipid Biosynthesis CL(16:0/19:0cycw7/16:1(9Z)/19:0cycw7)317
Phospholipid Biosynthesis CL(16:0/19:0cycw7/17:0cycw7/16:0)317
Phospholipid Biosynthesis CL(16:0/19:0cycw7/17:0cycw7/17:0cycw7)317
Phospholipid Biosynthesis CL(16:0/19:0cycw7/17:0cycw7/19:0cycw7)317
Phospholipid Biosynthesis CL(16:0/19:0cycw7/18:1(9Z)/18:1(9Z))319
Phospholipid Biosynthesis CL(19:0cycw7/17:0cycw7/14:0/17:0cycw7)315
Phospholipid Biosynthesis CL(19:0cycw7/17:0cycw7/14:0/19:0cycw7)315
Phospholipid Biosynthesis CL(19:0cycw7/17:0cycw7/17:0cycw7/14:0)315
Phospholipid Biosynthesis CL(19:0cycw7/17:0cycw7/17:0cycw7/19:0cycw7)315
Phospholipid Biosynthesis CL(19:0cycw7/17:0cycw7/19:0cycw7/14:0)315
Phospholipid Biosynthesis CL(19:0cycw7/17:0cycw7/19:0cycw7/17:0cycw7)315
Phospholipid Biosynthesis CL(16:0/19:0cycw7/18:1(9Z)/19:0cycw7)317
Phospholipid Biosynthesis CL(16:0/19:0cycw7/19:0cycw7/14:0)317
Phospholipid Biosynthesis CL(16:0/19:0cycw7/19:0cycw7/16:1(9Z))317
Phospholipid Biosynthesis CL(16:0/19:0cycw7/19:0cycw7/17:0cycw7)317
Phospholipid Biosynthesis CL(16:0/19:0cycw7/19:0cycw7/18:1(9Z))317
Phospholipid Biosynthesis CL(19:0cycw7/18:1(9Z)/14:0/14:0)317
Phospholipid Biosynthesis CL(19:0cycw7/18:1(9Z)/14:0/18:1(9Z))316
Phospholipid Biosynthesis CL(16:1(9Z)/14:0/14:0/16:1(9Z))321
Phospholipid Biosynthesis CL(16:1(9Z)/14:0/14:0/18:1(9Z))321
Phospholipid Biosynthesis CL(16:1(9Z)/14:0/14:0/19:0cycw7)321
Phospholipid Biosynthesis CL(16:1(9Z)/14:0/16:1(9Z)/14:0)321
Phospholipid Biosynthesis CL(19:0cycw7/18:1(9Z)/14:0/19:0cycw7)316
Phospholipid Biosynthesis CL(16:1(9Z)/14:0/17:0cycw7/17:0cycw7)321
Phospholipid Biosynthesis CL(19:0cycw7/18:1(9Z)/17:0cycw7/17:0cycw7)316
Phospholipid Biosynthesis CL(19:0cycw7/18:1(9Z)/17:0cycw7/18:1(9Z))316
Phospholipid Biosynthesis CL(19:0cycw7/18:1(9Z)/18:1(9Z)/14:0)316
Phospholipid Biosynthesis CL(16:1(9Z)/14:0/18:1(9Z)/14:0)321
Phospholipid Biosynthesis CL(19:0cycw7/18:1(9Z)/18:1(9Z)/17:0cycw7)316
Phospholipid Biosynthesis CL(16:1(9Z)/14:0/18:1(9Z)/18:1(9Z))323
Phospholipid Biosynthesis CL(19:0cycw7/18:1(9Z)/19:0cycw7/14:0)316
Phospholipid Biosynthesis CL(16:1(9Z)/14:0/19:0cycw7/14:0)321
Phospholipid Biosynthesis CL(16:1(9Z)/14:0/19:0cycw7/19:0cycw7)321
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/14:0/15:0cycw5)317
Phospholipid Biosynthesis CL(19:0cycw7/19:0cycw7/14:0/14:0)316
Phospholipid Biosynthesis CL(19:0cycw7/19:0cycw7/14:0/15:0cycw5)315
Phospholipid Biosynthesis CL(19:0cycw7/19:0cycw7/14:0/16:0)316
Phospholipid Biosynthesis CL(19:0cycw7/19:0cycw7/14:0/16:1(9Z))315
Phospholipid Biosynthesis CL(19:0cycw7/19:0cycw7/14:0/17:0cycw7)315
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/14:0/16:1(9Z))317
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/15:0cycw5/17:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/15:0cycw5/18:1(9Z))317
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/15:0cycw5/19:0cycw7)317
Phospholipid Biosynthesis CL(19:0cycw7/19:0cycw7/14:0/19:0cycw7)315
Phospholipid Biosynthesis CL(19:0cycw7/19:0cycw7/17:0cycw7/14:0)315
Phospholipid Biosynthesis CL(19:0cycw7/19:0cycw7/17:0cycw7/16:0)315
Phospholipid Biosynthesis CL(19:0cycw7/19:0cycw7/17:0cycw7/16:1(9Z))315
Phospholipid Biosynthesis CL(19:0cycw7/19:0cycw7/17:0cycw7/17:0cycw7)315
Phospholipid Biosynthesis CL(19:0cycw7/19:0cycw7/19:0cycw7/14:0)315
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/16:0/16:1(9Z))319
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/16:1(9Z)/14:0)317
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/16:1(9Z)/15:0cycw5)317
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/16:1(9Z)/16:0)319
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/16:1(9Z)/16:1(9Z))319
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/16:1(9Z)/17:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/16:1(9Z)/18:1(9Z))319
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/16:1(9Z)/19:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/17:0cycw7/15:0cycw5)317
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/17:0cycw7/16:1(9Z))317
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/17:0cycw7/17:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/18:1(9Z)/15:0cycw5)317
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/18:1(9Z)/16:1(9Z))319
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/18:1(9Z)/18:1(9Z))319
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/19:0cycw7/15:0cycw5)317
Phospholipid Biosynthesis CL(17:0cycw7/18:1(9Z)/17:0cycw7/14:0)316
Phospholipid Biosynthesis CL(17:0cycw7/18:1(9Z)/17:0cycw7/17:0cycw7)316
Phospholipid Biosynthesis CL(17:0cycw7/18:1(9Z)/17:0cycw7/18:1(9Z))316
Phospholipid Biosynthesis CL(17:0cycw7/18:1(9Z)/17:0cycw7/19:0cycw7)316
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/19:0cycw7/16:1(9Z))317
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/19:0cycw7/19:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/14:0/14:0)323
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/14:0/16:0)323
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/14:0/16:1(9Z))322
Phospholipid Biosynthesis CL(17:0cycw7/18:1(9Z)/18:1(9Z)/14:0)316
Phospholipid Biosynthesis CL(17:0cycw7/18:1(9Z)/19:0cycw7/17:0cycw7)316
Phospholipid Biosynthesis CL(17:0cycw7/19:0cycw7/14:0/14:0)316
Phospholipid Biosynthesis CL(17:0cycw7/19:0cycw7/14:0/17:0cycw7)315
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/16:0/14:0)322
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/16:0/17:0cycw7)322
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/16:0/18:1(9Z))325
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/16:0/19:0cycw7)322
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/16:1(9Z)/14:0)322
Phospholipid Biosynthesis CL(17:0cycw7/19:0cycw7/14:0/19:0cycw7)315
Phospholipid Biosynthesis CL(17:0cycw7/19:0cycw7/17:0cycw7/14:0)315
Phospholipid Biosynthesis CL(17:0cycw7/19:0cycw7/17:0cycw7/19:0cycw7)315
Phospholipid Biosynthesis CL(17:0cycw7/19:0cycw7/19:0cycw7/14:0)315
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/16:1(9Z)/16:0)324
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/16:1(9Z)/16:1(9Z))325
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/16:1(9Z)/17:0cycw7)322
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/16:1(9Z)/18:1(9Z))325
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/16:1(9Z)/19:0cycw7)322
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/17:0cycw7/16:0)322
Phospholipid Biosynthesis CL(18:1(9Z)/14:0/14:0/17:0cycw7)321
Phospholipid Biosynthesis CL(18:1(9Z)/14:0/14:0/18:1(9Z))321
Phospholipid Biosynthesis CL(18:1(9Z)/14:0/14:0/19:0cycw7)321
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/17:0cycw7/16:1(9Z))322
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/17:0cycw7/17:0cycw7)322
Phospholipid Biosynthesis CL(18:1(9Z)/14:0/17:0cycw7/14:0)321
Phospholipid Biosynthesis CL(18:1(9Z)/14:0/17:0cycw7/17:0cycw7)321
Phospholipid Biosynthesis CL(18:1(9Z)/14:0/18:1(9Z)/14:0)321
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/18:1(9Z)/16:0)326
Phospholipid Biosynthesis CL(18:1(9Z)/14:0/19:0cycw7/14:0)321
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/18:1(9Z)/16:1(9Z))325
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/18:1(9Z)/18:1(9Z))325
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/19:0cycw7/16:0)322
Phospholipid Biosynthesis CL(18:1(9Z)/14:0/19:0cycw7/19:0cycw7)321
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/14:0/15:0cycw5)317
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/19:0cycw7/16:1(9Z))322
Phospholipid Biosynthesis CL(16:1(9Z)/16:0/19:0cycw7/19:0cycw7)322
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/14:0/14:0)321
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/14:0/15:0cycw5)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/14:0/16:0)321
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/14:0/16:1(9Z))320
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/14:0/18:1(9Z))317
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/15:0cycw5/14:0)317
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/15:0cycw5/17:0cycw7)317
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/15:0cycw5/19:0cycw7)317
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/16:0/18:1(9Z))320
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/16:1(9Z)/18:1(9Z))319
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/14:0/17:0cycw7)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/14:0/18:1(9Z))320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/14:0/19:0cycw7)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/16:1(9Z)/14:0)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/16:1(9Z)/17:0cycw7)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/16:1(9Z)/18:1(9Z))323
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/16:1(9Z)/19:0cycw7)320
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/17:0cycw7/15:0cycw5)317
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/17:0cycw7/17:0cycw7)317
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/17:0cycw7/18:1(9Z))317
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/18:1(9Z)/14:0)317
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/18:1(9Z)/15:0cycw5)317
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/18:1(9Z)/16:0)320
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/18:1(9Z)/16:1(9Z))319
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/18:1(9Z)/17:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/17:0cycw7/14:0)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/17:0cycw7/15:0cycw5)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/17:0cycw7/16:0)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/17:0cycw7/16:1(9Z))320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/17:0cycw7/17:0cycw7)320
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/18:1(9Z)/18:1(9Z))319
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/18:1(9Z)/19:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/17:0cycw7/18:1(9Z))320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/17:0cycw7/19:0cycw7)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/18:1(9Z)/14:0)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/18:1(9Z)/15:0cycw5)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/18:1(9Z)/16:0)324
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/18:1(9Z)/16:1(9Z))323
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/18:1(9Z)/17:0cycw7)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/18:1(9Z)/18:1(9Z))323
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/18:1(9Z)/19:0cycw7)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/19:0cycw7/14:0)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/19:0cycw7/15:0cycw5)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/19:0cycw7/16:0)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/19:0cycw7/16:1(9Z))320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/19:0cycw7/17:0cycw7)320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/19:0cycw7/18:1(9Z))320
Phospholipid Biosynthesis CL(16:1(9Z)/16:1(9Z)/19:0cycw7/19:0cycw7)320
Phospholipid Biosynthesis CL(16:1(9Z)/17:0cycw7/14:0/16:1(9Z))317
Phospholipid Biosynthesis CL(16:1(9Z)/17:0cycw7/14:0/17:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/17:0cycw7/16:1(9Z)/14:0)317
Phospholipid Biosynthesis CL(16:1(9Z)/17:0cycw7/16:1(9Z)/17:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/17:0cycw7/17:0cycw7/14:0)317
Phospholipid Biosynthesis CL(16:1(9Z)/17:0cycw7/17:0cycw7/16:1(9Z))317
Phospholipid Biosynthesis CL(16:1(9Z)/17:0cycw7/17:0cycw7/17:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/17:0cycw7/17:0cycw7/18:1(9Z))317
Phospholipid Biosynthesis CL(16:1(9Z)/17:0cycw7/17:0cycw7/19:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/17:0cycw7/18:1(9Z)/17:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/17:0cycw7/18:1(9Z)/18:1(9Z))319
Phospholipid Biosynthesis CL(16:1(9Z)/17:0cycw7/19:0cycw7/17:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/17:0cycw7/19:0cycw7/19:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/14:0/14:0)322
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/14:0/16:1(9Z))321
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/14:0/18:1(9Z))321
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/16:1(9Z)/14:0)321
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/16:1(9Z)/17:0cycw7)321
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/16:1(9Z)/18:1(9Z))323
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/19:0cycw7/15:0cycw5)317
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/19:0cycw7/18:1(9Z))317
Phospholipid Biosynthesis CL(18:1(9Z)/15:0cycw5/19:0cycw7/19:0cycw7)317
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/14:0/14:0)324
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/14:0/16:0)324
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/14:0/18:1(9Z))323
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/16:0/19:0cycw7)323
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/17:0cycw7/16:0)323
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/17:0cycw7/17:0cycw7)323
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/17:0cycw7/18:1(9Z))323
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/18:1(9Z)/14:0)323
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/18:1(9Z)/16:0)325
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/16:1(9Z)/19:0cycw7)321
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/17:0cycw7/16:1(9Z))321
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/17:0cycw7/17:0cycw7)321
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/17:0cycw7/18:1(9Z))321
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/18:1(9Z)/14:0)321
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/18:1(9Z)/16:1(9Z))326
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/18:1(9Z)/17:0cycw7)323
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/18:1(9Z)/18:1(9Z))326
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/18:1(9Z)/19:0cycw7)323
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/19:0cycw7/16:0)323
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/19:0cycw7/18:1(9Z))323
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/19:0cycw7/19:0cycw7)323
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/14:0/14:0)323
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/18:1(9Z)/16:1(9Z))324
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/18:1(9Z)/17:0cycw7)321
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/18:1(9Z)/18:1(9Z))324
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/18:1(9Z)/19:0cycw7)321
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/19:0cycw7/16:1(9Z))321
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/14:0/16:1(9Z))322
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/14:0/18:1(9Z))322
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/16:1(9Z)/14:0)322
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/16:1(9Z)/17:0cycw7)322
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/19:0cycw7/18:1(9Z))321
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/16:1(9Z)/19:0cycw7)322
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/17:0cycw7/16:1(9Z))322
Phospholipid Biosynthesis CL(16:1(9Z)/18:1(9Z)/19:0cycw7/19:0cycw7)321
Phospholipid Biosynthesis CL(16:1(9Z)/19:0cycw7/14:0/14:0)318
Phospholipid Biosynthesis CL(16:1(9Z)/19:0cycw7/14:0/16:1(9Z))317
Phospholipid Biosynthesis CL(16:1(9Z)/19:0cycw7/14:0/19:0cycw7)317
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/17:0cycw7/17:0cycw7)322
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/17:0cycw7/18:1(9Z))322
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/18:1(9Z)/14:0)322
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/18:1(9Z)/16:1(9Z))324
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/18:1(9Z)/18:1(9Z))325
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/18:1(9Z)/19:0cycw7)322
Phospholipid Biosynthesis CL(16:1(9Z)/19:0cycw7/16:1(9Z)/14:0)317
Phospholipid Biosynthesis CL(16:1(9Z)/19:0cycw7/16:1(9Z)/17:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/19:0cycw7/16:1(9Z)/19:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/19:0cycw7/17:0cycw7/16:1(9Z))317
Phospholipid Biosynthesis CL(16:1(9Z)/19:0cycw7/17:0cycw7/17:0cycw7)317
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/19:0cycw7/16:1(9Z))322
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/19:0cycw7/18:1(9Z))322
Phospholipid Biosynthesis CL(16:1(9Z)/19:0cycw7/17:0cycw7/19:0cycw7)317
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/19:0cycw7/19:0cycw7)322
Phospholipid Biosynthesis CL(18:1(9Z)/17:0cycw7/14:0/14:0)318
Phospholipid Biosynthesis CL(18:1(9Z)/17:0cycw7/14:0/17:0cycw7)317
Phospholipid Biosynthesis CL(18:1(9Z)/17:0cycw7/14:0/18:1(9Z))317
Phospholipid Biosynthesis CL(16:1(9Z)/19:0cycw7/18:1(9Z)/18:1(9Z))319
Phospholipid Biosynthesis CL(16:1(9Z)/19:0cycw7/18:1(9Z)/19:0cycw7)317
Phospholipid Biosynthesis CL(18:1(9Z)/17:0cycw7/17:0cycw7/14:0)317
Phospholipid Biosynthesis CL(16:1(9Z)/19:0cycw7/19:0cycw7/14:0)317
Phospholipid Biosynthesis CL(18:1(9Z)/17:0cycw7/17:0cycw7/17:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/19:0cycw7/19:0cycw7/16:1(9Z))317
Phospholipid Biosynthesis CL(16:1(9Z)/19:0cycw7/19:0cycw7/17:0cycw7)317
Phospholipid Biosynthesis CL(16:1(9Z)/19:0cycw7/19:0cycw7/18:1(9Z))317
Phospholipid Biosynthesis CL(18:1(9Z)/17:0cycw7/17:0cycw7/18:1(9Z))317
Phospholipid Biosynthesis CL(18:1(9Z)/17:0cycw7/17:0cycw7/19:0cycw7)317
Phospholipid Biosynthesis CL(18:1(9Z)/17:0cycw7/18:1(9Z)/14:0)317
Phospholipid Biosynthesis CL(18:1(9Z)/17:0cycw7/18:1(9Z)/17:0cycw7)317
Phospholipid Biosynthesis CL(18:1(9Z)/17:0cycw7/19:0cycw7/17:0cycw7)317
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/14:0/14:0)322
Phospholipid Biosynthesis CL(17:0cycw7/15:0cycw5/14:0/14:0)316
Phospholipid Biosynthesis CL(17:0cycw7/15:0cycw5/14:0/17:0cycw7)315
Phospholipid Biosynthesis CL(17:0cycw7/15:0cycw5/16:0/17:0cycw7)315
Phospholipid Biosynthesis CL(17:0cycw7/15:0cycw5/16:1(9Z)/17:0cycw7)315
Phospholipid Biosynthesis CL(17:0cycw7/15:0cycw5/17:0cycw7/14:0)315
Phospholipid Biosynthesis CL(17:0cycw7/15:0cycw5/17:0cycw7/15:0cycw5)315
Phospholipid Biosynthesis CL(17:0cycw7/15:0cycw5/17:0cycw7/16:0)315
Phospholipid Biosynthesis CL(17:0cycw7/15:0cycw5/17:0cycw7/16:1(9Z))315
Phospholipid Biosynthesis CL(17:0cycw7/15:0cycw5/17:0cycw7/17:0cycw7)315
Phospholipid Biosynthesis CL(17:0cycw7/15:0cycw5/17:0cycw7/18:1(9Z))315
Phospholipid Biosynthesis CL(17:0cycw7/15:0cycw5/17:0cycw7/19:0cycw7)315
Phospholipid Biosynthesis CL(17:0cycw7/15:0cycw5/18:1(9Z)/17:0cycw7)315
Phospholipid Biosynthesis CL(17:0cycw7/15:0cycw5/19:0cycw7/17:0cycw7)315
Phospholipid Biosynthesis CL(17:0cycw7/16:0/14:0/16:0)317
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/14:0/15:0cycw5)321
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/14:0/16:0)322
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/14:0/16:1(9Z))321
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/14:0/17:0cycw7)321
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/14:0/18:1(9Z))321
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/14:0/19:0cycw7)321
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/17:0cycw7/14:0)321
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/17:0cycw7/15:0cycw5)321
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/17:0cycw7/16:0)321
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/17:0cycw7/16:1(9Z))321
Phospholipid Biosynthesis CL(17:0cycw7/16:0/14:0/17:0cycw7)316
Phospholipid Biosynthesis CL(17:0cycw7/16:0/16:0/14:0)316
Phospholipid Biosynthesis CL(17:0cycw7/16:0/16:0/17:0cycw7)316
Phospholipid Biosynthesis CL(17:0cycw7/16:0/16:1(9Z)/17:0cycw7)316
Phospholipid Biosynthesis CL(17:0cycw7/16:0/17:0cycw7/14:0)316
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/17:0cycw7/17:0cycw7)321
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/17:0cycw7/18:1(9Z))321
Phospholipid Biosynthesis CL(17:0cycw7/16:0/17:0cycw7/16:0)316
Phospholipid Biosynthesis CL(17:0cycw7/16:0/17:0cycw7/16:1(9Z))316
Phospholipid Biosynthesis CL(17:0cycw7/16:0/17:0cycw7/17:0cycw7)316
Phospholipid Biosynthesis CL(17:0cycw7/16:0/17:0cycw7/18:1(9Z))316
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/17:0cycw7/19:0cycw7)321
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/18:1(9Z)/14:0)321
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/18:1(9Z)/17:0cycw7)321
Phospholipid Biosynthesis CL(18:1(9Z)/18:1(9Z)/19:0cycw7/14:0)321
Phospholipid Biosynthesis CL(17:0cycw7/16:0/17:0cycw7/19:0cycw7)316
Phospholipid Biosynthesis CL(17:0cycw7/16:0/18:1(9Z)/17:0cycw7)316
Phospholipid Biosynthesis CL(17:0cycw7/16:0/19:0cycw7/17:0cycw7)316
Phospholipid Biosynthesis CL(17:0cycw7/16:1(9Z)/14:0/17:0cycw7)316
Phospholipid Biosynthesis CL(17:0cycw7/16:1(9Z)/14:0/16:1(9Z))316
Phospholipid Biosynthesis CL(17:0cycw7/16:1(9Z)/16:1(9Z)/14:0)316
Phospholipid Biosynthesis CL(17:0cycw7/16:1(9Z)/17:0cycw7/14:0)316
Phospholipid Biosynthesis CL(17:0cycw7/16:1(9Z)/17:0cycw7/16:1(9Z))316
Phospholipid Biosynthesis CL(17:0cycw7/16:1(9Z)/17:0cycw7/17:0cycw7)316
Phospholipid Biosynthesis CL(17:0cycw7/16:1(9Z)/17:0cycw7/18:1(9Z))316
Phospholipid Biosynthesis CL(17:0cycw7/16:1(9Z)/17:0cycw7/19:0cycw7)316
Phospholipid Biosynthesis CL(17:0cycw7/16:1(9Z)/18:1(9Z)/17:0cycw7)316
Phospholipid Biosynthesis CL(17:0cycw7/16:1(9Z)/19:0cycw7/17:0cycw7)316
Phospholipid Biosynthesis CL(17:0cycw7/17:0cycw7/14:0/15:0cycw5)315
Phospholipid Biosynthesis CL(17:0cycw7/17:0cycw7/14:0/16:0)316
Phospholipid Biosynthesis CL(17:0cycw7/17:0cycw7/14:0/16:1(9Z))315
Phospholipid Biosynthesis CL(17:0cycw7/17:0cycw7/14:0/17:0cycw7)315
Phospholipid Biosynthesis CL(17:0cycw7/17:0cycw7/14:0/18:1(9Z))315
Phospholipid Biosynthesis CL(17:0cycw7/17:0cycw7/14:0/19:0cycw7)315
Phospholipid Biosynthesis CL(17:0cycw7/17:0cycw7/17:0cycw7/14:0)315
Phospholipid Biosynthesis CL(17:0cycw7/17:0cycw7/17:0cycw7/17:0cycw7)315
Phospholipid Biosynthesis CL(17:0cycw7/18:1(9Z)/14:0/14:0)317
Phospholipid Biosynthesis CL(17:0cycw7/18:1(9Z)/14:0/17:0cycw7)316
Phospholipid Biosynthesis CL(17:0cycw7/18:1(9Z)/14:0/18:1(9Z))316
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/18:1(9Z)/16:0)318
Phospholipid Biosynthesis CL(16:1(9Z)/15:0cycw5/15:0cycw5/14:0)317
Phospholipid Biosynthesis CL(10:0/10:0/10:0/10:0)316
Phospholipid Biosynthesis CL(16:0/12:0(3-OH)/16:0/12:0(3-OH))318
Phospholipid Biosynthesis CL(16:0/15:0/16:0/15:0)321
Phospholipid Biosynthesis CL(10:0/12:0/10:0/12:0)317
Phospholipid Biosynthesis CL(10:0/14:0/10:0/14:0)317
Phospholipid Biosynthesis CL(16:0/18:0/16:0/18:0)324
Phospholipid Biosynthesis CL(10:0/15:0/10:0/15:0)317
Phospholipid Biosynthesis CL(10:0/16:0/10:0/16:0)317
Phospholipid Biosynthesis CL(16:0/i-19:0/16:0/i-19:0)318
Phospholipid Biosynthesis CL(10:0/16:1(9Z)/10:0/16:1(9Z))317
Phospholipid Biosynthesis CL(16:1(9Z)/10:0(3-OH)/16:1(9Z)/10:0(3-OH))318
Phospholipid Biosynthesis CL(10:0/18:0/10:0/18:0)317
Phospholipid Biosynthesis CL(16:1(9Z)/12:0(3-OH)/16:1(9Z)/12:0(3-OH))318
Phospholipid Biosynthesis CL(10:0/18:1(9Z)/10:0/18:1(9Z))317
Phospholipid Biosynthesis CL(16:1(9Z)/15:0/16:1(9Z)/15:0)321
Phospholipid Biosynthesis CL(16:1(9Z)/18:0/16:1(9Z)/18:0)323
Phospholipid Biosynthesis CL(16:1(9Z)/i-19:0/16:1(9Z)/i-19:0)318
Phospholipid Biosynthesis CL(18:0/10:0/18:0/10:0)318
Phospholipid Biosynthesis CL(18:0/12:0/18:0/12:0)318
Phospholipid Biosynthesis CL(10:0/19:1(9Z)/10:0/19:1(9Z))316
Phospholipid Biosynthesis CL(12:0/10:0/12:0/10:0)318
Phospholipid Biosynthesis CL(18:0/14:0/18:0/14:0)321
Phospholipid Biosynthesis CL(18:0/15:0/18:0/15:0)321
Phospholipid Biosynthesis CL(18:0/16:0/18:0/16:0)325
Phospholipid Biosynthesis CL(12:0/14:0/12:0/14:0)318
Phospholipid Biosynthesis CL(12:0/15:0/12:0/15:0)318
Phospholipid Biosynthesis CL(18:0/16:1(9Z)/18:0/16:1(9Z))324
Phospholipid Biosynthesis CL(12:0/16:0/12:0/16:0)318
Phospholipid Biosynthesis CL(18:0/18:0/18:0/18:0)324
Phospholipid Biosynthesis CL(12:0/16:1(9Z)/12:0/16:1(9Z))318
Phospholipid Biosynthesis CL(18:0/18:1(9Z)/18:0/18:1(9Z))324
Phospholipid Biosynthesis CL(12:0/18:0/12:0/18:0)318
Phospholipid Biosynthesis CL(18:0/19:1(9Z)/18:0/19:1(9Z))317
Phospholipid Biosynthesis CL(12:0/18:1(9Z)/12:0/18:1(9Z))318
Phospholipid Biosynthesis CL(12:0/19:1(9Z)/12:0/19:1(9Z))317
Phospholipid Biosynthesis CL(18:1(9Z)/10:0(3-OH)/18:1(9Z)/10:0(3-OH))318
Phospholipid Biosynthesis CL(18:1(9Z)/15:0/18:1(9Z)/15:0)321
Phospholipid Biosynthesis CL(18:1(9Z)/19:1(9Z)/18:1(9Z)/19:1(9Z))317
Phospholipid Biosynthesis CL(19:1(9Z)/14:0/19:1(9Z)/14:0)316
Phospholipid Biosynthesis CL(19:1(9Z)/16:0/19:1(9Z)/16:0)316
Phospholipid Biosynthesis CL(19:1(9Z)/18:0/19:1(9Z)/18:0)316
Phospholipid Biosynthesis CL(19:1(9Z)/19:1(9Z)/19:1(9Z)/19:1(9Z))315
Phospholipid Biosynthesis CL(14:0/10:0/14:0/10:0)317
Phospholipid Biosynthesis CL(14:0/12:0/14:0/12:0)317
Phospholipid Biosynthesis CL(14:0/15:0/14:0/15:0)319
Phospholipid Biosynthesis CL(14:0/18:0/14:0/18:0)319
Phospholipid Biosynthesis CL(14:0/19:1(9Z)/14:0/19:1(9Z))316
Phospholipid Biosynthesis CL(15:0/10:0/15:0/10:0)317
Phospholipid Biosynthesis CL(15:0/12:0/15:0/12:0)317
Phospholipid Biosynthesis CL(15:0/14:0/15:0/14:0)320
Phospholipid Biosynthesis CL(15:0/15:0/15:0/15:0)318
Phospholipid Biosynthesis CL(15:0/16:0/15:0/16:0)319
Phospholipid Biosynthesis CL(15:0/16:1(9Z)/15:0/16:1(9Z))319
Phospholipid Biosynthesis CL(15:0/18:0/15:0/18:0)320
Phospholipid Biosynthesis CL(15:0/18:1(9Z)/15:0/18:1(9Z))319
Phospholipid Biosynthesis CL(15:0/19:1(9Z)/15:0/19:1(9Z))316
Phospholipid Biosynthesis CL(16:0/10:0/16:0/10:0)318
Phospholipid Biosynthesis CL(14:0/16:0/14:0/16:1(9Z))320
Phospholipid Biosynthesis CL(10:0(3-OH)/10:0/10:0(3-OH)/10:0)317
Phospholipid Biosynthesis CL(10:0(3-OH)/12:0(3-OH)/10:0(3-OH)/12:0(3-OH))317
Phospholipid Biosynthesis CL(10:0(3-OH)/12:0/10:0(3-OH)/12:0)317
Phospholipid Biosynthesis CL(10:0(3-OH)/15:0cycw5/10:0(3-OH)/15:0cycw5)316
Phospholipid Biosynthesis CL(10:0(3-OH)/16:1(9Z)/10:0(3-OH)/16:1(9Z))317
Phospholipid Biosynthesis CL(10:0(3-OH)/16:0/10:0(3-OH)/16:0)317
Phospholipid Biosynthesis CL(10:0(3-OH)/17:0cycw7/10:0(3-OH)/17:0cycw7)316
Phospholipid Biosynthesis CL(10:0(3-OH)/17:0cycw7/14:0/14:0)317
Phospholipid Biosynthesis CL(10:0(3-OH)/19:0cycw7/10:0(3-OH)/19:0cycw7)316
Phospholipid Biosynthesis CL(10:0(3-OH)/i-19:0/10:0(3-OH)/i-19:0)317
Phospholipid Biosynthesis CL(10:0/10:0(3-OH)/10:0/10:0(3-OH))317
Phospholipid Biosynthesis CL(10:0/12:0(3-OH)/10:0/12:0(3-OH))317
Phospholipid Biosynthesis CL(10:0/17:0cycw7/14:0/14:0)317
Phospholipid Biosynthesis CL(12:0(3-OH)/10:0(3-OH)/12:0(3-OH)/10:0(3-OH))317
Phospholipid Biosynthesis CL(12:0(3-OH)/10:0/12:0(3-OH)/10:0)317
Phospholipid Biosynthesis CL(12:0(3-OH)/12:0(3-OH)/12:0/12:0)316
Phospholipid Biosynthesis CL(12:0(3-OH)/12:0/12:0/12:0)317
Phospholipid Biosynthesis CL(12:0(3-OH)/14:0(3-OH)/12:0(3-OH)/14:0(3-OH))317
Phospholipid Biosynthesis CL(12:0(3-OH)/14:0/12:0(3-OH)/14:0)317
Phospholipid Biosynthesis CL(12:0(3-OH)/15:0/12:0(3-OH)/15:0)317
Phospholipid Biosynthesis CL(12:0(3-OH)/15:0cycw5/12:0(3-OH)/15:0cycw5)316
Phospholipid Biosynthesis CL(12:0(3-OH)/17:0cycw7/12:0(3-OH)/17:0cycw7)316
Phospholipid Biosynthesis CL(12:0(3-OH)/17:0cycw7/12:0/12:0)316
Phospholipid Biosynthesis CL(12:0(3-OH)/18:1(9Z)/12:0(3-OH)/18:1(9Z))317
Phospholipid Biosynthesis CL(12:0(3-OH)/19:0cycw7/12:0(3-OH)/19:0cycw7)316
Phospholipid Biosynthesis CL(12:0(3-OH)/i-19:0/12:0(3-OH)/i-19:0)317
Phospholipid Biosynthesis CL(12:0/10:0(3-OH)/12:0/10:0(3-OH))318
Phospholipid Biosynthesis CL(12:0/12:0(3-OH)/12:0/12:0)318
Phospholipid Biosynthesis CL(12:0/12:0/12:0/12:0)317
Phospholipid Biosynthesis CL(12:0/14:0(3-OH)/12:0/14:0(3-OH))318
Phospholipid Biosynthesis CL(12:0/17:0cycw7/12:0/12:0)317
Phospholipid Biosynthesis CL(12:0/i-19:0/12:0/i-19:0)318
Phospholipid Biosynthesis CL(14:0(3-OH)/12:0(3-OH)/14:0(3-OH)/12:0(3-OH))317
Phospholipid Biosynthesis CL(14:0(3-OH)/12:0/14:0(3-OH)/12:0)317
Phospholipid Biosynthesis CL(14:0(3-OH)/14:0(3-OH)/14:0/14:0)317
Phospholipid Biosynthesis CL(14:0(3-OH)/14:0/14:0/14:0)318
Phospholipid Biosynthesis CL(14:0(3-OH)/16:0/16:0/16:0)320
Phospholipid Biosynthesis CL(14:0(3-OH)/16:1(9Z)/14:0(3-OH)/16:1(9Z))317
Phospholipid Biosynthesis CL(14:0(3-OH)/16:1(9Z)/14:0/14:0)318
Phospholipid Biosynthesis CL(14:0(3-OH)/17:0cycw7/14:0(3-OH)/17:0cycw7)316
Phospholipid Biosynthesis CL(14:0(3-OH)/17:0cycw7/14:0/14:0)317
Phospholipid Biosynthesis CL(14:0/12:0(3-OH)/14:0/12:0(3-OH))317
Phospholipid Biosynthesis CL(14:0/14:0(3-OH)/14:0/14:0)318
Phospholipid Biosynthesis CL(15:0/10:0(3-OH)/15:0/10:0(3-OH))317
Phospholipid Biosynthesis CL(15:0/12:0(3-OH)/15:0/12:0(3-OH))317
Phospholipid Biosynthesis CL(15:0/14:0(3-OH)/14:0/14:0)318
Phospholipid Biosynthesis CL(15:0cycw5/10:0(3-OH)/15:0cycw5/10:0(3-OH))316
Phospholipid Biosynthesis CL(16:0/10:0(3-OH)/16:0/10:0(3-OH))318
Phospholipid Biosynthesis CL(16:0/14:0(3-OH)/16:0/14:0(3-OH))318
Phospholipid Biosynthesis CL(16:1(9Z)/10:0/14:0/14:0)319
Phospholipid Biosynthesis CL(16:1(9Z)/12:0/12:0/12:0)318
Phospholipid Biosynthesis CL(16:1(9Z)/14:0(3-OH)/14:0/14:0)319
Phospholipid Biosynthesis CL(16:1(9Z)/14:0(3-OH)/16:1(9Z)/14:0(3-OH))318
Phospholipid Biosynthesis CL(16:1(9Z)/19:0/14:0/14:0)319
Phospholipid Biosynthesis CL(16:1(9Z)/19:0/16:0/16:0)321
Phospholipid Biosynthesis CL(16:1(9Z)/19:0/16:1(9Z)/19:0)318
Phospholipid Biosynthesis CL(17:0/16:1(9Z)/14:0/14:0)318
Phospholipid Biosynthesis CL(17:0/16:1(9Z)/16:0/16:0)320
Phospholipid Biosynthesis CL(17:0cycw7/10:0(3-OH)/10:0/10:0)316
Phospholipid Biosynthesis CL(17:0cycw7/10:0(3-OH)/14:0/14:0)317
Phospholipid Biosynthesis CL(17:0cycw7/10:0(3-OH)/17:0cycw7/10:0(3-OH))316
Phospholipid Biosynthesis CL(17:0cycw7/10:0/14:0/14:0)317
Phospholipid Biosynthesis CL(17:0cycw7/12:0(3-OH)/12:0/12:0)316
Phospholipid Biosynthesis CL(17:0cycw7/12:0(3-OH)/17:0cycw7/12:0(3-OH))316
Phospholipid Biosynthesis CL(17:0cycw7/12:0/12:0/12:0)316
Phospholipid Biosynthesis CL(17:0cycw7/i-19:0/17:0cycw7/i-19:0)316
Phospholipid Biosynthesis CL(18:0/10:0/10:0/10:0)318
Phospholipid Biosynthesis CL(18:0/12:0/12:0/12:0)318
Phospholipid Biosynthesis CL(18:1(11Z)/10:0/10:0/10:0)317
Phospholipid Biosynthesis CL(18:1(11Z)/12:0/12:0/12:0)317
Phospholipid Biosynthesis CL(18:1(11Z)/17:0/14:0/14:0)318
Phospholipid Biosynthesis CL(18:1(11Z)/19:0/14:0/14:0)318
Phospholipid Biosynthesis CL(18:1(11Z)/19:0/18:1(11Z)/19:0)317
Phospholipid Biosynthesis CL(18:1(11Z)/19:0/19:0/19:0)317
Phospholipid Biosynthesis CL(18:1(9Z)/12:0(3-OH)/18:1(9Z)/12:0(3-OH))318
Phospholipid Biosynthesis CL(19:0/16:1(9Z)/14:0/14:0)319
Phospholipid Biosynthesis CL(19:0/16:1(9Z)/16:0/16:0)321
Phospholipid Biosynthesis CL(19:0/16:1(9Z)/19:0/16:1(9Z))318
Phospholipid Biosynthesis CL(19:0/18:1(11Z)/14:0/14:0)319
Phospholipid Biosynthesis CL(19:0/18:1(11Z)/19:0/18:1(11Z))318
Phospholipid Biosynthesis CL(19:0/18:1(11Z)/19:0/19:0)318
Phospholipid Biosynthesis CL(19:0cycw7/10:0(3-OH)/10:0/10:0)316
Phospholipid Biosynthesis CL(19:0cycw7/10:0(3-OH)/19:0cycw7/10:0(3-OH))316
Phospholipid Biosynthesis CL(19:0cycw7/12:0(3-OH)/12:0/12:0)316
Phospholipid Biosynthesis CL(19:0cycw7/12:0(3-OH)/19:0cycw7/12:0(3-OH))316
Phospholipid Biosynthesis CL(19:0cycw8/10:0/10:0/10:0)316
Phospholipid Biosynthesis CL(19:1(9Z)/16:1(9Z)/19:1(9Z)/16:1(9Z))316
Phospholipid Biosynthesis CL(i-19:0/10:0(3-OH)/10:0/10:0)318
Phospholipid Biosynthesis CL(i-19:0/10:0(3-OH)/i-19:0/10:0(3-OH))318
Phospholipid Biosynthesis CL(i-19:0/10:0/i-19:0/10:0)318
Phospholipid Biosynthesis CL(i-19:0/12:0(3-OH)/12:0/12:0)318
Phospholipid Biosynthesis CL(i-19:0/12:0(3-OH)/i-19:0/12:0(3-OH))318
Phospholipid Biosynthesis CL(i-19:0/12:0/i-19:0/12:0)318
Phospholipid Biosynthesis CL(i-19:0/14:0(3-OH)/14:0/14:0)319
Phospholipid Biosynthesis CL(i-19:0/14:0(3-OH)/i-19:0/14:0(3-OH))318
Phospholipid Biosynthesis CL(i-19:0/14:0/14:0/14:0)319
Phospholipid Biosynthesis CL(i-19:0/14:0/i-19:0/14:0)318
Phospholipid Biosynthesis CL(i-19:0/17:0cycw7/19:0/19:0)317
Phospholipid Biosynthesis CL(i-19:0/19:0cycw7/19:0/19:0)317
Phospholipid Biosynthesis CL(i-19:0/i-19:0/i-19:0/i-19:0)319
Phospholipid Biosynthesis CL(16:0/16:0/16:0/16:0)324
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/16:0/14:0)323
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/16:0/17:0cycw7)323
Phospholipid Biosynthesis CL(18:1(9Z)/16:0/16:1(9Z)/18:1(9Z))325
Phospholipid Biosynthesis CL(18:1(9Z)/16:1(9Z)/18:1(9Z)/17:0cycw7)322
Phospholipid Biosynthesis CL(15:0cycw5/15:0cycw5/15:0cycw5/15:0cycw5)315
glycerol degradation V08
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-20490
Orexin receptor pathway2915
Amino acid metabolism in triple-negative breast cancer cells016
glycerol degradation46
cytidine-5'-diphosphate-glycerol biosynthesis315
glycerol degradation I310
triacylglycerol degradation78
monoacylglycerol metabolism (yeast)212
superpathway of microbial D-galacturonate and D-glucuronate degradation3592
glycerol degradation to butanol1035
glycerol degradation III613
1,3-propanediol biosynthesis (engineered)1535
cardiolipin biosynthesis I814
glycerol and glycerophosphodiester degradation412
glycerol degradation V416
glycerol degradation II318
superpathway of glycerol degradation to 1,3-propanediol826
D-galacturonate degradation III612
monoacylglycerol metabolism312
glycerol biosynthesis412
superpathway of phospholipid biosynthesis027
ester phospholipid biosynthesis021
glycerol metabolism011
glycerol degradation IV16
SK UDPglcnac19
Lipid droplet metabolism04
Glycerophospholipid biosynthetic pathway3233
Lipid particles composition62
Metabolism overview078
Biochemical pathways: part I0466
Thermogenesis018
Glucose homeostasis021

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency1.38250.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency2.68320.000221.22318,912.5098AID743036; AID743053
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency28.18380.011212.4002100.0000AID1030
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency77.74210.003041.611522,387.1992AID1159552
retinoid X nuclear receptor alphaHomo sapiens (human)Potency52.63830.000817.505159.3239AID1159527; AID1159531
estrogen nuclear receptor alphaHomo sapiens (human)Potency6.68240.000229.305416,493.5996AID743080
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency50.11870.001024.504861.6448AID588535
activating transcription factor 6Homo sapiens (human)Potency55.49270.143427.612159.8106AID1159516
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency17.78280.010039.53711,122.0200AID588545
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency22.19170.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency47.30790.000627.21521,122.0200AID651741
lamin isoform A-delta10Homo sapiens (human)Potency0.35480.891312.067628.1838AID1487
Cellular tumor antigen p53Homo sapiens (human)Potency13.33320.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain B, EUKARYOTIC TRANSLATION INITIATION FACTOR 4EHomo sapiens (human)Kd110,000.0000110,000.0000110,000.0000110,000.0000AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (124)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2009Cell cycle (Georgetown, Tex.), Jun-15, Volume: 8, Issue:12
Crystallization of eIF4E complexed with eIF4GI peptide and glycerol reveals distinct structural differences around the cap-binding site.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID681134TP_TRANSPORTER: Daunomycin accumulation in Caco-2 cells2004British journal of pharmacology, Oct, Volume: 143, Issue:3
Inhibitory effect of a bitter melon extract on the P-glycoprotein activity in intestinal Caco-2 cells.
AID687624Activity of Bacillus stearothermophilus alpha-glucosidase assessed as production of p-nitrophenol using p-nitrophenyl-alpha-D-glucopyranoside as substrate at 50 mM after 3 mins by spectrophotometer2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Cellular zwitterionic metabolite analogs simultaneously enhance reaction rate, thermostability, salt tolerance, and substrate specificity of α-glucosidase.
AID687626Activity of commercial yeast alpha-glucosidase assessed as production of p-nitrophenol using p-nitrophenyl-alpha-D-glucopyranoside as substrate at 50 mM after 3 mins by spectrophotometer2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Cellular zwitterionic metabolite analogs simultaneously enhance reaction rate, thermostability, salt tolerance, and substrate specificity of α-glucosidase.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID687625Activity of Saccharomyces cerevisiae alpha-glucosidase assessed as production of p-nitrophenol using p-nitrophenyl-alpha-D-glucopyranoside as substrate at 50 mM after 3 mins by spectrophotometer2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Cellular zwitterionic metabolite analogs simultaneously enhance reaction rate, thermostability, salt tolerance, and substrate specificity of α-glucosidase.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID349603Inhibition of human recombinant KAT1 expressed in Sf9 cells assessed as decrease in enzyme activity at 25 % ligand concentration2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Structural insight into the inhibition of human kynurenine aminotransferase I/glutamine transaminase K.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID30433Compound was tested for inhibition of Human acrosin by polyols1981Journal of medicinal chemistry, Nov, Volume: 24, Issue:11
Inhibition of human acrosin by monosaccharides and related compounds: structure-activity relationships.
AID167125Eye irritation potential accessed using Draize in vivo rabbit eye irritation test2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Mapping property distributions of molecular surfaces: algorithm and evaluation of a novel 3D quantitative structure-activity relationship technique.
AID189629The capillary permeability of radioligand was measured in Rat brain1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability.
AID26811Partition coefficient (logP)1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26,479)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010710 (40.45)18.7374
1990's3210 (12.12)18.2507
2000's4594 (17.35)29.6817
2010's5937 (22.42)24.3611
2020's2028 (7.66)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 112.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index112.49 (24.57)
Research Supply Index10.27 (2.92)
Research Growth Index4.60 (4.65)
Search Engine Demand Index221.38 (26.88)
Search Engine Supply Index2.05 (0.95)

This Compound (112.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials979 (3.50%)5.53%
Reviews882 (3.15%)6.00%
Case Studies326 (1.16%)4.05%
Observational20 (0.07%)0.25%
Other25,776 (92.11%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (116)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Determination of the Sun Protection Factor (SPF) and in Vitro UVA Protection Factor (UVAPF) of Four Developmental Sunscreen Formulations [NCT03157583]8 participants (Actual)Interventional2017-06-21Completed
Double-Blind Randomized Placebo-Control Trial to Evaluate Electrocardiogram Effects of HPN-100 as Defined by Clinical and Supratherapeutic Dose in Healthy Men and Women [NCT01135680]Phase 198 participants (Actual)Interventional2010-05-31Completed
Can Maximising Time in Range Using Automated Insulin Delivery and a Low Carbohydrate Diet Restore the Glucagon Response to Hypoglycaemic in Type 1 Diabetes? [NCT04614168]24 participants (Anticipated)Interventional2021-07-26Recruiting
A Switch-Over, Open-Label Study of the Safety, Pharmacokinetics, and Efficacy of HPN-100, Followed by Long-Term Treatment With HPN-100, in Pediatric Subjects Under 6 Years of Age With Urea Cycle Disorders (UCDs) [NCT01347073]Phase 323 participants (Actual)Interventional2011-07-31Completed
Rectal Indomethacin Decreases the Incidence of Pancreatitis Following Endoscopic Retrograde Cholangiopancreatography in High-risk Patients [NCT02110810]Phase 3160 participants (Actual)Interventional2014-01-31Completed
Peanut Sublingual Immunotherapy Induction of Clinical Tolerance of Newly Diagnosed Peanut Allergic 12 to 48 Month Old Children [NCT02304991]Phase 250 participants (Actual)Interventional2015-01-31Completed
Glycerin Suppositories Used Prophylactically in Premature Infants (SUPP): a Pilot Randomized Placebo-controlled Trial [NCT02153606]30 participants (Anticipated)Interventional2015-01-31Recruiting
Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy [NCT04937062]Early Phase 150 participants (Anticipated)Interventional2021-03-01Enrolling by invitation
"Etude Pilote, Comparative, Monocentrique, randomisée, en Cross Over, en Double Aveugle, Contre Placebo, Testant l'efficacité de l'Huile triheptanoïne Dans Les Hémiplégies Alternantes de l'Enfant HEMIHEP" [NCT02408354]Phase 210 participants (Actual)Interventional2015-04-15Completed
Accessible and Affordable Moisturizers for Atopic Eczema: the 2am Atopic Eczema Study [NCT02084472]120 participants (Actual)Interventional2013-02-28Completed
Expanded Access Protocol for an Intermediate Size Population - RAVICTI for Byler Disease [NCT02094222]0 participants Expanded AccessNo longer available
Efficacy and Safety of Glycerin Suppositories for Treatment of Feeding Intolerance in Very Low Birth Weight Infants [NCT02149407]230 participants (Anticipated)Interventional2014-05-31Recruiting
Single Center, Open, Cross-over, Phase III Study for Safety and Efficacy (Subjective and Instrumental) Comparative Evaluation Between Dermacyd Silver and Glycerine Vegetal Soap Granado Traditional for Intimate Use in Menopauses Woman. [NCT01126606]Phase 370 participants (Actual)Interventional2010-08-31Completed
Efficacy and Safety of KLYX Versus Glycerine Enema in Chinese Patients With Constipation - a Randomised, Assessor-blind Pilot Study [NCT01335386]Phase 260 participants (Actual)Interventional2010-04-30Completed
Evaluation of Routine Administration of Glycerin Suppositories to Improve Bowel Function in Patients With Uncomplicated Gastroschisis [NCT03355326]Phase 416 participants (Actual)Interventional2017-10-01Terminated(stopped due to Unable to sufficiently recruit candidates)
To Investigate the Effectiveness of Topical Glycerine Sulphate, Hirudoid Cream and Nil Application in Treating Peripheral Cannula Related Phlebitis [NCT01226069]147 participants (Actual)Interventional2009-11-30Completed
A Phase 2 Randomised Controlled Trial of a NOVel Moisturiser for Atopic Dermatitis: Effect on the Skin Barrier in Adults With a Predisposition to a Skin Barrier Defect [NCT03901144]Phase 250 participants (Actual)Interventional2019-02-21Completed
Single Center, Open, Cross-over, Phase III Study for Comparative Evaluation of Safety Use and Efficacy in the Odor Reduce and Vaginal Moisturize Increase for Intimates Use Products Dermacyd Femina Delicata, Dermacyd Femina Breeze, Dermacyd Teen Sweet Flow [NCT01158365]Phase 3230 participants (Actual)Interventional2010-07-31Completed
Observation of Effect and Complication of Two Types of Nasogastric Tube Feeding Enteral Nutrition for Elderly Dysphagia Patients After Stroke [NCT03844139]100 participants (Anticipated)Observational2019-02-13Recruiting
Oral Glycerol and High-Dose Rectal Paracetamol to Improve the Prognosis of Childhood Bacterial Meningitis - A Prospective, Randomized, and Double-Blind Clinical Study Using a Two-by-Two Factorial Design [NCT00619203]Phase 3466 participants (Actual)Interventional2008-03-31Completed
The Effects of Glycerol as an Optical Clearing Agent for Visualization of the Middle Ear [NCT05497934]Phase 150 participants (Anticipated)Interventional2022-10-01Not yet recruiting
Evaluation of Fecal Microbiome Changes After Antegrade Continence Enema Placement and Initiation of Bowel Flush Regimen [NCT05821309]Phase 450 participants (Anticipated)Interventional2023-06-08Recruiting
Brown Fat Energy Metabolism During Cold Exposure: Effects of Fructose- or Glucose-rich Diet in Healthy Subjects [NCT03188835]15 participants (Actual)Interventional2017-05-23Completed
A Multidisciplinary Approach to the Treatment of Encopresis in Children With Autism Spectrum Disorders [NCT03197922]Phase 3117 participants (Actual)Interventional2017-10-25Completed
Phenylbutyrate Response As a Biomarker for Alpha-Synuclein Clearance From Brain [NCT02046434]Phase 138 participants (Actual)Interventional2014-01-31Completed
EndoscoPic Submucosal dIssection Using geL Versus glycerOl for Submucosal iNjection: a Randomized Controlled Multicentric Trial (EPSILON) [NCT04977401]32 participants (Actual)Interventional2021-09-21Terminated(stopped due to Urgent Medical Device Product (ORISE Gel Submucosal Liftiong Agent) Removal by sponsor)
Rectally Administered Indomethacin to Prevent Post-ESWL-pancreatitis (RIPEP) [NCT02797067]Phase 41,370 participants (Actual)Interventional2016-05-31Completed
Glycerol Block of the Trigeminal Ganglion in Trigeminal Neuralgia Using a New Neuronavigation-based Surgical Technique [NCT02624661]Phase 1/Phase 21 participants (Actual)Interventional2016-05-31Terminated(stopped due to technical problems)
Sublingual Immunotherapy for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled, Phase I/II Pilot Study With a Whole Peanut Extract [NCT00580606]Phase 1/Phase 240 participants (Actual)Interventional2007-12-31Completed
The Administration of Saline Enema Versus Glycerin Suppository as a Treatment Intervention for Meconium Obstruction of Prematurity (MOP) and to Study the Impact on the Resolution of MOP, Time to Reach Full Enteral Feeds, Gut Microbiome, and Gut-brain Axis [NCT06048614]95 participants (Anticipated)Interventional2023-09-30Not yet recruiting
A Multi-Center, Randomized, Double-Blind, Placebo Controlled, Study on the Use of Rho-Kinase Inhibitor to Reduce Ore Prevent Proliferative Vitreoretinopathy (PVR) in Eyes With Rhegmatogenous Retinal Detachment (RRD) at High Risk of PVR [NCT05660447]Phase 2/Phase 380 participants (Anticipated)Interventional2023-02-06Recruiting
G Protein-coupled Receptor in the Intestine (GPR 119) Stimulated GLP-1 Secretion [NCT01043445]8 participants (Actual)Interventional2009-09-30Completed
Genetics of Environmental Asthma: Differential Gene Expression in the Lung and Peripheral Blood After Inhaled Allergen Challenge [NCT00671593]Phase 140 participants (Actual)Interventional2006-10-31Terminated(stopped due to funding terminated)
Phase IV Study of Nasal Salmon Calcitonin in the Treatment of Symptoms and Signs of Fibromyalgia [NCT00754884]Phase 40 participants (Actual)Interventional2008-10-31Withdrawn(stopped due to Study drug was not longer available in our country.)
Safety Study of Milk Peptide Supplementation in Healthy Volunteers: a Randomized Placebo Controlled Clinical Trial [NCT01412658]Phase 173 participants (Actual)Interventional2006-11-30Completed
Comparison of Efficacy of Glycerol, Two Topical Steroids, and a Topical Immune Modulator Against Experimentally Induced Skin Irritation [NCT00779792]Phase 436 participants (Actual)Interventional2008-09-30Active, not recruiting
Study of Gluconeogenesis in Very Low Birth Weight Infants Receiving Total Parenteral Nutrition [NCT00005889]96 participants Interventional1999-10-31Recruiting
[NCT00152945]10 participants (Actual)Interventional2005-04-30Completed
Mitochondrial Function in Patients With Severe Liver Disease [NCT02457702]2 participants (Actual)Interventional2015-10-31Terminated(stopped due to Unable to recruit. Only 2 subjects completed.)
A Double Blind, Placebo Controlled, Dose Escalation Trial of Glycerol Phenylbutyrate Corrector Therapy for Cystic Fibrosis [NCT02323100]Phase 1/Phase 213 participants (Actual)Interventional2018-12-02Terminated(stopped due to funding ended)
Choline Supplementation in Children With Fetal Alcohol Spectrum Disorders [NCT01911299]Phase 255 participants (Actual)Interventional2013-05-31Completed
Validation of a System Using Aerosol Glycerine to Detect and Localize Intraoperatively Pulmonary Air Leaks [NCT05971719]200 participants (Anticipated)Interventional2023-07-20Recruiting
[NCT00243711]Phase 2/Phase 3286 participants (Actual)Interventional2005-09-30Completed
Transition From Buphenyl to RAVICTI for the Therapy of Byler Disease [NCT01949766]0 participants Expanded AccessNo longer available
A Randomised, Controlled, Open-Label Parallel Arm Study of Safety, PK and Ammonia Control of RAVICTI® (Glycerol Phenylbutyrate) Oral Liquid and Sodium Phenylbutyrate in Phenylbutyrate Treatment Naïve Patients With Urea Cycle Disorders [NCT03335488]Phase 416 participants (Actual)Interventional2018-02-20Completed
Effect of Glycerol-Electrolyte Beverages on Fluid Balance in Healthy Euhydrated Men and Women at Rest [NCT06185595]42 participants (Anticipated)Interventional2024-01-31Recruiting
Characterization of Nicotine Exposure and Urge-to-Smoke Following a Single Controlled Administration and Short-Term Ad Lib Use of Electronic Cigarettes and Conventional Cigarettes in Adult Smokers [NCT02210754]24 participants (Actual)Interventional2014-03-31Completed
Double-blind, Randomised, Prospective, Placebo Controlled Parallel Group Phase II Study to Investigate the Effect of Glycerol Phenylbutyrate (GPB) on Neurofilament Light Chain (NfL) Levels in Patients With Corticobasal Syndrome (CBS) [NCT05983588]Phase 232 participants (Anticipated)Interventional2023-12-31Not yet recruiting
Evaluation of Glycerol Phenylbutyrate (PBA) Use in Endoplasmic Reticulum Stress Reduction in ATF6-/- Patients [NCT04041232]Early Phase 12 participants (Anticipated)Interventional2023-05-31Not yet recruiting
... Study to Evaluate Efficacy and Safety of Perennial Sublingual SIT With a Solution of Grass Pollen Allergen ... in Children With Clinically Relevant Grass Pollen Sensitivity in Comparison to a ... Standard Treatment With Add on Placebo [NCT00841256]Phase 3207 participants (Actual)Interventional2008-02-29Completed
A Single Site, Three Arm, Open Label Comparative Preference Study to Evaluate the Preference of Consumers and Health Care Professionals for the Use of Shapes by PolyMem Wound Dressings and Shapes by PolyMem Silver Wound Dressings, Each Compared to Antibio [NCT00727870]Phase 490 participants (Anticipated)Interventional2008-07-31Active, not recruiting
Monitoring of the Bone Free Flaps With Microdialysis [NCT03935139]40 participants (Anticipated)Interventional2019-07-22Recruiting
[NCT02117687]Phase 480 participants (Actual)Interventional2014-05-14Completed
Pharmacological or Cold-induced Activation of Brown Adipose Tissue Metabolism [NCT02811289]22 participants (Actual)Interventional2016-08-05Completed
Multicenter Controlled Parallel-Groups Trial to Evaluate the Efficacy, Safety and Acceptability of TGO Buccal Spray Versus a Saliva Substitute in the Treatment of Psychotropic Medicines-Induced Xerostomia [NCT00332618]74 participants Observational2003-09-30Completed
Diabetic Macular Oedema: the Retinal Thickness as a Function of Changes in Plasma Osmolality Evaluated by OCT. [NCT00333671]15 participants (Actual)Interventional2004-12-31Completed
An International Randomised Controlled Trial to Establish the Effects of Low-dose rtPA and the Effects of Early Intensive Blood Pressure Lowering in Patients With Acute Ischaemic Stroke [NCT01422616]Phase 34,587 participants (Actual)Interventional2012-03-31Completed
Clinical Evaluation of the Effect of Moisturising Cream on Skin Moisture in Atopic Dermatitis [NCT00846235]Phase 424 participants (Actual)Interventional2008-12-31Completed
A Prospective Study of the Effect of Modified Colonoscopy Bowel Preparation Program on Intestinal Cleaning, Examination and Disease in Patients With Inflammatory Bowel Disease [NCT05485103]144 participants (Anticipated)Interventional2022-09-01Recruiting
A Randomized, Masked Exploratory Trial Comparing the Effect of Two Different Over-the-Counter Artificial Tear Preparations on Tear Film Break-up Time [NCT00681265]16 participants (Actual)Interventional2008-06-30Completed
Safe Excipient Exposure in Neonates and Small ChildreN - a Retrospective, Descriptive Study Off the Amount of Ethanol, Propylene Glycol, Benzyl Alcohol, Parabens, Acesulfam k, Aspartame, Glycerol, Sorbitol and Polysorbate-80 Exposed to Pediatric Patients [NCT02545712]630 participants (Actual)Observational2016-01-31Active, not recruiting
"EVALUATION OF ACUTE AND SUBACUTE EFFECTS OF NICOTINE FREE ELECTRONIC CIGARETTE (NFEC) VAPORS -Aim 2.1 of Adverse Effects of Inhaled Nicotine From Tobacco and E-cigarettes." [NCT02585791]30 participants (Actual)Interventional2017-02-22Terminated(stopped due to due to recent release reports from CDC about lung injury due to vaping, the PI and IRB decided to terminate the study)
Sentinel Cohort for the Response to Emerging Antimicrobial Resistance With Containment Microbiota Restoration Therapy Trial [NCT05780801]Phase 110 participants (Actual)Interventional2023-04-24Active, not recruiting
Use of Glycerol Phenylbutyrate (Ravicti™) as a Chaperone to Stabilize Enzyme in Patients With MCAD Deficiency Due to the Common MCAD 985A>G (K304E) Mutation [NCT01881984]Phase 14 participants (Actual)Interventional2013-06-30Completed
A Single-Center, Double-Masked, Randomized Study Evaluating the Tolerability and Efficacy of CWT-f-002 Lubricant Eye Drops Compared to Systane® Preservative-Free Eye Drops in the Treatment of the Signs and Symptoms of Dry Eye Disease (DED) [NCT05660681]34 participants (Actual)Interventional2022-12-12Completed
A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years [NCT02044341]Phase 3304 participants (Actual)Interventional2013-12-31Completed
Idiopathic Hypertensive Anal Canal: a Place of Internal Sphincterotomy [NCT00927849]63 participants (Actual)Interventional2002-09-30Completed
A Multi-center, Randomized, Single-blind Clinical Study of the Comparative Safety and Efficacy of Docusate Sodium and Sorbitol Rectal Solution and Glycerine Enemas in Patients With Constipation [NCT01474499]Phase 3300 participants (Actual)Interventional2011-09-30Completed
Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye [NCT00987727]Phase 482 participants (Actual)Interventional2009-11-30Completed
[NCT00761202]Phase 450 participants (Actual)Interventional2007-08-31Completed
Effectiveness of Nano-hydroxyapetite Care Paste in Reducing Dentinhypersenstitivity: A Double Blind Randomized Control Trial [NCT02936830]Phase 463 participants (Actual)Interventional2016-10-31Completed
The Potential Role for Adenosine in the Haemodynamic Effects of Free Fatty Acids [NCT00184899]20 participants Interventional2005-08-31Completed
Clinical Evaluation of Venus Versa Octipolar Applicator for Reduction of Abdomen Circumference [NCT02492997]44 participants (Actual)Interventional2015-05-14Terminated(stopped due to Trial was terminated early due to slow enrollment.)
Effectiveness of Remineralization Agents on the Prevention of Dental Bleaching Induced Sensitivity [NCT04855279]64 participants (Actual)Interventional2019-01-07Completed
Randomized Phase II Study of Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane With and Without ImmTher for Newly Diagnosed High Risk Ewing's Sarcoma [NCT00003667]Phase 20 participants Interventional1998-09-30Completed
A Randomised, Controlled, Double-Blind Study to Examine Nicotine Pharmacokinetics and Smoking Behaviour in Healthy Smokers When Smoking Cigarettes Containing Different Commonly Used Ingredients [NCT03272295]40 participants (Actual)Interventional2017-09-12Completed
A Randomised Trial to Establish the Effects of Early Intensive Blood Pressure Lowering on Death and Disability in Patients With Stroke Due to Acute Intracerebral Haemorrhage [NCT00226096]404 participants (Actual)Interventional2005-11-30Completed
A Double-blinded, Placebo-controlled Study of Peanut Sublingual Immunotherapy in Children - DBPC Peanut SLIT [NCT00597727]Phase 260 participants (Actual)Interventional2008-01-31Completed
Training Effects on Skeletal Muscle Fatty Acid Metabolism [NCT00786487]33 participants (Actual)Interventional2009-01-31Completed
A Randomized Controlled Trial of the Effectiveness of Three Different Oral Moisturizers in Palliative Care Patients. [NCT03400969]30 participants (Anticipated)Interventional2018-03-01Recruiting
[NCT01010282]288 participants (Actual)Interventional2009-11-30Completed
Effects of Acute Glycerol Ingestion on Performance, Metabolic and Biochemical Markers in International Athletes [NCT05295836]4 participants (Actual)Interventional2022-02-10Completed
Emollients in the Management of Atopic Dermatitis in Children: Prevention of Flares. [NCT01779258]Phase 3347 participants (Actual)Interventional2013-02-28Completed
An Interdisciplinary Approach to the Treatment of Encopresis in Children With Autism Spectrum Disorders [NCT02383758]22 participants (Actual)Interventional2015-02-01Completed
[NCT00938704]Phase 471 participants (Actual)Interventional2009-06-30Completed
Insulin Sensitivity, Glucose - and Fat Metabolism in Patients With Psoriasis [NCT02978001]32 participants (Actual)Observational2016-08-31Completed
Safety and Tolerability of Artificial Tears in Dry Eye Subjects [NCT00932477]47 participants (Actual)Interventional2009-08-31Completed
Assessing the Efficacy of Antipyrine Benzocaine Otic Solution in the Ear Canal to Decrease Usage of Rescue Inhalers in Moderate to Severe Asthmatic Adults. [NCT02153541]Phase 250 participants (Anticipated)Interventional2023-04-01Not yet recruiting
The Role of Selective Thermal Radiofrequency Saddle Rhizotomy In Managing Interactable Malignant Perineal Pain: A Comparative Study [NCT03084575]Phase 240 participants (Anticipated)Interventional2016-02-29Enrolling by invitation
Efficacy of Prophylactic Glycerin Suppositories for Feeding Intolerance in Very Low Birth Weight Preterm Infants: a Randomized Trial [NCT01799629]220 participants (Anticipated)Interventional2013-03-31Recruiting
Glycerin-Preserved, Human-Donor, Corneoscleral Patch Grafts for Glaucoma Drainage Devices [NCT04949347]100 participants (Actual)Observational2017-02-22Completed
Acute Effects of Propylene Glycol/Glycerol Intake on Cardiorespiratory Blood Parameters [NCT03404011]24 participants (Actual)Interventional2018-01-15Completed
Comparison of Transanal Irrigation and Glycerol Suppositories in Treatment of Low Anterior Resection Syndrome: A Multicentre Randomised Controlled Trial [NCT04087421]Phase 3114 participants (Anticipated)Interventional2019-09-17Recruiting
A Randomized, Double Blind Phase 1 Safety, Acceptability, and Pharmacokinetic Study Comparing Three Formulations of Tenofovir 1% Gel Administered Rectally to HIV-1 Seronegative Adults [NCT01575405]Phase 113 participants (Actual)Interventional2013-03-31Completed
An Exploratory, Double-Blinded, Randomized, Pharmacokinetic and Safety Study of Three Rectally-Applied Tenofovir 1% Microbicide Gel Formulations [NCT01575418]Phase 19 participants (Actual)Interventional2013-03-31Completed
[NCT01339936]Phase 2/Phase 340 participants (Actual)Interventional2011-03-31Completed
The Use of Glycerin Suppositories to Reduce Hyperbilirubinemia in Premature Infants Requiring Phototherapy [NCT01746511]79 participants (Actual)Interventional2012-07-31Completed
Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging [NCT02833415]Phase 440 participants (Actual)Interventional2016-03-31Completed
Belladonna and Opium Rectal Suppository Effect on Postoperative Pain and Nausea Following Total Laparoscopic and Robotic-Assisted Hysterectomy [NCT03657407]Phase 456 participants (Actual)Interventional2016-06-01Completed
A Randomised Controlled Trial to Evaluate the Effect of a New Skin Care Regimen on Skin Barrier Function in Those With Podoconiosis in Ethiopia [NCT02839772]Phase 3193 participants (Actual)Interventional2014-01-31Completed
Safety and Efficacy of Human Microbiota Transplantation for Overweight and Obese Type 2 Diabetes Mellitus ( SETOM ): A Randomized, Double-blind, Placebo-controlled Clinical Study [NCT05253768]Phase 240 participants (Anticipated)Interventional2022-02-28Not yet recruiting
[NCT00544713]228 participants (Actual)Interventional2007-09-30Completed
Glycerol-Phenylbutyrate Treatment in Children With MCT Mutation (Allan-Herndon- Dudley Syndrome) [NCT05019417]Phase 2/Phase 36 participants (Anticipated)Interventional2021-06-30Recruiting
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Study to Assess the Safety and Efficacy of UX007 in Subjects With Glucose Transporter Type 1 Deficiency Syndrome [NCT01993186]Phase 236 participants (Actual)Interventional2014-02-28Completed
Randomized, Double Blind, Clinical Study for Evaluating the Efficacy and the Tolerability of a Cosmetic Active Ingredient Intended for Subjects With Atopic Dermatitis. Controlled Study vs Placebo [NCT05057351]44 participants (Actual)Interventional2020-09-01Completed
Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear [NCT00691197]Phase 2/Phase 3246 participants (Actual)Interventional2008-03-31Completed
An International Randomised Controlled Trial to Establish the Effects of Early Intensive Blood Pressure Lowering in Patients With Intracerebral Haemorrhage. [NCT00716079]2,839 participants (Actual)Interventional2008-09-30Completed
[NCT00514852]316 participants (Actual)Interventional2007-10-31Completed
TILIA for inSomnia During HOrmonal Therapy in Breast Cancer Survivors [NCT06061666]80 participants (Anticipated)Interventional2023-06-01Recruiting
CRAMPS Trial: Controlled Randomized Trial Assessing Maternal Post-partum Pain With Suppositories [NCT01271855]Phase 4100 participants (Actual)Interventional2009-07-22Completed
A Phase 2 Randomized Sequence Open Label Expanded Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel [NCT01687218]Phase 2195 participants (Actual)Interventional2013-09-25Completed
An Open Label Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate (GPB; RAVICTI®) in Pediatric Subjects Under Two Years of Age With Urea Cycle Disorders (UCDs) [NCT02246218]Phase 427 participants (Actual)Interventional2014-12-31Completed
Randomized Controlled Double-blinded Clinical Trial of an Herbal Mouthrinse for Radiotherapy Induced Mucositis in Cancer Patients [NCT01898091]Phase 250 participants (Actual)Interventional2013-07-31Completed
Role of Fatty Acid Oxidation Defects in Insulin Sensitivity [NCT02517307]52 participants (Actual)Interventional2016-02-29Completed
Comparative Study of Negative Pressure Wound Therapy and Allogeneic Human Skin Grafts for Wound Bed Preparation in Necrotising Soft Tissue Infections [NCT02314468]0 participants (Actual)Interventional2013-10-31Withdrawn(stopped due to No funding)
A Within Subjects Comparison of Two Antegrade Flushing Regimens in Children [NCT02435069]Phase 45 participants (Actual)Interventional2016-02-09Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00514852 (10) [back to overview]Change From Baseline at Day 30 in Subjective Evaluation of Symptom of Dryness Score
NCT00514852 (10) [back to overview]Change From Baseline at Day 30 in Schirmer Test, With Anesthesia
NCT00514852 (10) [back to overview]Change From Baseline at Day 30 in Ocular Surface Disease Index© Questionnaire Score
NCT00514852 (10) [back to overview]Change From Baseline at Day 30 in Ocular Surface (Corneal) Staining With Fluorescein
NCT00514852 (10) [back to overview]Change From Baseline at Day 30 in Ocular Surface (Conjunctival) Staining With Fluorescein
NCT00514852 (10) [back to overview]Vision Subscale of the Ocular Surface Disease Index Questionnaire© at Day 30
NCT00514852 (10) [back to overview]Patient Acceptability Score (Vision) at Day 30
NCT00514852 (10) [back to overview]Change From Baseline at Day 30 in Tear Break-Up Time, With Fluorescein
NCT00514852 (10) [back to overview]Ocular Surface Staining With Fluorescein (Central Cornea) at Day 30
NCT00514852 (10) [back to overview]Patient Acceptability Score (Dryness) at Day 30
NCT00544713 (13) [back to overview]Best Corrected Visual Acuity (BCVA) Status at Day 90
NCT00544713 (13) [back to overview]Change From Baseline in Study Product Usage at Day 90
NCT00544713 (13) [back to overview]Patient Acceptability- Percentage of Patients Who Rated Artificial Tears (AT) as Acceptable at Day 90
NCT00544713 (13) [back to overview]Patient Acceptability (Sensory) - Percentage of Patients Who Rated Artificial Tears (AT) as Acceptable at Day 90
NCT00544713 (13) [back to overview]Number of Patients Prescribed to Each Dosing Regimen at Day 14 and Day 60
NCT00544713 (13) [back to overview]Change From Baseline of Total Higher Order Aberration (HOA) of the Worse Eye at Day 90
NCT00544713 (13) [back to overview]Change From Baseline of the Worse Eye in Tear Break-Up Time (TBUT) at Day 90
NCT00544713 (13) [back to overview]Change From Baseline of the Worse Eye in Schirmer's Test at Day 90
NCT00544713 (13) [back to overview]Change From Baseline of the Worse Eye in Corneal Topography Measured by Humphrey Atlas at Day 90
NCT00544713 (13) [back to overview]Change From Baseline of the Worse Eye in Corneal Topography as Measured by Pentacam at Day 90
NCT00544713 (13) [back to overview]Change From Baseline of the Worse Eye in Corneal Staining With Fluorescein at Day 90
NCT00544713 (13) [back to overview]Post LASIK Dry Eye Symptoms as Measured by Ocular Surface Disease Index (OSDI©) Score at Day 90
NCT00544713 (13) [back to overview]Change From Baseline of the Worse Eye in Conjunctival Staining With Lissamine Green at Day 90
NCT00580606 (7) [back to overview]Number of Crossover Participants With Serious Adverse Events (SAEs) During 44 Weeks of Open Label Peanut Protein Consumption
NCT00580606 (7) [back to overview]Number of Participants With Serious Adverse Events (SAEs)
NCT00580606 (7) [back to overview]Percent of Crossover Participants Who Successfully Consumed 5,000 mg of Peanut Powder or at Least a 10-fold Increase in the Amount of Peanut Powder Compared to Their Baseline Oral Food Challenge After 44 Weeks of Open Label Peanut Protein Consumption
NCT00580606 (7) [back to overview]Percent of Participants Who Achieved a Maintenance Dose of 1,386 mcg
NCT00580606 (7) [back to overview]Percent of Participants Who Successfully Consumed 10,000 mg of Peanut Powder
NCT00580606 (7) [back to overview]Percent of Participants Who Successfully Consumed 5,000 mg of Peanut Powder or at Least a 10-fold Increase in the Amount of Peanut Powder Compared to Their Baseline Oral Food Challenge
NCT00580606 (7) [back to overview]Percent of Crossover Participants Who Achieved an Open Label Peanut Protein Consumption Maintenance Dose of 3,696 mcg
NCT00597727 (2) [back to overview]Percentage of Subjects Tolerating a Peanut Oral Food Challenge 2-4 Weeks After Discontining Peanut SLIT Dosing
NCT00597727 (2) [back to overview]Percentage of Subjects Who Can Tolerate the Peanut Oral Food Challenge After 12 Months of Peanut SLIT Dosing
NCT00681265 (2) [back to overview]Noninvasive Tear Film Break-up Time
NCT00681265 (2) [back to overview]Fluorescein Tear Film Break-up Time
NCT00691197 (4) [back to overview]Corneal Staining
NCT00691197 (4) [back to overview]Best Corrected Visual Acuity
NCT00691197 (4) [back to overview]Patient Acceptability
NCT00691197 (4) [back to overview]Patient Preference
NCT00716079 (2) [back to overview]Death at 90 Days
NCT00716079 (2) [back to overview]A Composite of Death or Dependency, With Dependency Being Defined by a Score of 3 to 5 on the Modified Rankin Scale (mRS)
NCT00761202 (6) [back to overview]Ocular Comfort and Ocular Symptoms on Visual Analogue Scale
NCT00761202 (6) [back to overview]Daily Eyedrop Usage
NCT00761202 (6) [back to overview]Conjunctival Hyperaemia
NCT00761202 (6) [back to overview]Conjunctival Staining by Lissamine Green
NCT00761202 (6) [back to overview]Corneal Staining by Fluorescein
NCT00761202 (6) [back to overview]Lipid Layer Pattern Assessment
NCT00786487 (1) [back to overview]Insulin Sensitivity as Measured by Hyperinsulinemic Euglycemic Clamp at a Single Time Point (6 Hrs) After Intralipid or Glycerol Infusion
NCT00927849 (1) [back to overview]Relieve of Anal Pain
NCT00932477 (4) [back to overview]The Number of Ophthalmic Adverse Events at 1 Week
NCT00932477 (4) [back to overview]Tolerability Questionnaire Mean Scores at 1 Week
NCT00932477 (4) [back to overview]Number of Patients With at Least One Severity Grade Increase in Biomicroscopy Findings at 1 Week
NCT00932477 (4) [back to overview]Best-Corrected Visual Acuity (BCVA) Status at 1 Week
NCT00938704 (5) [back to overview]Change From Baseline in Tear Breakup Time (TBUT) at Week 2
NCT00938704 (5) [back to overview]Change From Baseline in Ocular Surface Disease Index (OSDI) at Week 2
NCT00938704 (5) [back to overview]Change From Baseline in Corneal Staining at Week 2
NCT00938704 (5) [back to overview]Change From Baseline in Conjunctival Staining (Temporal) at Week 2
NCT00938704 (5) [back to overview]Change From Baseline in Conjunctival Staining (Nasal) at Week 2
NCT00987727 (2) [back to overview]Change From Baseline in Ocular Surface Disease Index (OSDI) Questionnaire Score at Day 35
NCT00987727 (2) [back to overview]Change From Baseline in Global Ocular Staining Score at Day 35
NCT01010282 (5) [back to overview]Change From Baseline in Conjunctival Staining Severity Score at Day 90
NCT01010282 (5) [back to overview]Change From Baseline in Corneal Staining at Day 90
NCT01010282 (5) [back to overview]Change From Baseline in Subjective Evaluation of Symptom of Dryness (SESoD)Score at Day 90
NCT01010282 (5) [back to overview]Change From Baseline in Tear Break-up Time (TBUT) at Day 90
NCT01010282 (5) [back to overview]Change From Baseline in the Ocular Surface Disease Index (OSDI) Total Score at Day 90
NCT01271855 (2) [back to overview]Pain Level Twenty Four Hours After Delivery
NCT01271855 (2) [back to overview]Patient Satisfaction
NCT01339936 (3) [back to overview]Ocular Surface Disease Index Score
NCT01339936 (3) [back to overview]Tear Break Up Time
NCT01339936 (3) [back to overview]Tear Film Evaporation Rate
NCT01347073 (5) [back to overview]Adverse Events
NCT01347073 (5) [back to overview]Hyperammonemic Crisis
NCT01347073 (5) [back to overview]Frequency of Ammonia Levels Greater Than the Upper Limit of Normal (ULN) on HPN-100 Compared With NaPBA
NCT01347073 (5) [back to overview]Blood Ammonia
NCT01347073 (5) [back to overview]Adverse Events
NCT01687218 (12) [back to overview]Pharmacokinetics: End Period Tenofovir-Diphosphate (TFV-DP) Concentrations (log10 ng/mg) in Rectal Tissue
NCT01687218 (12) [back to overview]Acceptability: Participant Self-report of Liking the Product. H1-Overall How do You Feel About the Product You Used Recently?
NCT01687218 (12) [back to overview]Pharmacokinetics: Tenofovir (TFV) Concentrations (log10 ng/mL) in Blood Plasma
NCT01687218 (12) [back to overview]Pharmacokinetics: Tenofovir (TFV) Concentrations (log10 ng/mg) in Rectal Sponge
NCT01687218 (12) [back to overview]Pharmacokinetics: Emtricitabine (FTC) Concentrations (log10 ng/mL) in Blood Plasma
NCT01687218 (12) [back to overview]Pharmacokinetics: Emtricitabine (FTC) Concentrations (log10 ng/mg) in Rectal Sponge
NCT01687218 (12) [back to overview]Adherence: Percentage of Prescribed Doses Taken Orally or Administered Rectally in an 8-week Period
NCT01687218 (12) [back to overview]Safety: Grade 2 or Higher Adverse Events
NCT01687218 (12) [back to overview]Acceptability: Participant Self-report of Ease of Use. I1-Overall How Easy or Difficult Was it to Use the Product?
NCT01687218 (12) [back to overview]Acceptability: Participant Self-report of Likelihood of Product Use if Shown to be Effective. N1-If This Product Provides Some Protection How Likely Would You be to Take it?
NCT01687218 (12) [back to overview]Pharmacokinetics: End Period Emtricitabine (FTC) Concentrations (log10 ng/mg) in Rectal Tissue
NCT01687218 (12) [back to overview]Pharmacokinetics: End Period Tenofovir (TFV) Concentrations (log10 ng/mg) in Rectal Tissue
NCT01746511 (5) [back to overview]Length of Initial Round of Phototherapy
NCT01746511 (5) [back to overview]Number of Episodes of Repeat Phototherapy
NCT01746511 (5) [back to overview]Peak Total Serum Bilirubin Level
NCT01746511 (5) [back to overview]Total Number of Hours of Required Phototherapy
NCT01746511 (5) [back to overview]Rate of Decline in Bilirubin Levels (mg/dL/hr)
NCT01898091 (1) [back to overview]Maximum Change in Mean Mouth and Throat Soreness (MTS) Score From Baseline Through Weeks of Radiation Therapy Using the MTS Question of the Modified Oral Mucositis Daily Questionnaire*.
NCT01993186 (19) [back to overview]Percent Reduction From Baseline to Week 8 in Frequency of Observable Seizures (Normalized to a 4-Week Rate)
NCT01993186 (19) [back to overview]Change From Baseline to Week 8 in Distance Traveled (in Percent Predicted) as Measured by 6MWT
NCT01993186 (19) [back to overview]Change From Baseline to Week 8 in Distance Traveled (in Meters) as Measured by 6-Minute Walk Test (6MWT)
NCT01993186 (19) [back to overview]Change From Baseline to Week 8 in CANTAB, Spatial Span (SSP) Span Length Scores, GEE
NCT01993186 (19) [back to overview]Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Discontinuations Due to TEAEs During the Placebo-Controlled Period
NCT01993186 (19) [back to overview]Percent Reduction From Baseline Over Time in Frequency of Observable Seizures (Normalized to a 4-Week Rate)
NCT01993186 (19) [back to overview]Percent Reduction From Baseline Over Time in Frequency of Absence Seizures (Normalized to a 4-week Rate)
NCT01993186 (19) [back to overview]Percent Reduction From Baseline Over Time in Frequency of Total Seizures (Normalized to a 4-Week Rate)
NCT01993186 (19) [back to overview]Time (in Minutes) to Onset of Paroxysmal Exertional Dyskinesia (PED) as Measured During 6MWT Over Time Through Week 8
NCT01993186 (19) [back to overview]Change From Baseline to Week 8 in CANTAB, Spatial Working Memory (SWM) Scores, GEE
NCT01993186 (19) [back to overview]Change From Baseline to Week 8 in CANTAB, Paired Associates Learning (PAL) Scores, GEE
NCT01993186 (19) [back to overview]Change From Baseline to Week 8 in Cambridge Neuropsychological Test Automated Battery (CANTAB), Reaction Time (RTI) Scores, Generalized Estimating Equation (GEE)
NCT01993186 (19) [back to overview]Percentage of Participants With at Least a 50% Reduction From Baseline to Week 8 in Frequency of Total Seizures
NCT01993186 (19) [back to overview]Percentage of Participants With at Least 50% Reduction From Baseline to Week 8 in Frequency of Observable Seizures
NCT01993186 (19) [back to overview]Percentage of Participants With at Least 50% Reduction From Baseline to Week 8 in Frequency of Absence Seizures
NCT01993186 (19) [back to overview]Percent Reduction From Baseline to Week 8 in Frequency of Total Seizures (Normalized to a 4-Week Rate)
NCT01993186 (19) [back to overview]Number of Participants With TEAEs, Serious TEAEs and Discontinuations Due to TEAEs During the Extension Period
NCT01993186 (19) [back to overview]Percent Reduction From Baseline to Week 8 in Frequency of Absence Seizures (Normalized to a 4-Week Rate)
NCT01993186 (19) [back to overview]Change From Baseline to Week 8 in Gross Motor Function Measure-88 (GMFM-88) Total Score
NCT02117687 (14) [back to overview]Change From Baseline in the Schirmer Test in the Study Eye
NCT02117687 (14) [back to overview]Change From Baseline in Tear Break-up Time (TBUT) in the Study Eye
NCT02117687 (14) [back to overview]Conjunctival Hyperaemia in the Study Eye
NCT02117687 (14) [back to overview]Change From Baseline in Ocular Surface Disease Index© (OSDI) Score
NCT02117687 (14) [back to overview]Change From Baseline in Global Ocular Staining Score in the Study Eye
NCT02117687 (14) [back to overview]Change From Baseline in Global Ocular Staining Score in the Study Eye
NCT02117687 (14) [back to overview]Change From Baseline in Corneal Staining in the Study Eye
NCT02117687 (14) [back to overview]Change From Baseline in Conjunctival Staining in the Study Eye
NCT02117687 (14) [back to overview]Investigator Global Assessment of Treatment Efficacy on a 4-Point Scale
NCT02117687 (14) [back to overview]Study Product Use
NCT02117687 (14) [back to overview]Subject Assessment of Dry Eye Symptoms on a 5-Point Scale
NCT02117687 (14) [back to overview]Subject Assessment of Treatment Acceptability on a 5-Point Scale
NCT02117687 (14) [back to overview]Subject Global Assessment of Treatment Efficacy on a 5-Point Scale
NCT02117687 (14) [back to overview]Work Productivity and Activity Impairment Questionnaire Score
NCT02246218 (54) [back to overview]Amino Acid Assessment: Baseline and Change From Baseline in Leucine Up to Month 24: Cohort of 0 Months to <2 Months Participants
NCT02246218 (54) [back to overview]Amino Acid Assessment: Baseline and Change From Baseline in Leucine Up to Month 24: Cohort of 2 Months to <2 Years Participants
NCT02246218 (54) [back to overview]Amino Acid Assessment: Baseline and Change From Baseline in Sum of Glutamine and Glutamate Up to Month 24: Cohort of 0 Months to <2 Months Participants
NCT02246218 (54) [back to overview]Amino Acid Assessment: Baseline and Change From Baseline in Sum of Glutamine and Glutamate Up to Month 24: Cohort of 2 Months to <2 Years Participants
NCT02246218 (54) [back to overview]Amino Acid Assessment: Baseline and Change From Baseline in Valine Up to Month 24: Cohort of 2 Months to <2 Years Participants
NCT02246218 (54) [back to overview]Assessment of Growth and Development: Baseline and Change From Baseline in BMI Z-Score Up to Month 24: Cohort of 0 Months to <2 Months Participants
NCT02246218 (54) [back to overview]Assessment of Growth and Development: Baseline and Change From Baseline in Body Mass Index (BMI) Z-Score Up to Month 24: Cohort of 2 Months to <2 Years Participants
NCT02246218 (54) [back to overview]Assessment of Growth and Development: Baseline and Change From Baseline in Body Surface Area (BSA) Z-Score Up to Month 24: Cohort of 2 Months to <2 Years Participants
NCT02246218 (54) [back to overview]Assessment of Growth and Development: Baseline and Change From Baseline in BSA Z-Score Up to Month 24: Cohort of 0 Months to <2 Months Participants
NCT02246218 (54) [back to overview]Assessment of Urinary PAA Concentrations on the First Full Day of RAVICTI Dosing: Cohort of 0 Months to <2 Months Participants
NCT02246218 (54) [back to overview]Assessment of Urinary PAA Concentrations on the First Full Day of RAVICTI Dosing: Cohort of 2 Months to <2 Years Participants
NCT02246218 (54) [back to overview]Assessment of Urinary PAA Concentrations Up to End of Trial: Cohort of 0 Months to <2 Months Participants
NCT02246218 (54) [back to overview]Assessment of Urinary PAA Concentrations Up to End of Trial: Cohort of 2 Months to <2 Years Participants
NCT02246218 (54) [back to overview]Assessment of Urinary PAGN Concentrations on the First Full Day of RAVICTI Dosing: Cohort of 0 Months to <2 Months Participants
NCT02246218 (54) [back to overview]Assessment of Urinary PAGN Concentrations on the First Full Day of RAVICTI Dosing: Cohort of 2 Months to <2 Years Participants
NCT02246218 (54) [back to overview]Assessment of Urinary PAGN Concentrations Up to End of Trial: Cohort of 0 Months to <2 Months Participants
NCT02246218 (54) [back to overview]Assessment of Urinary PAGN Concentrations Up to End of Trial: Cohort of 2 Months to <2 Years Participants
NCT02246218 (54) [back to overview]Number of Participants With TEAEs, Serious TEAEs, Deaths, and Discontinuations Due to TEAEs: Cohort of 0 Months to <2 Months Participants
NCT02246218 (54) [back to overview]Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Deaths, and Discontinuations Due to TEAEs: Cohort of 2 Months to <2 Years Participants
NCT02246218 (54) [back to overview]Amino Acid Assessment: Baseline and Change From Baseline in Valine Up to Month 24: Cohort of 0 Months to <2 Months Participants
NCT02246218 (54) [back to overview]Percentage of Participants With Successful Transition to RAVICTI With Controlled Ammonia (i.e. No Clinical Symptoms and Ammonia < 100 μmol/L): Cohort of 0 Months to <2 Months Participants
NCT02246218 (54) [back to overview]Percentage of Participants With Successful Transition to RAVICTI With Controlled Ammonia (i.e. No Clinical Symptoms and Ammonia < 100 μmol/L): Cohort of 2 Months to <2 Years Participants
NCT02246218 (54) [back to overview]Plasma PAA AUC(0-last) on the First Full Day of RAVICTI Dosing: Cohort of 0 Months to <2 Months Participants
NCT02246218 (54) [back to overview]Plasma PAA AUC(0-last) on the First Full Day of RAVICTI Dosing: Cohort of 2 Months to <2 Years Participants
NCT02246218 (54) [back to overview]Plasma PAA Cmax on the First Full Day of RAVICTI Dosing: Cohort of 0 Months to <2 Months Participants
NCT02246218 (54) [back to overview]Plasma PAA Cmin on the First Full Day of RAVICTI Dosing: Cohort of 0 Months to <2 Months Participants
NCT02246218 (54) [back to overview]Plasma PAA Cmin on the First Full Day of RAVICTI Dosing: Cohort of 2 Months to <2 Years Participants
NCT02246218 (54) [back to overview]Plasma PAA Tmax on the First Full Day of RAVICTI Dosing: Cohort of 0 Months to <2 Months Participants
NCT02246218 (54) [back to overview]Plasma PAA Tmax on the First Full Day of RAVICTI Dosing: Cohort of 2 Months to <2 Years Participants
NCT02246218 (54) [back to overview]Plasma PAGN AUC(0-last) on the First Full Day of RAVICTI Dosing: Cohort of 0 Months to <2 Months Participants
NCT02246218 (54) [back to overview]Plasma PAGN AUC(0-last) on the First Full Day of RAVICTI Dosing: Cohort of 2 Months to <2 Years Participants
NCT02246218 (54) [back to overview]Plasma PAGN Cmax on the First Full Day of RAVICTI Dosing: Cohort of 0 Months to <2 Months Participants
NCT02246218 (54) [back to overview]Plasma PAGN Cmin on the First Full Day of RAVICTI Dosing: Cohort of 0 Months to <2 Months Participants
NCT02246218 (54) [back to overview]Plasma PAGN Cmin on the First Full Day of RAVICTI Dosing: Cohort of 2 Months to <2 Years Participants
NCT02246218 (54) [back to overview]Plasma PAGN Tmax on the First Full Day of RAVICTI Dosing: Cohort of 0 Months to <2 Months Participants
NCT02246218 (54) [back to overview]Plasma PAGN Tmax on the First Full Day of RAVICTI Dosing: Cohort of 2 Months to <2 Years Participants
NCT02246218 (54) [back to overview]Plasma PBA Area Under the Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC[0-last]) on the First Full Day of RAVICTI Dosing: Cohort of 2 Months to <2 Years Participants
NCT02246218 (54) [back to overview]Plasma PBA AUC(0-last) on the First Full Day of RAVICTI Dosing: Cohort of 0 Months to <2 Months Participants
NCT02246218 (54) [back to overview]Plasma PBA Cmax on the First Full Day of RAVICTI Dosing: Cohort of 0 Months to <2 Months Participants
NCT02246218 (54) [back to overview]Plasma PBA Cmin on the First Full Day of RAVICTI Dosing: Cohort of 0 Months to <2 Months Participants
NCT02246218 (54) [back to overview]Plasma PBA Minimum Plasma Concentration (Cmin) on the First Full Day of RAVICTI Dosing: Cohort of 2 Months to <2 Years Participants
NCT02246218 (54) [back to overview]Plasma PBA Time to Cmax (Tmax) on the First Full Day of RAVICTI Dosing: Cohort of 2 Months to <2 Years Participants
NCT02246218 (54) [back to overview]Plasma PBA Tmax on the First Full Day of RAVICTI Dosing: Cohort of 0 Months to <2 Months Participants
NCT02246218 (54) [back to overview]Plasma Phenylacetate/Phenylacetic Acid (PAA) Cmax on the First Full Day of RAVICTI Dosing: Cohort of 2 Months to <2 Years Participants
NCT02246218 (54) [back to overview]Plasma Phenylacetylglutamine (PAGN) Cmax on the First Full Day of RAVICTI Dosing: Cohort of 2 Months to <2 Years Participants
NCT02246218 (54) [back to overview]Plasma Phenylbutyrate/Phenylbutyric Acid (PBA) Maximum Plasma Concentration (Cmax) on the First Full Day of RAVICTI Dosing: Cohort of 2 Months to <2 Years Participants
NCT02246218 (54) [back to overview]Rate of HACs: Cohort of 0 Months to <2 Months Participants
NCT02246218 (54) [back to overview]Rate of Hyperammonemic Crises (HACs): Cohort of 2 Months to <2 Years Participants
NCT02246218 (54) [back to overview]Amino Acid Assessment: Baseline and Change From Baseline in Glutamate Up to Month 24: Cohort of 0 Months to <2 Months Participants
NCT02246218 (54) [back to overview]Amino Acid Assessment: Baseline and Change From Baseline in Glutamate Up to Month 24: Cohort of 2 Months to <2 Years Participants
NCT02246218 (54) [back to overview]Amino Acid Assessment: Baseline and Change From Baseline in Glutamine Up to Month 24: Cohort of 0 Months to <2 Months Participants
NCT02246218 (54) [back to overview]Amino Acid Assessment: Baseline and Change From Baseline in Glutamine Up to Month 24: Cohort of 2 Months to <2 Years Participants
NCT02246218 (54) [back to overview]Amino Acid Assessment: Baseline and Change From Baseline in Isoleucine Up to Month 24: Cohort of 0 Months to <2 Months Participants
NCT02246218 (54) [back to overview]Amino Acid Assessment: Baseline and Change From Baseline in Isoleucine Up to Month 24: Cohort of 2 Months to <2 Years Participants
NCT02304991 (6) [back to overview]Change in Immune Parameters With Peanut SLIT Versus Placebo SLIT (Peanut Skin Prick Test)
NCT02304991 (6) [back to overview]Change in Immune Parameters With Peanut SLIT Versus Placebo SLIT (Peanut-specific IgE)
NCT02304991 (6) [back to overview]Change in Immune Parameters With Peanut SLIT Versus Placebo SLIT (Peanut-specific IgG4)
NCT02304991 (6) [back to overview]Desensitization After 36 Months of Peanut SLIT or Placebo SLIT
NCT02304991 (6) [back to overview]Number of Participants Experiencing Serious Adverse Events With Peanut SLIT Versus Placebo SLIT
NCT02304991 (6) [back to overview]Tolerance 3 Months After Discontinuing Peanut SLIT or Placebo SLIT
NCT02383758 (4) [back to overview]Percent Continent
NCT02383758 (4) [back to overview]Mean Clinical Global Impression for Severity (CGI-S) Score
NCT02383758 (4) [back to overview]Mean Clinical Global Impression for Improvement (CGI-I) Score
NCT02383758 (4) [back to overview]Percent Independence
NCT02435069 (8) [back to overview]Number of Participants Experiencing Vagal Symptoms With Flush
NCT02435069 (8) [back to overview]NS and USP Glycerin Flush Solution Dosing Frequency Necessary to Achieve Continence
NCT02435069 (8) [back to overview]Flush Volume
NCT02435069 (8) [back to overview]Fecal Soiling - Quantitative Count Detailing the Number of Episodes of Fecal Incontinence Per Day on NS and USP Glycerin
NCT02435069 (8) [back to overview]Fecal Soiling - Number of Participants That Gained and Maintained Continence on Each Flushing Regimen
NCT02435069 (8) [back to overview]Cramping With Flush
NCT02435069 (8) [back to overview]Change in Stool Calprotectin Levels Assessed Through Comparing Levels Obtained Following Completion of NS and USP Glycerin Dosing Phases With the Baseline Value For Each Subject
NCT02435069 (8) [back to overview]Number of Participants With Any Electrolyte Abnormality
NCT02492997 (2) [back to overview]Subject Satisfaction With Treatment
NCT02492997 (2) [back to overview]Abdominal Circumference
NCT02797067 (3) [back to overview]the Severity of Post-ESWL Pancreatitis Measured as Consensus Definitions for the Major Complications of ERCP(Endoscopic Retrograde Cholangiopancreatography )
NCT02797067 (3) [back to overview]the Incidence and Severity of Asymptomatic Hyperamylasemia and Other Post-ESWL Complications
NCT02797067 (3) [back to overview]the Incidence of Post-ESWL Pancreatitis
NCT02833415 (1) [back to overview]Change in Glycerol Enrichment
NCT02839772 (17) [back to overview]Total Number of All Participants With the Presence of a Bad Odour Emanating From Their Lower Limbs.
NCT02839772 (17) [back to overview]Change in Number of Work Days Lost in Previous Month Due to Adenolymphangitis (ADL)
NCT02839772 (17) [back to overview]Change in Largest Lower Leg Circumference
NCT02839772 (17) [back to overview]Change in Largest Foot Circumference
NCT02839772 (17) [back to overview]Number of Wounds on Lower Legs/Feet of Participants.
NCT02839772 (17) [back to overview]Change in TEWL at Top of Outer Lower Legs
NCT02839772 (17) [back to overview]Correlation Between Number of Work Days Lost Due to Adenolymphangitis and Number of Wounds
NCT02839772 (17) [back to overview]Stage of Podoconiosis in Each Leg of All Participants at Baseline and 4th Visit
NCT02839772 (17) [back to overview]Change in TEWL at Base of Outer Lower Legs
NCT02839772 (17) [back to overview]Change in Stratum Corneum Hydration (SCH) at the Top of Outer Lower Legs
NCT02839772 (17) [back to overview]Change in Stratum Corneum Hydration at Base of Outer Lower Leg
NCT02839772 (17) [back to overview]Change in Stratum Corneum Hydration at Top of Feet
NCT02839772 (17) [back to overview]Change in TEWL at Mid-point Outer Lower Legs
NCT02839772 (17) [back to overview]Change in Stratum Corneum Hydration (SCH) at Mid-point Outer Lower Leg.
NCT02839772 (17) [back to overview]Change in TEWL at Top of Feet
NCT02839772 (17) [back to overview]Amharic Dermatology Life Quality Index (DLQI)
NCT02839772 (17) [back to overview]Total Number of Trophic Skin Changes (Mossy Changes) All Participants at Baseline and 4th Visit
NCT03157583 (2) [back to overview]Spectrum of Sun Protection
NCT03157583 (2) [back to overview]Arithmetic Mean of Individual Sun Protection Factor (SPFi) Values
NCT03335488 (5) [back to overview]Rate of Drug Discontinuations (Percentage of Participants Who Discontinued Study Drug) Due to Any Reason in the Initial Treatment Period
NCT03335488 (5) [back to overview]Plasma Ammonia Area Under the Curve (AUC) 0 to 8h at the End of the Initial Treatment Period
NCT03335488 (5) [back to overview]Peak Plasma Concentration (Cmax) of Ammonia at the End of the Initial Treatment Period
NCT03335488 (5) [back to overview]Change From Baseline in Fasting Plasma Ammonia Levels During the Initial Treatment Period
NCT03335488 (5) [back to overview]Rate of Treatment Success (Percentage of Participants Defined as Treatment Success at Week 4) During the Initial Treatment Period
NCT03355326 (7) [back to overview]Days on Total Parenteral Nutrition (TPN)
NCT03355326 (7) [back to overview]Hospital Length of Stay
NCT03355326 (7) [back to overview]Number of Participants With Post-operative Complications
NCT03355326 (7) [back to overview]Number of Participants With Sequela of Long Term Total Parenteral Nutrition (TPN) Administration
NCT03355326 (7) [back to overview]Time to First Bowel Movement
NCT03355326 (7) [back to overview]Number of Participants With Infectious Complications
NCT03355326 (7) [back to overview]Time to Full Enteral Feeds
NCT03657407 (4) [back to overview]Time Until Cleared for PACU Discharge
NCT03657407 (4) [back to overview]Post-operative Pain: VAS
NCT03657407 (4) [back to overview]Number of Participants for Which Anti-emetics Were Received in PACU
NCT03657407 (4) [back to overview]Narcotic Use
NCT03901144 (5) [back to overview]Skin Barrier Strengthening Effect by Measurement of Trans Epidermal Water Loss (TEWL) Before and After Induction of Skin Irritation
NCT03901144 (5) [back to overview]Skin Barrier Strengthening Effect by Measurement of Skin Redness Before Induction of Skin Irritation as Assessed by Visual Scoring
NCT03901144 (5) [back to overview]Skin Barrier Strengthening Effect by Measurement of Skin Redness Before and After Induction of Skin Irritation as Assessed by the Erythema Index (Change From Day 29 to Day 31)
NCT03901144 (5) [back to overview]Skin Barrier Strengthening Effect by Measurement of Skin Redness Before and After Induction of Skin Irritation as Assessed by Mexameter (Change From Day 29 to Day 31)
NCT03901144 (5) [back to overview]Skin Barrier Strengthening Effect by Measurement of Skin Redness After Induction of Skin Irritation as Assessed by Visual Scoring

Change From Baseline at Day 30 in Subjective Evaluation of Symptom of Dryness Score

Measures dry eye severity on a scale of 0-4 (0 = none, 4 = severe) (NCT00514852)
Timeframe: Change from baseline at Day 30

,
InterventionUnits on a scale (Mean)
Day 1 (Baseline)Day 7Day 30
Carboxymethylcellulose and Glycerin Based Artificial Tear2.8-0.5-0.7
Carboxymethylcellulose Based Artificial Tear2.8-0.5-0.7

[back to top]

Change From Baseline at Day 30 in Schirmer Test, With Anesthesia

Schirmer Test measures the rate of the secretion of tears (NCT00514852)
Timeframe: Change from baseline at Day 30

,
Interventionmm/5min (Mean)
Day 1 (Baseline)Day 7Day 30
Carboxymethylcellulose and Glycerin Based Artificial Tear9.21.21.7
Carboxymethylcellulose Based Artificial Tear8.61.21.8

[back to top]

Change From Baseline at Day 30 in Ocular Surface Disease Index© Questionnaire Score

Ocular Surface Disease Index© Questionnaire Score is measured on 12 domains; a 5-point scale (0-4) for each domain. Sum of the domain scores is normalized to a severity scale of 0-100 (0 = no symptoms, 100 = maximum severity) (NCT00514852)
Timeframe: Change from baseline at Day 30

,
InterventionUnits on a scale (Mean)
Day 1 (Baseline)Day 7Day 30
Carboxymethylcellulose and Glycerin Based Artificial Tear44-12.6-16.3
Carboxymethylcellulose Based Artificial Tear45.2-13.6-16.6

[back to top]

Change From Baseline at Day 30 in Ocular Surface (Corneal) Staining With Fluorescein

Sum of corneal staining over 5 zones; each zone was measured on a modified Oxford Scheme of 0-5 (0=no staining, 5=most severe staining), with total score from 0-25 (0= no staining, 25 = most severe staining) (NCT00514852)
Timeframe: Change from baseline at Day 30

,
InterventionUnits on a scale (Mean)
Day 1 (Baseline)Day 7Day 30
Carboxymethylcellulose and Glycerin Based Artificial Tear4.0-1.2-1.3
Carboxymethylcellulose Based Artificial Tear4.4-0.9-1.5

[back to top]

Change From Baseline at Day 30 in Ocular Surface (Conjunctival) Staining With Fluorescein

Sum of conjunctival staining over 6 zones; each zone was measured on a modified Oxford Scheme of 0-5 (0=no staining, 5=most severe staining), with total score from 0-30 (0=no staining, 30=most severe staining) (NCT00514852)
Timeframe: Change from baseline at Day 30

,
InterventionUnits on a scale (Mean)
Day 1 (Baseline)Day 7Day 30
Carboxymethylcellulose and Glycerin Based Artificial Tear4.9-1.1-1.7
Carboxymethylcellulose Based Artificial Tear5.1-1.0-1.5

[back to top]

Vision Subscale of the Ocular Surface Disease Index Questionnaire© at Day 30

Vision subscale of the Ocular Surface Disease Index Questionnaire© is measured on 6 domains; a 5-point scale (0-4) for each domain. Sum of the domain scores is normalized to a severity scale of 0-100 (0 = no symptoms, 100 = maximum severity) (NCT00514852)
Timeframe: Day 30

,
InterventionUnits on a scale (Mean)
Day 1 (Baseline)Day 7Day 30
Carboxymethylcellulose and Glycerin Based Artificial Tear37.624.822.8
Carboxymethylcellulose Based Artificial Tear41.626.925.6

[back to top]

Patient Acceptability Score (Vision) at Day 30

Vision Quality Visual Analog Scale is measured on a 0-100 point scale (0 = very poor, has never been worse, 100 = excellent, has never been better). (NCT00514852)
Timeframe: Day 30

,
InterventionUnits on a scale (Mean)
Day 1 (Baseline)Day 7Day 30
Carboxymethylcellulose and Glycerin Based Artificial Tear56.865.365.4
Carboxymethylcellulose Based Artificial Tear54.262.666.4

[back to top]

Change From Baseline at Day 30 in Tear Break-Up Time, With Fluorescein

Measures the stability of tear film. The average of 3 measures. (NCT00514852)
Timeframe: Change from baseline at Day 30

,
Interventionseconds (Mean)
Day 1 (Baseline)Day 7Day 30
Carboxymethylcellulose and Glycerin Based Artificial Tear4.30.91.1
Carboxymethylcellulose Based Artificial Tear4.30.90.9

[back to top]

Ocular Surface Staining With Fluorescein (Central Cornea) at Day 30

Central staining score is based on modified Oxford Scheme measured on a scale of 0-5 (0= no staining, 5= most severe staining) (NCT00514852)
Timeframe: Day 30

,
InterventionUnits on a scale (Mean)
Day 1 (Baseline)Day 7Day 30
Carboxymethylcellulose and Glycerin Based Artificial Tear0.70.50.4
Carboxymethylcellulose Based Artificial Tear0.80.50.4

[back to top]

Patient Acceptability Score (Dryness) at Day 30

Dryness Severity Visual Analog Scale is measured on a 0-100 point scale (0 = could not be worse, 100 = none at all). (NCT00514852)
Timeframe: Day 30

,
InterventionUnits on scale (Mean)
Day 1 (Baseline)Day 7Day 30
Carboxymethylcellulose and Glycerin Based Artificial Tear47.460.763.3
Carboxymethylcellulose Based Artificial Tear44.657.763.8

[back to top]

Best Corrected Visual Acuity (BCVA) Status at Day 90

"BCVA status at Day 90 reported as the number of patients whose scores were either Better, No Change, or Worse than their scores at baseline. The status was tabulated as number of lines read correctly at Day 90 minus the number of lines read correctly at baseline. Better equals increase of 2 lines or more; No Change equals change between -2 to +2 lines; Worse equals decrease of 2 lines or more. BCVA is measured using a special eye chart a nd is reported as the number of lines (5 letters per line) read correctly." (NCT00544713)
Timeframe: Day 90

,
InterventionNumber of Patients (Number)
BetterNo ChangeWorse
Carboxymethylcellulose and Glycerin Based Artificial Tear81041
Carboxymethylcellulose Based Artificial Tear71070

[back to top]

Change From Baseline in Study Product Usage at Day 90

Change from baseline in the study product usage (average number of uses per day) at Day 90. A negative number change from baseline indicates a reduction in eye drop usage (improvement). (NCT00544713)
Timeframe: Baseline, Day 90

,
InterventionNumber of study product uses per day (Mean)
Baseline (108/108)Change from Baseline at Day 90 (108/105)
Carboxymethylcellulose and Glycerin Based Artificial Tear7.9-4.9
Carboxymethylcellulose Based Artificial Tear7.9-4.5

[back to top]

Patient Acceptability- Percentage of Patients Who Rated Artificial Tears (AT) as Acceptable at Day 90

"A questionnaire was administered to all patients to evaluate the acceptability of the Artificial Tears (referred to as AT). Percentage of patients responding either Agree or Strongly Agree at day 90 was tabulated. The potential response categories included Strongly Agree, Agree, Neither Agree Nor Disagree, Disagree and Strongly Disagree." (NCT00544713)
Timeframe: Day 90

,
InterventionPercentage of Patients (Number)
Liked using these AT (112/110)AT helped eyes feel comfortable (112/110)AT were soothing to eyes (111/110)AT protected eyes from dryness (112/109)AT protected eyes from low humidity (112/110)Vision was normal few min.after AT use(112/110)Few min. after use, AT gave clear vision(111/110)AT helped eyes heal from surgery (112/110)AT helped eyes feel same as pre-LASIK (111/110)It's good to use AT after surgery(111/109)
Carboxymethylcellulose and Glycerin Based Artificial Tear88.494.695.588.478.693.894.683.985.697.3
Carboxymethylcellulose Based Artificial Tear93.694.595.489.982.792.794.586.489.196.3

[back to top]

Patient Acceptability (Sensory) - Percentage of Patients Who Rated Artificial Tears (AT) as Acceptable at Day 90

"A patient acceptability - sensory questionnaire was administered to all patients to evaluate the acceptability of the Artificial Tears (AT). Percentage of patients responding either Agree or Strongly Agree at day 90 was tabulated. The potential response categories included Strongly Agree, Agree, Neither Agree Nor Disagree, Disagree and Strongly Disagree." (NCT00544713)
Timeframe: Day 90

,
InterventionPercentage of Patients (Number)
Thickness of AT is just right (112/109)AT did not interfere with vision (112/108)AT did not cause my eyes to get crusty (112/108)AT were easy to use (112/109)AT were convenient to use (112/109)AT were important to a good outcome (111/109)AT were helpful to achieve comfort (112/109)AT were helpful to achieve good vision (112/109)I no longer feel I need to use AT (111/108)
Carboxymethylcellulose and Glycerin Based Artificial Tear79.564.366.199.196.482.092.071.443.2
Carboxymethylcellulose Based Artificial Tear87.282.480.699.191.780.793.676.138.0

[back to top]

Number of Patients Prescribed to Each Dosing Regimen at Day 14 and Day 60

Number of patients prescribed to each dosing regimen at Day 14 and Day 60. At each visit from Day 14 (the first post-operative visit) to Day 60, patients were prescribed to 1 to 4 dosing regimens based on the investigator's clinical evaluation. Dosing schedule options were: At least every 2 hours while awake, 6 to 8 times per day, 3 to 5 times per day, at 1 to 2 times per day. (NCT00544713)
Timeframe: Day 14, Day 60

,
InterventionNumber of patients (Number)
Day 14: at least every 2 hrs (113/110)Day 14: 6-8 times a day (113/110)Day 14: 3-5 times a day (113/110)Day 14: 1-2 times a day (113/110)Day 60: at least every 2 hrs (109/107)Day 60: 6-8 times a day (109/107)Day 60: 3-5 times a day (109/107)Day 60: 1-2 times a day (109/107)
Carboxymethylcellulose and Glycerin Based Artificial Tear20305854126231
Carboxymethylcellulose Based Artificial Tear22305443146030

[back to top]

Change From Baseline of Total Higher Order Aberration (HOA) of the Worse Eye at Day 90

Change from Baseline in total HOA of the worse eye. The total HOA number is measured using a machine that calculates and detects changes in the cornea which could occur post Lasik surgery. A negative number change from baseline indicates an improvement. (NCT00544713)
Timeframe: Baseline, Day 90

,
InterventionMicrons (Mean)
BaselineChange from Baseline at Day 90
Carboxymethylcellulose and Glycerin Based Artificial Tear0.521-0.058
Carboxymethylcellulose Based Artificial Tear0.520-0.047

[back to top]

Change From Baseline of the Worse Eye in Tear Break-Up Time (TBUT) at Day 90

Change from Baseline in TBUT of the worse eye at Day 90. TBUT is the time required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film. A positive number change from baseline indicates an increase in TBUT (improvement). (NCT00544713)
Timeframe: Baseline, Day 90

,
InterventionNumber of seconds (Mean)
BaselineChange from Baseline at Day 90
Carboxymethylcellulose and Glycerin Based Artificial Tear13.66-0.92
Carboxymethylcellulose Based Artificial Tear13.25-0.87

[back to top]

Change From Baseline of the Worse Eye in Schirmer's Test at Day 90

Change from baseline in Schirmer's Test results at Day 90 in the worse eye. The Schirmer's Test measures the rate of the secretion of tears produced by the eye over 5 minutes. The results indicate the presence of dry eye (Normal = greater than or equal to 15 millimeters (mm) of tears, Dry Eye = less than 15 mm of tears). The smaller the number, the more severe the dry eye. (NCT00544713)
Timeframe: Baseline, Day 90

,
InterventionMillimeters of Tears (Mean)
BaselineChange from Baseline at Day 90
Carboxymethylcellulose and Glycerin Based Artificial Tear16.3-0.3
Carboxymethylcellulose Based Artificial Tear13.51.7

[back to top]

Change From Baseline of the Worse Eye in Corneal Topography Measured by Humphrey Atlas at Day 90

Change from Baseline in corneal topography of the worse eye as measured by a Humphrey Atlas system which calculates a number. Corneal topography is anon-invasive medical imaging technique for mapping the surface curvature of the cornea (the outer structure of the eye). The higher the number the more irregular the cornea. A Humphrey Atlas system detects irregular conditions in the cornea with a range from 0 = best to 2.5 = worst. A negative number change from baseline indicates an improvement. (NCT00544713)
Timeframe: Baseline, Day 90

,
InterventionUnits on a scale (Mean)
BaselineChange from Baseline at Day 90
Carboxymethylcellulose and Glycerin Based Artificial Tear1.32-0.49
Carboxymethylcellulose Based Artificial Tear1.25-0.26

[back to top]

Change From Baseline of the Worse Eye in Corneal Topography as Measured by Pentacam at Day 90

Change from Baseline in corneal topography of the worse eye as measured using a Pentacam system which calculates a number. Corneal topography is a non-invasive medical imaging technique for mapping the surface of the eye. The Pentacam system measures the pupil and anterior segment (the front part of the eye) which provides a range from 10 (best) to 60 (worst). A negative number change from baseline indicates an improvement. (NCT00544713)
Timeframe: Baseline, Day 90

,
InterventionUnits on a scale (Mean)
BaselineChange from Baseline at Day 90
Carboxymethylcellulose and Glycerin Based Artificial Tear31.95-2.12
Carboxymethylcellulose Based Artificial Tear32.32-2.24

[back to top]

Change From Baseline of the Worse Eye in Corneal Staining With Fluorescein at Day 90

Change from Baseline in corneal staining of the worse eye at Day 90. Sum of corneal staining over 5 zones; each zone was measured on a modified Oxford Scheme (0 = no staining and 5 = severe staining), for a minimum score of 0 and a maximum score of 25. The higher the grade score, the worse the dry eye condition. A negative change from baseline represents a decrease in corneal staining (improvement). (NCT00544713)
Timeframe: Baseline, Day 90

,
InterventionScores on a Scale (Mean)
BaselineChange from Baseline at Day 90
Carboxymethylcellulose and Glycerin Based Artificial Tear0.50.0
Carboxymethylcellulose Based Artificial Tear0.50.0

[back to top]

Post LASIK Dry Eye Symptoms as Measured by Ocular Surface Disease Index (OSDI©) Score at Day 90

Measured on 12 domains (categories); a 5-point scale for each domain (0 = best, no dry eye symptoms, 4 = worst, constant dry eye symptoms). Sum of the domain scores is normalized (standardized) to a severity scale of 0-100 (0 = no symptoms (best score), 100 = maximum severity (worst score)). (NCT00544713)
Timeframe: Day 90

InterventionScores on a Scale (Mean)
Carboxymethylcellulose and Glycerin Based Artificial Tear8.32
Carboxymethylcellulose Based Artificial Tear6.43

[back to top]

Change From Baseline of the Worse Eye in Conjunctival Staining With Lissamine Green at Day 90

Change from Baseline in conjunctival staining of the worse eye using Lissamine Green staining procedure. Sum of conjunctival staining over 6 zones; each zone was measured on a modified Oxford Scheme (0 = no staining and 5 = severe staining), with a minimum score of 0 and a maximum score of 30. The higher the grade score, the worse dry eye condition. A negative number change from baseline represents a decrease in corneal staining (improvement). (NCT00544713)
Timeframe: Baseline, Day 90

,
InterventionScores on a Scale (Mean)
BaselineChange from Baseline at Day 90
Carboxymethylcellulose and Glycerin Based Artificial Tear1.00.0
Carboxymethylcellulose Based Artificial Tear0.8-0.3

[back to top]

Number of Crossover Participants With Serious Adverse Events (SAEs) During 44 Weeks of Open Label Peanut Protein Consumption

All subjects who were in the Placebo group during the double-blind phase of the study who initiated crossover peanut sublingual immunotherapy during the open label phase of the study will be included. (NCT00580606)
Timeframe: Initiation of open label peanut protein study therapy through Week 44 of open label peanut protein consumption

Interventionparticipants (Number)
High Dose Peanut SLIT Crossover (Open Label)0

[back to top]

Number of Participants With Serious Adverse Events (SAEs)

This study graded the severity of Adverse Events experienced by participants according to the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 3. (NCT00580606)
Timeframe: Baseline through Week 44 (Double Blind Period)

Interventionparticipants (Number)
Low Dose Peanut SLIT (Double Blind)1
Placebo (Double Blind)0

[back to top]

Percent of Crossover Participants Who Successfully Consumed 5,000 mg of Peanut Powder or at Least a 10-fold Increase in the Amount of Peanut Powder Compared to Their Baseline Oral Food Challenge After 44 Weeks of Open Label Peanut Protein Consumption

Desensitization Assessment: Participants who successfully consumed without dose-limiting symptoms 5,000 mg of peanut powder or at least a 10-fold increase in the amount of peanut powder compared to their baseline oral food challenge during a double-blind placebo-controlled oral food challenge were counted as successes. (NCT00580606)
Timeframe: Week 44 after initiating crossover open label peanut protein consumption

InterventionPercentage of participants (Number)
High Dose Peanut SLIT Crossover (Open Label)43.8

[back to top]

Percent of Participants Who Achieved a Maintenance Dose of 1,386 mcg

During the build-up phase, escalation was to occur every 2 weeks until the 1,386 mcg maintenance dose was reached. The maximum time allowed for the build-up phase was 36 weeks; the dose achieved by 36 weeks was considered the maintenance dose. (NCT00580606)
Timeframe: Week 44 (Double Blind Period)

InterventionPercentage of participants (Number)
Low Dose Peanut SLIT (Double Blind)85.0
Placebo (Double Blind)95.0

[back to top]

Percent of Participants Who Successfully Consumed 10,000 mg of Peanut Powder

Tolerance Assessment: Participants who successfully consumed without dose-limiting symptoms 10,000 mg of peanut powder during a double-blind placebo-controlled oral food challenge were then given an open feeding of peanut butter and those who successfully consumed the open feeding were counted as successes. (NCT00580606)
Timeframe: Approximately 8 weeks after discontinuing study therapy after 3 years on maintenance study therapy

Interventionpercentage of participants (Number)
Low Dose Peanut SLIT (Double Blind to Open Label)10.0
Placebo (DB) Crossed Over to High Dose Peanut SLIT (OL)11.8

[back to top]

Percent of Participants Who Successfully Consumed 5,000 mg of Peanut Powder or at Least a 10-fold Increase in the Amount of Peanut Powder Compared to Their Baseline Oral Food Challenge

Desensitization Assessment: Participants who successfully consumed without dose-limiting symptoms 5,000 mg of peanut powder or at least a 10-fold increase in the amount of peanut powder compared to their baseline oral food challenge during a double-blind placebo-controlled oral food challenge were counted as successes. (NCT00580606)
Timeframe: Week 44 (Double Blind Period)

InterventionPercentage of participants (Number)
Low Dose Peanut SLIT (Double Blind)70
Placebo (Double Blind)15

[back to top]

Percent of Crossover Participants Who Achieved an Open Label Peanut Protein Consumption Maintenance Dose of 3,696 mcg

During the build-up phase, escalation was to occur every 2 weeks until the 3,696 mcg maintenance dose was reached. The maximum time allowed for the build-up phase was 36 weeks; the dose achieved by 36 weeks was considered the maintenance dose. (NCT00580606)
Timeframe: Week 44 after initiating crossover open label peanut protein consumption

InterventionPercentage of participants (Number)
High Dose Peanut SLIT Crossover (Open Label)88.2

[back to top]

Percentage of Subjects Tolerating a Peanut Oral Food Challenge 2-4 Weeks After Discontining Peanut SLIT Dosing

Upon completion of 36-60 months of peanut SLIT treatment, subjects underwent a double-blind placebo controlled food challenge (DBPCFC) to assess desensitization (an increase in reaction threshold while on therapy). A DBPCFC involves the ingestion of small increasing amounts of peanut up to a cumulative total amount. Peanut SLIT therapy was then discontinued for 2-4 weeks to assess for persistence of the desensitization response called sustained unresponsiveness (SU). The secondary clinical efficacy outcome of the study was the percentage of peanut allergic subjects who completed a 5000 mg peanut protein DBPCFC without developing symptoms 2-4 weeks after discontinuing peanut SLIT therapy. (NCT00597727)
Timeframe: 36-60 months

Interventionpercentage of participants (Number)
Ext Maint Open Label Peanut SLIT26.1
Early Unblinded Peanut SLIT28.6
Pilot Peanut SLIT Rollover Cohort0

[back to top]

Percentage of Subjects Who Can Tolerate the Peanut Oral Food Challenge After 12 Months of Peanut SLIT Dosing

Upon completion of 12 months of peanut SLIT treatment, subjects underwent a double-blind placebo controlled food challenge (DBPCFC) to assess desensitization (an increase in reaction threshold while on therapy). A DBPCFC involves the ingestion of small increasing amounts of peanut up to a cumulative total amount. The primary clinical efficacy outcome of the study was the percentage of peanut allergic subjects who completed a 2500 mg peanut protein DBPCFC without developing symptoms after 12 months of peanut SLIT therapy. (NCT00597727)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Blinded Peanut SLIT45.5
Blinded Placebo SLIT0
Early Unblinded Peanut SLIT11.8
Pilot Peanut SLIT Rollover Cohort66.7

[back to top]

Noninvasive Tear Film Break-up Time

State-of-the-art methodology to assess tear stability. (NCT00681265)
Timeframe: 15 minutes after eye drop instillation

Interventionseconds (Mean)
New Formulation of Glycerin 1% Eye Drop14.67
Propylene Glycol and PEG 400 Eye Drop7.4

[back to top]

Fluorescein Tear Film Break-up Time

Standard clinical assessment methodology for assessing tear stability. (NCT00681265)
Timeframe: 120 minutes after eye drops instillation

Interventionseconds (Mean)
New Formulation of Glycerin 1% Eye Drop11.13
Propylene Glycol and PEG 400 Eye Drop6.21

[back to top]

Corneal Staining

Corneal staining of greater or equal to grade 2 at day 90. Grading scale: 0 = None Present; 1 = Trace Finding; 2 = Mild Finding; 3 = Moderate Finding; 4 = Severe Finding (NCT00691197)
Timeframe: Day 90

InterventionParticipants (Number)
Carboxymethylcellulose Sodium and Glycerin0
Carboxymethylcellulose Sodium1

[back to top]

Best Corrected Visual Acuity

Percentage of Subjects Tabulated by Changes in Line Number at Day 90 from Baseline; Visual Acuity measured by LogMar reported as Snellen equivalents. Better: an increase of 2 lines or more in at least one eye; No Change: a change less than +/- 2 lines in both eyes; Worse: a decrease of 2 lines or more in at least one eye. (NCT00691197)
Timeframe: Change from Baseline at Day 90

,
InterventionPercentage of Participants (Number)
BetterNo ChangeWorse
Carboxymethylcellulose Sodium1.3398.670
Carboxymethylcellulose Sodium and Glycerin0.6598.061.29

[back to top]

Patient Acceptability

"A questionnaire was administered to all patients to evaluate the acceptability of the Rewetting Drops (RD) with use with Contact Lenses (CL). Table below shows the percentage of participants responding either Agree or Strongly Agree at day 90. Number of participants answering question is indicated as (number of Test subjects/number of Control subjects)" (NCT00691197)
Timeframe: Day 90

,
InterventionPercentage of Participants (Number)
Liked using the RD (160/78)RD gave good comfort during day (161/79)RD on CL gave good initial comfort (161/79)At day's end,CL felt better after RD use (161/78)Could wear CL longer when using RD (161/79)Vision was normal soon after using RD (161/79)Vision with CL was better after RD use (161/79)Would likely purchase these RD (161/79)Eyes felt better after CL removal (161/79)
Carboxymethylcellulose Sodium82.184.854.462.844.381.041.868.443.1
Carboxymethylcellulose Sodium and Glycerin72.578.849.051.646.685.731.050.438.5

[back to top]

Patient Preference

"Percentage of patients who used pre-study rewetting drops and answered Agree or Strongly Agree when asked if they preferred the study drops (SD) over their pre-study drops(PSD)." (NCT00691197)
Timeframe: Day 30

,
InterventionPercentage of participants (Number)
Prefer SD over PSDSD more comfortable overall than PSD
Carboxymethylcellulose Sodium41.534.1
Carboxymethylcellulose Sodium and Glycerin47.253.2

[back to top]

Death at 90 Days

(NCT00716079)
Timeframe: 90 days

Interventionparticipants (Number)
Intensive Blood-Pressure Lowering166
Guideline-Recommended Blood-Pressure Lowering170

[back to top]

A Composite of Death or Dependency, With Dependency Being Defined by a Score of 3 to 5 on the Modified Rankin Scale (mRS)

(NCT00716079)
Timeframe: 90 days

Interventionparticipants (Number)
Intensive Blood-Pressure Lowering719
Guideline-Recommended Blood-Pressure Lowering785

[back to top]

Ocular Comfort and Ocular Symptoms on Visual Analogue Scale

Mean comfort judged on a 100 point visual analogue scale (0=Very Poor, 100=Excellent) (NCT00761202)
Timeframe: week 1, month 1

,
InterventionUnits on a scale (Mean)
Ocular Comfort - Waking (Wk.1)Ocular Comfort - Daytime (Wk.1)Ocular Comfort - Evening (Wk.1)Ocular Comfort - Waking (Mo.1)Ocular Comfort - Daytime (Mo.1)Ocular Comfort - Evening (Mo.1)
Carboxymethylcellulose and Glycerin67.0563.2057.1565.0568.5760.38
Sodium Hyaluronate58.8168.2163.3863.5670.4865.06

[back to top]

Daily Eyedrop Usage

Average daily eyedrop use (NCT00761202)
Timeframe: Month 1

Interventiondrops/day (Mean)
Carboxymethylcellulose and Glycerin3.7
Sodium Hyaluronate3.3

[back to top]

Conjunctival Hyperaemia

Percentage of conjunctival response reported in terms of limbal hyperaemia for the worst responses over the area at each point on a five point scale (0=clear/white conjunctiva, 1=slight redness, 2=Mild redness, 3=Moderate redness, 4=Severe redness) (NCT00761202)
Timeframe: week 1, month 1

,
InterventionPercentage of Participants (Number)
Week 1 - Clear/WhiteWeek 1 - SlightWeek 1 - MildWeek 1 - ModerateWeek 1 - SevereMonth 1 - Clear/WhiteMonth 1 - SlightMonth 1 - MildMonth 1 - ModerateMonth 1 - Severe
Carboxymethylcellulose and Glycerin5.075.017.52.50.00.071.428.60.00.0
Sodium Hyaluronate3.859.636.50.00.00.071.228.80.00.0

[back to top]

Conjunctival Staining by Lissamine Green

Percentage of cases of limbal staining by lissamine green at each point on a five point scale (0 = None, 1 = Trace, 2 = Mild, 3 = Moderate, 4 = Severe) (NCT00761202)
Timeframe: week 1, month 1

,
InterventionPercentage of Participants (Number)
Week 1 - NoneWeek 1 - TraceWeek 1 - MildWeek 1 - ModerateWeek 1 - SevereMonth 1 - NoneMonth 1 - TraceMonth 1 - MildMonth 1 - ModerateMonth 1 - Severe
Carboxymethylcellulose and Glycerin50.017.517.515.00.078.611.99.50.00.0
Sodium Hyaluronate53.815.425.05.80.050.017.325.07.70.0

[back to top]

Corneal Staining by Fluorescein

Percentage of cases of limbal staining by sodium fluorescein at each point on a five point scale (0 = None, 1 = Trace, 2 = Mild, 3 = Moderate, 4 = Severe) (NCT00761202)
Timeframe: week 1, month 1

,
InterventionPercentage of Participants (Number)
Week 1 - NoneWeek 1 - TraceWeek 1 - MildWeek 1 - ModerateWeek 1 - SevereMonth 1 - NoneMonth 1 - TraceMonth 1 - MildMonth 1 - ModerateMonth 1 - Severe
Carboxymethylcellulose and Glycerin45.025.015.015.00.073.821.44.80.00.0
Sodium Hyaluronate57.715.425.01.90.051.915.426.95.80.0

[back to top]

Lipid Layer Pattern Assessment

Lipid layer thickness as determined by lipid layer mixing pattern. A high mixing pattern = thick lipid layer. (NCT00761202)
Timeframe: Week 1, month 1

,
InterventionLipid Layer Mixing Pattern (Median)
Week 1Month 1
Carboxymethylcellulose and Glycerin4.503.00
Sodium Hyaluronate5.505.00

[back to top]

Insulin Sensitivity as Measured by Hyperinsulinemic Euglycemic Clamp at a Single Time Point (6 Hrs) After Intralipid or Glycerol Infusion

Insulin sensitivity (M value: Glucose infusion rate/kg FFM/min)measured at single time point 6 hours after initiating either intralipid or glycerol infusion) (NCT00786487)
Timeframe: at 6 hours after starting lipid/glycerol infusion

InterventionM value (Mean)
Lipid Trained8
Glycerol Trained12
Lipid Untrained6
Glycerol Untrained11

[back to top]

Relieve of Anal Pain

using a visual analog scale (VAS) with which each patients noted the severity of pain at each evaluated time using a linear between zero (no pain) and 10 ( severe pain) (NCT00927849)
Timeframe: one year after the procedure

Interventionscore in scale (Mean)
Surgical Group Lateral Sphincterotomy4.16
Glycein Trinitrate Group4.18
Botilinium Toxin Injection4.2

[back to top]

The Number of Ophthalmic Adverse Events at 1 Week

The number of ophthalmic adverse events (AE) at 1 week. An ophthalmic AE is any unfavorable and unintended sign, symptom, or disease related to the eye which occurs during the use of the study investigational product (NCT00932477)
Timeframe: 1 Week

,,
InterventionNumber of adverse events (Number)
Eye pruritis (itching)Abnormal sensation in eyeErythema (redness) of eyelidEyelid irritation
Artificial Tear Formulation 10000
Artificial Tear Formulation 20000
Glycerin and Polysorbate 80 Based Artificial Tear2111

[back to top]

Tolerability Questionnaire Mean Scores at 1 Week

Tolerability Questionnaire mean scores at 1 week. The Tolerability Questionnaire includes 8 tolerability questions on selected performance measures. All questions are scored based on continuous visual analog scale from 0-100. The first 4 questions presented measure increasing tolerability where 0=worst and 100=best. The second set of 4 questions presented measure decreasing tolerability where 0=best and 100=worst. (NCT00932477)
Timeframe: 1 Week

,,
InterventionScores on a scale (Mean)
How comfortable is drop in the eye?How soothing is drop in the eye?How moistening/lubricating is drop in the eye?How clear is vision with drop in the eye?How much stickiness with drop in the eye?How much blur with drop in the eye?How much burning/stinging with drop in the eye?How much discomfort with drop in the eye?
Artificial Tear Formulation 170.165.168.066.024.633.214.819.3
Artificial Tear Formulation 270.765.965.961.119.532.414.318.9
Glycerin and Polysorbate 80 Based Artificial Tear57.353.457.453.031.448.927.927.1

[back to top]

Number of Patients With at Least One Severity Grade Increase in Biomicroscopy Findings at 1 Week

Number of patients with at least one severity grade increase in biomicroscopy findings at 1 week. Eyes are examined with a special microscope (biomicroscopy), and findings scored using a 5-point scale (0=none, +0.5=trace, +1=mild, +2=moderate, +3=severe). An increase in severity grade indicates worsening. (NCT00932477)
Timeframe: 1 Week

,,
InterventionNumber of Patients (Number)
Pterygium (cornea)Punctate keratitis (cornea)Vital dye staining of cornea present
Artificial Tear Formulation 1100
Artificial Tear Formulation 2011
Glycerin and Polysorbate 80 Based Artificial Tear020

[back to top]

Best-Corrected Visual Acuity (BCVA) Status at 1 Week

"BCVA status at 1 week reported as the number of patients whose scores were either Better, No Change, or Worse than their scores at baseline. The status was tabulated as number of lines read correctly at 1 week minus the number of lines read correctly at baseline. Better equals increase of 2 lines or more in at least 1 eye; No Change equals change between -2 to +2 lines in either eye; Worse equals decrease of 2 lines or more in at least 1 eye. BCVA is measured using a special eye chart and is reported as the number of lines (5 letters per line) read correctly." (NCT00932477)
Timeframe: 1 Week

,,
InterventionNumber of Patients (Number)
BetterNo ChangeWorse
Artificial Tear Formulation 10461
Artificial Tear Formulation 20452
Glycerin and Polysorbate 80 Based Artificial Tear0461

[back to top]

Change From Baseline in Tear Breakup Time (TBUT) at Week 2

Change from baseline in TBUT at Week 2. TBUT is defined as the time required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film. A positive number change from baseline indicates improvement. (NCT00938704)
Timeframe: Baseline, Week 2

,
InterventionSeconds (Mean)
BaselineWeek 2
Carboxymethylcellulose 0.5%, Glycerin 0.9%6.5012.919
Sodium Hyaluronate 0.18%5.9142.538

[back to top]

Change From Baseline in Ocular Surface Disease Index (OSDI) at Week 2

Change from baseline in OSDI at Week 2. The OSDI consists of 12 questions measuring the presence of ocular symptoms. Each of the 12 questions is assessed using a 5-point scale (0=none of the time; 4=all of the time). The score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI scores are associated with greater severity. A negative number change from baseline indicates improvement. (NCT00938704)
Timeframe: Baseline, Week 2

,
InterventionScores on a Scale (Mean)
BaselineWeek 2
Carboxymethylcellulose 0.5%, Glycerin 0.9%56.06-27.048
Sodium Hyaluronate 0.18%54.292-28.303

[back to top]

Change From Baseline in Corneal Staining at Week 2

Change from baseline in corneal staining at Week 2. Staining of the cornea following ocular administration of fluorescein dye was graded using a 6-point scale (0=no staining, 5=diffuse staining). The higher the grade score, the worse the dry eye severity. A negative number change from baseline indicates improvement. (NCT00938704)
Timeframe: Baseline, Week 2

,
InterventionScores on a Scale (Mean)
BaselineWeek 2
Carboxymethylcellulose 0.5%, Glycerin 0.9%1.818-1.288
Sodium Hyaluronate 0.18%1.608-1.23

[back to top]

Change From Baseline in Conjunctival Staining (Temporal) at Week 2

Change from baseline in conjunctival (temporal) staining at Week 2. Staining of the conjunctiva following ocular administration of lissamine green dye was graded using a 6-point scale (0=no staining, 5=diffuse staining). The higher the grade score, the worse the dry eye severity. A negative number change from baseline indicates improvement. (NCT00938704)
Timeframe: Baseline, Week 2

,
InterventionScores on a Scale (Mean)
BaselineWeek 2
Carboxymethylcellulose 0.5%, Glycerin 0.9%1.818-1.152
Sodium Hyaluronate 0.18%1.919-1.216

[back to top]

Change From Baseline in Conjunctival Staining (Nasal) at Week 2

Change from baseline in conjunctival staining (nasal) at Week 2. Staining of the conjunctiva following ocular administration of lissamine green dye was graded using a 6-point scale (0=no staining, 5=diffuse staining). The higher the grade score, the worse the dry eye severity. A negative number change from baseline indicates improvement. (NCT00938704)
Timeframe: Baseline, Week 2

,
InterventionScores on a Scale (Mean)
BaselineWeek 2
Carboxymethylcellulose 0.5%, Glycerin 0.9%1.758-1.061
Sodium Hyaluronate 0.18%2.000-1.459

[back to top]

Change From Baseline in Ocular Surface Disease Index (OSDI) Questionnaire Score at Day 35

Change from baseline in Ocular Surface Disease Index (OSDI) questionnaire score at Day 35. The OSDI questionnaire consists of 12 questions measuring the presence of ocular symptoms. Each of the 12 questions is assessed using a 5-point scale (where 0=none of the time and 4=all of the time). The score is converted to a 0-100 point score where 0 is no symptoms and 100 is most symptoms. (NCT00987727)
Timeframe: Baseline, Day 35

,
InterventionNumber on a scale (score) (Mean)
BaselineDay 35
Carboxymethylcellulose 0.5% and Glycerin 0.9% (OPTIVE® MD)49.05-13.58
Sodium Hyaluronate 0.18% (VISMED® Multi)51.98-13.66

[back to top]

Change From Baseline in Global Ocular Staining Score at Day 35

Change from baseline in global ocular staining score (range from 0-15) at Day 35. The global ocular staining score is the sum of three different staining severities, each with a score of 0-5 on a 6-point scale, where 0 is no staining (best) and 5 is diffuse staining (worst). (NCT00987727)
Timeframe: Baseline, Day 35

,
InterventionNumber on a scale (score) (Mean)
BaselineDay 35
Carboxymethylcellulose 0.5% and Glycerin 0.9% (OPTIVE® MD)5.4-1.8
Sodium Hyaluronate 0.18% (VISMED® Multi)5.9-1.8

[back to top]

Change From Baseline in Conjunctival Staining Severity Score at Day 90

Change from baseline in conjunctival staining severity score at day 90. The conjunctiva is the clear membrane covering the white surface of the eye. Conjunctival staining following ocular administration of lissamine green dye was graded using a 6-point scale (0=no staining, 5=severe staining) over 6 areas of the white part of the eye for a minimum score of 0 and a maximum score of 30. The higher the score, the worse the dry eye condition. A negative number change from baseline represents a decrease in the severity of conjunctival staining (improvement). (NCT01010282)
Timeframe: Baseline (Day 1), Day 90

,,
InterventionScores on a scale (Mean)
Baseline (Day 1)Change from Baseline at Day 90
Artificial Tears Formulation 15.1-0.5
Artificial Tears Formulation 24.9-0.7
Glycerin and Polysorbate 80 Based Artificial Tear5.2-0.7

[back to top]

Change From Baseline in Corneal Staining at Day 90

Change from baseline in corneal staining at day 90. The cornea is the transparent front part of the eye which covers the iris and pupil. Corneal staining following administration of fluorescein dye in the eye is graded using a 6-point scale (0=no staining, 5=severe staining) over 5 areas of the clear central part of the eye for a minimum score of 0 and maximum score of 25. The higher the grade score, the worse the dry eye condition. A negative number change from baseline represents a decrease in corneal staining (improvement). (NCT01010282)
Timeframe: Baseline (Day 1), Day 90

,,
InterventionScores on a scale (Mean)
Baseline (Day 1)Change from Baseline at Day 90
Artificial Tears Formulation 14.20.2
Artificial Tears Formulation 24.2-0.5
Glycerin and Polysorbate 80 Based Artificial Tear4.50.8

[back to top]

Change From Baseline in Subjective Evaluation of Symptom of Dryness (SESoD)Score at Day 90

Change from baseline in SESoD score at day 90. The SESoD is a 5-point scale where 0 equals no dryness, 1 equals trace dryness, 2 equals mild dryness, 3 equals moderate dryness, and 4 equals severe dryness. A negative number change from baseline indicates a decrease (improvement) in the symptom of dryness. (NCT01010282)
Timeframe: Baseline (Day 1), Day 90

,,
InterventionScores on a Scale (Mean)
Baseline (Day 1)Change from Baseline at Day 90
Artificial Tears Formulation 12.7-0.7
Artificial Tears Formulation 22.8-0.7
Glycerin and Polysorbate 80 Based Artificial Tear2.8-0.7

[back to top]

Change From Baseline in Tear Break-up Time (TBUT) at Day 90

Change from baseline in TBUT at day 90. TBUT is the time required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film. A positive number change from baseline indicates an increase in TBUT (improvement). (NCT01010282)
Timeframe: Baseline (Day 1), Day 90

,,
InterventionSeconds (Mean)
Baseline (Day 1)Change from Baseline at Day 90
Artificial Tears Formulation 14.901.49
Artificial Tears Formulation 25.042.02
Glycerin and Polysorbate 80 Based Artificial Tear5.091.81

[back to top]

Change From Baseline in the Ocular Surface Disease Index (OSDI) Total Score at Day 90

Change from baseline in the OSDI total score at day 90. The OSDI is a 12-question survey for patients to document their dry eye disease symptoms. The OSDI consists of a 5-point scale (0=none of the time and 4=all of the time), with higher scores representing greater disability. The scores are totaled over the 12 questions and converted to a score of 0-100 (0=no disability and 100=complete disability). A negative number change from baseline represents an improvement. (NCT01010282)
Timeframe: Baseline (Day 1), Day 90

,,
InterventionScores on a Scale (Mean)
Baseline (Day 1)Change from Baseline at Day 90
Artificial Tears Formulation 133.6-7.2
Artificial Tears Formulation 235.1-10.6
Glycerin and Polysorbate 80 Based Artificial Tear37.3-9.1

[back to top]

Pain Level Twenty Four Hours After Delivery

The primary outcome is pain measured at 24-hours after delivery. Patients will be asked to report a Visual Analog Scale (VAS) pain score at 24-hours after delivery. This scale ranges from 0 to 10 (0=no pain and 10=worst pain). (NCT01271855)
Timeframe: Twenty-four hours

Interventionunits on a scale (Median)
Glycerin Suppository1
Belladonna and Opioid Suppository2

[back to top]

Patient Satisfaction

Patients' satisfaction with their pain control is recorded at the time of discharge using a five point scale ranging from 1 (Not Satisfied) to 3 (Okay) to 5 (Very Satisfied). (NCT01271855)
Timeframe: Discharge

Interventionunits on a scale (Median)
Glycerin Suppository4
Belladonna and Opioid Suppository5

[back to top]

Ocular Surface Disease Index Score

"The OSDI is a 12-item patient-reported outcomes questionnaire designed to assess the range of ocular surface symptoms, their severity, and their impact on the patient's ability to function.~The OSDI items are scored on a 0 to 4 Likert-type scale, where 0 = None of the time, 1 = Some of the time, 2 = Half of the time, 3 = Most of the time, and 4 = All of the time. Using individual item responses, an overall OSDI score is calculated. The overall OSDI score ranges from 0 to 100, where a score of 100 corresponds to complete disability while a score of 0 corresponds to no disability." (NCT01339936)
Timeframe: after 30 days of eye drop usage

Interventionpoints (Mean)
Investigational Eye Drop26.8

[back to top]

Tear Break Up Time

The tear film break-up-time (BUT) is the time elapsed between eye opening after a blink, and the appearance of the first dark spot within the tear film when observed with a wide diffuse light source of the Tearscope. This measurement is indicative of the tear film stability. Three independent measurements were recorded in each case and the median value over the three measurements calculated. The latter value constituted the secondary endpoint used in the analysis. (NCT01339936)
Timeframe: after 30 days of eyedrop usage

Interventionseconds (Mean)
Investigational Eye Drop5.8

[back to top]

Tear Film Evaporation Rate

The rate of evaporation of the tears from the ocular surface was measured. To do so the participant was required to wear a sealed goggle over the eye, which served to isolate the air surrounding the ocular surface. The temperature and humidity were measured within the sealed goggle during closed eye and open eye situations. The evaporation from the ocular surface was calculated by taking the difference between the evaporation rate of the skin taken during the closed eye measurement and the evaporation rate taken during the open eye measurement. The rate of evaporation was measured in 10^-7 g/cm^2 /s and recorded for relative humidity of 25% to 35%. (NCT01339936)
Timeframe: after 30 days of eyedrop usage

Intervention10^-7g/cm^2/sec (Mean)
Investigational Eye Drop26.0

[back to top]

Adverse Events

Rate of adverse events during the Safety Extension portion of the protocol ( please note: HPN-100 treatment only during Safety Extension ) (NCT01347073)
Timeframe: 12 months

Interventionparticipants (Number)
HPN-10023

[back to top]

Hyperammonemic Crisis

Rate of HAC during pre-enrollment on NaPBA compared to HAC during HPN-100 treatment (NCT01347073)
Timeframe: 1 year

Interventionnumber of crises (Number)
Pre-enrollment29
Long-term Phase12

[back to top]

Frequency of Ammonia Levels Greater Than the Upper Limit of Normal (ULN) on HPN-100 Compared With NaPBA

Ammonia values were converted to SI units (umol/L) and normalized to a standard ULN of 35 umol/L prior to analysis (NCT01347073)
Timeframe: 2 weeks

InterventionAmmonia Values > ULN (Number)
NaPBA22
HPN-1008

[back to top]

Blood Ammonia

24-hour ammonia AUC of blood ammonia levels on Days 1 (NaPBA) and 10 (HPN-100) were compared. Ammonia was assessed at Hour 0 (pre-first dose, fasted), Hour 8 (~2-4 hours after lunch or the second main meal and dose of NaPBA), Hour 12 (~4 hours after the last main meal) and 24 hours post-first dose (pre-first dose on following day, fasted). (NCT01347073)
Timeframe: 2 weeks

Interventionumol/L*hours (Mean)
NaPBA914.43
HPN-100647.63

[back to top]

Adverse Events

Rate of adverse events during the Switch-Over portion of the Protocol (NCT01347073)
Timeframe: 2 weeks

Interventionparticipants (Number)
NaPBA0
HPN-1006

[back to top]

Pharmacokinetics: End Period Tenofovir-Diphosphate (TFV-DP) Concentrations (log10 ng/mg) in Rectal Tissue

Compare end period tenofovir-diphosphate (TFV-DP) concentrations in rectal tissue among daily FTC/TDF tablet, daily TFV RG 1% gel, and RAI-associated TFV RG 1% gel groups. (NCT01687218)
Timeframe: 27 weeks (three 8-week product use periods with 1-week washout periods between them)

Interventionlog10 ng/mg (Mean)
Product 11.52
Product 22.06
Product 31.54

[back to top]

Acceptability: Participant Self-report of Liking the Product. H1-Overall How do You Feel About the Product You Used Recently?

To evaluate and compare acceptability of daily FTC/TDF tablet, daily TFV RG 1% gel, and RAI-associated TFV RG 1% gel. Consistent with the acceptability endpoint of liking the product, a variable was created by combining from Section H. Liking the Product of the MTN-017 Follow-up Behavioral Questionnaire question 1A and question 1BC. Categories 1 and 2 were combined and categories 3 and 4 were combined to create a dichotomous variable. (NCT01687218)
Timeframe: 27 weeks (three 8-week product use periods with 1-week washout periods between them)

,,
Interventionparticipants (Number)
Disliked Very Much/A LittleLiked Very Much/A Little
Product 116163
Product 247134
Product 338145

[back to top]

Pharmacokinetics: Tenofovir (TFV) Concentrations (log10 ng/mL) in Blood Plasma

Compare tenofovir concentrations in blood plasma among daily FTC/TDF tablet, daily TFV RG 1% gel, and RAI-associated TFV RG 1% gel groups. (NCT01687218)
Timeframe: 27 weeks (three 8-week product use periods with 1-week washout periods between them)

,,
Interventionlog10 ng/mL (Mean)
Mid-Period TFV ConcentrationEnd Period TFV Concentration
Product 11.851.77
Product 20.420.37
Product 3-0.01-0.02

[back to top]

Pharmacokinetics: Tenofovir (TFV) Concentrations (log10 ng/mg) in Rectal Sponge

Compare tenofovir concentrations in rectal sponge specimens among daily FTC/TDF tablet, daily TFV RG 1% gel, and RAI-associated TFV RG 1% gel groups. (NCT01687218)
Timeframe: 27 weeks (three 8-week product use periods with 1-week washout periods between them)

,,
Interventionlog10 ng/mg (Mean)
Initiate Period TFV ConcentrationMid-Period TFV ConcentrationEnd Period TFV Concentration
Product 1-1.530.710.66
Product 2-1.650.971.00
Product 3-1.29-0.030.01

[back to top]

Pharmacokinetics: Emtricitabine (FTC) Concentrations (log10 ng/mL) in Blood Plasma

Compare emtricitabine concentrations in blood plasma among daily FTC/TDF tablet, daily TFV RG 1% gel, and RAI-associated TFV RG 1% gel groups. (NCT01687218)
Timeframe: 27 weeks (three 8-week product use periods with 1-week washout periods between them)

,,
Interventionlog10 ng/mL (Mean)
Mid-Period FTC ConcentrationEnd Period FTC Concentration
Product 12.342.25
Product 2-0.35-0.37
Product 3-0.37-0.33

[back to top]

Pharmacokinetics: Emtricitabine (FTC) Concentrations (log10 ng/mg) in Rectal Sponge

Compare emtricitabine concentrations in rectal sponge among daily FTC/TDF tablet, daily TFV RG 1% gel, and RAI-associated TFV RG 1% gel groups. (NCT01687218)
Timeframe: 27 weeks (three 8-week product use periods with 1-week washout periods between them)

,,
Interventionlog10 ng/mg (Mean)
Initiate Period FTC ConcentrationMid-Period FTC ConcentrationEnd Period FTC Concentration
Product 1-1.750.310.14
Product 2-1.76-1.76-1.80
Product 3-1.57-1.67-1.69

[back to top]

Adherence: Percentage of Prescribed Doses Taken Orally or Administered Rectally in an 8-week Period

Compare percentage of prescribed doses taken orally or administered rectally in an 8-week period based on the Final Converged Rates. Final Converged Rates were measured first via self-report through Short Message Service (SMS). The clinic staff also reported the most likely number of doses taken. Finally, the MTN Behavioral Research Working Group (BRWG) provided the final estimate of the number of doses taken for each participant for each period based on self-report, staff estimates and PK testing results. Note that these final judgement data are missing if PK results are missing. (NCT01687218)
Timeframe: 27 weeks (three 8-week product use periods with 1-week washout periods between them)

,,
InterventionParticipants (Count of Participants)
Less Than 80%At or Greater than 80%
Product 112173
Product 231153
Product 313170

[back to top]

Safety: Grade 2 or Higher Adverse Events

Compare the safety profiles of daily FTC/TDF tablet, daily TFV RG 1% gel, and RAI-associated TFV RG 1% gel. Analysis of the primary endpoint of grade 2 or higher AEs was performed on only the evaluable participants based on the principle of intent-to-treat (ITT) whereby participants who were randomized were included in the analysis regardless of whether or not they received product in a given period (i.e, were lost to follow-up, or terminated early and/or were on a product hold). (NCT01687218)
Timeframe: 27 weeks (three 8-week product use periods with 1-week washout periods between them)

Interventionparticipants (Number)
Product 164
Product 261
Product 356

[back to top]

Acceptability: Participant Self-report of Ease of Use. I1-Overall How Easy or Difficult Was it to Use the Product?

To evaluate and compare acceptability of daily FTC/TDF tablet, daily TFV RG 1% gel, and RAI-associated TFV RG 1% gel. Consistent with the acceptability endpoint of ease of use, a variable was created to compare regimens. This variable combines questions 1A and 1BC from Section I. Ease of Use of the MTN-017 Follow-up Behavioral Questionnaire. Categories 1 and 2 were combined and categories 3 and 4 were combined to create dichotomous variables. (NCT01687218)
Timeframe: 27 weeks (three 8-week product use periods with 1-week washout periods between them)

,,
Interventionparticipants (Number)
Very Difficult/DifficultVery Easy/Easy
Product 114169
Product 224160
Product 318165

[back to top]

Acceptability: Participant Self-report of Likelihood of Product Use if Shown to be Effective. N1-If This Product Provides Some Protection How Likely Would You be to Take it?

To evaluate and compare acceptability of daily FTC/TDF tablet, daily TFV RG 1% gel, and RAI-associated TFV RG 1% gel. Consistent with the acceptability endpoint of likelihood to use product in the future, a variable was created by combining Section N. Likelihood to Use Product in the Future of the MTN-017 Follow-up Behavioral Questionnaire questions 1A, 1B, and 1C. Categories 1 and 2 were combined and categories 3 and 4 were combined to create a dichotomous variable. (NCT01687218)
Timeframe: 27 weeks (three 8-week product use periods with 1-week washout periods between them)

,,
Interventionparticipants (Number)
Very Unlikely/UnlikelyVery Likely/Likely
Product 124159
Product 252132
Product 331145

[back to top]

Pharmacokinetics: End Period Emtricitabine (FTC) Concentrations (log10 ng/mg) in Rectal Tissue

Compare end period emtricitabine concentrations in rectal tissue among daily FTC/TDF tablet, daily TFV RG 1% gel, and RAI-associated TFV RG 1% gel groups. (NCT01687218)
Timeframe: 27 weeks (three 8-week product use periods with 1-week washout periods between them)

Interventionlog10 ng/mg (Mean)
Product 1-0.35
Product 2-1.26
Product 3-1.26

[back to top]

Pharmacokinetics: End Period Tenofovir (TFV) Concentrations (log10 ng/mg) in Rectal Tissue

Compare end period tenofovir concentrations in rectal tissue among daily FTC/TDF tablet, daily TFV RG 1% gel, and RAI-associated TFV RG 1% gel groups. (NCT01687218)
Timeframe: 27 weeks (three 8-week product use periods with 1-week washout periods between them)

Interventionlog10 ng/mg (Mean)
Product 10.18
Product 20.84
Product 30.02

[back to top]

Length of Initial Round of Phototherapy

time start to time finally off phototherapy, including any breaks during which they were off (NCT01746511)
Timeframe: from time of enrollment to time of discharge, for a maximum of 10 weeks

Interventionhours (Mean)
Glycerin Suppository118
No Glycerin Suppository81

[back to top]

Number of Episodes of Repeat Phototherapy

"Bilirubin levels are checked at regular intervals after phototherapy is discontinued to make sure levels are safe. Depending on rate of rise and predetermined unsafe bilirubin level, phototherapy may be restarted." (NCT01746511)
Timeframe: from time of enrollment to time of discharge, for a maximum of 10 weeks

Interventionepisodes of repeat phototherapy (Median)
Glycerin Suppository0
No Glycerin Suppository0

[back to top]

Peak Total Serum Bilirubin Level

Bilirubin levels were checked every 12 hours while the infant was under phototherapy. A bilirubin level was then to be checked at least twice, 8-12 hours or longer apart, following discontinuation of phototherapy. (NCT01746511)
Timeframe: from time of enrollment to time of discharge every 12 hours while under phototherapy, for a maximum of 10 weeks

Interventionmg/dL (Mean)
Glycerin Suppository11.3
No Glycerin Suppository12.0

[back to top]

Total Number of Hours of Required Phototherapy

(NCT01746511)
Timeframe: from time of enrollment to time of discharge, for a maximum of 10 weeks

Interventionhours (Mean)
Glycerin Suppository72
No Glycerin Suppository61

[back to top]

Rate of Decline in Bilirubin Levels (mg/dL/hr)

Absolute change over time from peak to first discontinuation of phototherapy lights (NCT01746511)
Timeframe: from time of enrollment to time of discharge, for a maximum of 10 weeks

Interventionmg/dL/hr (Mean)
Glycerin Suppository0.4
No Glycerin Suppository0.4

[back to top]

Maximum Change in Mean Mouth and Throat Soreness (MTS) Score From Baseline Through Weeks of Radiation Therapy Using the MTS Question of the Modified Oral Mucositis Daily Questionnaire*.

"Severity is assessed as the maximum change in mean mouth and throat soreness (MTS) score from baseline during the weeks of RT, using MTS question of the validated Oral Mucositis Daily Questionnaire (modified OMDQ): During the past 24 hours, how much mouth and throat soreness did you have? The MTS score is a 5-point score, ranging from 0=No soreness to 4=Extreme soreness. We compared the maximum change in MTS score between the two groups using the Wilcoxon rank sum test with a one-sided alpha of 0.05." (NCT01898091)
Timeframe: MTS score is collected at the baseline visit and once each week during the 7 weeks of radiation therapy.

Interventionunits on a scale (Mean)
Neem Mouthrinse1.91
Placebo Mouthrinse1.47

[back to top]

Percent Reduction From Baseline to Week 8 in Frequency of Observable Seizures (Normalized to a 4-Week Rate)

Reduction from baseline to Week 8 in frequency of seizures (normalized to a 4-week rate): observable seizures measured for 6 weeks after 2-week titration by diary. Observable seizures from the diary include generalized tonic-clonic, generalized tonic, generalized clonic, generalized atonic, partial/focal with secondary generalization, myoclonic, myoclonic (astatic) atonic, myoclonic tonic, complex partial/focal, simple partial/focal motor, simple partial/focal sensory, and simple partial/focal psychological. A negative value indicates an increase in frequency. (NCT01993186)
Timeframe: Baseline, Week 8

Interventionpercent reduction in seizures per 4 wks (Median)
UX0070.0
Placebo0.0

[back to top]

Change From Baseline to Week 8 in Distance Traveled (in Percent Predicted) as Measured by 6MWT

Participants were instructed to walk the length of a pre-measured 20-30 meter course in a hallway for 6 consecutive minutes. The total distance walked (meters) in a 6 minute period was recorded. The percent of predicted normal distance walked was determined based on published normative data. (NCT01993186)
Timeframe: Baseline, Week 8

Interventionpercent of predicted distance (Least Squares Mean)
UX007-1.338
Placebo0.016

[back to top]

Change From Baseline to Week 8 in Distance Traveled (in Meters) as Measured by 6-Minute Walk Test (6MWT)

Participants were instructed to walk the length of a pre-measured 20-30 meter course in a hallway for 6 consecutive minutes. The total distance walked (meters) in a 6 minute period was recorded. (NCT01993186)
Timeframe: Baseline, Week 8

Interventionmeters (Least Squares Mean)
UX007-10.336
Placebo-3.439

[back to top]

Change From Baseline to Week 8 in CANTAB, Spatial Span (SSP) Span Length Scores, GEE

CANTAB measures neuropsychological function using a standardized, computerized battery of tests designed to assess visual memory, working memory, new learning and reaction time. SSP Span Length (SSPSLF) assesses the cognitive domain of sequential memory, with scores on a discrete, ordinal scale from 2 to 9; higher scores indicate better function. GEE statistical model. (NCT01993186)
Timeframe: Baseline, Week 8

Interventionscore on a scale (Least Squares Mean)
UX0070.019
Placebo-0.041

[back to top]

Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Discontinuations Due to TEAEs During the Placebo-Controlled Period

An adverse event (AE) was defined as any untoward medical occurrence, whether or not considered drug related. A serious AE was defined as an AE or suspected adverse reaction that at any dose resulted in any of the following outcomes: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, a congenital anomaly/birth defect, or an important medical event that may have jeopardized the subject and may have required medical or surgical intervention to prevent one of the outcomes listed in the definition. An AE was considered a TEAE if it occurred or worsened in severity on or after the date of the first dose of study drug. An AE was considered a UX007 emergent adverse event if it occurred or worsened in severity on or after the first date of first dose of UX007 during the study. (NCT01993186)
Timeframe: Weeks 0 to 8

,
InterventionParticipants (Count of Participants)
TEAESerious TEAEGrade 3 or 4 TEAETEAE Leading to Study DiscontinuationTEAE Leading to DeathGastrointestinal TEAERelated TEAERelated Serious TEAERelated Gastrointestinal TEAEUX007 Emergent AESerious UX007 Emergent AE
Placebo90000550400
UX0072212001818017221

[back to top]

Percent Reduction From Baseline Over Time in Frequency of Observable Seizures (Normalized to a 4-Week Rate)

Reduction from baseline over time in frequency of seizures (normalized to a 4-week rate): observable seizures measured for 6 weeks after 2-week titration by diary. Observable seizures from the diary include generalized tonic-clonic, generalized tonic, generalized clonic, generalized atonic, partial/focal with secondary generalization, myoclonic, myoclonic (astatic) atonic, myoclonic tonic, complex partial/focal, simple partial/focal motor, simple partial/focal sensory, and simple partial/focal psychological. A negative value indicates an increase in frequency. (NCT01993186)
Timeframe: Baseline, Week 26, Week 31, Week 36, Week 52

,
Interventionpercent reduction in seizures per 4 wks (Median)
Week 26Week 31Week 36Week 52
Placebo-27.70.0-49.8-10.3
UX0070.023.642.531.0

[back to top]

Percent Reduction From Baseline Over Time in Frequency of Absence Seizures (Normalized to a 4-week Rate)

Reduction from baseline to Week 8 in frequency of absence seizures measured overnight by EEG. Absence seizures from EEG include absence awake (>=10 sec), absence sleep (>=10 sec), indeterminate absence awake (3-10 sec), and indeterminate absence sleep (3-10 sec). A negative value indicates an increase in frequency. (NCT01993186)
Timeframe: Baseline, Week 26, Week 31

,
Interventionpercent reduction in seizures per 4 wks (Median)
Week 26Week 31
Placebo0.00.0
UX0070.00.0

[back to top]

Percent Reduction From Baseline Over Time in Frequency of Total Seizures (Normalized to a 4-Week Rate)

Reduction from baseline over time in frequency of seizures (normalized to a 4-week rate): observable seizures measured for 6 weeks after 2-week titration by diary and absence seizures measured overnight by EEG. Observable seizures from the diary include generalized tonic-clonic, generalized tonic, generalized clonic, generalized atonic, partial/focal with secondary generalization, myoclonic, myoclonic (astatic) atonic, myoclonic tonic, complex partial/focal, simple partial/focal motor, simple partial/focal sensory, and simple partial/focal psychological. Absence seizures from EEG include absence awake (>=10 sec), absence sleep (>=10 sec), indeterminate absence awake (3-10 sec), and indeterminate absence sleep (3-10 sec). A negative value indicates an increase in frequency. (NCT01993186)
Timeframe: Baseline, Week 26, Week 31

,
Interventionpercent reduction of seizures per 4 wks (Median)
Week 26Week 31
Placebo0.05.3
UX0077.842.7

[back to top]

Time (in Minutes) to Onset of Paroxysmal Exertional Dyskinesia (PED) as Measured During 6MWT Over Time Through Week 8

For the 6MWT, subjects were instructed to walk the length of a pre-measured 20-30 meter course in a hallway for 6 consecutive minutes. The total distance walked (meters) in a 6 minute period was recorded. PED occurring during the 6MWT was assessed. (PED is characterized by transient abnormal, involuntary movements primarily affecting the legs and feet, and typically precipitated by prolonged exertion.) (NCT01993186)
Timeframe: Baseline, Week 4, Week 8

Interventionminutes (Mean)
Week 4Week 8
UX0074.71.8

[back to top]

Change From Baseline to Week 8 in CANTAB, Spatial Working Memory (SWM) Scores, GEE

CANTAB measures neuropsychological function using a standardized, computerized battery of tests designed to assess visual memory, working memory, new learning and reaction time. SWM between errors (SWMBE48) assesses the cognitive domain of working memory, with scores on a discrete, ordinal scale from 0 to 360; lower scores indicate better function. SWM strategy (SWMS68) assesses the cognitive domain of executive function/strategy, with scores on a discrete, ordinal scale from 4 to 28; lower scores indicate better function. GEE statistical model. (NCT01993186)
Timeframe: Baseline, Week 8

,
Interventionscore on a scale (Least Squares Mean)
SWMBE48SWMS68
Placebo2.2400.022
UX0071.0030.060

[back to top]

Change From Baseline to Week 8 in CANTAB, Paired Associates Learning (PAL) Scores, GEE

CANTAB measures neuropsychological function using a standardized, computerized battery of tests designed to assess visual memory, working memory, new learning and reaction time. PAL total errors adjusted (PALTEA) assesses the cognitive domain of episodic memory/new learning, with scores on a discrete, ordinal scale from 0 to 137; lower scores indicate better function. PAL first trial memory score (PALFTMS) assesses the cognitive domain of episodic memory, with scores on a discrete, ordinal scale from 0 to 27; higher scores indicate better function. GEE statistical model. (NCT01993186)
Timeframe: Baseline, Week 8

,
Interventionscore on a scale (Least Squares Mean)
PALTEAPALFTMS
Placebo-27.8493.105
UX007-10.0822.574

[back to top]

Change From Baseline to Week 8 in Cambridge Neuropsychological Test Automated Battery (CANTAB), Reaction Time (RTI) Scores, Generalized Estimating Equation (GEE)

CANTAB measures neuropsychological function using a standardized, computerized battery of tests designed to assess visual memory, working memory, new learning and reaction time. RTI Simple choice reaction time standard deviation (RTISRTSD) assesses the cognitive domain of attention, with scores on a continuous range from 0 to 5000; lower scores indicate better function. RTI median simple choice reaction time (RTIMDSRT) assesses the cognitive domain of reaction time, with scores on a continuous range from 100 to 5100; lower scores indicate better function. RTI median 5-choice reaction time (RTIMDFRT) assesses the cognitive domain of reaction time, with scores on a continuous range from 100 to 5100; lower scores indicate better function. GEE statistical model. (NCT01993186)
Timeframe: Baseline, Week 8

,
Interventionscore on a scale (Least Squares Mean)
RTISRTSDRTIMDSRTRTIMDFRT
Placebo44.082-48.15749.112
UX00741.69815.512-14.723

[back to top]

Percentage of Participants With at Least a 50% Reduction From Baseline to Week 8 in Frequency of Total Seizures

Seizure response, defined as the percentage of participants with at least 50% reduction from randomization to Week 8 in frequency of total seizures. Includes observable generalized and partial-onset seizures measured for 6 weeks by diary and absence seizures measured overnight by EEG. Observable seizures from the diary include generalized tonic-clonic, generalized tonic, generalized clonic, generalized atonic, partial/focal with secondary generalization, myoclonic, myoclonic (astatic) atonic, myoclonic tonic, complex partial/focal, simple partial/focal motor, simple partial/focal sensory, and simple partial/focal psychological. Absence seizures from EEG include absence awake (>=10 sec), absence sleep (>=10 sec), indeterminate absence awake (3-10 sec), and indeterminate absence sleep (3-10 sec). (NCT01993186)
Timeframe: Baseline, Week 8

Interventionpercentage of participants (Number)
UX00720.0
Placebo36.4

[back to top]

Percentage of Participants With at Least 50% Reduction From Baseline to Week 8 in Frequency of Observable Seizures

Observable seizure response, defined as the percentage of participants with at least 50% reduction from randomization to Week 8 in frequency of observable seizures. Observable seizures from the diary include generalized tonic-clonic, generalized tonic, generalized clonic, generalized atonic, partial/focal with secondary generalization, myoclonic, myoclonic (astatic) atonic, myoclonic tonic, complex partial/focal, simple partial/focal motor, simple partial/focal sensory, and simple partial/focal psychological. (NCT01993186)
Timeframe: Baseline, Week 8

Interventionpercentage of participants (Number)
UX0075.9
Placebo30.0

[back to top]

Percentage of Participants With at Least 50% Reduction From Baseline to Week 8 in Frequency of Absence Seizures

Absence seizure response, defined as the percentage of participants with at least 50% reduction from randomization to Week 8 in frequency of absence seizures. Absence seizures from EEG include absence awake (>=10 sec), absence sleep (>=10 sec), indeterminate absence awake (3-10 sec), and indeterminate absence sleep (3-10 sec). (NCT01993186)
Timeframe: Baseline, Week 8

Interventionpercentage of participants (Number)
UX00723.5
Placebo16.7

[back to top]

Percent Reduction From Baseline to Week 8 in Frequency of Total Seizures (Normalized to a 4-Week Rate)

Reduction from baseline to Week 8 in frequency of seizures (normalized to a 4-week rate): observable seizures measured for 6 weeks after 2-week titration by diary and absence seizures measured overnight by EEG. Observable seizures from the diary include generalized tonic-clonic, generalized tonic, generalized clonic, generalized atonic, partial/focal with secondary generalization, myoclonic, myoclonic (astatic) atonic, myoclonic tonic, complex partial/focal, simple partial/focal motor, simple partial/focal sensory, and simple partial/focal psychological. Absence seizures from EEG include absence awake (>=10 sec), absence sleep (>=10 sec), indeterminate absence awake (3-10 sec), and indeterminate absence sleep (3-10 sec). A negative value indicates an increase in frequency. (NCT01993186)
Timeframe: Baseline, Week 8

Interventionpercent reduction of seizures per 4 wks (Median)
UX00712.6
Placebo0.0

[back to top]

Number of Participants With TEAEs, Serious TEAEs and Discontinuations Due to TEAEs During the Extension Period

An AE was defined as any untoward medical occurrence, whether or not considered drug related. A serious AE was defined as an AE or suspected adverse reaction that at any dose resulted in any of the following outcomes: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, a congenital anomaly/birth defect, or an important medical event that may have jeopardized the subject and may have required medical or surgical intervention to prevent one of the outcomes listed in the definition. An AE was considered a TEAE if it occurred or worsened in severity on or after the date of the first dose of study drug. An AE was considered a UX007 emergent adverse event if it occurred or worsened in severity on or after the first date of first dose of UX007 during the study. (NCT01993186)
Timeframe: Weeks 9 to 52 plus 30 days

,
InterventionParticipants (Count of Participants)
TEAESerious TEAEGrade 3 or 4 TEAETEAE Leading to Study DiscontinuationTEAE Leading to DeathGastrointestinal TEAERelated TEAERelated Serious TEAERelated Gastrointestinal TEAEUX007 Emergent AESerious UX007 Emergent AE
Placebo11000010808110
UX0072121101519013212

[back to top]

Percent Reduction From Baseline to Week 8 in Frequency of Absence Seizures (Normalized to a 4-Week Rate)

Reduction from baseline to Week 8 in frequency of absence seizures measured overnight by EEG. Absence seizures from EEG include absence awake (>=10 sec), absence sleep (>=10 sec), indeterminate absence awake (3-10 sec), and indeterminate absence sleep (3-10 sec). A negative value indicates an increase in frequency. (NCT01993186)
Timeframe: Baseline, Week 8

Interventionpercent reduction in seizures per 4 wks (Median)
UX0070.0
Placebo0.0

[back to top]

Change From Baseline to Week 8 in Gross Motor Function Measure-88 (GMFM-88) Total Score

"The GMFM-88 is a standardized observational measure of abilities that includes the following 5 domains: lying/rolling, sitting, crawling/kneeling, standing, and walking/running/jumping. The GMFM-88 scores include the following:~Lying & Rolling Score, Range 0-100%, higher is better~Sitting Score, Range 0-100%, higher is better~Crawling & Kneeling Score, Range 0-100%, higher is better~Standing Score, Range 0-100%, higher is better~Walking, Running & Jumping Score, Range 0-100%, higher is better~Total Score = (Sum of 5 Above Scores) / 5, Range 0-100%, higher is better." (NCT01993186)
Timeframe: Baseline, Week 8

Interventionscore on a scale (Least Squares Mean)
UX0073.209
Placebo1.642

[back to top]

Change From Baseline in the Schirmer Test in the Study Eye

The Schirmer's Test measures the rate of secretion of tears produced by the study eye over 5 minutes. The results indicate the presence of dry eye (Normal = greater than or equal to 10 millimeters (mm) of tears, Dry Eye = less than 10 mm of tears). The smaller the number, the more severe the dry eye. A positive number change from baseline indicates an increase in tears (improvement) and a negative number change from baseline indicates a decrease in tears (worsening). (NCT02117687)
Timeframe: Baseline, Day 35

,
InterventionMillimeters (mm)/5 Minutes (Mean)
BaselineChange from Baseline at Day 35
OPTIVE FUSION™11.10.1
VISMED® Multi8.71.0

[back to top]

Change From Baseline in Tear Break-up Time (TBUT) in the Study Eye

TBUT is the time required for dry spots to appear on the surface of the eye after blinking in the worse eye. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film. A positive number change from baseline indicates an increase in TBUT (improvement) and a negative number change from baseline indicates a decrease in TBUT (worsening). (NCT02117687)
Timeframe: Baseline, Day 35

,
InterventionSeconds (Mean)
BaselineChange from Baseline at Day 35
OPTIVE FUSION™5.520.6
VISMED® Multi5.750.7

[back to top]

Conjunctival Hyperaemia in the Study Eye

Macroscopic conjunctival hyperemia (eye redness) is graded in the study eye on a 5-point scale (none, trace, mild, moderate, severe). (NCT02117687)
Timeframe: Baseline, Day 35, Month 3

,
InterventionSubjects (Number)
Baseline - NoneBaseline - TraceBaseline - MildBaseline - ModerateBaseline SevereDay 35 - NoneDay 35 - TraceDay 35 - MildDay 35 - ModerateDay 35 - SevereMonth 3 - NoneMonth 3 - TraceMonth 3 - MildMonth 3 - ModerateMonth 3 - Severe
OPTIVE FUSION™8131310179900228500
VISMED® Multi81110201210810147910

[back to top]

Change From Baseline in Ocular Surface Disease Index© (OSDI) Score

The OSDI is a 12-question survey for patients to document their dry eye disease symptoms on a 5-point scale (0=none of the time and 4=all of the time). Higher scores represent greater disability. Scores are totaled over the 12 questions and converted to a score of 0-100 (0=no disability and 100=complete disability). A negative number change from baseline represents an improvement and a positive number change from baseline represents a worsening. (NCT02117687)
Timeframe: Baseline, Day 35

,
InterventionScores on a Scale (Mean)
BaselineChange from Baseline at Day 35
OPTIVE FUSION™45.5-10.3
VISMED® Multi44.4-12.9

[back to top]

Change From Baseline in Global Ocular Staining Score in the Study Eye

Global ocular staining of the study eye was graded from 0 to 15 and was the sum of corneal fluorescein staining severity, nasal conjunctiva lissamine green staining severity, and temporal conjunctiva lissamine green staining severity. Staining of the cornea followed ocular administration of fluorescein dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Staining of the conjunctiva followed ocular administration of lissamine green dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Conjunctival staining was evaluated in two zones, nasal and temporal. (NCT02117687)
Timeframe: Baseline, Month 3

,
InterventionScores on a Scale (Mean)
BaselineChange from Baseline at Day 35
OPTIVE FUSION™5.2-2.5
VISMED® Multi5.2-2.4

[back to top]

Change From Baseline in Global Ocular Staining Score in the Study Eye

Global ocular staining of the study eye was graded from 0 to 15 and was the sum of corneal fluorescein staining severity, nasal conjunctiva lissamine green staining severity, and temporal conjunctiva lissamine green staining severity. Staining of the cornea followed ocular administration of fluorescein dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Staining of the conjunctiva followed ocular administration of lissamine green dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). Conjunctival staining was evaluated in two zones, nasal and temporal. (NCT02117687)
Timeframe: Baseline, Day 35

,
InterventionScores on a Scale (Mean)
BaselineChange from Baseline at Day 35
OPTIVE FUSION™5.2-1.5
VISMED® Multi5.2-1.6

[back to top]

Change From Baseline in Corneal Staining in the Study Eye

The cornea is the transparent front part of the eye which covers the iris and pupil. Staining of the cornea followed ocular administration of fluorescein dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining). A negative number change from baseline represents a decrease in corneal staining (improvement) and a positive number change from baseline represents an increase in corneal staining (worsening). (NCT02117687)
Timeframe: Baseline, Day 35, Month 3

,
InterventionScores on a Scale (Mean)
BaselineChange from Baseline at Day 35Change from Baseline at Month 3
OPTIVE FUSION™1.7-0.4-0.8
VISMED® Multi1.9-0.7-0.9

[back to top]

Change From Baseline in Conjunctival Staining in the Study Eye

The conjunctiva is the clear membrane covering the white surface of the eye. Staining of the conjunctiva followed ocular administration of lissamine green dye and was graded on a 6-point scale (0=no staining to 5=diffuse staining) in the temporal and nasal locations. A negative number change from baseline represents a decrease in corneal staining (improvement) and a positive number change from baseline represents an increase in corneal staining (worsening). (NCT02117687)
Timeframe: Baseline, Day 35, Month 3

,
InterventionScores on a Scale (Mean)
Baseline - TemporalChange from Baseline at Day 35 - TemporalChange from Baseline at Month 3 - TemporalBaseline - NasalChange from Baseline at Day 35 - NasalChange from Baseline at Month 3 - Nasal
OPTIVE FUSION™1.7-0.5-0.81.9-0.6-0.9
VISMED® Multi1.6-0.5-0.81.7-0.5-0.7

[back to top]

Investigator Global Assessment of Treatment Efficacy on a 4-Point Scale

Investigators assess global treatment efficacy on a 4-point scale (very satisfactory, satisfactory, poor, very poor). (NCT02117687)
Timeframe: Day 35, Month 3

,
InterventionSubjects (Number)
Day 35 - Very SatisfactoryDay 35 - SatisfactoryDay 35 - PoorDay 35 - Very PoorMonth 3 - Very SatisfactoryMonth 3 - SatisfactoryMonth 3 - PoorMonth 3 - Very Poor
OPTIVE FUSION™131750151550
VISMED® Multi81940101191

[back to top]

Study Product Use

The number of times the study product is administered per day is recorded. (NCT02117687)
Timeframe: Day 8, Day 35, Month 3

,
InterventionNumber of Times/Day (Mean)
Day 8Day 35Month 3
OPTIVE FUSION™3.633.773.71
VISMED® Multi3.473.393.42

[back to top]

Subject Assessment of Dry Eye Symptoms on a 5-Point Scale

Subjects assess dry eye symptoms on a 5-point scale (none, mild, moderate, severe, very severe). (NCT02117687)
Timeframe: Baseline, Day 35, Month 3

,
InterventionSubjects (Number)
Baseline Stinging/Burning - None (N=32,28)Baseline Stinging/Burning - Mild (N=32,28)Baseline Stinging/Burning - Moderate (N=32,28)Baseline Stinging/Burning - Severe (N=32,28)Baseline Stinging/Burning - Very Severe (N=32,28)Day 35 Stinging/Burning - NoneDay 35 Stinging/Burning - MildDay 35 Stinging/Burning - ModerateDay 35 Stinging/Burning - SevereDay 35 Stinging/Burning - Very SevereMonth 3 Stinging/Burning - NoneMonth 3 Stinging/Burning - MildMonth 3 Stinging/Burning - ModerateMonth 3 Stinging/Burning - SevereMonth 3 Stinging/Burning - Very SevereBaseline Itching - None (N=32,28)Baseline Itching - Mild (N=32,28)Baseline Itching - Moderate (N=32,28)Baseline Itching - Severe (N=32,28)Baseline Itching - Very Severe (N=32,28)Day 35 Itching- NoneDay 35 Itching- MildDay 35 Itching- ModerateDay 35 Itching- SevereDay 35 Itching- Very SevereMonth 3 Itching- NoneMonth 3 Itching- MildMonth 3 Itching- ModerateMonth 3 Itching- SevereMonth 3 Itching- Very SevereBaseline Sandiness/Grittiness - None (N=32,28)Baseline Sandiness/Grittiness - Mild (N=32,28)Baseline Sandiness/Grittiness - Moderate (N=32,28)Baseline Sandiness/Grittiness - Severe (N=32,28)Bsln Sandiness/Grittiness-Very Severe (N=32,28)Day 35 Sandiness/Grittiness - NoneDay 35 Sandiness/Grittiness - MildDay 35 Sandiness/Grittiness - ModerateDay 35 Sandiness/Grittiness - SevereDay 35 Sandiness/Grittiness - Very SevereMonth 3 Sandiness/Grittiness - NoneMonth 3 Sandiness/Grittiness - MildMonth 3 Sandiness/Grittiness - ModerateMonth 3 Sandiness/Grittiness - SevereMonth 3 Sandiness/Grittiness - Very SevereBaseline Blurred Vision - None (N=32,28)Baseline Blurred Vision - Mild (N=32,28)Baseline Blurred Vision - Moderate (N=32,28)Baseline Blurred Vision - Severe (N=32,28)Baseline Blurred Vision - Very Severe (N=32,28)Day 35 Blurred Vision - NoneDay 35 Blurred Vision - MildDay 35 Blurred Vision - ModerateDay 35 Blurred Vision - SevereDay 35 Blurred Vision - Very SevereMonth 3 Blurred Vision - NoneMonth 3 Blurred Vision - MildMonth 3 Blurred Vision - ModerateMonth 3 Blurred Vision - SevereMonth 3 Blurred Vision - Very SevereBaseline Dryness - None (N=32,28)Baseline Dryness - Mild (N=32,28)Baseline Dryness - Moderate (N=32,28)Baseline Dryness - Severe (N=32,28)Baseline Dryness - Very Severe (N=32,28)Day 35 Dryness - NoneDay 35 Dryness - MildDay 35 Dryness - ModerateDay 35 Dryness - SevereDay 35 Dryness - Very SevereMonth 3 Dryness - NoneMonth 3 Dryness - MildMonth 3 Dryness - ModerateMonth 3 Dryness - SevereMonth 3 Dryness - Very SevereBaseline Light Sensitivity - None (N=32,28)Baseline Light Sensitivity - Mild (N=32,28)Baseline Light Sensitivity - Moderate (N=32,28)Baseline Light Sensitivity - Severe (N=32,28)Baseline Light Sensitivity - Very Severe (N=32,28)Day 35 Light Sensitivity - NoneMonth 3 Light Sensitivity - SevereMonth 3 Light Sensitivity - Very SevereDay 35 Light Sensitivity - MildDay 35 Light Sensitivity - ModerateDay 35 Light Sensitivity - SevereDay 35 Light Sensitivity - Very SevereMonth 3 Light Sensitivity - NoneMonth 3 Light Sensitivity - MildMonth 3 Light Sensitivity - ModerateBaseline Painful or Sore - None (N=31,28)Baseline Painful or Sore - Mild (N=31,28)Baseline Painful or Sore - Moderate (N=31,28)Baseline Painful or Sore - Severe (N=31,28)Baseline Painful or Sore - Very Severe (N=31,28)Day 35 Painful or Sore - NoneDay 35 Painful or Sore - MildDay 35 Painful or Sore - ModerateDay 35 Painful or Sore - SevereDay 35 Painful or Sore - Very SevereMonth 3 Painful or Sore - NoneMonth 3 Painful or Sore - MildMonth 3 Painful or Sore - ModerateMonth 3 Painful or Sore - SevereMonth 3 Painful or Sore - Very Severe (N=34,31)Baseline Other - None (N=3,1)Baseline Other - Mild (N=3,1)Baseline Other - Moderate (N=3,1)Baseline Other - Severe (N=3,1)Baseline Other - Very Severe (N=3,1)Day 35 Other - None (N=1,3)Day 35 Other - Mild (N=1,3)Day 35 Other - Moderate (N=1,3)Day 35 Other - Severe (N=1,3)Day 35 Other - Very Severe (N=1,3)Month 3 Other - None (N=1,3)Month 3 Other - Mild (N=1,3)Month 3 Other - Moderate (N=1,3)Month 3 Other - Severe (N=1,3)Month 3 Other - Very Severe (N=1,3)
OPTIVE FUSION™071771512171051415106812601081520101211202619507131410717920118103016108102076111213133481670212174014149455161851516801215405209105171020001000010000100
VISMED® Multi14139128173165136157132871321108931151282481342841531107731139711149512121012335147235146328675283711742108181342591322931621000010011110011

[back to top]

Subject Assessment of Treatment Acceptability on a 5-Point Scale

Subjects assess treatment acceptability (likability and comfort) on a 5-point scale (strongly agree, agree, neither agree nor disagree, disagree, strongly disagree). (NCT02117687)
Timeframe: Day 35

,
InterventionSubjects (Number)
Liked - Strongly Agree (N=35,30)Liked - Agree (N=35,30)Liked - Neither Agree nor Disagree (N=35,30)Liked - Disagree (N=35,30)Liked - Strongly Disagree (N=35,30)Comfortable - Strongly AgreeComfortable - AgreeComfortable - Neither Agree nor DisagreeComfortable - DisagreeComfortable - Strongly Disagree
OPTIVE FUSION™1412621916721
VISMED® Multi810921913621

[back to top]

Subject Global Assessment of Treatment Efficacy on a 5-Point Scale

Subjects assess global treatment efficacy compared to baseline on a 5-point scale (much worse, worse, about the same, improved, much improved). (NCT02117687)
Timeframe: Baseline, Day 35, Month 3

,
InterventionSubjects (Number)
Day 35 - Much WorseDay 35 - WorseDay 35 - About the SameDay 35 - ImprovedDay 35 - Much ImprovedMonth 3 - Much WorseMonth 3 - WorseMonth 3 - About the SameMonth 3 - ImprovedMonth 3 - Much Improved
OPTIVE FUSION™00122120011195
VISMED® Multi03111431310134

[back to top]

Work Productivity and Activity Impairment Questionnaire Score

The Work Productivity and Activity questionnaire assesses the effect of dry eye on the ability of subjects to work and perform regular activities on a scale from 0 to 10 during the past 7 days (0=dry eye had no effect on my work/daily activities to 10=dry eye completely prevented me from working/doing my daily activities). Since not all subjects were in full time employment during the study, not all items of the questionnaire were applicable to all subjects at each visit. Outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity. (NCT02117687)
Timeframe: Baseline, Day 35, Month 3

,
InterventionScores on a Scale (Mean)
Baseline - Work Productivity (N=11,13)Baseline - Activity ImpairmentDay 35 - Work Productivity (N=11,9)Day 35 - Activity Impairment (N=34,31)Month 3 - Work Productivity (N=11,10)Month 3 - Activity Impairment
OPTIVE FUSION™3.093.912.553.091.822.14
VISMED® Multi3.464.352.333.522.402.77

[back to top]

Amino Acid Assessment: Baseline and Change From Baseline in Leucine Up to Month 24: Cohort of 0 Months to <2 Months Participants

(NCT02246218)
Timeframe: Baseline, Day 7, Month 2, Month 3, Month 4, Month 5, Month 6, Month 9, Month 12, Month 15, Month 18, Month 24

Interventionμmol/L (Mean)
BaselineDay 7 change from BaselineMonth 2 change from BaselineMonth 3 change from BaselineMonth 4 change from BaselineMonth 5 change from BaselineMonth 6 change from BaselineMonth 9 change from BaselineMonth 12 change from BaselineMonth 15 change from BaselineMonth 18 change from BaselineMonth 24 change from Baseline
RAVICTI: Age 0 to < 2 Months133.67-81.91-60.80-51.66-82.82-118.55-11.85-115.09-249.50-195.756.00-82.54

[back to top]

Amino Acid Assessment: Baseline and Change From Baseline in Leucine Up to Month 24: Cohort of 2 Months to <2 Years Participants

(NCT02246218)
Timeframe: Baseline, Day 7, Month 2, Month 3, Month 4, Month 5, Month 6, Month 9, Month 12, Month 15, Month 24

Interventionµmol/L (Mean)
BaselineDay 7 change from BaselineMonth 2 change from BaselineMonth 3 change from BaselineMonth 4 change from BaselineMonth 5 change from BaselineMonth 6 change from BaselineMonth 9 change from BaselineMonth 12 change from BaselineMonth 15 change from BaselineMonth 24 change from Baseline
RAVICTI: Age 2 Months to < 2 Years90.86-0.839.80-33.00-31.25-39.50-25.40-19.13-34.37-40.00-1.50

[back to top]

Amino Acid Assessment: Baseline and Change From Baseline in Sum of Glutamine and Glutamate Up to Month 24: Cohort of 0 Months to <2 Months Participants

(NCT02246218)
Timeframe: Baseline, Day 7, Month 2, Month 3, Month 4, Month 5, Month 6, Month 9, Month 12, Month 15, Month 18, Month 24

Interventionμmol/L (Mean)
BaselineDay 7 change from BaselineMonth 2 change from BaselineMonth 3 change from BaselineMonth 4 change from BaselineMonth 5 change from BaselineMonth 6 change from BaselineMonth 9 change from BaselineMonth 12 change from BaselineMonth 15 change from BaselineMonth 18 change from BaselineMonth 24 change from Baseline
RAVICTI: Age 0 to < 2 Months593.8047.85-2.4634.96-95.21-42.39-94.51-22.66-172.75-78.00-181.50-203.83

[back to top]

Amino Acid Assessment: Baseline and Change From Baseline in Sum of Glutamine and Glutamate Up to Month 24: Cohort of 2 Months to <2 Years Participants

(NCT02246218)
Timeframe: Baseline, Day 7, Month 2, Month 3, Month 4, Month 5, Month 6, Month 9, Month 12, Month 15, Month 24

Interventionµmol/L (Mean)
BaselineDay 7 change from BaselineMonth 2 change from BaselineMonth 3 change from BaselineMonth 4 change from BaselineMonth 5 change from BaselineMonth 6 change from BaselineMonth 9 change from BaselineMonth 12 change from BaselineMonth 15 change from BaselineMonth 24 change from Baseline
RAVICTI: Age 2 Months to < 2 Years872.86-238.83-166.80-390.33-265.75-370.00-115.40-415.73-428.30-110.00243.00

[back to top]

Amino Acid Assessment: Baseline and Change From Baseline in Valine Up to Month 24: Cohort of 2 Months to <2 Years Participants

(NCT02246218)
Timeframe: Baseline, Day 7, Month 2, Month 3, Month 4, Month 5, Month 6, Month 9, Month 12, Month 15, Month 24

Interventionµmol/L (Mean)
BaselineDay 7 change from BaselineMonth 2 change from BaselineMonth 3 change from BaselineMonth 4 change from BaselineMonth 5 change from BaselineMonth 6 change from BaselineMonth 9 change from BaselineMonth 12 change from BaselineMonth 15 change from BaselineMonth 24 change from Baseline
RAVICTI: Age 2 Months to < 2 Years171.434.0040.60-27.33-31.50-56.00-21.60-11.90-48.87-46.005.00

[back to top]

Assessment of Growth and Development: Baseline and Change From Baseline in BMI Z-Score Up to Month 24: Cohort of 0 Months to <2 Months Participants

To assess any effect of study drug treatment on growth, Z-scores were calculated to express the deviation from a reference population for BMI. The Z-scores are based on the World Health Organization's Child Growth Standards charts. Negative Z-scores indicate lower than typical for age and gender while positive scores indicate higher than typical for age and gender. (NCT02246218)
Timeframe: Baseline, Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 9, Month 12, Month 15, Month 18, Month 24

Interventionz-score (Mean)
BaselineMonth 1 change from BaselineMonth 2 change from BaselineMonth 3 change from BaselineMonth 4 change from BaselineMonth 5 change from BaselineMonth 6 change from BaselineMonth 9 change from BaselineMonth 12 change from BaselineMonth 15 change from BaselineMonth 18 change from BaselineMonth 24 change from Baseline
RAVICTI: Age 0 to < 2 Months-0.0544-0.2158-0.2598-0.1617-0.02640.08280.01360.46140.66460.68300.33080.7743

[back to top]

Assessment of Growth and Development: Baseline and Change From Baseline in Body Mass Index (BMI) Z-Score Up to Month 24: Cohort of 2 Months to <2 Years Participants

To assess any effect of study drug treatment on growth, Z-scores were calculated to express the deviation from a reference population for BMI. The Z-scores are based on the World Health Organization's Child Growth Standards charts. Negative Z-scores indicate lower than typical for age and gender while positive scores indicate higher than typical for age and gender. (NCT02246218)
Timeframe: Baseline, Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 9, Month 12, Month 15, Month 18, Month 24

Interventionz-score (Mean)
BaselineMonth 1 change from BaselineMonth 2 change from BaselineMonth 3 change from BaselineMonth 4 change from BaselineMonth 5 change from BaselineMonth 6 change from BaselineMonth 9 change from BaselineMonth 12 change from BaselineMonth 15 change from BaselineMonth 18 change from BaselineMonth 24 change from Baseline
RAVICTI: Age 2 Months to < 2 Years0.8107-0.2385-0.02490.18150.44340.14840.24970.64070.4164-0.2997-0.20380.5581

[back to top]

Assessment of Growth and Development: Baseline and Change From Baseline in Body Surface Area (BSA) Z-Score Up to Month 24: Cohort of 2 Months to <2 Years Participants

To assess any effect of study drug treatment on growth, Z-scores were calculated to express the deviation from a reference population for BSA. The Z-scores are based on weight-for-length charts. Negative Z-scores indicate lower than typical for age and gender while positive scores indicate higher than typical for age and gender. (NCT02246218)
Timeframe: Baseline, Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 9, Month 12, Month 15, Month 18, Month 24

Interventionz-score (Mean)
BaselineMonth 1 change from BaselineMonth 2 change from BaselineMonth 3 change from BaselineMonth 4 change from BaselineMonth 5 change from BaselineMonth 6 change from BaselineMonth 9 change from BaselineMonth 12 change from BaselineMonth 15 change from BaselineMonth 18 change from BaselineMonth 24 change from Baseline
RAVICTI: Age 2 Months to < 2 Years0.7143-0.2105-0.07040.10650.33650.10430.18420.48750.2944-0.3661-0.22140.4310

[back to top]

Assessment of Growth and Development: Baseline and Change From Baseline in BSA Z-Score Up to Month 24: Cohort of 0 Months to <2 Months Participants

To assess any effect of study drug treatment on growth, Z-scores were calculated to express the deviation from a reference population for BSA. The Z-scores are based on weight-for-length charts. Negative Z-scores indicate lower than typical for age and gender while positive scores indicate higher than typical for age and gender. (NCT02246218)
Timeframe: Baseline, Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 9, Month 12, Month 15, Month 18, Month 24

Interventionz-score (Mean)
BaselineMonth 1 change from BaselineMonth 2 change from BaselineMonth 3 change from BaselineMonth 4 change from BaselineMonth 5 change from BaselineMonth 6 change from BaselineMonth 9 change from BaselineMonth 12 change from BaselineMonth 15 change from BaselineMonth 18 change from BaselineMonth 24 change from Baseline
RAVICTI: Age 0 to < 2 Months-0.19800.23360.20060.26840.23720.18100.29020.16790.13080.15950.10500.7341

[back to top]

Assessment of Urinary PAA Concentrations on the First Full Day of RAVICTI Dosing: Cohort of 0 Months to <2 Months Participants

(NCT02246218)
Timeframe: Hour 0 and between 0.5 and 1.5 hours, 1.5 and 2.5 hours, 4 and 6 hours, 7.5 and 8.5 hours, and between 12 and 24 hours after the first dose of the day on Day 1 for stable participants and on Day 2 for participants in HAC

Interventionμg/mL (Mean)
Hour 00.5 to 1.5 hours1.5 to 2.5 hours4 to 6 hours7.5 to 8.5 hours12 to 24 hours
RAVICTI: Age 0 to < 2 Months11.146.262.534.622.835.2

[back to top]

Assessment of Urinary PAA Concentrations on the First Full Day of RAVICTI Dosing: Cohort of 2 Months to <2 Years Participants

(NCT02246218)
Timeframe: Hour 0 and between 0.5 and 1.5 hours, 1.5 and 2.5 hours, 4 and 6 hours, 7.5 and 8.5 hours, and between 12 and 24 hours after the first dose of the day on Day 1 for stable participants and on Day 2 for participants in HAC

Interventionμg/mL (Mean)
Hour 00.5 to 1.5 hours1.5 to 2.5 hours4 to 6 hours7.5 to 8.5 hours12 to 24 hours
RAVICTI: Age 2 Months to < 2 Years18.786.507.292.604.484.31

[back to top]

Assessment of Urinary PAA Concentrations Up to End of Trial: Cohort of 0 Months to <2 Months Participants

(NCT02246218)
Timeframe: Day 7, Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 9, Month 15, End of Trial (up to Month 15)

Interventionμg/mL (Mean)
Day 7Month 1Month 2Month 3Month 4Month 5Month 6Month 9Month 12Month 15End of trial
RAVICTI: Age 0 to < 2 Months23.714.612.314.46.413.25.511.86.04.911.6

[back to top]

Assessment of Urinary PAA Concentrations Up to End of Trial: Cohort of 2 Months to <2 Years Participants

(NCT02246218)
Timeframe: Day 7, Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 9, Month 15, Month 18, End of Trial (up to Month 18)

Interventionμg/mL (Mean)
Day 7Month 1Month 2Month 3Month 4Month 5Month 6Month 9Month 15Month 18End of trial
RAVICTI: Age 2 Months to < 2 Years5.824.443.694.657.143.271.594.102.041.647.0

[back to top]

Assessment of Urinary PAGN Concentrations on the First Full Day of RAVICTI Dosing: Cohort of 0 Months to <2 Months Participants

(NCT02246218)
Timeframe: Hour 0 and between 0.5 and 1 hour, 1.5 and 2.5 hours, 4 and 6 hours, 7.5 and 8.5 hours, and between 12 and 24 hours after the first dose of the day on Day 1 for stable participants and on Day 2 for participants in HAC

Interventionμg/mL (Mean)
Hour 00.5 to 1.5 hours1.5 to 2.5 hours4 to 6 hours7.5 to 8.5 hours12 to 24 hours
RAVICTI: Age 0 to < 2 Months3530.431828174622603530.434404

[back to top]

Assessment of Urinary PAGN Concentrations on the First Full Day of RAVICTI Dosing: Cohort of 2 Months to <2 Years Participants

(NCT02246218)
Timeframe: Hour 0 and between 0.5 and 1 hour, 1.5 and 2.5 hours, 4 and 6 hours, 7.5 and 8.5 hours, and between 12 and 24 hours after the first dose of the day on Day 1 for stable participants and on Day 2 for participants in HAC

Interventionμg/mL (Mean)
Hour 00.5 to 1.5 hours1.5 to 2.5 hours4 to 6 hours7.5 to 8.5 hours12 to 24 hours
RAVICTI: Age 2 Months to < 2 Years327341403145520239507561

[back to top]

Assessment of Urinary PAGN Concentrations Up to End of Trial: Cohort of 0 Months to <2 Months Participants

(NCT02246218)
Timeframe: Day 7, Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 9, Month 12, Month 15, End of Trial (up to Month 15)

Interventionμg/mL (Mean)
Day 7Month 1Month 2Month 3Month 4Month 5Month 6Month 9Month 12Month 15End of trial
RAVICTI: Age 0 to < 2 Months46434517411670372826697358837006584739156939

[back to top]

Assessment of Urinary PAGN Concentrations Up to End of Trial: Cohort of 2 Months to <2 Years Participants

(NCT02246218)
Timeframe: Day 7, Month 1, Month 2, Month 3, Month 4, Month 5, Month 6, Month 9, Month 12, Month 15, Month 18, End of Trial (up to Month 18)

Interventionμg/mL (Mean)
Day 7Month 1Month 2Month 3Month 4Month 5Month 6Month 9Month 12Month 15Month 18End of trial
RAVICTI: Age 2 Months to < 2 Years885962747386114562141661295347935725806400525025333

[back to top]

Number of Participants With TEAEs, Serious TEAEs, Deaths, and Discontinuations Due to TEAEs: Cohort of 0 Months to <2 Months Participants

An AE is any untoward medical occurrence, whether or not the event is considered related to the study drug. A serious AE is any AE that: results in death; is life threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. TEAEs are defined as AEs with an onset date on or after the first dose of study medication until study discontinuation. The Investigator assessed the causal relationship of each TEAE to the study drug as not related, possibly related, or probably related. (NCT02246218)
Timeframe: From the first dose of study treatment through 30 days after the final dose (mean [SD] duration of treatment was 10.67 [6.142] months).

InterventionParticipants (Count of Participants)
≥ 1 TEAE≥ 1 Related TEAE≥ 1 Serious TEAE≥ 1 Serious Related TEAEFatal Outcome TEAE≥ 1 TEAE Leading to Study Discontinuation
RAVICTI: Age 0 to < 2 Months161011001

[back to top]

Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Deaths, and Discontinuations Due to TEAEs: Cohort of 2 Months to <2 Years Participants

An adverse event (AE) is any untoward medical occurrence, whether or not the event is considered related to the study drug. A serious AE is any AE that: results in death; is life threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. TEAEs are defined as AEs with an onset date on or after the first dose of study medication until study discontinuation. The Investigator assessed the causal relationship of each TEAE to the study drug as not related, possibly related, or probably related. (NCT02246218)
Timeframe: From the first dose of study treatment through 30 days after the final dose (mean [SD] duration of treatment was 9.13 [6.838] months).

InterventionParticipants (Count of Participants)
≥ 1 TEAE≥ 1 Related TEAE≥ 1 Serious TEAE≥ 1 Serious Related TEAEFatal Outcome TEAE≥ 1 TEAE Leading to Study Discontinuation
RAVICTI: Age 2 Months to < 2 Years1046011

[back to top]

Amino Acid Assessment: Baseline and Change From Baseline in Valine Up to Month 24: Cohort of 0 Months to <2 Months Participants

(NCT02246218)
Timeframe: Baseline, Day 7, Month 2, Month 3, Month 4, Month 5, Month 6, Month 9, Month 12, Month 15, Month 18, Month 24

Interventionμmol/L (Mean)
BaselineDay 7 change from BaselineMonth 2 change from BaselineMonth 3 change from BaselineMonth 4 change from BaselineMonth 5 change from BaselineMonth 6 change from BaselineMonth 9 change from BaselineMonth 12 change from BaselineMonth 15 change from BaselineMonth 18 change from BaselineMonth 24 change from Baseline
RAVICTI: Age 0 to < 2 Months181.49-63.96-39.04-23.86-74.41-98.672.64-90.40-238.25-137.0038.00-72.78

[back to top]

Percentage of Participants With Successful Transition to RAVICTI With Controlled Ammonia (i.e. No Clinical Symptoms and Ammonia < 100 μmol/L): Cohort of 0 Months to <2 Months Participants

"The percentage of participants with successful transition is based on Investigator response to the question, Has transition to 100% RAVICTI been successful with controlled ammonia? For participants < 2 months of age, after a minimum of 24 hours of ammonia monitoring following the first full dose of RAVICTI alone, the participant was effectively transitioned when following conditions were met: no signs and symptoms of hyperammonemia; ammonia level less than 100 μmol/L (without normalization of ammonia, ie, without conversion of values from local laboratories with varying normal ranges to standardized values); and eligible for discharge per Investigator judgment." (NCT02246218)
Timeframe: Up to Day 4

Interventionpercentage of participants (Number)
RAVICTI: Age 0 to < 2 Months100

[back to top]

Percentage of Participants With Successful Transition to RAVICTI With Controlled Ammonia (i.e. No Clinical Symptoms and Ammonia < 100 μmol/L): Cohort of 2 Months to <2 Years Participants

"The percentage of participants with successful transition is based on Investigator response to the question, Has transition to 100% RAVICTI been successful with controlled ammonia? For participants 2 months of age and older, after a minimum of 24 hours of ammonia monitoring following the first full dose of RAVICTI alone, the participant was effectively transitioned when following conditions were met: no signs and symptoms of hyperammonemia; ammonia level less than 100 μmol/L (without normalization of ammonia, ie, without conversion of values from local laboratories with varying normal ranges to standardized values); and eligible for discharge per Investigator judgment." (NCT02246218)
Timeframe: Up to Day 4

Interventionpercentage of participants (Number)
RAVICTI: Age 2 Months to < 2 Years100

[back to top]

Plasma PAA AUC(0-last) on the First Full Day of RAVICTI Dosing: Cohort of 0 Months to <2 Months Participants

(NCT02246218)
Timeframe: Hour 0 and between 4 and 6 hours, 8 hours, and between 12 and 24 hours after the first dose of the day on Day 1 for stable participants and on Day 2 for participants in HAC

Interventionμg*hr/mL (Mean)
RAVICTI: Age 0 to < 2 Months1321.18

[back to top]

Plasma PAA AUC(0-last) on the First Full Day of RAVICTI Dosing: Cohort of 2 Months to <2 Years Participants

(NCT02246218)
Timeframe: Hour 0 and between 4 and 6 hours, 8 hours, and between 12 and 24 hours after the first dose of the day on Day 1 for stable participants and on Day 2 for participants in HAC

Interventionμg*hr/mL (Mean)
RAVICTI: Age 2 Months to < 2 Years246.126

[back to top]

Plasma PAA Cmax on the First Full Day of RAVICTI Dosing: Cohort of 0 Months to <2 Months Participants

(NCT02246218)
Timeframe: Hour 0 and between 4 and 6 hours, 8 hours, and between 12 and 24 hours after the first dose of the day on Day 1 for stable participants and on Day 2 for participants in HAC

Interventionμg/mL (Mean)
RAVICTI: Age 0 to < 2 Months115.3

[back to top]

Plasma PAA Cmin on the First Full Day of RAVICTI Dosing: Cohort of 0 Months to <2 Months Participants

(NCT02246218)
Timeframe: Hour 0 and between 4 and 6 hours, 8 hours, and between 12 and 24 hours after the first dose of the day on Day 1 for stable participants and on Day 2 for participants in HAC

Interventionμg/mL (Mean)
RAVICTI: Age 0 to < 2 Months98.98

[back to top]

Plasma PAA Cmin on the First Full Day of RAVICTI Dosing: Cohort of 2 Months to <2 Years Participants

(NCT02246218)
Timeframe: Hour 0 and between 4 and 6 hours, 8 hours, and between 12 and 24 hours after the first dose of the day on Day 1 for stable participants and on Day 2 for participants in HAC

Interventionμg/mL (Mean)
RAVICTI: Age 2 Months to < 2 Years4.197

[back to top]

Plasma PAA Tmax on the First Full Day of RAVICTI Dosing: Cohort of 0 Months to <2 Months Participants

(NCT02246218)
Timeframe: Hour 0 and between 4 and 6 hours, 8 hours, and between 12 and 24 hours after the first dose of the day on Day 1 for stable participants and on Day 2 for participants in HAC

Interventionhours (Mean)
RAVICTI: Age 0 to < 2 Months9.85

[back to top]

Plasma PAA Tmax on the First Full Day of RAVICTI Dosing: Cohort of 2 Months to <2 Years Participants

(NCT02246218)
Timeframe: Hour 0 and between 4 and 6 hours, 8 hours, and between 12 and 24 hours after the first dose of the day on Day 1 for stable participants and on Day 2 for participants in HAC

Interventionhours (Mean)
RAVICTI: Age 2 Months to < 2 Years7.422

[back to top]

Plasma PAGN AUC(0-last) on the First Full Day of RAVICTI Dosing: Cohort of 0 Months to <2 Months Participants

(NCT02246218)
Timeframe: Hour 0 and between 4 and 6 hours, 8 hours, and between 12 and 24 hours after the first dose of the day on Day 1 for stable participants and on Day 2 for participants in HAC

Interventionμg*hr/mL (Mean)
RAVICTI: Age 0 to < 2 Months1384.12

[back to top]

Plasma PAGN AUC(0-last) on the First Full Day of RAVICTI Dosing: Cohort of 2 Months to <2 Years Participants

(NCT02246218)
Timeframe: Hour 0 and between 4 and 6 hours, 8 hours, and between 12 and 24 hours after the first dose of the day on Day 1 for stable participants and on Day 2 for participants in HAC

Interventionμg*hr/mL (Mean)
RAVICTI: Age 2 Months to < 2 Years583.835

[back to top]

Plasma PAGN Cmax on the First Full Day of RAVICTI Dosing: Cohort of 0 Months to <2 Months Participants

(NCT02246218)
Timeframe: Hour 0 and between 4 and 6 hours, 8 hours, and between 12 and 24 hours after the first dose of the day on Day 1 for stable participants and on Day 2 for participants in HAC

Interventionμg/mL (Mean)
RAVICTI: Age 0 to < 2 Months102.1

[back to top]

Plasma PAGN Cmin on the First Full Day of RAVICTI Dosing: Cohort of 0 Months to <2 Months Participants

(NCT02246218)
Timeframe: Hour 0 and between 4 and 6 hours, 8 hours, and between 12 and 24 hours after the first dose of the day on Day 1 for stable participants and on Day 2 for participants in HAC

Interventionμg/mL (Mean)
RAVICTI: Age 0 to < 2 Months69.39

[back to top]

Plasma PAGN Cmin on the First Full Day of RAVICTI Dosing: Cohort of 2 Months to <2 Years Participants

(NCT02246218)
Timeframe: Hour 0 and between 4 and 6 hours, 8 hours, and between 12 and 24 hours after the first dose of the day on Day 1 for stable participants and on Day 2 for participants in HAC

Interventionμg/mL (Mean)
RAVICTI: Age 2 Months to < 2 Years20.62

[back to top]

Plasma PAGN Tmax on the First Full Day of RAVICTI Dosing: Cohort of 0 Months to <2 Months Participants

(NCT02246218)
Timeframe: Hour 0 and between 4 and 6 hours, 8 hours, and between 12 and 24 hours after the first dose of the day on Day 1 for stable participants and on Day 2 for participants in HAC

Interventionhours (Mean)
RAVICTI: Age 0 to < 2 Months11.72

[back to top]

Plasma PAGN Tmax on the First Full Day of RAVICTI Dosing: Cohort of 2 Months to <2 Years Participants

(NCT02246218)
Timeframe: Hour 0 and between 4 and 6 hours, 8 hours, and between 12 and 24 hours after the first dose of the day on Day 1 for stable participants and on Day 2 for participants in HAC

Interventionhours (Mean)
RAVICTI: Age 2 Months to < 2 Years6.573

[back to top]

Plasma PBA Area Under the Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC[0-last]) on the First Full Day of RAVICTI Dosing: Cohort of 2 Months to <2 Years Participants

(NCT02246218)
Timeframe: Hour 0 and between 4 and 6 hours, 8 hours, and between 12 and 24 hours after the first dose of the day on Day 1 for stable participants and on Day 2 for participants in HAC

Interventionμg*hr/mL (Mean)
RAVICTI: Age 2 Months to < 2 Years280.936

[back to top]

Plasma PBA AUC(0-last) on the First Full Day of RAVICTI Dosing: Cohort of 0 Months to <2 Months Participants

(NCT02246218)
Timeframe: Hour 0 and between 4 and 6 hours, 8 hours, and between 12 and 24 hours after the first dose of the day on Day 1 for stable participants and on Day 2 for participants in HAC

Interventionμg*hr/mL (Mean)
RAVICTI: Age 0 to < 2 Months374.53

[back to top]

Plasma PBA Cmax on the First Full Day of RAVICTI Dosing: Cohort of 0 Months to <2 Months Participants

(NCT02246218)
Timeframe: Hour 0 and between 4 and 6 hours, 8 hours, and between 12 and 24 hours after the first dose of the day on Day 1 for stable participants and on Day 2 for participants in HAC

Interventionμg/mL (Mean)
RAVICTI: Age 0 to < 2 Months46.2

[back to top]

Plasma PBA Cmin on the First Full Day of RAVICTI Dosing: Cohort of 0 Months to <2 Months Participants

(NCT02246218)
Timeframe: Hour 0 and between 4 and 6 hours, 8 hours, and between 12 and 24 hours after the first dose of the day on Day 1 for stable participants and on Day 2 for participants in HAC

Interventionμg/mL (Mean)
RAVICTI: Age 0 to < 2 Months4.8

[back to top]

Plasma PBA Minimum Plasma Concentration (Cmin) on the First Full Day of RAVICTI Dosing: Cohort of 2 Months to <2 Years Participants

(NCT02246218)
Timeframe: Hour 0 and between 4 and 6 hours, 8 hours, and between 12 and 24 hours after the first dose of the day on Day 1 for stable participants and on Day 2 for participants in HAC

Interventionμg/mL (Mean)
RAVICTI: Age 2 Months to < 2 Years1.697

[back to top]

Plasma PBA Time to Cmax (Tmax) on the First Full Day of RAVICTI Dosing: Cohort of 2 Months to <2 Years Participants

(NCT02246218)
Timeframe: Hour 0 and between 4 and 6 hours, 8 hours, and between 12 and 24 hours after the first dose of the day on Day 1 for stable participants and on Day 2 for participants in HAC

Interventionhours (Mean)
RAVICTI: Age 2 Months to < 2 Years8.383

[back to top]

Plasma PBA Tmax on the First Full Day of RAVICTI Dosing: Cohort of 0 Months to <2 Months Participants

(NCT02246218)
Timeframe: Hour 0 and between 4 and 6 hours, 8 hours, and between 12 and 24 hours after the first dose of the day on Day 1 for stable participants and on Day 2 for participants in HAC

Interventionhours (Mean)
RAVICTI: Age 0 to < 2 Months9.39

[back to top]

Plasma Phenylacetate/Phenylacetic Acid (PAA) Cmax on the First Full Day of RAVICTI Dosing: Cohort of 2 Months to <2 Years Participants

(NCT02246218)
Timeframe: Hour 0 and between 4 and 6 hours, 8 hours, and between 12 and 24 hours after the first dose of the day on Day 1 for stable participants and on Day 2 for participants in HAC

Interventionμg/mL (Mean)
RAVICTI: Age 2 Months to < 2 Years36.52

[back to top]

Plasma Phenylacetylglutamine (PAGN) Cmax on the First Full Day of RAVICTI Dosing: Cohort of 2 Months to <2 Years Participants

(NCT02246218)
Timeframe: Hour 0 and between 4 and 6 hours, 8 hours, and between 12 and 24 hours after the first dose of the day on Day 1 for stable participants and on Day 2 for participants in HAC

Interventionμg/mL (Mean)
RAVICTI: Age 2 Months to < 2 Years62.45

[back to top]

Plasma Phenylbutyrate/Phenylbutyric Acid (PBA) Maximum Plasma Concentration (Cmax) on the First Full Day of RAVICTI Dosing: Cohort of 2 Months to <2 Years Participants

(NCT02246218)
Timeframe: Hour 0 and between 4 and 6 hours, 8 hours, and between 12 and 24 hours after the first dose of the day on Day 1 for stable participants and on Day 2 for participants in HAC

Interventionμg/mL (Mean)
RAVICTI: Age 2 Months to < 2 Years42.44

[back to top]

Rate of HACs: Cohort of 0 Months to <2 Months Participants

HAC is defined as having signs and symptoms consistent with hyperammonemia (such as but not limited to frequent vomiting, nausea, headache, lethargy, irritability, combativeness, and/or somnolence) associated with high blood ammonia and requiring medical intervention. Rate of HACs per 6 months during the safety extension was calculated as sum of (number of HAC) / sum of (days during first 6 months starting on Day 8 or number days on RAVICTI, whichever is less) across all participants in the corresponding group. (NCT02246218)
Timeframe: Day 8 through up to Month 6

InterventionHACs per half-year of patient exposure (Number)
RAVICTI: Age 0 to < 2 Months0.003

[back to top]

Rate of Hyperammonemic Crises (HACs): Cohort of 2 Months to <2 Years Participants

HAC is defined having signs and symptoms consistent with hyperammonemia (such as but not limited to frequent vomiting, nausea, headache, lethargy, irritability, combativeness, and/or somnolence) associated with high blood ammonia and requiring medical intervention. Rate of HACs per 6 months during the safety extension is calculated as sum of (number of HAC) / sum of (days during first 6 months starting on Day 8 or number days on RAVICTI, whichever is less) across all participants in the corresponding group. (NCT02246218)
Timeframe: Day 8 through up to Month 6

InterventionHACs per half-year of patient exposure (Number)
RAVICTI: Age 2 Months to < 2 Years0.005

[back to top]

Amino Acid Assessment: Baseline and Change From Baseline in Glutamate Up to Month 24: Cohort of 0 Months to <2 Months Participants

(NCT02246218)
Timeframe: Baseline, Day 7, Month 2, Month 3, Month 4, Month 5, Month 6, Month 9, Month 12, Month 15, Month 18, Month 24

Interventionμmol/L (Mean)
BaselineDay 7 change from BaselineMonth 2 change from BaselineMonth 3 change from BaselineMonth 4 change from BaselineMonth 5 change from BaselineMonth 6 change from BaselineMonth 9 change from BaselineMonth 12 change from BaselineMonth 15 change from BaselineMonth 18 change from BaselineMonth 24 change from Baseline
RAVICTI: Age 0 to < 2 Months84.9726.8125.1650.0518.7757.4343.6533.418.7525.752.5016.10

[back to top]

Amino Acid Assessment: Baseline and Change From Baseline in Glutamate Up to Month 24: Cohort of 2 Months to <2 Years Participants

(NCT02246218)
Timeframe: Baseline, Day 7, Month 2, Month 3, Month 4, Month 5, Month 6, Month 9, Month 12, Month 15, Month 24

Interventionµmol/L (Mean)
BaselineDay 7 change from BaselineMonth 2 change from BaselineMonth 3 change from BaselineMonth 4 change from BaselineMonth 5 change from BaselineMonth 6 change from BaselineMonth 9 change from BaselineMonth 12 change from BaselineMonth 15 change from BaselineMonth 24 change from Baseline
RAVICTI: Age 2 Months to < 2 Years122.43-54.507.80-16.33-13.000.25-2.2030.8022.2039.0048.00

[back to top]

Amino Acid Assessment: Baseline and Change From Baseline in Glutamine Up to Month 24: Cohort of 0 Months to <2 Months Participants

(NCT02246218)
Timeframe: Baseline, Day 7, Month 2, Month 3, Month 4, Month 5, Month 6, Month 9, Month 12, Month 15, Month 18, Month 24

Interventionμmol/L (Mean)
BaselineDay 7 change from BaselineMonth 2 change from BaselineMonth 3 change from BaselineMonth 4 change from BaselineMonth 5 change from BaselineMonth 6 change from BaselineMonth 9 change from BaselineMonth 12 change from BaselineMonth 15 change from BaselineMonth 18 change from BaselineMonth 24 change from Baseline
RAVICTI: Age 0 to < 2 Months508.8321.04-27.62-15.09-113.98-99.82-138.16-56.08-181.50-103.75-184.00-219.93

[back to top]

Amino Acid Assessment: Baseline and Change From Baseline in Glutamine Up to Month 24: Cohort of 2 Months to <2 Years Participants

(NCT02246218)
Timeframe: Baseline, Day 7, Month 2, Month 3, Month 4, Month 5, Month 6, Month 9, Month 12, Month 15, Month 24

Interventionµmol/L (Mean)
BaselineDay 7 change from BaselineMonth 2 change from BaselineMonth 3 change from BaselineMonth 4 change from BaselineMonth 5 change from BaselineMonth 6 change from BaselineMonth 9 change from BaselineMonth 12 change from BaselineMonth 15 change from BaselineMonth 24 change from Baseline
RAVICTI: Age 2 Months to < 2 Years750.43-184.33-174.60-374.00-252.75-370.25-113.20-446.53-450.50-149.00195.00

[back to top]

Amino Acid Assessment: Baseline and Change From Baseline in Isoleucine Up to Month 24: Cohort of 0 Months to <2 Months Participants

(NCT02246218)
Timeframe: Baseline, Day 7, Month 2, Month 3, Month 4, Month 5, Month 6, Month 9, Month 12, Month 15, Month 18, Month 24

Interventionμmol/L (Mean)
BaselineDay 7 change from BaselineMonth 2 change from BaselineMonth 3 change from BaselineMonth 4 change from BaselineMonth 5 change from BaselineMonth 6 change from BaselineMonth 9 change from BaselineMonth 12 change from BaselineMonth 15 change from BaselineMonth 18 change from BaselineMonth 24 change from Baseline
RAVICTI: Age 0 to < 2 Months142.68-49.09-1.62-20.46-67.32-75.45-35.94-73.09-178.50-139.501.00-55.31

[back to top]

Amino Acid Assessment: Baseline and Change From Baseline in Isoleucine Up to Month 24: Cohort of 2 Months to <2 Years Participants

(NCT02246218)
Timeframe: Baseline, Day 7, Month 2, Month 3, Month 4, Month 5, Month 6, Month 9, Month 12, Month 15, Month 24

Interventionµmol/L (Mean)
BaselineDay 7 change from BaselineMonth 2 change from BaselineMonth 3 change from BaselineMonth 4 change from BaselineMonth 5 change from BaselineMonth 6 change from BaselineMonth 9 change from BaselineMonth 12 change from BaselineMonth 15 change from BaselineMonth 24 change from Baseline
RAVICTI: Age 2 Months to < 2 Years54.862.674.20-25.67-20.25-20.00-16.40-6.73-13.33-18.001.50

[back to top]

Change in Immune Parameters With Peanut SLIT Versus Placebo SLIT (Peanut Skin Prick Test)

"The change in immune parameters over time associated with the induction of clinical desensitization compared to the failure to achieve clinical desensitization.~Peanut-skin prick test measured at baseline and at completion of peanut SLIT (36 months). Change in skin prick test reported in mm wheal diameter." (NCT02304991)
Timeframe: 0 months to 36 months

Interventionmm (Mean)
Peanut (Liquid Peanut Extract) SLIT-7.7
Placebo Glycerin SLIT1.8

[back to top]

Change in Immune Parameters With Peanut SLIT Versus Placebo SLIT (Peanut-specific IgE)

"The change in immune parameters over time associated with the induction of clinical desensitization compared to the failure to achieve clinical desensitization.~Peanut-specific IgE measured at baseline and at completion of peanut SLIT (36 months). Change in IgE reported in kUA/L." (NCT02304991)
Timeframe: 0 months to 36 months

InterventionkUA/L of peanut-specific IgE (Mean)
Peanut (Liquid Peanut Extract) SLIT-19.4
Placebo Glycerin SLIT65.2

[back to top]

Change in Immune Parameters With Peanut SLIT Versus Placebo SLIT (Peanut-specific IgG4)

"The change in immune parameters over time associated with the induction of clinical desensitization compared to the failure to achieve clinical desensitization.~Peanut-specific IgG4 measured at baseline and at completion of peanut SLIT (36 months). Change in IgG4 reported in mg/L." (NCT02304991)
Timeframe: 0 months to 36 months

Interventionmg/L of peanut-specific IgG4 (Mean)
Peanut (Liquid Peanut Extract) SLIT3.9
Placebo Glycerin SLIT-0.2

[back to top]

Desensitization After 36 Months of Peanut SLIT or Placebo SLIT

"The primary outcome of this study will be a statistically significant difference in the challenge score of the treatment group versus the placebo group during DBPCFC after 36 months of peanut SLIT (desensitization).~DBPCFC Challenge Score scale:~Minimum score = 0; Maximum score = 7 Larger challenge score equals more successful desensitization. 0mg = 0; 3mg = 1; 13mg = 2; 43mg = 3; 143mg = 4; 443mg = 5; 1443mg = 6; and 4443mg = 7." (NCT02304991)
Timeframe: 36 months

Interventionscore on a scale (Mean)
Peanut (Liquid Peanut Extract) SLIT4.9
Placebo Glycerin SLIT2.5

[back to top]

Number of Participants Experiencing Serious Adverse Events With Peanut SLIT Versus Placebo SLIT

Incidence of all serious adverse events from initial enrollment through the end of the 3 month avoidance period reported as the number of participants experiencing a serious adverse event. (NCT02304991)
Timeframe: 39 months

InterventionParticipants (Count of Participants)
Peanut (Liquid Peanut Extract) SLIT0
Placebo Glycerin SLIT1

[back to top]

Tolerance 3 Months After Discontinuing Peanut SLIT or Placebo SLIT

"A secondary outcome of this study will be a statistically significant difference in the challenge score of the treatment group versus the placebo group during the DBPCFC performed 3 months after discontinuing therapy (tolerance).~DBPCFC Challenge Score scale:~Minimum score = 0; Maximum score = 7 Larger challenge score equals more successful desensitization. 0mg = 0; 3mg = 1; 13mg = 2; 43mg = 3; 143mg = 4; 443mg = 5; 1443mg = 6; and 4443mg = 7." (NCT02304991)
Timeframe: 39 months

Interventionscore on a scale (Mean)
Peanut (Liquid Peanut Extract) SLIT4.0
Placebo Glycerin SLIT1.0

[back to top]

Percent Continent

The percentage of participant's with continent bowel movements (control of passage of stool from the bowel). (NCT02383758)
Timeframe: Baseline, Post-Intervention (Week 2) , Follow Up (Week 4)

,
Interventionpercentage of participants (Number)
BaselinePost-Intervention (Week 2)Follow Up (Week 4)
Treatment Program065
Waitlist Control000

[back to top]

Mean Clinical Global Impression for Severity (CGI-S) Score

An independent evaluator (IE) will use the parent target problem (PTP) interview to help caregivers estimate the frequency of encopresis as well as its impact on the family. From this description, the IE (who will be blind to treatment assignment) will generate a brief narrative describing the participant's encopresis. This narrative will be used by the IE to rate the overall severity on the 7-point Clinical Global Impression for Severity (CGI-S). Clinical Global Impression of Severity (CGI-S) Scale is a clinician's assessment of patient's severity of illness. The score ranges from 1 = normal, not at all ill to 7 = among the most extremely ill patients (NCT02383758)
Timeframe: Baseline, Post-Intervention (Week 6), Post-Intervention (Week 10)

,
Interventionunits on a scale (Mean)
BaselinePost-Intervention (Week 6)Post-Intervention (Week 10)
Treatment Program5.45.04.3
Waitlist Control5.25.04.9

[back to top]

Mean Clinical Global Impression for Improvement (CGI-I) Score

An independent evaluator (IE) will use the parent target problem (PTP) interview to help caregivers estimate the frequency of encopresis as well as its impact on the family. From this description, the IE (who will be blind to treatment assignment) will generate a brief narrative describing the participant's encopresis. This narrative will be used by the IE to rate the overall severity on the 7-point Clinical Global Impression for Improvement (CGI-I). Clinical Global Impression for Improvement (CGI-I) Scale is a clinician's assessment of a patient's change in condition from baseline.The score ranges from 0 = not assessed, 1 = very much improved, through 7 = very much worse. (NCT02383758)
Timeframe: Post-Intervention (Week 6), Post-Intervention (Week 10)

,
Interventionunits on a scale (Mean)
Post-Intervention (Week 6)Post-Intervention (Week 10)
Treatment Program3.02.1
Waitlist Control3.83.6

[back to top]

Percent Independence

Percent independence is the percentage of independent bowel movements recorded by a caregiver. A continent bowel movement without the use of any medications will constitute an independent bowel movement. (NCT02383758)
Timeframe: Baseline, Post-Intervention (Week 2) , Follow Up (Week 4)

,
Interventionpercentage of participants (Number)
BaselinePost-Intervention (Week 2)Follow Up (week 4)
Treatment Program005
Waitlist Control000

[back to top]

Number of Participants Experiencing Vagal Symptoms With Flush

Vagal symptoms including nausea, vomiting, sweating, dizziness, and pallor were noted by the parent. The parent was instructed to call if the child had any vagal symptoms. Documentation of any vagal symptoms was completed by the parent and child on a data-collection form at the time of occurrence. Data was analyzed as a percentage of subjects experiencing vagal symptoms during flush with NS and USP glycerin. (NCT02435069)
Timeframe: Data collection started with the first flush administered following discharge from the hospital and was collected with every subsequent flush through completion of the study, an average of 115 days.

InterventionParticipants (Count of Participants)
Vagal Symptoms With NS FLush0
Vagal Symptoms With USP Glycerin Flush1

[back to top]

NS and USP Glycerin Flush Solution Dosing Frequency Necessary to Achieve Continence

Flush administration frequency necessary to achieve continence was recorded as a single measure per subject per flush solution obtained as the number of flushes in the last three days of each dosing phase and recorded as either daily (1), every other day (2), or every third day (3). The larger the value, the less frequent the flush, the better the clinical outcome. Dosing frequency was measured using direct observational recording completed by the parent or child. Descriptive analysis included mean, and standard deviation. Inferential statistical analysis was accomplished using a two-tailed, two-sample pooled variance t test with a significance level set at 0.05. Descriptive and inferential statistics were calculated on the data from the last day of the completed NS and USP Glycerin phases of the study. (NCT02435069)
Timeframe: Frequency of administration data was collected as the total number of flushes recieved over the last three days of each dosing phase for both NS and USP Glycerin and recorded as either daily (1), every other day (2), or every third day

InterventionFlush administration/day (Mean)
Dosing Frequency on NS1
Dosing Frequency on USP Glycerin1.6

[back to top]

Flush Volume

Flush volume was measured in mL/flush using a graduated cylinder and recorded by the parent or child with each flush and later calculated in mL/kg. Data derived from the last flush of the completed dosing phase of both NS and USP Glycerin were used to calculate flush volume. Descriptive analysis included mean, median, range, and standard deviation. Reported data excludes subjects who failed to gain and maintain continence on either flushing regimen. (NCT02435069)
Timeframe: Data for analysis was collected from the last flush of the NS and USP Glycerin dosing phase of the study

InterventionmL/flush (Mean)
Flush Volume of NS39.215
Flush Volume of USP Glycerin1.475

[back to top]

Fecal Soiling - Quantitative Count Detailing the Number of Episodes of Fecal Incontinence Per Day on NS and USP Glycerin

Fecal soiling was defined as non-toilet elimination, which was tracked and documented by the parent/child as direct event recording and tallied as the number of pairs of underwear/protective undergarments soiled with stool per day. Descriptive statistics included mean and standard deviation. Inferential statistical analysis was accomplished using a two-tailed, two-sample pooled variance t test with a significance level set at 0.05, calculated on the data from the last day of the completed NS and USP Glycerin phases of the study. Power analysis conducted using data from this study with α = 0.5, power of .80, correlation between two means of .598, and effect size of 1.554 estimated a sample size of 11 would be needed to minimize the risk of a Type II error to (20%). (NCT02435069)
Timeframe: Data collection began following consent and procedural training and was collected daily from day 1 for the duration of the study, an average of 135 days.

Interventionunderwear soiled/day (Mean)
Episodes of Fecal Incontinence on NS Antegrade Flush2
Episodes of Fecal Incontinence on USP Glycerin Antegrade Flush0.2

[back to top]

Fecal Soiling - Number of Participants That Gained and Maintained Continence on Each Flushing Regimen

Fecal soiling was defined as non-toilet elimination, which was tracked and documented by the parent/child as direct event recording and tallied as the number of pairs of underwear/protective undergarments soiled with stool per day. The purpose of this outcome measure was to document the number of individuals who gained continence on NS and USP glycerin. Descriptive statistics was limited to percentage of total participants who achieved continence on each flushing regimen. Data was calculated on the last data point in the final phase for both the NS and USP glycerin flush. (NCT02435069)
Timeframe: Data collection started following consent and procedural training and was collected daily from day 1 for the duration of the study, an average of 135 days.

InterventionParticipants (Count of Participants)
Subjects Continent on NS Antegrade Flush1
Subjects Continent on USP Glycerin4

[back to top]

Cramping With Flush

Cramping with flush was measured using the Wong Baker Faces Pain Rating Scale (WBFPRS). The WBFPRS has undergone extensive testing and has well established psychometrics in the pediatric population. The scale ranges from 0 (very happy without pain) to 10 (the worse pain imaginable). Each pain level is associated with a facial expression. The child is asked to choose the face that best describes his/her level of discomfort (ordinal data). The parent was instructed to call if the child had flushing regimen-associated discomfort greater than a 4 on the WBFPRS. Documentation of pain severity was completed by the parent and child on a data-collection form at the time of occurrence. Descriptive statistics including mean and standard deviation. Inferential statistical analysis was accomplished using a two-tailed, two-sample pooled variance t test with a significance level set at 0.05. Descriptive and inferential statistics were calculated on the last data point in the dosing phase. (NCT02435069)
Timeframe: Data analysis was completed on data obtained during the last flush in both the NS and USP Glycerin dosing phase

Interventionunits on a scale (Mean)
Pain With NS Antegrade Flush Administration0
Pain With USP Glycerin Antegrade Flush Administration0.4

[back to top]

Change in Stool Calprotectin Levels Assessed Through Comparing Levels Obtained Following Completion of NS and USP Glycerin Dosing Phases With the Baseline Value For Each Subject

Stool calprotectin was used to evaluate the impact of NS and USP Glycerin antegrade flush on colonic health. Calprotectin levels were obtained at baseline and following completion of the NS and USP Glycerin dosing phase of the study. Descriptive data analysis included mean and standard deviation for each flush regimen. Inferential statistical analysis was accomplished using a two-tailed, two-sample pooled variance t test with a significance level set at 0.05. Both descriptive and inferential data analysis was calculated on the difference in calprotectin levels between samples obtained at baseline and samples obtained following the completion of the NS and USP Glycerin flush (value at completion of dosing phase - baseline value). The assumption was the length of each dosing phase was sufficient to achieve a credible active washout period and therefore levels obtained at the end of a phase reflected flushing regimen effects colonic health regardless of flush order. (NCT02435069)
Timeframe: Collection dates included a baseline sample (week 1) and at the completion of the dosing trail for both NS and USP glycerin for a total of 3 samples

Interventionμg/g (Mean)
Calprotectin Levels Following NS FLush133.7
Calprotectin Levels Following USP Glycerin FLush108

[back to top]

Number of Participants With Any Electrolyte Abnormality

Evaluated impact of NS and USP Glycerin antegrade flush on serum electrolytes using a blood test called a Basic Metabolic Panel. Data analysis limited to percentage of subjects demonstrating any electrolyte abnormality on NS or USP glycerin. (NCT02435069)
Timeframe: Collection dates included a baseline sample (week 1) and at the completion of the dosing trail for both NS and USP glycerin for a total of 3 samples

InterventionParticipants (Count of Participants)
Elelctrolye Abnormalities on NS FLush0
Elelctrolye Abnormalities on USP Glycerin FLush0

[back to top]

Subject Satisfaction With Treatment

Subject 5-point Likert Satisfaction Assessment Scale where 4 = Very satisfied; 3 = Satisfied; 2 = Having no opinion; 1 = Unsatisfied and 0 = Very unsatisfied. (NCT02492997)
Timeframe: 1 month post treatment series

,
InterventionParticipants (Count of Participants)
Very satisfiedSatisfiedHaving no opinionUnsatisfiedVery unsatisfied
Control Group01534
Treatment Group38210

[back to top]

Abdominal Circumference

Abdominal circumference measurement of the treated area at 1 month after the last treatment performed by controlled tape measurement (NCT02492997)
Timeframe: 1 month post treatment series

Interventioncm (Mean)
Treatment Group90.18
Control Group88.05

[back to top]

the Severity of Post-ESWL Pancreatitis Measured as Consensus Definitions for the Major Complications of ERCP(Endoscopic Retrograde Cholangiopancreatography )

Post-ESWL complications are also stratified as mild, moderate and severe depending mainly on the length of hospitalization and the need for invasive treatment. (NCT02797067)
Timeframe: up to 1 months

,
InterventionParticipants (Count of Participants)
MildModerateSevere
Glycerin7950
Indomethacin5910

[back to top]

the Incidence and Severity of Asymptomatic Hyperamylasemia and Other Post-ESWL Complications

"Asymptomatic hyperamylasemia was defined as an increase in serum amylase compared with pre-ESWL levels and beyond the upper limit of the normal range but showing no related symptoms. Serum amylase will be measured in all study patients at 3 and 24 hours after the procedure and subsequently at clinical discretion.~Other post-ESWL complications including bleeding, infection, steinstrasse and perforation.~Bleeding is related to clinical evidence,the level of hemoglobin ( measured at 24 hours after the procedure and at clinical discretion) and treatments.~Infection is related to temperature and treatment. Steinstrasse is related to abdominal pain degree and the combination of other complications.~Perforation is related to treatment." (NCT02797067)
Timeframe: up to 1 months

,
InterventionParticipants (Count of Participants)
InfectionSteinstrassePerforationAsymptomatic HyperamylasemiaHematuriaHematemesisMelena
Glycerin1311197251416
Indomethacin50018918919

[back to top]

the Incidence of Post-ESWL Pancreatitis

Patients were identified as post-ESWL pancreatitis if meeting two out of three criteria: pain consistent with acute pancreatitis; amylase or lipase>3 times normal limit; characteristic findings on imaging, in according to the Revised Atlanta International consensus. (NCT02797067)
Timeframe: up to 1 months

InterventionParticipants (Count of Participants)
Indomethacin60
Glycerin84

[back to top]

Change in Glycerol Enrichment

[U-13C3] glycerol enrichment in plasma blood glucose over time will be measured by nuclear magnetic resonance spectroscopy. This is a percentage change from baseline to follow up in the percent enrichment of exogenous glycerol in blood glucose. We are unable to report a measure of central tendency and dispersion as the outcome is a percent change in the area under the enrichment curve for each group between baseline and follow-up. There is no measure of central tendency for these measurements without bootstrapping, which was not performed. (NCT02833415)
Timeframe: 3 months

InterventionPercentage change (Number)
Empagliflozin6.5
Placebo1.4

[back to top]

Total Number of All Participants With the Presence of a Bad Odour Emanating From Their Lower Limbs.

Change in the presence of bad odour emanating from wounds on participant's lower legs/feet as determined by clinic nurse. Bad odour results in social stigma and impacts of quality of life. (NCT02839772)
Timeframe: Change from baseline following 3 months of intervention

InterventionParticipants (Number)
Participants With Bad Odour From Legs/Feet at Baseline114
Participants With Bad Odour From Legs/Feet at 4th Visit3

[back to top] [back to top]

Change in Largest Lower Leg Circumference

Measured by clinic nurse in centimetres with a disposable tape measure at the point of largest circumference on the foot. (NCT02839772)
Timeframe: Change from baseline following 3 months of intervention

InterventionCentimetres (Mean)
Control Group-3.86
Experimental Group-4.14

[back to top]

Change in Largest Foot Circumference

Measured by clinic nurse in centimetres with a disposable tape measure at the point of largest circumference on the foot (NCT02839772)
Timeframe: Change from baseline following 3 months of intervention

InterventionCentimetres (Mean)
Control Group-2.34
Experimental Group-2.90

[back to top]

Number of Wounds on Lower Legs/Feet of Participants.

"Observation and count of number of wounds (all breaches of the stratum corneum including areas of fungal infection) on lower legs/feet by clinic nurse.~Breaches in the skin and areas of fungal infection are more likely to occur in those with an impaired skin barrier function.A reduction in the number of wounds indicates an improvement in SBF." (NCT02839772)
Timeframe: Change from baseline following 3 months of intervention

InterventionWounds (Number)
Number of Wounds at Baseline962
Number of Wounds 4th Visit29

[back to top]

Change in TEWL at Top of Outer Lower Legs

Trans-epidermal water loss (TEWL) was measured with a Vapometer (non-invasive probe) on the outer lower leg 8 cms below the head of the fibula. TEWL is the water lost through the skin under non-sweating conditions. It is the major indicator of healthy skin. A reduction in TEWL indicates a positive effect on skin barrier function. It is generally recommended that differences or percentage changes are reported rather than absolute values. (NCT02839772)
Timeframe: Change from baseline following 3 months of intervention

,
Interventiong/m2/h (Mean)
Right leg TEWL at 1st visitLeft leg TEWL at 1st visitRight leg TEWL at 4th visitLeft leg TEWL at 4th visit
Control Group12.7413.528.769.09
Experimental Group13.4313.277.067.53

[back to top]

Correlation Between Number of Work Days Lost Due to Adenolymphangitis and Number of Wounds

Statistical calculation of the correlation between the number of work days lost in the previous month due to leg pain (adenolymphangitis) and the number of wounds present on the lower leg/foot. Wounds on the lower legs/feet may produce a bad odour. (NCT02839772)
Timeframe: From baseline monthly for 3 months

InterventionSpearman's correlation coefficient (Number)
Correlation at baselineCorrelation at 2nd visitCorrelation at 3rd visitCorrelation at 4th visit
Correlation Between Number of Wounds and Days Lost Due to ADL0.2520.3060.2910.265

[back to top]

Stage of Podoconiosis in Each Leg of All Participants at Baseline and 4th Visit

Podoconiosis Staging System (1-5) used with 5 the most severe stage. This staging system was specifically designed for those with podoconiosis. Legs with stages 1, 2 or 3 were categorised with mild/moderate disease and those with stages 4,5 with severe disease. (NCT02839772)
Timeframe: Change from baseline following 3 months of intervention

,
InterventionLegs/feet (Number)
Right leg stage nilLeft legs stage nilRight legs stage 1Left legs stage 1Right leg stage 2Left leg stage 2Right leg stage 3Left leg stage 3Right leg stage 4Left leg stage 4Right leg stage 5Left leg stage 5Right leg missing dataLeft leg missing data
Stage of Podoconiosis 1st Visit212220636619177275151400
Stage of Podoconiosis 4th Visit2156495053646829210011

[back to top]

Change in TEWL at Base of Outer Lower Legs

"Trans-epidermal water loss (TEWL) was measured with a Vapometer (non- invasive probe) at a specific point on the outer lower leg 8cms above the external malleolus. A reduction in TEWL indicates a positive effect on skin barrier function.It is generally recommended that differences or percentage changes are reported rather than absolute values.~TEWL is the water lost through the skin under non-sweating conditions. It is the major indicator of healthy skin. A reduction in TEWL indicates a positive effect on skin barrier function. It is generally recommended that differences or percentage changes are reported rather than absolute values." (NCT02839772)
Timeframe: Change from baseline following 3 months of intervention

,
Interventiong/m2/h (Mean)
Right leg TEWL at 1st visitLeft leg TEWL at 1st visitRight leg TEWL at 4th visitLeft leg TEWL at 4th visit
Control Group16.4517.3211.5011.87
Experimental Group16.8017.029.309.88

[back to top]

Change in Stratum Corneum Hydration (SCH) at the Top of Outer Lower Legs

Stratum corneum hydration was measured at a specific point at top of outer lower leg (8cms below the head of the fibula) with a MoistureMeter (non-invasive probe).This measures skin capacitance in arbitrary units. It is generally recommended that differences or percentage changes are reported rather than absolute values. Increases in stratum corneum hydration indicate a positive effect on skin barrier function. (NCT02839772)
Timeframe: Change from baseline following 3 months of intervention

,
InterventionArbitrary units (Mean)
Right leg SCH 1st visitLeft leg SCH 1st visitRight leg SCH 4th visitLeft leg SCH 4th visit
Control Group9.609.8213.7315.30
Experimental Group9.059.2516.2416.10

[back to top]

Change in Stratum Corneum Hydration at Base of Outer Lower Leg

Stratum corneum hydration was measured at the base of the outer lower leg 8 cms above the external malleolus. It was measured with a MoistureMeter (non-invasive probe).This measures skin capacitance in arbitrary units. It is generally recommended that differences or percentage changes are reported rather than absolute values. Increases in stratum corneum hydration indicate a positive effect on skin barrier function. (NCT02839772)
Timeframe: Change from baseline following 3 months of intervention

,
InterventionArbitrary units (Mean)
Right leg SCH 1st visitLeft leg SCH at 1st visitRight leg SCH 4th visitLeft leg SCH 4th visit
Control Group8.468.2614.2514.47
Experimental Group8.568.8515.9316.47

[back to top]

Change in Stratum Corneum Hydration at Top of Feet

Stratum corneum hydration measured at a specific point on the middle top of the foot with a MoistureMeter (non-invasive probe).This measures skin capacitance in arbitrary units. It is generally recommended that differences or percentage changes are reported rather than absolute values. Increases in stratum corneum hydration indicate a positive effect on skin barrier function. (NCT02839772)
Timeframe: Change from baseline following 3 months of intervention

,
InterventionArbitrary units (Mean)
Right leg SCH at 1st visitLeft leg SCH at 1st visitRight leg SCH at 4th visitLeft leg SCH 4th visit
Control Group8.488.3915.3115.14
Experimental Group8.508.8717.2917.47

[back to top]

Change in TEWL at Mid-point Outer Lower Legs

Trans-epidermal water loss (TEWL) was measured with a Vapometer (non- invasive probe) at a specific point on the outer lower leg. This was mid-way between the measurement site at the top of the outer leg and the site at the base of the outer lower leg. TEWL is the water lost through the skin under non-sweating conditions. It is the major indicator of healthy skin. A reduction in TEWL indicates a positive effect on skin barrier function. It is generally recommended that differences or percentage changes are reported rather than absolute values. (NCT02839772)
Timeframe: Change from baseline following 3 months of intervention

,
Interventiong/m2/h (Mean)
Right leg TEWL at 1st visitLeft leg TEWL at 1st visitRight leg TEWL at 4th visitLeft leg TEWL at 4th visit
Control Group14.0215.469.8710.34
Experimental Group14.5714.558.228.61

[back to top]

Change in Stratum Corneum Hydration (SCH) at Mid-point Outer Lower Leg.

SCH was measured mid-way between the measurement site at the top of the outer leg and the site at the base of the outer lower leg. It was measured with a MoistureMeter (non-invasive probe).This measures skin capacitance in arbitrary units. It is generally recommended that differences or percentage changes are reported rather than absolute values. Increases in stratum corneum hydration indicate a positive effect on skin barrier function. (NCT02839772)
Timeframe: Change from baseline following 3 months of intervention

,
InterventionArbitrary units (Mean)
Right leg SCH at 1st visitLeft leg SCH at 1st visitRight leg SCH at 4th visitLeft leg SCH at 4th visit
Control Group9.209.3913.8814.56
Experimental Group8.869.0515.9015.95

[back to top]

Change in TEWL at Top of Feet

"Trans-epidermal water loss (TEWL) was measured with a Vapometer (non- invasive probe) at a specific point on the top of the foot. A reduction in TEWL indicates a positive effect on skin barrier function.It is generally recommended that differences or percentage changes are reported rather than absolute values.~TEWL is the water lost through the skin under non-sweating conditions. It is the major indicator of healthy skin. A reduction in TEWL indicates a positive effect on skin barrier function. It is generally recommended that differences or percentage changes are reported rather than absolute values." (NCT02839772)
Timeframe: Change from baseline following 3 months of intervention

,
Interventiong/m2/h (Mean)
Right foot 1st visitLeft foot 1st visitRight foot 4th visitLeft foot 4th visit
Control Group21.9723.0114.9015.38
Experimental Group22.8822.4713.1513.49

[back to top]

Amharic Dermatology Life Quality Index (DLQI)

The Amharic version of the DLQI has been validated for use in Ethiopia where Amharic is the official working language. The index is divided into 4 sections covering leisure, work and school, personal relationships and treatment. The maximum score of 30 indicates a high impact on quality of life. The lowest score zero. A reduction in the number indicates an improvement in quality of life. Participants were verbally questioned by the clinic nurse or social worker as most participants were illiterate. (NCT02839772)
Timeframe: Change from baseline following 3 months of intervention

,
Interventionunits on a scale (Mean)
DLQI at baselineDLQI 4th visit
Control Group21.614.12
Experimental Group21.073.94

[back to top]

Total Number of Trophic Skin Changes (Mossy Changes) All Participants at Baseline and 4th Visit

Total number of observed trophic changes (mossy eruptions on the skin of the lower legs/feet characteristic of podoconiosis) in all participants by clinic nurse at baseline and at 4th visit. Trophic changes were either present or not present. (NCT02839772)
Timeframe: Change from baseline following 3 months of intervention

InterventionTrophic skin changes (Number)
Total Number of Trophic Skin Changes at Baseline312
Total Number of Trophic Skin Changes at 4th Visit237

[back to top]

Spectrum of Sun Protection

Broad spectrum of sun protection was calculated by the ratio of the arithmetic mean of SPF to the arithmetic mean of UVAPF. Higher values represents increased SPF protection. (NCT03157583)
Timeframe: Up to 30 minutes post UV exposure

InterventionRatio (Number)
Test Product 13.11
Test Product 22.98
Test Product 32.88
Test Product 42.95
Reference (for UVAPFi and SPFi Calculation)1.13

[back to top]

Arithmetic Mean of Individual Sun Protection Factor (SPFi) Values

Arithmetic mean of all valid SPFi values of each product on each participant was calculated from the individual Minimal Erythemal Dose (MED) on product treated (MEDp) test sites in relation to unprotected (MEDu) test sites 16-24 hours after exposure to ultraviolet (UV) radiation. SPFi = MEDp/MEDu. No inferential statistical analysis was performed for this outcome.The provisional MEDu was the lowest dose of UV radiation that produces the first perceptible unambiguous erythema with defined borders appearing over most of the field of UV exposure.Higher values represents increased SPF protection. (NCT03157583)
Timeframe: Up to 24 hours post UV exposure

InterventionRatio (Mean)
Test Product 133.1
Test Product 235.2
Test Product 335.2
Test Product 445.2
Reference Product (for SPFi Calculation)15.6

[back to top]

Rate of Drug Discontinuations (Percentage of Participants Who Discontinued Study Drug) Due to Any Reason in the Initial Treatment Period

(NCT03335488)
Timeframe: Baseline through Week 4

Interventionpercentage of participants (Number)
RAVICTI0
NaPBA0

[back to top]

Plasma Ammonia Area Under the Curve (AUC) 0 to 8h at the End of the Initial Treatment Period

(NCT03335488)
Timeframe: Week 4: hour 0 (predose), and hours 4 and 8 postdose

Interventionµmol*h /L (Mean)
RAVICTI331.8
NaPBA258.9

[back to top]

Peak Plasma Concentration (Cmax) of Ammonia at the End of the Initial Treatment Period

(NCT03335488)
Timeframe: Week 4: hour 0 (predose), and hours 4 and 8 postdose

Interventionµmol/L (Mean)
RAVICTI60.2
NaPBA38.1

[back to top]

Change From Baseline in Fasting Plasma Ammonia Levels During the Initial Treatment Period

(NCT03335488)
Timeframe: Baseline, Initial Treatment Period Week 1, Week 2, Week 3, Week 4 (0, 4, 8 hours post dose)

,
Interventionµmol/L (Mean)
Week 1Week 2Week 3Week 4: 0 hourWeek 4: 4 hours postdoseWeek 4: 8 hours postdose
NaPBA0.0-10.4-10.9-0.3-1.1-0.7
RAVICTI6.525.57.42.12.623.4

[back to top]

Rate of Treatment Success (Percentage of Participants Defined as Treatment Success at Week 4) During the Initial Treatment Period

"A participant was considered a Treatment Success for the assigned treatment arm if the participant had not experienced an unprovoked hyperammonemic crisis (HAC) (i.e., a HAC that cannot be attributed to one or more specific precipitating factors such as infection, intercurrent illness, diet noncompliance, treatment noncompliance, etc.) on the assigned treatment and had met at least 2 of the following 3 criteria:~Had absolute values at the 3 time points (pre-dose, after dose at 4 hours and 8 hours) of plasma ammonia levels which do not exceed ULN at the Week 4(End of Initial Treatment Period visit)~Had normal (≤ ULN) glutamine levels at the Week 4 (End of Initial Treatment Period visit at the time point Zero Hour.~Had normal (≤ ULN) essential amino acids including branched chain amino acid levels (threonine, phenylalanine, methionine, lysine, leucine, isoleucine, histidine, valine) at the End of Initial Treatment Period visit at time point Zero Hour." (NCT03335488)
Timeframe: Week 4

Interventionpercentage of participants (Number)
RAVICTI81.8
NaPBA80.0

[back to top]

Days on Total Parenteral Nutrition (TPN)

total time that patient required Total Parenteral Nutrition (TPN) feeds (NCT03355326)
Timeframe: 2 months

Interventiondays (Median)
Glycerin Suppository Group19.0
Non-suppository Group20.5

[back to top]

Hospital Length of Stay

time from admission (birth) to hospital discharge (NCT03355326)
Timeframe: ~3 months

Interventiondays (Median)
Glycerin Suppository Group26.5
Non-suppository Group23.5

[back to top]

Number of Participants With Post-operative Complications

Any complications during the admission after start of study; these include anything including infections, necrotizing enterocolitis (NEC), small bowel obstruction (SBO), and Total Parenteral Nutrition (TPN)-induced cholestasis. (NCT03355326)
Timeframe: ~3 months

InterventionParticipants (Count of Participants)
Glycerin Suppository Group2
Non-suppository Group2

[back to top]

Number of Participants With Sequela of Long Term Total Parenteral Nutrition (TPN) Administration

Any complications related to TPN administration, including TPN-induced cholestasis and hyperbilirubinemia (NCT03355326)
Timeframe: ~3 months

InterventionParticipants (Count of Participants)
Glycerin Suppository Group0
Non-suppository Group0

[back to top]

Time to First Bowel Movement

time from study start time after closure to first bowel movement (NCT03355326)
Timeframe: 1 month

Interventiondays (Median)
Glycerin Suppository Group2.5
Non-suppository Group3.0

[back to top]

Number of Participants With Infectious Complications

Any complications related to infections during the admission after start of study; these include infections such as line infections, wound infections, pneumonia, and urinary tract infection (UTI) (NCT03355326)
Timeframe: ~3 months

InterventionParticipants (Count of Participants)
Glycerin Suppository Group2
Non-suppository Group2

[back to top]

Time to Full Enteral Feeds

time from study start time to goal full feeds by enteral route (per oral (PO), orogastric (OG), gastrostomy tube (gtube)). (NCT03355326)
Timeframe: 2 months

Interventiondays (Median)
Glycerin Suppository Group18.5
Non-suppository Group17.0

[back to top]

Time Until Cleared for PACU Discharge

Time elapsed from conclusion of surgery until criteria for PACU discharge met (NCT03657407)
Timeframe: up to 4 hours

Interventionminutes (Mean)
Belladonna & Opium91.3
Placebo110.6

[back to top]

Post-operative Pain: VAS

Visual analog pain scale (VAS) (0 to 10, 0 = no pain, 10 = maximum pain), averaged over duration of PACU stay until discharge criteria met (NCT03657407)
Timeframe: up to 4 hours

Interventionscore on a scale (Mean)
Belladonna & Opium4.1
Placebo4.8

[back to top]

Number of Participants for Which Anti-emetics Were Received in PACU

Binary assessment of whether anti-emetics received in PACU (NCT03657407)
Timeframe: up to 4 hours

InterventionParticipants (Count of Participants)
Belladonna & Opium10
Placebo11

[back to top]

Narcotic Use

Cumulative oral and intravenous narcotics received in PACU until PACU discharge criteria met (NCT03657407)
Timeframe: up to 4 hours

InterventionOral Morphine Equivalents in mg (Mean)
Belladonna & Opium19.3
Placebo21.3

[back to top]

Skin Barrier Strengthening Effect by Measurement of Trans Epidermal Water Loss (TEWL) Before and After Induction of Skin Irritation

The change in TEWL from treated and untreated skin before and after induction of skin irritation with SLS. SLS increases TEWL. An effective treatment protects skin from irritation and less TEWL increase is anticipated compared to untreated skin (NCT03901144)
Timeframe: day 29 prior to irritant application and day 31 following application

InterventionTEWL (g/m^2·h) change from day 29 to 31 (Mean)
Test Cream (2% Urea/20% Glycerol)19.790
Reference Cream 1: Miniderm® 20% Cream (20% Glycerol)24.680
Reference Cream 2: Diprobase® Cream (Cream Without Humectants)29.648
Untreated28.646

[back to top]

Skin Barrier Strengthening Effect by Measurement of Skin Redness Before Induction of Skin Irritation as Assessed by Visual Scoring

Skin redness by visual scoring on treated and untreated skin before induction of skin irritation with SLS. Skin redness was evaluated on a 4-point visual scale from 0 to 3, where 0 indicates no redness/reaction and 3 indicates strong erythema. (NCT03901144)
Timeframe: Skin redness was scored on day 29

Interventionunits on a scale (Mean)
Test Cream (2% Urea/20% Glycerol)0
Reference Cream 1: Miniderm® 20% Cream (20% Glycerol)0
Reference Cream 2: Diprobase® Cream (Cream Without Humectants)0
Untreated0

[back to top]

Skin Barrier Strengthening Effect by Measurement of Skin Redness Before and After Induction of Skin Irritation as Assessed by the Erythema Index (Change From Day 29 to Day 31)

Skin redness measurement by Objective Erythema (2D Skin Imaging) on treated and untreated skin before (day 29) and after (day 31) induction of skin irritation with SLS. Captured 2D images are analysed to determine the skin erythema index (degree of redness, arbitrary numerical value), where a higher value denotes a stronger reaction/more redness. An effective treatment is anticipated to protect the skin from irritation, i.e. a weaker reaction from SLS/less redness compared to the untreated skin. Data is presented as change from day 29 to day 31 (NCT03901144)
Timeframe: The 2D Skin Imaging was performed on day 15, day 29 and on day 31. Only day 29 and 31 was included in the statistical analysis

InterventionArbitrary Units (Mean)
Test Cream (2% Urea/20% Glycerol)13.261
Reference Cream 1: Miniderm® 20% Cream (20% Glycerol)14.833
Reference Cream 2: Diprobase® Cream (Cream Without Humectants)17.981
Untreated16.747

[back to top]

Skin Barrier Strengthening Effect by Measurement of Skin Redness Before and After Induction of Skin Irritation as Assessed by Mexameter (Change From Day 29 to Day 31)

Objective skin redness measurement by Mexameter on treated and untreated skin before (day 29) and after (day 31) induction of skin irritation with SLS. Skin redness is measured using a C&K Mexameter probe to quantify SLS-induced skin irritation (arbitrary numerical scale). An effective treatment is anticipated to protect the skin from irritation, i.e. a weaker reaction from SLS/less redness compared to the untreated skin. Data is presented as change from day 29 to day 31 (NCT03901144)
Timeframe: Measured on day 29 and 31

InterventionArbitrary Units (Mean)
Test Cream (2% Urea/20% Glycerol)80.859
Reference Cream 1: Miniderm® 20% Cream (20% Glycerol)82.893
Reference Cream 2: Diprobase® Cream (Cream Without Humectants)106.39
Untreated98.951

[back to top]

Skin Barrier Strengthening Effect by Measurement of Skin Redness After Induction of Skin Irritation as Assessed by Visual Scoring

Skin redness by visual scoring on treated and untreated skin after induction of skin irritation with SLS. Skin redness was evaluated on a 4-point visual scale from 0 to 3, where 0 indicates no redness/reaction and 3 indicates strong erythema. (NCT03901144)
Timeframe: Skin redness was scored on day 31

Interventionunits on a scale (Mean)
Test Cream (2% Urea/20% Glycerol)0.99
Reference Cream 1: Miniderm® 20% Cream (20% Glycerol)1.08
Reference Cream 2: Diprobase® Cream (Cream Without Humectants)1.45
Untreated1.35

[back to top]